<?xml version="1.0" encoding="UTF-8"?>
<search_results count="532">
  <query>Pegasys</query>
<!-- Additional study fields may be added over time -->  <study rank="1">
    <nct_id>NCT01259856</nct_id>
    <title>Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>High Risk Polycythemia Vera</condition>
      <condition>High Risk Essential Thrombocythemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEGASYS</intervention>
      <intervention type="Drug">Hydroxyurea</intervention>
      <intervention type="Drug">Aspirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ronald Hoffman</lead_sponsor>
      <collaborator>Myeloproliferative Disorders-Research Consortium</collaborator>
      <collaborator>National Cancer Institute (NCI)</collaborator>
      <collaborator>Roche Pharma AG</collaborator>
      <collaborator>QIAGEN Marseille</collaborator>
      <collaborator>Icahn School of Medicine at Mount Sinai</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GCO 09-1300-00002</other_id>
      <other_id>P01CA108671</other_id>
      <other_id>MPD-RC 112</other_id>
    </other_ids>
    <first_received>December 7, 2010</first_received>
    <start_date>September 2011</start_date>
    <completion_date>June 2024</completion_date>
    <last_updated>June 4, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2024</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To compare hematologic response rates in patients randomized to treatment with Pegylated Interferon Alfa-2a vs Hydroxyurea in two strata of patients with high risk polycythemia vera (PV) or high risk essential thrombocythemia (ET).</outcome_measure>
      <outcome_measure>To compare the toxicity, safety and tolerability of therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea) in the study populations by recording the adverse events that occur during the study using the CTC 4.0 as the guide.</outcome_measure>
      <outcome_measure>To compare the hematologic partial response rates on therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea).</outcome_measure>
      <outcome_measure>To compare specific pre-defined toxicity and tolerance of therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea) and validate the utility of sequential structured symptom assessment package of patient reported outcome instruments.</outcome_measure>
      <outcome_measure>To compare the impact of therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea) on key biomarkers of the disease(s) by measuring the JAK2 allele burden.</outcome_measure>
      <outcome_measure>To compare the impact of therapy on JAK2-V617F (JAK2), CALR, hematopoietic cell clonality in platelets and granulocytes in females, bone marrow histopathology, and cytogenetic abnormalities.</outcome_measure>
      <outcome_measure>To estimate survival and incidence of development of myelodysplastic syndrome, myelofibrosis, or leukemic transformation after therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea).</outcome_measure>
      <outcome_measure>To estimate incidence of major cardiovascular events after therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea).</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
      <country>Ireland</country>
      <country>Italy</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>District of Columbia</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Kansas</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Utah</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01259856</url>
  </study>
  <study rank="2">
    <nct_id>NCT01259817</nct_id>
    <title>Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>High Risk Polycythemia Vera</condition>
      <condition>High Risk Essential Thrombocythemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEGASYS</intervention>
      <intervention type="Drug">Aspirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ronald Hoffman</lead_sponsor>
      <collaborator>Myeloproliferative Disorders-Research Consortium</collaborator>
      <collaborator>National Cancer Institute (NCI)</collaborator>
      <collaborator>Roche Pharma AG</collaborator>
      <collaborator>QIAGEN Marseille</collaborator>
      <collaborator>Icahn School of Medicine at Mount Sinai</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>188</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GCO 09-1300 001</other_id>
      <other_id>P01CA108671</other_id>
      <other_id>MPD-RC 111</other_id>
    </other_ids>
    <first_received>December 6, 2010</first_received>
    <start_date>September 2011</start_date>
    <completion_date>June 2018</completion_date>
    <last_updated>June 4, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluate the ability of Pegylated Interferon Alfa-2a to achieve Complete Response or Partial Response in patients with (1) high risk polycythemia vera or (2) high risk essential thrombocythemia or (3) splanchnic vein thrombosis</outcome_measure>
      <outcome_measure>To evaluate the toxicity and tolerability of therapy Pegylated Interferon Alfa-2a in each of the 3 strata by recording the number of adverse events that occur during the study by using CTC 4.0 as the guide.</outcome_measure>
      <outcome_measure>To measure the impact of Pegylated Interferon Alfa-2a on key biomarkers of the disease(s)by measuring the JAK2 allele burden.</outcome_measure>
      <outcome_measure>To evaluate specific pre-defined toxicity and tolerance of Pegylated Interferon Alfa-2a through a sequential structured symptom assessment package of patient reported outcome instruments.</outcome_measure>
      <outcome_measure>To estimate survival, and incidence of development of myelodysplastic syndrome, myelofibrosis, or leukemic transformation during therapy Pegylated Interferon Alfa-2a.</outcome_measure>
      <outcome_measure>Estimate the observed incidence of major cardiovascular events during therapy Pegylated Interferon Alfa-2a.</outcome_measure>
      <outcome_measure>To measure the impact of Pegylated Interferon Alfa-2a on JAK2-V617F, CALR, hematopoietic cell clonality in platelets and granulocytes in females, bone marrow histopathology, and cytogenetic abnormalities.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>District of Columbia</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Kansas</state>
      <state>Maryland</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Utah</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01259817</url>
  </study>
  <study rank="3">
    <nct_id>NCT01937728</nct_id>
    <title>Tailored Regimens of PEGASYSÂ® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">A: Peg-interferon alpha-2a &amp; Ribavirin</intervention>
      <intervention type="Drug">B: Peg-interferon alpha-2a &amp; Ribavirin</intervention>
      <intervention type="Drug">C: Peg-interferon alpha-2a &amp; Ribavirin</intervention>
      <intervention type="Drug">D: Peg-interferon alpha-2a &amp; Ribavirin</intervention>
      <intervention type="Drug">E: Peg-interferon alpha-2a &amp; Ribavirin</intervention>
      <intervention type="Drug">F: Peg-interferon alpha-2a &amp; Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kaohsiung Medical University Chung-Ho Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>750</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KMUH-IRB-970119</other_id>
    </other_ids>
    <first_received>June 21, 2013</first_received>
    <start_date>March 2010</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>September 4, 2013</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01937728</url>
  </study>
  <study rank="4">
    <nct_id>NCT00594880</nct_id>
    <title>Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon-alpha 2a, 180 mcg/week sc</intervention>
      <intervention type="Drug">Pegylated Interferon-alpha 2a, 90 mcg/week sc</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>The Wistar Institute</lead_sponsor>
      <collaborator>National Institutes of Health (NIH)</collaborator>
      <collaborator>National Institute of Allergy and Infectious Diseases (NIAID)</collaborator>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>23</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>DAIDS-ES 10401</other_id>
      <other_id>U01AI065279</other_id>
    </other_ids>
    <first_received>January 4, 2008</first_received>
    <start_date>January 2008</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>January 28, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>January 24, 2013</firstreceived_results_date>
    <primary_completion_date>November 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HIV Viral Load &lt; 400 Copies/ml</outcome_measure>
      <outcome_measure>HIV Viral Load &lt; 48 Copies/ml</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Pennsylvania</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00594880</url>
  </study>
  <study rank="5">
    <nct_id>NCT01392170</nct_id>
    <title>Pegasys in Patients With Chronic Myeloid Leukemia (CML)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Leukemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-IFNÃ¡-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>M.D. Anderson Cancer Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2011-0184</other_id>
      <other_id>NCI-2011-01465</other_id>
    </other_ids>
    <first_received>July 8, 2011</first_received>
    <start_date>October 2011</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>April 13, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>March 31, 2015</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Achieved of Major Molecular Response (MMR) or Complete Molecular Response (CMR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01392170</url>
  </study>
  <study rank="6">
    <nct_id>NCT00917761</nct_id>
    <title>Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Entecavir and peginterferon (Pegasys) (52 weeks)</intervention>
      <intervention type="Drug">Peginterferon (Pegasys) (96 weeks)</intervention>
      <intervention type="Drug">Peginterferon (Pegasys) (48 weeks)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>National Science Council, Taiwan</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>950924</other_id>
    </other_ids>
    <first_received>June 8, 2009</first_received>
    <start_date>February 2007</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>December 19, 2012</last_updated>
    <last_verified>December 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HBV virologic response (HBV DNA &lt; 2,000 IU/mL) 6 months after the cessation of treatment</outcome_measure>
      <outcome_measure>ALT normalization rate (ALT &lt; 40 IU/L) 6 months after the cessation of treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00917761</url>
  </study>
  <study rank="7">
    <nct_id>NCT00545233</nct_id>
    <title>A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
      <intervention type="Drug">Pioglitazone</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>155</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML21301</other_id>
    </other_ids>
    <first_received>October 16, 2007</first_received>
    <start_date>January 2008</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>April 10, 2012</last_updated>
    <last_verified>April 2012</last_verified>
    <firstreceived_results_date>February 8, 2012</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Initiation of Pegasys Plus Copegus in log10 Hepatitis C Virus Ribonucleic Acid (HCV RNA) Viral Load to Week 12 of Anti-HCV Therapy</outcome_measure>
      <outcome_measure>Change From Initiation of Pegasys Plus Copegus in log10 HCV RNA Viral Load to Week 24 and Week 48 of Anti-HCV Therapy</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Virologic Response</outcome_measure>
      <outcome_measure>Percentage of Participants With a â¥ 2 log10 Decrease in HCV RNA From Initiation of Pegasys Plus Copegus to Weeks 4, 12, 24, 48, 60, 72</outcome_measure>
      <outcome_measure>Percentage of Participants With a Virological Relapse at Week 72 (24 Weeks After the End of Anti-HCV Treatment)</outcome_measure>
      <outcome_measure>Percentage of Participants With a Confirmed Virological Breakthrough up to 48 Weeks</outcome_measure>
      <outcome_measure>Percentage of Nonresponders During the 48 Week Anti-HCV Treatment Period</outcome_measure>
      <outcome_measure>Change in Log10 HCV RNA Viral Load at Assessments From Randomization to 16 Weeks of Pioglitazone Pretreatment Run-In Period for the Pioglitazone Arm Only</outcome_measure>
      <outcome_measure>Change From Baseline in Fasting Plasma Glucose Levels at Each Time Point Assessed</outcome_measure>
      <outcome_measure>Change From Baseline in Fasting Insulin Levels at Each Time Point Assessed.</outcome_measure>
      <outcome_measure>Change From Baseline in Fasting Hemoglobin A1C (HbA1c) Concentrations at Each Time Point Assessed</outcome_measure>
      <outcome_measure>Change From Baseline in Homeostasis Model Assessment (HOMA) Scores at Each Time Point Assessed</outcome_measure>
      <outcome_measure>Change From Baseline in Serum Triglyceride Concentrations at Each Time-point Assessed</outcome_measure>
      <outcome_measure>Change From Baseline in Total Cholesterol Levels at Each Time-point Assessed</outcome_measure>
      <outcome_measure>Change From Baseline in Low-density Lipoprotein (LDL-cholesterol) Levels at Each Time-point Assessed</outcome_measure>
      <outcome_measure>Change From Baseline in High-density Lipoprotein (HDL-cholesterol) Levels at Each Time-point Assessed</outcome_measure>
      <outcome_measure>Change From Baseline in Tumor Necrosis Factor Alpha (TNF-Î±) at Each Time Point Assessed</outcome_measure>
      <outcome_measure>Change From Baseline in Transforming Growth Factor Beta (TGF-Î²) Levels at Each Time Point Assessed</outcome_measure>
      <outcome_measure>Change From Baseline in Adiponectin Levels at Each Time Point Assessed</outcome_measure>
      <outcome_measure>Change From Baseline in Leptin Levels at Each Time Point Assessed</outcome_measure>
      <outcome_measure>Change From Baseline in Free Fatty Acid Levels at Each Time Point Assessed</outcome_measure>
      <outcome_measure>Percentage of Participants With Beck Depression Inventory Fast Screen (BDI-FS) Score â¥ 4 at Each Time Point Assessed</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Iowa</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maine</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00545233</url>
  </study>
  <study rank="8">
    <nct_id>NCT00707772</nct_id>
    <title>PegasysÂ® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Hemophilia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEGASYSÂ® (Peginterferon Alfa-2a (40KD)) Plus COPEGUSÂ® (Ribavirin)</intervention>
      <intervention type="Drug">PEGASYSÂ® (Peginterferon Alfa-2a (40KD)) Plus COPEGUSÂ® (Ribavirin)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Baqiyatallah Medical Sciences University</lead_sponsor>
      <collaborator>Baqiyatallah Research Center for Gastroenterology and Liver Diseases</collaborator>
      <collaborator>Tehran Hepatitis Center</collaborator>
      <collaborator>Guilan Research Center for Gastroenterology and Liver Diseases</collaborator>
      <collaborator>Tabriz Research Center for Gastroenterology and Liver Diseases</collaborator>
      <collaborator>Shahid Beheshti Medical University</collaborator>
      <collaborator>Research Center for Gastroenterology and Liver Disease, Iran University of Medical Sciences, Firoozgar Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>BRCGL-07-03</other_id>
    </other_ids>
    <first_received>June 26, 2008</first_received>
    <start_date>March 2007</start_date>
    <completion_date>September 2009</completion_date>
    <last_updated>September 16, 2009</last_updated>
    <last_verified>September 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Early Virologic Response</outcome_measure>
      <outcome_measure>End of Treatment Response</outcome_measure>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
      <outcome_measure>Rapid Virologic Response</outcome_measure>
      <outcome_measure>Tolerability of drugs for whole therapy period</outcome_measure>
      <outcome_measure>Biochemical response (ALT)</outcome_measure>
      <outcome_measure>Laboratory Parameters</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Iran, Islamic Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00707772</url>
  </study>
  <study rank="9">
    <nct_id>NCT01639547</nct_id>
    <title>Sustained Virological Response (SVR)Rate of Pegasys Plus Ribavirin in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a plus Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chang Gung Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>410</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CTC-133</other_id>
    </other_ids>
    <first_received>June 28, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>July 27, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response</outcome_measure>
      <outcome_measure>Virological Response Rate at week 2</outcome_measure>
      <outcome_measure>Virological response at end of treatment</outcome_measure>
      <outcome_measure>Correlation of virological response and SVR rate</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01639547</url>
  </study>
  <study rank="10">
    <nct_id>NCT01641926</nct_id>
    <title>A Study of the Safety and Efficacy of PEG-Intronâ¢ Versus PEGASYSâ¢ in Participants With Chronic Hepatitis B (P08450)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PEG-Intronâ¢</intervention>
      <intervention type="Biological">PEGASYSâ¢</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>402</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P08450</other_id>
      <other_id>MK-4031-376</other_id>
    </other_ids>
    <first_received>July 11, 2012</first_received>
    <start_date>November 2012</start_date>
    <completion_date>February 2016</completion_date>
    <last_updated>November 26, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of HBeAg(+) participants achieving HBeAg seroconversion at 24 weeks post-treatment</outcome_measure>
      <outcome_measure>Percentage of HBeAg(-) participants achieving hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels &lt;2000 IU/mL at 24 weeks post-treatment</outcome_measure>
      <outcome_measure>Percentage of HBeAg(+) participants achieving HBV DNA &lt;2000 IU/mL at 24 weeks post-treatment</outcome_measure>
      <outcome_measure>Percentage of HBeAg(+) participants achieving alanine aminotransferase (ALT) normalization at 24 weeks post-treatment</outcome_measure>
      <outcome_measure>Percentage of HBeAg(+) participants achieving the combined response of HBeAg seroconversion and HBV DNA &lt;2000 IU/mL at 24 weeks post-treatment</outcome_measure>
      <outcome_measure>Percentage of HBeAg(-) participants achieving ALT normalization at 24 weeks post-treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01641926</url>
  </study>
  <study rank="11">
    <nct_id>NCT02233075</nct_id>
    <title>REP 2139-Ca / Pegasysâ¢ Combination Therapy in Hepatitis B / Hepatitis D Co-infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic HBV Infection (HBeAg Negative)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">REP 2139-Ca + Pegasys (TM)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>REPLICor Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>REP 301</other_id>
    </other_ids>
    <first_received>September 1, 2014</first_received>
    <start_date>September 2014</start_date>
    <completion_date>July 2016</completion_date>
    <last_updated>October 21, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients experiencing a treatment-related adverse event.</outcome_measure>
      <outcome_measure>Number of patients with reduction of serum HBsAg.</outcome_measure>
      <outcome_measure>Number of patients with reduced serum HDV antigen / HDV RNA</outcome_measure>
      <outcome_measure>Number of patients with controlled HBV / HDV infection following treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Moldova, Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02233075</url>
  </study>
  <study rank="12">
    <nct_id>NCT01623336</nct_id>
    <title>BIP48 (Peginterferon Alfa 2b 48kDa) Compared With PegasysÂ® (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BIP 48 (Peginterferon alfa 2b 48kDA)</intervention>
      <intervention type="Drug">Peginterferon alfa 2a 40kDA</intervention>
      <intervention type="Drug">BIP 48 (Peginterferon alfa 2b 48kDA)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)</lead_sponsor>
      <collaborator>Hospital de Clinicas de Porto Alegre</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>740</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Bio-equivalence Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>11/0468</other_id>
    </other_ids>
    <first_received>June 13, 2012</first_received>
    <start_date>January 2012</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>June 15, 2012</last_updated>
    <last_verified>November 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>BIP48II/III</acronym>
    <primary_completion_date>August 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The rate of sustained virologic response - SVR - measured by PCR at 24 weeks after treatment.</outcome_measure>
      <outcome_measure>Frequency of adverse events</outcome_measure>
      <outcome_measure>Virologic response at the end of treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Brazil</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01623336</url>
  </study>
  <study rank="13">
    <nct_id>NCT01378104</nct_id>
    <title>100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Sustained Virologic Response</condition>
      <condition>IL28B Polymorphism</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa 2a (pegasys)</intervention>
      <intervention type="Drug">peginterferon alfa-2a (pegasys)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>The Catholic University of Korea</lead_sponsor>
      <collaborator>Ulsan University Hospital</collaborator>
      <collaborator>NHIC Ilsan hospital</collaborator>
      <collaborator>Inje University</collaborator>
      <collaborator>Soonchunhyang University Hospital</collaborator>
      <collaborator>Yonsei University</collaborator>
      <collaborator>Chungnam National University</collaborator>
      <collaborator>Keimyung University</collaborator>
      <collaborator>Kyungpook National University</collaborator>
      <collaborator>Konyang University Hospital</collaborator>
      <collaborator>Inha University Hospital</collaborator>
      <collaborator>Hallym University Medical Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>178</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PEGASYS100:80</other_id>
    </other_ids>
    <first_received>June 16, 2011</first_received>
    <start_date>October 2008</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>February 3, 2013</last_updated>
    <last_verified>February 2013</last_verified>
    <firstreceived_results_date>December 14, 2012</firstreceived_results_date>
    <primary_completion_date>September 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response Depending on the Dosage of Peginterferon Alfa 2a</outcome_measure>
      <outcome_measure>IL28B Polymorphism Effect on SVR</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Korea, Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01378104</url>
  </study>
  <study rank="14">
    <nct_id>NCT01331850</nct_id>
    <title>A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">RO5024048</intervention>
      <intervention type="Drug">danoprevir</intervention>
      <intervention type="Drug">ritonavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>381</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>WV21913</other_id>
      <other_id>2010-019585-90</other_id>
    </other_ids>
    <first_received>March 28, 2011</first_received>
    <start_date>May 2011</start_date>
    <completion_date>January 2013</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR) of danoprevir/ritonavir with RO5024048 and Copegus in patients with previous partial or null response to peginterferon/ribavirin treatment</outcome_measure>
      <outcome_measure>Sustained virological response (SVR) of danoprevir/ritonavir with Pegasys and Copegus in patients with previous partial response to peginterferon/ribavirin treatment</outcome_measure>
      <outcome_measure>Sustained virological response (SVR) of danoprevir/ritonavir and RO5024048 with Pegasys and Copegus in patients with previous partial or null response to peginterferon/ribavirin treatment</outcome_measure>
      <outcome_measure>Sustained virological response (SVR) of danoprevir/ritonavir and RO5024048 with Pegasys and Copegus followed by 24 weeks of Pegasys and Copegus treatment in patients with previous null response to peginterferon/ribavirin treatment</outcome_measure>
      <outcome_measure>Safety (Incidence of adverse events) of danoprevir, RO5024048 and Copegus</outcome_measure>
      <outcome_measure>Safety (Incidence of adverse events) of danoprevir, Pegasys and Copegus</outcome_measure>
      <outcome_measure>Safety (Incidence of adverse events) of danoprevir, RO5024048, Pegasys and Copegus</outcome_measure>
      <outcome_measure>Virological response over time</outcome_measure>
      <outcome_measure>Change in danoprevir plasma concentration</outcome_measure>
      <outcome_measure>Change in RO5024048 plasma concentration</outcome_measure>
      <outcome_measure>Hepatitis C virus drug resistance profile</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Mexico</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Louisiana</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oregon</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01331850</url>
  </study>
  <study rank="15">
    <nct_id>NCT00921180</nct_id>
    <title>Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Entecavir and peginterferon alfa-2a</intervention>
      <intervention type="Drug">Placebo and peginterferon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>National Science Council, Taiwan</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>148</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>950922</other_id>
    </other_ids>
    <first_received>June 15, 2009</first_received>
    <start_date>February 2007</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>December 19, 2012</last_updated>
    <last_verified>December 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HBeAg seroconversion rate 6 months after the cessation of therapy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00921180</url>
  </study>
  <study rank="16">
    <nct_id>NCT00800735</nct_id>
    <title>A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated-interferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV21928</other_id>
      <other_id>2008-002022-10</other_id>
    </other_ids>
    <first_received>October 23, 2008</first_received>
    <start_date>April 2009</start_date>
    <completion_date>March 2012</completion_date>
    <last_updated>September 30, 2013</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>July 5, 2013</firstreceived_results_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Who Experienced at Least 1 Adverse Event.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Austria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Maryland</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oregon</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00800735</url>
  </study>
  <study rank="17">
    <nct_id>NCT00491244</nct_id>
    <title>Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-NaÃ¯ve Hemodialysis Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a and ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>National Science Council, Taiwan</collaborator>
      <collaborator>Department of Health, Executive Yuan, R.O.C. (Taiwan)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>377</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>200703010M</other_id>
    </other_ids>
    <first_received>June 23, 2007</first_received>
    <start_date>June 2007</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>January 13, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>September 29, 2013</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR)Rate</outcome_measure>
      <outcome_measure>Adverse Event (AE)-Related Withdrawal Rate</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00491244</url>
  </study>
  <study rank="18">
    <nct_id>NCT00707850</nct_id>
    <title>PegasysÂ® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Thalassemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEGASYSÂ® (Peginterferon Alfa-2a (40KD)) Plus COPEGUSÂ® (Ribavirin)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Baqiyatallah Medical Sciences University</lead_sponsor>
      <collaborator>Baqiyatallah Research Center for Gastroenterology and Liver Diseases</collaborator>
      <collaborator>Tehran Hepatitis Center</collaborator>
      <collaborator>Guilan Research Center for Gastroenterology and Liver Diseases</collaborator>
      <collaborator>Tabriz Research Center for Gastroenterology and Liver Diseases</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>BRCGL-08-06</other_id>
    </other_ids>
    <first_received>June 26, 2008</first_received>
    <start_date>May 2007</start_date>
    <completion_date>September 2009</completion_date>
    <last_updated>August 30, 2010</last_updated>
    <last_verified>September 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Early Virologic Response</outcome_measure>
      <outcome_measure>End of Treatment Response</outcome_measure>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
      <outcome_measure>Rapid Virologic Response</outcome_measure>
      <outcome_measure>Tolerability of drugs for whole therapy period</outcome_measure>
      <outcome_measure>Biochemical response (ALT)</outcome_measure>
      <outcome_measure>Laboratory Parameters</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Iran, Islamic Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00707850</url>
  </study>
  <study rank="19">
    <nct_id>NCT00932971</nct_id>
    <title>HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis D</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-IFN alfa-2a, Tenofovir</intervention>
      <intervention type="Drug">PEG-IFN alfa-2a, placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>HepNet Study House, German Liverfoundation</lead_sponsor>
      <collaborator>Hannover Clinical Trial Center GmbH</collaborator>
      <collaborator>Hoffmann-La Roche</collaborator>
      <collaborator>Gilead Sciences</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>Hep-Net-HIDIT-II</other_id>
      <other_id>EudraCT-No.: 2008-005560-13</other_id>
    </other_ids>
    <first_received>July 3, 2009</first_received>
    <start_date>June 2009</start_date>
    <completion_date>May 2017</completion_date>
    <last_updated>December 3, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HIDIT-II</acronym>
    <primary_completion_date>May 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Negativation of HDV-RNA at the end of therapy</outcome_measure>
      <outcome_measure>Negativation of HDV-RNA at week 48 of treatment</outcome_measure>
      <outcome_measure>Negativation of HDV-RNA 24 weeks after the end of treatment</outcome_measure>
      <outcome_measure>Normalization of ALT levels at the end of treatment and at the end of follow-up</outcome_measure>
      <outcome_measure>HDV-RNA-levels over time</outcome_measure>
      <outcome_measure>Suppression of HBV-DNA below 6 IU/ml using the Cobas TaqMan assay at treatment weeks 48 and 96 and 24 weeks after treatment</outcome_measure>
      <outcome_measure>Liver histology at end of treatment (Ishak score for inflammation and fibrosis)</outcome_measure>
      <outcome_measure>Quantitative HBsAg levels over time. Loss of HBsAg and development of anti-HBs antibodies, intrahepatic cccDNA and HBV-DNA levels over time</outcome_measure>
      <outcome_measure>HBV- and HDV-virus-specific T cell responses during therapy and after 24 weeks of follow up if virological and biochemical efficacy has been shown</outcome_measure>
      <outcome_measure>Virological long-term outcome</outcome_measure>
      <outcome_measure>Clinical long-term outcome</outcome_measure>
      <outcome_measure>Quality of Life</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
      <country>Greece</country>
      <country>Romania</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00932971</url>
  </study>
  <study rank="20">
    <nct_id>NCT01667432</nct_id>
    <title>An Observational Study of Peginterferon Alfa-2a (PEGASYSÂ®) in Patients With HBeAg Positive or HBeAg Negative Chronic Hepatitis B</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>141</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML25626</other_id>
    </other_ids>
    <first_received>August 15, 2012</first_received>
    <start_date>July 2011</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>November 3, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>October 1, 2015</firstreceived_results_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Suppression of HBV DNA to &lt; 2,000 IU/ml at the End of the Study</outcome_measure>
      <outcome_measure>Percentage of Patients With Suppression of HBV DNA &lt; 2,000 IU/ml</outcome_measure>
      <outcome_measure>In HBeAg Positive Patients: Percentage of Patients Who Become HBeAg Negative and Anti-HBe Positive</outcome_measure>
      <outcome_measure>Percentage of Participants With Suppression of HBV DNA to &lt; 80 IU/ml at the End of Treatment</outcome_measure>
      <outcome_measure>HBsAg Clearance: Percentage of Patients Who Become HBsAg Negative</outcome_measure>
      <outcome_measure>Correlation of HBsAg Clearance With Other On-treatment Factors in HBeAg Positive and HBeAg Negative Patients</outcome_measure>
      <outcome_measure>Correlation of HBsAg Clearance With Pre-treatment Factors in HBeAg Positive and HBeAg Negative Patients</outcome_measure>
      <outcome_measure>Incidence of Serum ALT Normalization: Serum ALT/ALT Ratio</outcome_measure>
      <outcome_measure>Safety: Incidence of Adverse Events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Bulgaria</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01667432</url>
  </study>
  <study rank="21">
    <nct_id>NCT01387763</nct_id>
    <title>A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Polycythemia Vera</condition>
      <condition>Essential Thrombocythemia</condition>
      <condition>Primary Myelofibrosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PegIntron</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">PegIntron</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Hydrea</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Thomas Stauffer Larsen</lead_sponsor>
      <collaborator>Odense University Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>daliah2011</other_id>
    </other_ids>
    <first_received>June 23, 2011</first_received>
    <start_date>January 2012</start_date>
    <completion_date>January 2020</completion_date>
    <last_updated>April 20, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>DALIAH</acronym>
    <primary_completion_date>January 2020</primary_completion_date>
    <outcome_measures>
      <outcome_measure>molecular response (changes from baseline)</outcome_measure>
      <outcome_measure>toxicity (discontinuation of therapy due to intolerability)</outcome_measure>
      <outcome_measure>Quality of life (changes from baseline)</outcome_measure>
      <outcome_measure>Histopathological response (changes from baseline)</outcome_measure>
      <outcome_measure>Sustained molecular response (changes from level at time of discontinuation of therapy)</outcome_measure>
      <outcome_measure>Neutralizing antibodies against PegIntron and Pegasys</outcome_measure>
      <outcome_measure>hematological response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Denmark</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01387763</url>
  </study>
  <study rank="22">
    <nct_id>NCT01225380</nct_id>
    <title>A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, PegasysÂ® and CopegusÂ® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GS-9190</intervention>
      <intervention type="Drug">GS-9256</intervention>
      <intervention type="Biological">PegasysÂ®</intervention>
      <intervention type="Drug">CopegusÂ®</intervention>
      <intervention type="Drug">GS-9190 placebo</intervention>
      <intervention type="Drug">GS-9256</intervention>
      <intervention type="Biological">PegasysÂ®</intervention>
      <intervention type="Drug">CopegusÂ®</intervention>
      <intervention type="Drug">GS-9190 placebo</intervention>
      <intervention type="Drug">GS-9256 placebo</intervention>
      <intervention type="Biological">PegasysÂ®</intervention>
      <intervention type="Drug">CopegusÂ®</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>324</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-196-0123</other_id>
    </other_ids>
    <first_received>October 18, 2010</first_received>
    <start_date>October 2010</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>December 20, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR) defined as undetectable HCV RNA 24 weeks after treatment cessation</outcome_measure>
      <outcome_measure>Safety and tolerability of therapy as measured by frequency of laboratory abnormalities, reported adverse events, and discontinuations due to adverse events</outcome_measure>
      <outcome_measure>Emergence of viral resistance following initiation of therapy with GS-9190 and GS-9256</outcome_measure>
      <outcome_measure>Viral dynamics and steady state pharmacokinetics of GS-9190 and GS-9256 when administered in combination with PEG and RBV; measured by HCV RNA levels and plasma concentrations of GS-9190 and GS-9256 over time</outcome_measure>
      <outcome_measure>Long-term assessment of plasma HCV RNA in subjects who achieve SVR</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Czech Republic</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01225380</url>
  </study>
  <study rank="23">
    <nct_id>NCT02573025</nct_id>
    <title>A Bioequivalence Study of Peginterferon (PEG-IFN) Alfa-2a Benzyl Alcohol (BA)-Free Formulation Versus PEG-IFN Alfa-2a (PegasysÂ®) Following Subcutaneous Administration</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-IFN alfa-2a BA-free formulation</intervention>
      <intervention type="Drug">PEG-IFN alfa-2a market formulation</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>277</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Bio-equivalence Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>YV29573</other_id>
    </other_ids>
    <first_received>October 8, 2015</first_received>
    <start_date>September 2015</start_date>
    <completion_date>April 2016</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Observed maximum concentration (Cmax) for PEG-IFN alfa-2a</outcome_measure>
      <outcome_measure>Area under the concentration-time curve (AUC) for PEG-IFN alfa-2a from time zero to 816 hours (AUC0-816h)</outcome_measure>
      <outcome_measure>Area under the concentration-time curve for PEG-IFN alfa-2a from time zero extrapolated to infinity (AUC0-inf)</outcome_measure>
      <outcome_measure>Time to reach Cmax (tmax) for PEG-IFN alfa-2a</outcome_measure>
      <outcome_measure>Terminal half-life (tÂ½) for PEG-IFN alfa-2a</outcome_measure>
      <outcome_measure>Percentage of participants with adverse events</outcome_measure>
      <outcome_measure>Number of participants with clinically significant vital signs assessments</outcome_measure>
      <outcome_measure>Number of participants with clinically significant laboratory assessments</outcome_measure>
      <outcome_measure>Electrocardiogram (ECG) assessment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
      <country>Hong Kong</country>
      <country>New Zealand</country>
      <country>Singapore</country>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02573025</url>
  </study>
  <study rank="24">
    <nct_id>NCT01479868</nct_id>
    <title>A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Virus Genotype-1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Pegylated interferon alpha-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>109</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR018334</other_id>
      <other_id>TMC435-TiDP16-C212</other_id>
    </other_ids>
    <first_received>October 18, 2011</first_received>
    <start_date>October 2011</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>October 28, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>August 26, 2014</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 12 (SVR 12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 24 (SVR 24)</outcome_measure>
      <outcome_measure>Percentage of Participants With Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Less Than (&lt;) 25 International Units (IU/mL) Undetectable or Detectable/Undetectable</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Failure</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants With Normalized Alanine Aminotransferase Levels</outcome_measure>
      <outcome_measure>Percentage of Human Immunodeficiency Virus (HIV) Participants With Virologic Failure</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Log10 Plasma Human Immunodeficiency Virus (HIV) Viral Load</outcome_measure>
      <outcome_measure>Mean Change From Baseline in CD4+ Cell Count</outcome_measure>
      <outcome_measure>Change From Baseline in CD4+ Cell Count in Percentage</outcome_measure>
      <outcome_measure>Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>France</country>
      <country>Germany</country>
      <country>Portugal</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01479868</url>
  </study>
  <study rank="25">
    <nct_id>NCT00623428</nct_id>
    <title>A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>235</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MV21371</other_id>
      <other_id>2007-004993-15</other_id>
    </other_ids>
    <first_received>February 18, 2008</first_received>
    <start_date>June 2008</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>July 15, 2013</last_updated>
    <last_verified>July 2013</last_verified>
    <firstreceived_results_date>May 2, 2013</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With a Sustained Virologic Response 24 Weeks After Scheduled Completion of Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With a Sustained Virologic Response 24 Weeks After Actual End of Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Virological Response 72 Weeks After Treatment Initiation</outcome_measure>
      <outcome_measure>Percentage of Participants With Virological Response at End of Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Virological Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants With a Sustained Virologic Response 12 Weeks After Actual End of Treatment</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events (AEs)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>Germany</country>
      <country>Mexico</country>
      <country>Puerto Rico</country>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Louisiana</state>
      <state>Massachusetts</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00623428</url>
  </study>
  <study rank="26">
    <nct_id>NCT01271790</nct_id>
    <title>A Study of Response-Guided Duration of Combination Therapy With GS-9451, PegasysÂ® and CopegusÂ® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tegobuvir (GS-9190)</intervention>
      <intervention type="Drug">GS-9451</intervention>
      <intervention type="Biological">PegasysÂ®</intervention>
      <intervention type="Drug">CopegusÂ®</intervention>
      <intervention type="Drug">GS-9451</intervention>
      <intervention type="Drug">Tegobuvir placebo</intervention>
      <intervention type="Biological">PegasysÂ®</intervention>
      <intervention type="Drug">CopegusÂ®</intervention>
      <intervention type="Drug">Tegobuvir placebo</intervention>
      <intervention type="Drug">GS-9451 placebo</intervention>
      <intervention type="Biological">PegasysÂ®</intervention>
      <intervention type="Drug">CopegusÂ®</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>245</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-196-0140</other_id>
    </other_ids>
    <first_received>January 5, 2011</first_received>
    <start_date>October 2010</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>January 8, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response</outcome_measure>
      <outcome_measure>Safety and tolerability of therapy</outcome_measure>
      <outcome_measure>Emergence of viral resistance following initiation of therapy with GS 9190 and GS 9451</outcome_measure>
      <outcome_measure>Viral dynamics and steady state pharmacokinetics</outcome_measure>
      <outcome_measure>Durability of response in subjects who achieve SVR</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01271790</url>
  </study>
  <study rank="27">
    <nct_id>NCT02570191</nct_id>
    <title>A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML18092</other_id>
    </other_ids>
    <first_received>October 5, 2015</first_received>
    <start_date>November 2004</start_date>
    <completion_date>February 2007</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy: Hepatitis B Virus - Deoxy ribonucleic acid (HBV-DNA) less than (&lt;)20,000 Copies per milliliter (copies/mL) At End of Follow-Up</outcome_measure>
      <outcome_measure>Alanine Transaminase (ALT) Normalization at the End of Follow-Up</outcome_measure>
      <outcome_measure>Efficacy: Loss of Hepatitis B Virus Antigen ( HBsAg) and Seroconversion at End of Follow-Up</outcome_measure>
      <outcome_measure>Hepatitis B Virus (HBV) DNA Below the Limit of Quantification At the End of Follow-Up</outcome_measure>
      <outcome_measure>HBV DNA Suppression &lt;20000 Copies/mL at the End of Treatment</outcome_measure>
      <outcome_measure>Alanine Transaminase (ALT) Normalization at the End of Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Bulgaria</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02570191</url>
  </study>
  <study rank="28">
    <nct_id>NCT02598063</nct_id>
    <title>A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Adefovir dipivoxil</intervention>
      <intervention type="Drug">Lamivudine</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>255</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML18376</other_id>
    </other_ids>
    <first_received>November 4, 2015</first_received>
    <start_date>October 2005</start_date>
    <completion_date>April 2009</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HBeAg seroconversion (defined as loss of HBeAg and presence of anti-HBe) at Week 72</outcome_measure>
      <outcome_measure>Loss of HBeAg</outcome_measure>
      <outcome_measure>Reduction in hepatitis B virus deoxyribonucleic acid (HBV DNA)</outcome_measure>
      <outcome_measure>Alanine transaminase (ALT) normalization</outcome_measure>
      <outcome_measure>Hepatitis B surface antigen (HBsAg) seroconversion</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
      <country>Hong Kong</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02598063</url>
  </study>
  <study rank="29">
    <nct_id>NCT02604823</nct_id>
    <title>A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>307</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML17700</other_id>
    </other_ids>
    <first_received>November 4, 2015</first_received>
    <start_date>November 2003</start_date>
    <completion_date>November 2005</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2005</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants with HBV deoxyribonucleic acid (DNA) less than (&lt;) 100,000 copies per milliliters (copies/mL)</outcome_measure>
      <outcome_measure>Percentage of participants with HBeAg seroconversion</outcome_measure>
      <outcome_measure>Number of participants who achieved HBV DNA levels below limit of detection</outcome_measure>
      <outcome_measure>Number of participants with HBsAg loss</outcome_measure>
      <outcome_measure>Number of participants with both Hepatitis B Surface Antigen (HBsAg) loss and presence of Anti-HBs</outcome_measure>
      <outcome_measure>Number of participants with alanine aminotransferase (ALT) normalization</outcome_measure>
      <outcome_measure>Number of participants with combined response (HBV DNA &lt;100,000 copies/mL, HBeAg loss, and ALT normalization)</outcome_measure>
      <outcome_measure>Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02604823</url>
  </study>
  <study rank="30">
    <nct_id>NCT00627926</nct_id>
    <title>A Phase 3 Study of Telaprevir in Combination With PegasysÂ® and CopegusÂ® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated Interferon Alfa 2a</intervention>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
      <collaborator>Tibotec Pharmaceutical Limited</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1095</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX07-950-108</other_id>
    </other_ids>
    <first_received>February 22, 2008</first_received>
    <start_date>March 2008</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>July 16, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>June 22, 2011</firstreceived_results_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels 24 Weeks After Last Planned Dose of Study Treatment</outcome_measure>
      <outcome_measure>Number of Subjects With Undetectable HCV RNA at Week 72</outcome_measure>
      <outcome_measure>Number of Subjects Achieving Rapid Viral Response (RVR), Demonstrated by Achieving Undetectable HCV RNA 4 Weeks After Starting Study Treatment</outcome_measure>
      <outcome_measure>Number of Subjects Achieving Extended Rapid Viral Response (eRVR), Demonstrated by Achieving Undetectable HCV RNA at Week 4 and at Week 12</outcome_measure>
      <outcome_measure>Number of Subjects With Undetectable HCV RNA at Week 12</outcome_measure>
      <outcome_measure>Number of Subjects With Undetectable HCV RNA at End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Number of Subjects With Undetectable HCV RNA 12 Weeks After Last Planned Dose of Study Treatment</outcome_measure>
      <outcome_measure>Number of Subjects With Undetectable HCV RNA 24 Weeks After Last Actual Dose of Study Treatment</outcome_measure>
      <outcome_measure>Number of Subjects With Viral Relapse Planned and Viral Relapse Actual</outcome_measure>
      <outcome_measure>Biochemical Response: Number of Subjects With Grade 3 and 4 Shifts From Baseline in Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Levels</outcome_measure>
      <outcome_measure>Noninvasive Markers of Fibrosis: Number of Subjects With Improvement in FibroTest Analysis</outcome_measure>
      <outcome_measure>Fatigue Severity Scale (FSS) Total Score</outcome_measure>
      <outcome_measure>Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maine</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00627926</url>
  </study>
  <study rank="31">
    <nct_id>NCT01311947</nct_id>
    <title>Hepatitis B Virus Mutants and the Therapeutic Effect of Peginterferon Alfa-2a in HBeAg-Positive Chronic Hepatitis B</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>China Medical University Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>103</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>DMR99-IRB-313</other_id>
    </other_ids>
    <first_received>March 8, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>March 2012</completion_date>
    <last_updated>July 29, 2013</last_updated>
    <last_verified>July 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Therapeutic response to Peginterferon Alfa-2a in HBeAg-Positive Chronic Hepatitis B</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01311947</url>
  </study>
  <study rank="32">
    <nct_id>NCT01428063</nct_id>
    <title>Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Participants in Some Hepatitis C Virus (HCV) Trials</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Asunaprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>228</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-026</other_id>
      <other_id>2011-000836-27</other_id>
    </other_ids>
    <first_received>September 1, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>February 6, 2015</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy based on the proportion of subjects with Sustained virologic response (SVR)12 [HCV Ribonucleic acid (RNA) &lt; LOQ at Follow-up week 12] for all subjects infected with genotype 1 who are prior non-responders to Peginterferon Alfa-2a/Ribavirin</outcome_measure>
      <outcome_measure>Efficacy as determined by the proportion of subjects with SVR12 in genotype 2, 3 &amp; 4 prior non-responders to pegIFNÎ±-2a/RBV and treatment naive genotype 1b</outcome_measure>
      <outcome_measure>Safety measured by frequency of Serious Adverse Event(s) (SAE)s and discontinuations due to Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve HCV RNA &lt; Limit of quantitation (LOQ) (detectable or undetectable) for each HCV genotype and treatment regimen</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve HCV RNA undetectable for each HCV genotype and treatment regimen</outcome_measure>
      <outcome_measure>Drug-resistant variants associated with virologic failure for each HCV genotype and treatment regimen</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>Ireland</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>Mexico</country>
      <country>New Zealand</country>
      <country>Poland</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>Taiwan</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01428063</url>
  </study>
  <study rank="33">
    <nct_id>NCT00641654</nct_id>
    <title>Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and Ribavirin</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa-2a and ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a and ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GÃ¶teborg University</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>EudractCT 2006-003409-18</other_id>
    </other_ids>
    <first_received>March 17, 2008</first_received>
    <start_date>January 2007</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>August 29, 2012</last_updated>
    <last_verified>March 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>RelapC</acronym>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained viral response (SVR) rate defined as percentage of patients with non-detectable HCV-RNA 24 weeks after completion of the 24 or 48 week treatment period.</outcome_measure>
      <outcome_measure>Sustained viral response (SVR)rate and percentage of patients with normal serum ALT levels and its association with prespecified factors e.g. viral load</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00641654</url>
  </study>
  <study rank="34">
    <nct_id>NCT00420784</nct_id>
    <title>A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated Interferon Alfa 2a</intervention>
      <intervention type="Drug">Matching Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>465</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX06-950-106</other_id>
    </other_ids>
    <first_received>January 8, 2007</first_received>
    <start_date>February 2007</start_date>
    <completion_date>April 2009</completion_date>
    <last_updated>July 9, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>June 22, 2011</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Study Drug Dosing</outcome_measure>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma HCV RNA at Completion of Study Drug Dosing</outcome_measure>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma HCV RNA</outcome_measure>
      <outcome_measure>Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Number of Subjects With Viral Relapse</outcome_measure>
      <outcome_measure>Maximum (Cmax), Minimum (Cmin) and Average (Cavg) Plasma Concentration of Telaprevir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Germany</country>
      <country>Netherlands</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maine</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00420784</url>
  </study>
  <study rank="35">
    <nct_id>NCT01531166</nct_id>
    <title>A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated Interferon-alpha 2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Yonsei University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>4-2011-0461</other_id>
    </other_ids>
    <first_received>January 31, 2012</first_received>
    <start_date>January 2012</start_date>
    <completion_date>January 2015</completion_date>
    <last_updated>February 22, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HBsAg loss or appearance of anti-HBs antibody in treatment-naÃ¯ve Korean CHB patients treated with Pegasys</outcome_measure>
      <outcome_measure>Sustained suppression of HBV DNA</outcome_measure>
      <outcome_measure>HBeAg loss and seroconversion in HBeAg-positive CHB</outcome_measure>
      <outcome_measure>ALT normalization</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Korea, Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01531166</url>
  </study>
  <study rank="36">
    <nct_id>NCT00452023</nct_id>
    <title>PegasysÂ® in Patients With Myeloproliferative Diseases</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Myeloproliferative Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">IFN-alpha2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>M.D. Anderson Cancer Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>280</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>DM03-0109</other_id>
      <other_id>NCI-2012-01474</other_id>
    </other_ids>
    <first_received>March 22, 2007</first_received>
    <start_date>April 2005</start_date>
    <last_updated>November 18, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Patients with Complete Response (CR) or Partial Response (PR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00452023</url>
  </study>
  <study rank="37">
    <nct_id>NCT02576964</nct_id>
    <title>A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Carcinoma, Hepatocellular</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Capecitabine</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML18269</other_id>
    </other_ids>
    <first_received>October 14, 2015</first_received>
    <start_date>January 2005</start_date>
    <completion_date>November 2008</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Objective response rate</outcome_measure>
      <outcome_measure>Time to disease progression</outcome_measure>
      <outcome_measure>Duration of response</outcome_measure>
      <outcome_measure>Overall survival</outcome_measure>
      <outcome_measure>Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
      <country>Taiwan</country>
      <country>Thailand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02576964</url>
  </study>
  <study rank="38">
    <nct_id>NCT00800748</nct_id>
    <title>A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>373</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML19387</other_id>
      <other_id>2005-003932-23</other_id>
    </other_ids>
    <first_received>December 1, 2008</first_received>
    <start_date>January 2006</start_date>
    <completion_date>August 2010</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Incidence of adverse events</outcome_measure>
      <outcome_measure>Percentage of participants with sustained viral response</outcome_measure>
      <outcome_measure>Percentage of participants with viral response rate</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Czech Republic</country>
      <country>Slovakia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00800748</url>
  </study>
  <study rank="39">
    <nct_id>NCT00854802</nct_id>
    <title>A Study of Debio 025 (Alisporivir) Combined With Peg-IFNÎ±2a and Ribavirin in Treatment naÃ¯ve Chronic Hepatitis C Genotype 1 Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Debio 025</intervention>
      <intervention type="Drug">Peg-IFNÎ±2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Debio 025 placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Debiopharm International SA</lead_sponsor>
      <collaborator>Parexel</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>290</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>Debio 025-HCV-205</other_id>
      <other_id>2008-004605-34</other_id>
    </other_ids>
    <first_received>March 2, 2009</first_received>
    <start_date>January 2009</start_date>
    <completion_date>September 2010</completion_date>
    <last_updated>January 13, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants achieving sustained viral response (SVR) 72 weeks after treatment start</outcome_measure>
      <outcome_measure>Percentage of participants achieving a rapid viral response (RVR) after 4 weeks of treatment</outcome_measure>
      <outcome_measure>Percentage of participants achieving a complete early viral response (cEVR) after 12 weeks of treatment</outcome_measure>
      <outcome_measure>Percentage of participants achieving an early viral response (EVR) after 12 weeks of treatment</outcome_measure>
      <outcome_measure>Percentage of participants achieving an end-of-treatment response (ETR) at treatment end</outcome_measure>
      <outcome_measure>Percentage of participants achieving a sustained viral response 12 weeks after the end of treatment (SVR 12)</outcome_measure>
      <outcome_measure>Percentage of participants with sustained viral response 24 weeks after the end of treatment (SVR 24)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Romania</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00854802</url>
  </study>
  <study rank="40">
    <nct_id>NCT00336479</nct_id>
    <title>Phase 2 Study of VX-950, PegasysÂ®, and CopegusÂ® in Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated Interferon Alfa 2a</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>263</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX05-950-104</other_id>
    </other_ids>
    <first_received>June 9, 2006</first_received>
    <start_date>June 2006</start_date>
    <completion_date>February 2008</completion_date>
    <last_updated>June 25, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>June 22, 2011</firstreceived_results_date>
    <primary_completion_date>February 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Study Drug Dosing</outcome_measure>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma HCV RNA at Week 12 After the Completion of Study Drug Dosing</outcome_measure>
      <outcome_measure>Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Number of Subjects With Viral Relapse</outcome_measure>
      <outcome_measure>Maximum (Cmax), Minimum (Cmin) and Average (Cavg) Plasma Concentration of Telaprevir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00336479</url>
  </study>
  <study rank="41">
    <nct_id>NCT00207311</nct_id>
    <title>Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Fatty Liver</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Xenical, Pegasys, Copegus</intervention>
      <intervention type="Behavioral">Xenicare Program</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Brooke Army Medical Center</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
      <collaborator>The Geneva Foundation</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>C.2004.140</other_id>
    </other_ids>
    <first_received>September 13, 2005</first_received>
    <start_date>August 2005</start_date>
    <completion_date>May 2009</completion_date>
    <last_updated>February 13, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HCVNASH</acronym>
    <primary_completion_date>May 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR) defined as the percentage of participants with undetectable HCV-RNA as measured by the Roche AMPLICORTM HCV Test, v 2.0 (detection limit 50 IU/mL) at 24 weeks post completion of the treatment period</outcome_measure>
      <outcome_measure>Hepatic steatosis, necroinflammatory activity and fibrosis improvement at week 36 as determined by Dr. Elizabeth Brunt at Saint Louis University</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00207311</url>
  </study>
  <study rank="42">
    <nct_id>NCT00394277</nct_id>
    <title>A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>1175</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV18210</other_id>
    </other_ids>
    <first_received>October 30, 2006</first_received>
    <start_date>February 2007</start_date>
    <completion_date>April 2009</completion_date>
    <last_updated>July 30, 2010</last_updated>
    <last_verified>July 2010</last_verified>
    <firstreceived_results_date>May 27, 2010</firstreceived_results_date>
    <primary_completion_date>April 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virological Response (SVR)-24 (Scheduled Treatment Period)</outcome_measure>
      <outcome_measure>SVR-24 (Actual Treatment Period)</outcome_measure>
      <outcome_measure>SVR-12 (Scheduled Treatment Period)</outcome_measure>
      <outcome_measure>SVR-12 (Actual Treatment Period)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Germany</country>
      <country>Hungary</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Sweden</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Alaska</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Iowa</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
      <state>Wyoming</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00394277</url>
  </study>
  <study rank="43">
    <nct_id>NCT01006031</nct_id>
    <title>Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Liver Cirrhosis</condition>
      <condition>Hepatitis C Virus</condition>
      <condition>HIV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa-2a and Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Sociedad Andaluza de Enfermedades Infecciosas</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HEPAVIR_IFN_2009</other_id>
    </other_ids>
    <first_received>October 29, 2009</first_received>
    <start_date>October 2009</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>December 28, 2011</last_updated>
    <last_verified>December 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained viral response (undetectable serum HCV-RNA)</outcome_measure>
      <outcome_measure>Relationships between the plasma interferon an ribavirin concentrations and efficacy</outcome_measure>
      <outcome_measure>safety and tolerability of the studied medications</outcome_measure>
      <outcome_measure>The evolution of liver fibrosis will be evaluated comparing the basal and end of treatment results of transient elastometry</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01006031</url>
  </study>
  <study rank="44">
    <nct_id>NCT00077649</nct_id>
    <title>A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>188</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV17318</other_id>
    </other_ids>
    <first_received>February 10, 2004</first_received>
    <start_date>January 2004</start_date>
    <completion_date>April 2006</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Viral response compared to baseline\n</outcome_measure>
      <outcome_measure>SVR and end of treatment virological response\n\n</outcome_measure>
      <outcome_measure>Virological response</outcome_measure>
      <outcome_measure>AEs, laboratory parameters, vital signs, Beck Depression Inventory</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Iowa</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00077649</url>
  </study>
  <study rank="45">
    <nct_id>NCT00353418</nct_id>
    <title>A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>415</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV18209</other_id>
    </other_ids>
    <first_received>July 17, 2006</first_received>
    <start_date>June 2006</start_date>
    <completion_date>April 2009</completion_date>
    <last_updated>July 30, 2010</last_updated>
    <last_verified>July 2010</last_verified>
    <firstreceived_results_date>May 14, 2010</firstreceived_results_date>
    <primary_completion_date>April 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virological Response (SVR)</outcome_measure>
      <outcome_measure>Incidence of Adverse Events, Dose Reductions and Withdrawals Due to Anemia</outcome_measure>
      <outcome_measure>Virological Response at End of Treatment Period</outcome_measure>
      <outcome_measure>Virological Response at Weeks 4, 12 and 24</outcome_measure>
      <outcome_measure>Relapse of Virological Response</outcome_measure>
      <outcome_measure>Rapid Virological Response (RVR) by Week 4</outcome_measure>
      <outcome_measure>Early Virological Response (EVR), Partial EVR and Complete EVR by Week 12</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00353418</url>
  </study>
  <study rank="46">
    <nct_id>NCT01220596</nct_id>
    <title>Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepatitis B.</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Entecavir and Pegylated interferon Î±-2a Sequential Treatment Group</intervention>
      <intervention type="Drug">Pegylated interferon Î±-2a Monotreatment Group</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hanyang University</lead_sponsor>
      <collaborator>Roche Pharma AG</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>228</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML25206</other_id>
    </other_ids>
    <first_received>October 13, 2010</first_received>
    <start_date>June 2010</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>July 1, 2011</last_updated>
    <last_verified>June 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>POTENT</acronym>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HBeAg seroconversion</outcome_measure>
      <outcome_measure>the change of HBsAg titer</outcome_measure>
      <outcome_measure>the rate of combined HBeAg seroconversion and HBV DNA &lt; 300 copies/ml</outcome_measure>
      <outcome_measure>The rate of serum HBV DNA &lt; 300 copies</outcome_measure>
      <outcome_measure>The rate of ALT normalization</outcome_measure>
      <outcome_measure>The rate of HBsAg loss</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Korea, Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01220596</url>
  </study>
  <study rank="47">
    <nct_id>NCT01853254</nct_id>
    <title>A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>272</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV17590</other_id>
    </other_ids>
    <first_received>May 10, 2013</first_received>
    <start_date>September 2003</start_date>
    <completion_date>September 2011</completion_date>
    <last_updated>June 25, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>June 25, 2013</firstreceived_results_date>
    <primary_completion_date>September 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With at Least 1 Adverse Event</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Greece</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>Taiwan</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Idaho</state>
      <state>Indiana</state>
      <state>Iowa</state>
      <state>Kansas</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Minnesota</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01853254</url>
  </study>
  <study rank="48">
    <nct_id>NCT02263079</nct_id>
    <title>An Open-label Study of Pegasys in Combination With Lamivudine in Children With HBeAg-positive Chronic Hepatitis B in the Immune-Tolerant Phase</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lamivudine</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>114</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV25361</other_id>
      <other_id>2006-000977-31</other_id>
    </other_ids>
    <first_received>October 2, 2014</first_received>
    <start_date>December 2014</start_date>
    <completion_date>January 2024</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2024</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients with HBsAg loss at 24 weeks post-end of treatment (follow-up Week 24)/end of untreated observation (Week 80)</outcome_measure>
      <outcome_measure>Proportion of patients with HBeAg loss</outcome_measure>
      <outcome_measure>Proportion of patients with seroconversion to anti-HBs (loss of HBsAg and presence of anti-HBs)</outcome_measure>
      <outcome_measure>Proportion of patients with seroconversion to anti-HBe (loss of HBeAg and presence of anti-HBe)</outcome_measure>
      <outcome_measure>Composite outcome measure: Proportion of patients with HBV DNA levels: &lt; 10^5 IU/ml, &lt;10^4 IU/ml, undetectable; change from baseline in HBV DNA levels (by PCR or hybridization)</outcome_measure>
      <outcome_measure>Proportion of patients with HBeAg seroconversion and HBV DNA &lt;10^5 copies/ml (&lt;20,000 IU/ml) (composite outcome measure)</outcome_measure>
      <outcome_measure>Proportion of patients with HBeAg seroconversion and HBV DNA &lt;10^4 copies/ml (&lt;2,000 IU/ml) (composite outcome measure)</outcome_measure>
      <outcome_measure>Safety (composite outcome measure): incidence, nature, and severity of serious and non-serious adverse events (AEs);reasons for the discontinuation of any study medication;dose modifications;changes in vital signs / laboratory tests;effect on growth</outcome_measure>
      <outcome_measure>Safety (composite outcome measure): incidence, nature, and severity of persisting AEs, new-onset SAEs/non-serious AEs of special interest;changes in thyroid function from screening/baseline;effect on growth</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Belgium</country>
      <country>Dominican Republic</country>
      <country>Egypt</country>
      <country>Germany</country>
      <country>Guatemala</country>
      <country>India</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Taiwan</country>
      <country>Turkey</country>
      <country>Ukraine</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Missouri</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02263079</url>
  </study>
  <study rank="49">
    <nct_id>NCT01846832</nct_id>
    <title>A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a (PegIFNÎ±-2a)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen-Cilag International NV</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>232</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100981</other_id>
      <other_id>TMC435HPC3014</other_id>
      <other_id>2012-004905-29</other_id>
    </other_ids>
    <first_received>May 1, 2013</first_received>
    <start_date>September 2013</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>October 16, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The proportion (percentage) of participants infected wtih genotype 1 HCV with a sustained virologic response 12 weeks after planned end of treatment (SVR12)</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants infected wtih genotype 4 HCV with a sustained virologic response 12 weeks after planned end of treatment (SVR12)</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants who achieve rapid virologic response (RVR)</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants who achieve virologic response at Week 2 (W2VR)</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants with sustained virologic response 24 weeks after planned end of treatment (SVR24)</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants with sustained virologic response 12 weeks after planned end of treatment (SVR12)</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants with &gt; or = 2 log decrease in hepatitis C virus (HCV) RNA at each time point</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants with hepatitis C virus (HCV) RNA &lt; 25 IU/mL undetectable at each time point</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants with viral breakthrough</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants with viral relapse</outcome_measure>
      <outcome_measure>Change from Baseline in the Hepatitis C Treatment Symptom &amp; Impact Questionnaire (HCV SIQ) symptom and impact scores</outcome_measure>
      <outcome_measure>Change from Baseline in The Fatigue Severity Scale (FSS) total score</outcome_measure>
      <outcome_measure>Change from Baseline in The Center for Epidemiologic Studies Depression Scale (CES-D) score</outcome_measure>
      <outcome_measure>Change from Baseline in The Work Productivity and Activity Index (WPAI) for Hepatitis C missed work time, daily activity impairment, and productivity scores</outcome_measure>
      <outcome_measure>Change from Baseline in The EuroQol 5 Dimension (EQ5D) Visual Analog Scale (VAS) valuation index, and Descriptive System scores</outcome_measure>
      <outcome_measure>The proportion (percentage) of participants with normalized alanine aminotransferase (ALT) levels</outcome_measure>
      <outcome_measure>Change from Screening in liver disease stage assessment</outcome_measure>
      <outcome_measure>The number of participants reporting adverse events as a measure of safety and tolerability</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Saudi Arabia</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01846832</url>
  </study>
  <study rank="50">
    <nct_id>NCT00495131</nct_id>
    <title>Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa-2a plus ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a plus ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>National Science Council, Taiwan</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>308</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>200705080M</other_id>
    </other_ids>
    <first_received>June 29, 2007</first_received>
    <start_date>June 2006</start_date>
    <completion_date>July 2008</completion_date>
    <last_updated>September 7, 2009</last_updated>
    <last_verified>September 2009</last_verified>
    <firstreceived_results_date>December 21, 2008</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
      <outcome_measure>Sustained Biochemical Response</outcome_measure>
      <outcome_measure>Treatment-related Withdrawal Rate</outcome_measure>
      <outcome_measure>Histologic Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00495131</url>
  </study>
  <study rank="51">
    <nct_id>NCT00336518</nct_id>
    <title>Continuing Treatment With Pegasys and Copegus</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>MÃ¡jbetegekÃ©rt AlapÃ­tvÃ¡ny</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MBA 1/2005</other_id>
      <other_id>ML 20142</other_id>
      <other_id>EuDract: 2005-004531-22</other_id>
    </other_ids>
    <first_received>June 12, 2006</first_received>
    <start_date>June 2006</start_date>
    <completion_date>July 2009</completion_date>
    <last_updated>June 12, 2006</last_updated>
    <last_verified>August 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Sustained viral response given to continuation or prolongation of combined Pegasys&amp;Copegus treatment</outcome_measure>
      <outcome_measure>Histological response given to continuation or prolongation of combined Pegasys&amp;Copegus treatment measured by non-invasive methods</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Hungary</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00336518</url>
  </study>
  <study rank="52">
    <nct_id>NCT02097004</nct_id>
    <title>Study of Therapeutic Vaccination With Intensified Schedule Plus Pegasys Dual Therapy on Chronic Hepatitis B Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2a</intervention>
      <intervention type="Biological">HBV vaccination</intervention>
      <intervention type="Drug">Entecavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Seoul National University Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>E+VIP</other_id>
    </other_ids>
    <first_received>March 23, 2014</first_received>
    <start_date>April 2014</start_date>
    <completion_date>March 2017</completion_date>
    <last_updated>August 2, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>E+VIP</acronym>
    <primary_completion_date>March 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The rate of HBsAg-seroclearance</outcome_measure>
      <outcome_measure>The rate of HBsAg-seroconversion</outcome_measure>
      <outcome_measure>The Change of HBsAg level from baseline</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Korea, Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02097004</url>
  </study>
  <study rank="53">
    <nct_id>NCT01925820</nct_id>
    <title>Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegasys&amp;Entecavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>Roche Pharma AG</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>540</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>201205003MPC</other_id>
    </other_ids>
    <first_received>August 16, 2013</first_received>
    <start_date>January 2013</start_date>
    <last_updated>December 3, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Simultaneous achievement of HBsAg below 100 IU/mL and HBV DNA&lt;300 IU/mL</outcome_measure>
      <outcome_measure>serum HBV DNA &lt;2000 IU/mL,HBsAg &lt;1000 IU/mL,ALT normalization,HBsAg loss,entecavir resistance, HBsAg seroconversion,Fibrosis stages</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01925820</url>
  </study>
  <study rank="54">
    <nct_id>NCT00136318</nct_id>
    <title>Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Depression</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Escitalopram</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Charite University, Berlin, Germany</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>208</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
      <study_design>Masking: Double Blind (Subject, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML18075</other_id>
    </other_ids>
    <first_received>August 26, 2005</first_received>
    <start_date>January 2004</start_date>
    <completion_date>September 2008</completion_date>
    <last_updated>March 20, 2013</last_updated>
    <last_verified>March 2013</last_verified>
    <firstreceived_results_date>October 25, 2012</firstreceived_results_date>
    <acronym>CIPPAD</acronym>
    <primary_completion_date>September 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Montgomery Asberg Depression Scale (MADRS) With a Score of 13 or Higher</outcome_measure>
      <outcome_measure>Proportion of Patients Without Depression (Defined as a MADRS Score of 13 or Higher)</outcome_measure>
      <outcome_measure>Incidence of Major Depression Defined by Diagnostic and Statistical Manual IV (DSM-IV) Criteria</outcome_measure>
      <outcome_measure>Severe Depression Defined as a MADRS Score of 25 or Higher</outcome_measure>
      <outcome_measure>Health Related Quality of Life (HRQOL) Measured by the Short Form 36 (SF-36)</outcome_measure>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
      <outcome_measure>Tolerability</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00136318</url>
  </study>
  <study rank="55">
    <nct_id>NCT00435825</nct_id>
    <title>A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>551</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>WV19432</other_id>
    </other_ids>
    <first_received>February 15, 2007</first_received>
    <start_date>March 2007</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>June 19, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>March 20, 2013</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Hepatitis Be Antigen (HBeAg) Seroconversion 24 Weeks Following End of Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Hepatitis Be Antigen (HBeAg) Seroconversion at Week 72</outcome_measure>
      <outcome_measure>Percentage of Participants With Loss of Hepatitis Be Antigen (HBeAg) 24 Weeks Following End of Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Seroconversion 24 Weeks Following the End of Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Loss of Hepatitis B Surface Antigen (HBsAg) 24 Weeks Following End of Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Normal Alanine Aminotransferase (ALT)</outcome_measure>
      <outcome_measure>Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) Suppression &lt; 20,000 IU/mL 24 Weeks Following End of Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Hepatitis Deoxyribonucleic Acid (HBV-DNA) Suppression &lt; 2,000 IU/mL 24 Weeks Following End of Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Combined Endpoint Response 24 Weeks Following End of Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Dual Endpoint Response 24 Weeks Following End of Treatment</outcome_measure>
      <outcome_measure>Quantitative Serum Alanine Aminotransferase (ALT) 24 Weeks Following End of Treatment</outcome_measure>
      <outcome_measure>Quantitative HBV-DNA 24 Weeks Following End of Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>Brazil</country>
      <country>China</country>
      <country>France</country>
      <country>Germany</country>
      <country>Hong Kong</country>
      <country>Korea, Republic of</country>
      <country>New Zealand</country>
      <country>Russian Federation</country>
      <country>Singapore</country>
      <country>Taiwan</country>
      <country>Thailand</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Georgia</state>
      <state>New York</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00435825</url>
  </study>
  <study rank="56">
    <nct_id>NCT00597259</nct_id>
    <title>Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegasys plus Entecavir</intervention>
      <intervention type="Drug">Entecavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>Bristol-Myers Squibb</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>294</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>200710028M</other_id>
      <other_id>No other ID</other_id>
    </other_ids>
    <first_received>January 9, 2008</first_received>
    <start_date>January 2008</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>June 28, 2010</last_updated>
    <last_verified>June 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HBeAg seroconversion</outcome_measure>
      <outcome_measure>Serum ALT normalization, HBeAg loss, serum HBV DNA disappearance, HBsAg disappearance, histologic change, entecavir resistance</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00597259</url>
  </study>
  <study rank="57">
    <nct_id>NCT02407080</nct_id>
    <title>Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Polycythemia Vera</condition>
      <condition>Essential Thrombocythemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">RG7388</intervention>
      <intervention type="Drug">Pegasys</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>John Mascarenhas</lead_sponsor>
      <collaborator>Genentech, Inc.</collaborator>
      <collaborator>Roche Pharma AG</collaborator>
      <collaborator>Icahn School of Medicine at Mount Sinai</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GCO 14-1919</other_id>
    </other_ids>
    <first_received>March 24, 2015</first_received>
    <start_date>April 2015</start_date>
    <completion_date>April 2018</completion_date>
    <last_updated>April 16, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The dose limiting toxicity of RG7388</outcome_measure>
      <outcome_measure>The dose limiting toxicity of combination of RG7388 and Pegasys</outcome_measure>
      <outcome_measure>Hematologic response of PR + CR by modified ELN response criteria</outcome_measure>
      <outcome_measure>Molecular response by percent reduction in baseline JAK2V617F allele burden</outcome_measure>
      <outcome_measure>Changes in bone marrow histopathologic abnormalities</outcome_measure>
      <outcome_measure>Reduction in baseline reticulin/collagen fibrosis</outcome_measure>
      <outcome_measure>Incidence of venous and arterial thrombosis</outcome_measure>
      <outcome_measure>Changes in MPN related symptoms as measured by the MPN-SAF</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Utah</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02407080</url>
  </study>
  <study rank="58">
    <nct_id>NCT01906580</nct_id>
    <title>Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-IFNÎ±-2a</intervention>
      <intervention type="Drug">Entecavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Beijing 302 Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>105</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2011030D</other_id>
    </other_ids>
    <first_received>May 30, 2013</first_received>
    <start_date>July 2011</start_date>
    <completion_date>July 2016</completion_date>
    <last_updated>August 14, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>the rates of HBeAg seroconversion</outcome_measure>
      <outcome_measure>normalisation of ALT</outcome_measure>
      <outcome_measure>liver histological improvement</outcome_measure>
      <outcome_measure>The rates of HBsAg negative</outcome_measure>
      <outcome_measure>the rate of virological response</outcome_measure>
      <outcome_measure>the rate of HBeAg negative</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01906580</url>
  </study>
  <study rank="59">
    <nct_id>NCT01706575</nct_id>
    <title>A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Patients With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable HBV DNA Suppression</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">nucleos(t)ide analogues</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML28262</other_id>
      <other_id>2012-000080-25</other_id>
    </other_ids>
    <first_received>October 10, 2012</first_received>
    <start_date>April 2013</start_date>
    <completion_date>October 2015</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients with serum HBsAg decrease &gt;/= 50% from baseline to the end of the combination treatment Pegasys plus NA (Study Week 48)</outcome_measure>
      <outcome_measure>Proportion of patients with HBsAg decrease &gt;/=1 log10 IU/ml from baseline to Week 48</outcome_measure>
      <outcome_measure>Change in HBsAg levels</outcome_measure>
      <outcome_measure>Proportion of patients with HBsAg &lt;/= 0.05 UI/ml at Week 48</outcome_measure>
      <outcome_measure>Proportion of patients with HBsAg &lt;/= 0.05 UI/ml at Week 72</outcome_measure>
      <outcome_measure>Proportion of patients with HBsAg &lt;/= 0.05 UI/ml at Week 96</outcome_measure>
      <outcome_measure>HBsAg levels according to IL28B genotypes</outcome_measure>
      <outcome_measure>HBsAg levels according to IP-10 serum levels</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01706575</url>
  </study>
  <study rank="60">
    <nct_id>NCT01142700</nct_id>
    <title>A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus Genotype 1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-824393</intervention>
      <intervention type="Drug">BMS-824393</intervention>
      <intervention type="Drug">BMS-824393</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Peginterferon Alpha-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI451-004</other_id>
      <other_id>2010-018702-36</other_id>
    </other_ids>
    <first_received>June 3, 2010</first_received>
    <start_date>July 2010</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>March 14, 2011</last_updated>
    <last_verified>March 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety as measured by the frequency of serious adverse events (SAEs) and discontinuations due to adverse events (AEs)</outcome_measure>
      <outcome_measure>Antiviral activity as determined by the proportion of subjects with extended rapid virologic response (eRVR) defined as undetectable HCV RNA</outcome_measure>
      <outcome_measure>Proportion of subjects with rapid virologic response (RVR), defined as undetectable RNA</outcome_measure>
      <outcome_measure>Proportion of subjects with complete early virologic response (cEVR), defined as undetectable HCV RNA</outcome_measure>
      <outcome_measure>Proportion of subjects with a sustained virologic response (SVR), defined as HCV RNA undetectable</outcome_measure>
      <outcome_measure>Resistant variants associated with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01142700</url>
  </study>
  <study rank="61">
    <nct_id>NCT00917358</nct_id>
    <title>Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>National Science Council, Taiwan</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>42</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>940215</other_id>
    </other_ids>
    <first_received>June 8, 2009</first_received>
    <start_date>July 2005</start_date>
    <completion_date>June 2008</completion_date>
    <last_updated>December 19, 2012</last_updated>
    <last_verified>December 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00917358</url>
  </study>
  <study rank="62">
    <nct_id>NCT02565719</nct_id>
    <title>REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">REP 2139-Mg</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Zadaxin</intervention>
      <intervention type="Drug">Viread</intervention>
      <intervention type="Drug">REP 2165-Mg</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>REPLICor Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>REP 401</other_id>
    </other_ids>
    <first_received>September 29, 2015</first_received>
    <start_date>September 2015</start_date>
    <completion_date>December 2018</completion_date>
    <last_updated>November 4, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients with adverse events</outcome_measure>
      <outcome_measure>Number of patients with reduction of serum HBsAg</outcome_measure>
      <outcome_measure>Number of patients with controlled HBV infection following treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Moldova, Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02565719</url>
  </study>
  <study rank="63">
    <nct_id>NCT01087944</nct_id>
    <title>A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Device">autoinjector</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Device">pre-filled syringe</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NP25154</other_id>
    </other_ids>
    <first_received>March 9, 2010</first_received>
    <start_date>March 2010</start_date>
    <completion_date>June 2010</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Feasibility of peginterferon alfa-2a administration by autoinjector</outcome_measure>
      <outcome_measure>Safety and tolerability: Adverse events, laboratory parameters, ECG</outcome_measure>
      <outcome_measure>ease of handling of autoinjector versus pre-filled syringe, assessed by staff and patient</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Massachusetts</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>South Carolina</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01087944</url>
  </study>
  <study rank="64">
    <nct_id>NCT00081770</nct_id>
    <title>Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b; SCH 54031)</intervention>
      <intervention type="Drug">REBETOL (ribavirin; SCH 18908)</intervention>
      <intervention type="Biological">PEGASYS (peginterferon alfa-2a)</intervention>
      <intervention type="Drug">COPEGUS (ribavirin)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>4469</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P03471</other_id>
      <other_id>2552898</other_id>
    </other_ids>
    <first_received>April 20, 2004</first_received>
    <start_date>March 2004</start_date>
    <completion_date>November 2007</completion_date>
    <last_updated>March 31, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>November 3, 2008</firstreceived_results_date>
    <primary_completion_date>November 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR) Rate</outcome_measure>
      <outcome_measure>Mean Change From Baseline in the Log Viral Load at Treatment Week 4</outcome_measure>
      <outcome_measure>Virologic Response Rate at Treatment Week 12</outcome_measure>
      <outcome_measure>Mean Change From Baseline in the Log Viral Load at Treatment Week 2</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00081770</url>
  </study>
  <study rank="65">
    <nct_id>NCT01265511</nct_id>
    <title>Study of SCY-635, Pegasys and Copegus in Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">SCY-635</intervention>
      <intervention type="Drug">peginterferon alfa 2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Scynexis, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>SCY-635-201</other_id>
    </other_ids>
    <first_received>November 23, 2010</first_received>
    <start_date>November 2010</start_date>
    <completion_date>October 2011</completion_date>
    <last_updated>May 29, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Undetectable HCV RNA</outcome_measure>
      <outcome_measure>Partial early virologic response</outcome_measure>
      <outcome_measure>Incidence and severity of treatment emergent adverse events and changes in laboratory values as measures of Safety and tolerability</outcome_measure>
      <outcome_measure>Pharmacokinetic assessment of SCY-635</outcome_measure>
      <outcome_measure>Pharmacokinetics of peginterferon alfa 2a and Ribavirin (trough concentrations)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>North Carolina</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01265511</url>
  </study>
  <study rank="66">
    <nct_id>NCT00391638</nct_id>
    <title>Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TRUVADA (EMTRICITABINE + TENOFOVIR DF)</intervention>
      <intervention type="Biological">PEGASYS 180Î¼g (InterfÃ©ron pÃ©gylÃ© alpha -2a)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Agency for Research on AIDS and Viral Hepatitis</lead_sponsor>
      <collaborator>Gilead Sciences</collaborator>
      <collaborator>Roche Pharma AG</collaborator>
      <collaborator>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>56</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2006-004137-15</other_id>
      <other_id>ANRS HB 01 EMVIPEG</other_id>
    </other_ids>
    <first_received>October 23, 2006</first_received>
    <start_date>January 2007</start_date>
    <completion_date>October 2012</completion_date>
    <last_updated>January 14, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HB01EMVIPEG</acronym>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>proportion of patients with seroconversion HBe (loose of HBe antigen and acquisition of HBe antibody) and HBV DNA below 2.3 log10 copies per ml</outcome_measure>
      <outcome_measure>proportion of patients with negative HBe antigen.</outcome_measure>
      <outcome_measure>proportion of patients with HBV DNA under 2.3 log 10 copies per ml.</outcome_measure>
      <outcome_measure>proportion of seroconversion HBs.</outcome_measure>
      <outcome_measure>proportion of patients with no more HBs antigen.</outcome_measure>
      <outcome_measure>proportion of patients with HBV DNA below 2.3 log 10 copies per ml in relation with 3TC resistance or not before tenofovir treatment; increased of ALT before tenofovir treatment;duration of tenofovir treatment before study.</outcome_measure>
      <outcome_measure>Biological evolution and histological of hepatic activity and fibrosis.</outcome_measure>
      <outcome_measure>Biochemical response (ALT at normal value).</outcome_measure>
      <outcome_measure>proportion of patients with :seroconversion HBe and HBV DNA below 2.3 log 10 copies per ml</outcome_measure>
      <outcome_measure>HBV and HIV resistance mutations to tenofovir DF and Emtricitabine.</outcome_measure>
      <outcome_measure>Immunological and virological evolution of HIV infection.</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>Treatment adherence</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00391638</url>
  </study>
  <study rank="67">
    <nct_id>NCT00571714</nct_id>
    <title>Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alpha-2a and ribavirin</intervention>
      <intervention type="Drug">Peginterferon alpha-2a , ribavirin and betaine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Nebraska</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>44</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>159-07-FB</other_id>
    </other_ids>
    <first_received>December 11, 2007</first_received>
    <start_date>April 2008</start_date>
    <completion_date>March 2010</completion_date>
    <last_updated>June 23, 2010</last_updated>
    <last_verified>June 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Viral Response 24 weeks following the end of anti-viral therapy</outcome_measure>
      <outcome_measure>Comparison of rapid and early virologic response in the first 4 and 12 weeks of therapy</outcome_measure>
      <outcome_measure>Comparison of the safety of the two treatment regimens</outcome_measure>
      <outcome_measure>Comparison of ALT normalization between the two regimens</outcome_measure>
      <outcome_measure>Comparison of the effect on interferon gene signaling in peripheral blood mononuclear cells between the two regimens in the first 12 weeks of therapy.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Nebraska</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00571714</url>
  </study>
  <study rank="68">
    <nct_id>NCT00085917</nct_id>
    <title>Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Double dose pegylated interferon with weight based Ribavirin</intervention>
      <intervention type="Drug">standard dose pegylated interferon alfa -2a and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>29</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>040187</other_id>
      <other_id>04-I-0187</other_id>
    </other_ids>
    <first_received>June 16, 2004</first_received>
    <start_date>June 2004</start_date>
    <completion_date>November 2008</completion_date>
    <last_updated>June 21, 2011</last_updated>
    <last_verified>June 2011</last_verified>
    <firstreceived_results_date>April 12, 2010</firstreceived_results_date>
    <acronym>PIFNPK</acronym>
    <primary_completion_date>November 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Number of Participants With Normalization of Liver Enzymes</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00085917</url>
  </study>
  <study rank="69">
    <nct_id>NCT01459913</nct_id>
    <title>Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Pegylated Interferon Alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>239</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX11-950-114</other_id>
    </other_ids>
    <first_received>October 24, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>May 14, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>January 26, 2015</firstreceived_results_date>
    <acronym>CONCISE</acronym>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Subjects With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Subjects With Sustained Viral Response 4 Weeks After Last Planned Dose of Study Drug (SVR4)</outcome_measure>
      <outcome_measure>Percentage of Subjects With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Subjects With Sustained Viral Response at Week 72 (SVR72)</outcome_measure>
      <outcome_measure>Percentage of Subjects With Viral Relapse</outcome_measure>
      <outcome_measure>Percentage of Subjects With On-Treatment Virologic Failure</outcome_measure>
      <outcome_measure>Number of Subjects With Rapid Viral Response (RVR)</outcome_measure>
      <outcome_measure>Number of Subjects With Extended Rapid Viral Response (eRVR)</outcome_measure>
      <outcome_measure>Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Austria</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Poland</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01459913</url>
  </study>
  <study rank="70">
    <nct_id>NCT01056172</nct_id>
    <title>PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a and Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa-2a and Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pusan National University Yangsan Hospital</lead_sponsor>
      <collaborator>Severance Hospital</collaborator>
      <collaborator>Pusan National University Hospital</collaborator>
      <collaborator>Incheon St.Mary's Hospital</collaborator>
      <collaborator>Soon Chun Hyang University</collaborator>
      <collaborator>Inje University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>164</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PNUYH-CHC001</other_id>
    </other_ids>
    <first_received>January 25, 2010</first_received>
    <start_date>January 2010</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>April 18, 2012</last_updated>
    <last_verified>April 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR)</outcome_measure>
      <outcome_measure>AEs</outcome_measure>
      <outcome_measure>laboratory parameters</outcome_measure>
      <outcome_measure>vital signs</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Korea, Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01056172</url>
  </study>
  <study rank="71">
    <nct_id>NCT00226382</nct_id>
    <title>Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon-alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chinese University of Hong Kong</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Pegasys Study</other_id>
    </other_ids>
    <first_received>September 23, 2005</first_received>
    <start_date>January 2005</start_date>
    <completion_date>April 2008</completion_date>
    <last_updated>June 10, 2010</last_updated>
    <last_verified>October 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HBeAg positive patients response is defined as HBeAg loss and presence of anti-HBe (HBeAg seroconversion), HBeAg Negative patients response is defined as DNA&lt;20,000 copies/ml and ALT normalization both measured at week 72</outcome_measure>
      <outcome_measure>Percentage of patients with HBV DNA levels &lt;100,000 copies/ml at week 72, Percentage of patients with HBV DNA levels &lt;10,000 copies/ml at week 72</outcome_measure>
      <outcome_measure>- Percentage of patients with HBV DNA levels negative by PCR at week 72, ALT normalization at week 72, HBsAg seroconversion at week 72, Safety of treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00226382</url>
  </study>
  <study rank="72">
    <nct_id>NCT00227656</nct_id>
    <title>Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Breast Cancer</condition>
      <condition>Metastatic Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PEG-interferon alfa-2a</intervention>
      <intervention type="Drug">Capecitabine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>M.D. Anderson Cancer Center</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2004-0727</other_id>
      <other_id>MDA-2004-0727</other_id>
      <other_id>NCI-6810</other_id>
      <other_id>CDR0000443592</other_id>
    </other_ids>
    <first_received>September 26, 2005</first_received>
    <start_date>September 2005</start_date>
    <completion_date>November 2006</completion_date>
    <last_updated>December 10, 2012</last_updated>
    <last_verified>December 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Neurologic progression-free survival rate at 6 months</outcome_measure>
      <outcome_measure>Time to neurologic progression</outcome_measure>
      <outcome_measure>Overall survival</outcome_measure>
      <outcome_measure>Tumor response (complete response and partial response)</outcome_measure>
      <outcome_measure>Toxicity</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Kansas</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00227656</url>
  </study>
  <study rank="73">
    <nct_id>NCT02556307</nct_id>
    <title>A Study of the Effictiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribaverin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>270</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML22263</other_id>
    </other_ids>
    <first_received>September 21, 2015</first_received>
    <start_date>March 2009</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>September 21, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virological Response (SVR) According to Genotype and Previous Treatment</outcome_measure>
      <outcome_measure>Percentage of participants with undetectable hepatitis C virus (HCV) ribonucleic acid (RNA)</outcome_measure>
      <outcome_measure>Pre, during and post treatment values HCV RNA</outcome_measure>
      <outcome_measure>Pre, during and post treatment values of Thrombocytes</outcome_measure>
      <outcome_measure>Pre, during and post treatment values of leukocytes</outcome_measure>
      <outcome_measure>Pre, during and post treatment values of hemoglobin</outcome_measure>
      <outcome_measure>Treatment duration (in weeks) with peginterferon alfa-2a and ribavirin</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Slovenia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02556307</url>
  </study>
  <study rank="74">
    <nct_id>NCT01889433</nct_id>
    <title>An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Algeron</intervention>
      <intervention type="Drug">Pegasys</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Biocad</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>BCD-016-3</other_id>
    </other_ids>
    <first_received>June 26, 2013</first_received>
    <start_date>November 2013</start_date>
    <completion_date>November 2016</completion_date>
    <last_updated>November 12, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>EVR</outcome_measure>
      <outcome_measure>RVR</outcome_measure>
      <outcome_measure>SVR (24)</outcome_measure>
      <outcome_measure>EOT</outcome_measure>
      <outcome_measure>Biochemical Response</outcome_measure>
      <outcome_measure>Histological Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belarus</country>
      <country>India</country>
      <country>Russian Federation</country>
      <country>Thailand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01889433</url>
  </study>
  <study rank="75">
    <nct_id>NCT00412750</nct_id>
    <title>Efficacy and Safety of Telbivudine in Treatment naÃ¯ve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telbivudine (LdT)</intervention>
      <intervention type="Drug">peginterferon alpha-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>159</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CLDT600A2406</other_id>
    </other_ids>
    <first_received>December 15, 2006</first_received>
    <start_date>December 2006</start_date>
    <completion_date>February 2009</completion_date>
    <last_updated>June 14, 2011</last_updated>
    <last_verified>June 2011</last_verified>
    <firstreceived_results_date>December 2, 2010</firstreceived_results_date>
    <primary_completion_date>February 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Who Achieved HBV DNA Non-detectability With Peginterferon Alpha-2a Plus Telbivudine Combination Therapy Versus Peginterferon Alpha-2a Monotherapy</outcome_measure>
      <outcome_measure>Percentage of Participants With HBV DNA Non-detectability and Alanine Aminotransferase (ALT) Normalization at Week 12 and Week 24 in Participants With HBeAg-positive Chronic Hepatitis B (CHB)</outcome_measure>
      <outcome_measure>Change From Baseline in HBV DNA Concentration</outcome_measure>
      <outcome_measure>Percentage of Participants Who Experienced Virologic Breakthrough at Weeks 48 and 52</outcome_measure>
      <outcome_measure>Percentage of Participants With Hepatitis B 'e' Antigen (HBeAg) Loss and HBeAg Seroconversion</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieved HBV DNA Non-detectability With Telbivudine Monotherapy Versus Peginterferon Alpha-2a Monotherapy</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieved HBV DNA Non-detectability With Peginterferon Alpha-2a Plus Telbivudine Combination Therapy Versus Telbivudine Monotherapy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00412750</url>
  </study>
  <study rank="76">
    <nct_id>NCT00537407</nct_id>
    <title>A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Debio 025</intervention>
      <intervention type="Drug">Peg-IFNÎ±2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Debiopharm International SA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Debio 025-HCV-207</other_id>
    </other_ids>
    <first_received>September 28, 2007</first_received>
    <start_date>September 2007</start_date>
    <completion_date>April 2010</completion_date>
    <last_updated>May 1, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>April 1, 2015</firstreceived_results_date>
    <primary_completion_date>April 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in log10 Hepatitis C Virus RNA at Day 29 in the Debio 025 Triple Therapy Treatment Arms (A, D, and E)</outcome_measure>
      <outcome_measure>Change From Baseline in log10 Hepatitis C Virus RNA at Day 29 in the Debio 025 Monotherapy and Dual Therapy Treatment Arms (B and C)</outcome_measure>
      <outcome_measure>log10 Hepatitis C Virus RNA at Day 29</outcome_measure>
      <outcome_measure>Percentage of Participants With a Rapid Viral Response at Day 29</outcome_measure>
      <outcome_measure>Percentage of Participants With an Early Viral Response at Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With an End-of-treatment Response at the End of Treatment (Week 48 or 72)</outcome_measure>
      <outcome_measure>Percentage of Participants With a Sustained Viral Response 24 Weeks After the End of Treatment (Week 72 or 96)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00537407</url>
  </study>
  <study rank="77">
    <nct_id>NCT00881582</nct_id>
    <title>Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Renal Transplant</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa-2a plus ribavarin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>King Abdulaziz Medical City</lead_sponsor>
      <collaborator>Riyadh Military Hospital</collaborator>
      <collaborator>King Faisal Specialist Hospital &amp; Research Center</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>RMH-01-09</other_id>
    </other_ids>
    <first_received>April 14, 2009</first_received>
    <start_date>January 2009</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>September 13, 2012</last_updated>
    <last_verified>September 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
      <outcome_measure>Adverse event rate and number of cases of graft rejection</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Saudi Arabia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00881582</url>
  </study>
  <study rank="78">
    <nct_id>NCT01519960</nct_id>
    <title>A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>165</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>YV25718</other_id>
      <other_id>2011-002732-70</other_id>
    </other_ids>
    <first_received>December 6, 2011</first_received>
    <start_date>July 2012</start_date>
    <completion_date>August 2022</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2022</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HBeAg seroconversion (loss of HBeAg and presence of anti-HBe) 24 weeks after end of treatment/principal observation period with a further 4.5 years of follow-up</outcome_measure>
      <outcome_measure>HBsAg seroconversion (loss of HBsAg and presence of anti-HBs)</outcome_measure>
      <outcome_measure>Loss of HBeAg/HBsAg</outcome_measure>
      <outcome_measure>Serum alanine aminotransferase (ALT) levels</outcome_measure>
      <outcome_measure>Proportion of normal ALT</outcome_measure>
      <outcome_measure>HBV DNA levels</outcome_measure>
      <outcome_measure>Change in liver elasticity (elastography)</outcome_measure>
      <outcome_measure>Group C: Change in histological findings (liver biopsy)</outcome_measure>
      <outcome_measure>Pharmacokinetics: Area under the concentration-time curve (AUC)</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
      <outcome_measure>Safety: Growth</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>Belgium</country>
      <country>Bulgaria</country>
      <country>China</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Russian Federation</country>
      <country>Ukraine</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01519960</url>
  </study>
  <study rank="79">
    <nct_id>NCT00372385</nct_id>
    <title>Phase 2 Study of VX-950, PegasysÂ® With and Without CopegusÂ® in Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated Interferon Alfa 2a</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>334</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX05-950-104EU</other_id>
    </other_ids>
    <first_received>September 1, 2006</first_received>
    <start_date>August 2006</start_date>
    <completion_date>June 2008</completion_date>
    <last_updated>June 25, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>June 22, 2011</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Study Drug Dosing</outcome_measure>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma HCV RNA at Week 12 After the Completion of Study Drug Dosing</outcome_measure>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma HCV RNA at Completion of Study Drug Dosing</outcome_measure>
      <outcome_measure>Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Number of Subjects With Viral Relapse</outcome_measure>
      <outcome_measure>Maximum (Cmax), Minimum (Cmin) and Average (Cavg) Plasma Concentration of Telaprevir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>France</country>
      <country>Germany</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00372385</url>
  </study>
  <study rank="80">
    <nct_id>NCT00495391</nct_id>
    <title>Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitazoxanide</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Biological">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Romark Laboratories L.C.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>64</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>RM01-2025</other_id>
    </other_ids>
    <first_received>July 2, 2007</first_received>
    <start_date>July 2007</start_date>
    <completion_date>February 2010</completion_date>
    <last_updated>April 8, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>November 18, 2013</firstreceived_results_date>
    <acronym>STEALTHC-2</acronym>
    <primary_completion_date>February 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (HCV RNA Below Lower Limit of Detection)</outcome_measure>
      <outcome_measure>End of Treatment Response (HCV RNA Below Lower Limit of Detection)</outcome_measure>
      <outcome_measure>Early Virologic Response (HCV RNA Below Lower Limit of Detection)</outcome_measure>
      <outcome_measure>Rapid Virologic Response (HCV RNA Below Lower Limit of Detection)</outcome_measure>
      <outcome_measure>Changes in ALT</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>New York</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00495391</url>
  </study>
  <study rank="81">
    <nct_id>NCT00192647</nct_id>
    <title>A Study of Induction Dosing With Peginterferon Alfa-2a (40KD) and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>896</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML17908</other_id>
    </other_ids>
    <first_received>September 13, 2005</first_received>
    <start_date>September 2004</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants with sustained virologic response</outcome_measure>
      <outcome_measure>Percentage of participants with undetectable hepatitis C virus (HCV) ribonucleic acid (RNA)</outcome_measure>
      <outcome_measure>Percentage of participants with at least a 2-log drop in HCV RNA or unquantifiable/undetectable HCV RNA</outcome_measure>
      <outcome_measure>Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Mexico</country>
      <country>New Zealand</country>
      <country>Thailand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00192647</url>
  </study>
  <study rank="82">
    <nct_id>NCT01754974</nct_id>
    <title>Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus (HCV)</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon Lambda-1a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Biological">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI452-033</other_id>
      <other_id>2012-003508-11</other_id>
    </other_ids>
    <first_received>December 19, 2012</first_received>
    <start_date>March 2013</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>January 27, 2015</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>BASIS</acronym>
    <primary_completion_date>September 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects who develop treatment emergent cytopenic abnormalities (anemia as defined by Hb &lt; 10 g/dL, and/or neutropenia as defined by ANC &lt; 750 mm3 and/or thrombocytopenia as defined by platelets &lt; 50,000 mm3) in treatment-naive subjects</outcome_measure>
      <outcome_measure>Proportion of subjects with Sustained Virologic Response at Post-Treatment Follow-up Week 24 (SVR24), defined as Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt; Lower Limit of Quantitation of Assay (LLOQ)</outcome_measure>
      <outcome_measure>Proportion of subjects with Rapid Virologic Response (RVR) (HCV RNA not detected)</outcome_measure>
      <outcome_measure>Proportion of subjects with on-treatment Serious Adverse Events (SAEs) through end of treatment</outcome_measure>
      <outcome_measure>Proportion of subjects with dose reductions through end of treatment</outcome_measure>
      <outcome_measure>Proportion of subjects who discontinue due to Adverse Events (AEs) through end of treatment</outcome_measure>
      <outcome_measure>Proportion of subjects with on-treatment Interferon (IFN)-associated symptoms as determined by adverse event reporting</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Czech Republic</country>
      <country>Korea, Republic of</country>
      <country>Mexico</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01754974</url>
  </study>
  <study rank="83">
    <nct_id>NCT00845065</nct_id>
    <title>Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Other">Placebo</intervention>
      <intervention type="Biological">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>202</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05685</other_id>
    </other_ids>
    <first_received>February 13, 2009</first_received>
    <start_date>February 2009</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>October 10, 2011</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR) Rate in Full Analysis Set (FAS) Population.</outcome_measure>
      <outcome_measure>SVR Rate in the Modified Intent-to-Treat (mITT) Population</outcome_measure>
      <outcome_measure>Percentage of Participants With Early Virologic Response (EVR) Who Achieved SVR</outcome_measure>
      <outcome_measure>Number of Participants With Undetectable HCV-RNA at Follow-up Week 12</outcome_measure>
      <outcome_measure>Mean Log Change From Baseline to TW 4 in Viral Load by Visit</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00845065</url>
  </study>
  <study rank="84">
    <nct_id>NCT00087568</nct_id>
    <title>A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML16965</other_id>
    </other_ids>
    <first_received>July 12, 2004</first_received>
    <start_date>December 2002</start_date>
    <completion_date>August 2006</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients able to complete prescribed length of Pegasys plus ribavirin therapy\n</outcome_measure>
      <outcome_measure>Sum score of Beck Depression Inventory and Fatigue Severity Score, proportion of patients with each flu-like symptom, &gt;=2 log drop or undetectable HCV-RNA, or normal ALT levels, adverse events, laboratory values\n</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00087568</url>
  </study>
  <study rank="85">
    <nct_id>NCT01272310</nct_id>
    <title>Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Sheba Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>SHEBA-10-8033-YM-CTIL</other_id>
      <other_id>HCQ-001-IL</other_id>
    </other_ids>
    <first_received>January 3, 2011</first_received>
    <start_date>January 2011</start_date>
    <completion_date>July 2013</completion_date>
    <last_updated>January 6, 2011</last_updated>
    <last_verified>January 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from baseline in physical examination</outcome_measure>
      <outcome_measure>Change from baseline in vital Signs</outcome_measure>
      <outcome_measure>Change from baseline in clinical laboratory parameters</outcome_measure>
      <outcome_measure>Change from baseline in adverse events</outcome_measure>
      <outcome_measure>HCV RNA level</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01272310</url>
  </study>
  <study rank="86">
    <nct_id>NCT02474316</nct_id>
    <title>Combined Therapy With Peginterferon Alfa-2a With NA in NA-treated HBeAg Positive Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">nucleos(t)ide analgoue</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ruijin Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>366</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HOPE</other_id>
    </other_ids>
    <first_received>March 25, 2015</first_received>
    <start_date>August 2014</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>December 2, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants who achieve HBeAg seroconversion</outcome_measure>
      <outcome_measure>Number of participants who achieve HBeAg loss</outcome_measure>
      <outcome_measure>Number of participants who achieve HBsAg loss</outcome_measure>
      <outcome_measure>Number of participants who achieve HBsAg seroconversion</outcome_measure>
      <outcome_measure>HBsAg decline from baseline</outcome_measure>
      <outcome_measure>Percentage of participants who achieve HBsAg &lt;1000IU/mL</outcome_measure>
      <outcome_measure>Percentage of of participants who achieve HBsAg &lt;100IU/mL</outcome_measure>
      <outcome_measure>Number of participants who achieve combined response I (defined as HBeAg seroconversion and HBV DNA&lt;100000copies/mL)</outcome_measure>
      <outcome_measure>Number of participants who achieve combined response II (defined as HBeAg seroconversion and HBV DNA&lt;1000copies/mL)</outcome_measure>
      <outcome_measure>Number of participants who achieve dural response I (defined as HBeAg seroconversion and HBsAg&lt;1000IU/mL)</outcome_measure>
      <outcome_measure>Number of participants who achieve dural response II (defined as HBeAg seroconversion and HBsAg&lt;100IU/mL)</outcome_measure>
      <outcome_measure>Number of Participants with AE</outcome_measure>
      <outcome_measure>Number of Participants with SAE</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02474316</url>
  </study>
  <study rank="87">
    <nct_id>NCT00356486</nct_id>
    <title>Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin Î² in Patients Coinfected HCV/HIV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a, Ribavirin, epoetin-Î²</intervention>
      <intervention type="Drug">Peginterferon alfa-2a + Ribavirin for 12 weeks</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Germans Trias i Pujol Hospital</lead_sponsor>
      <collaborator>Fundacio Lluita Contra la SIDA</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>74</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CORAL-2</other_id>
      <other_id>2004 - 000907 -16</other_id>
    </other_ids>
    <first_received>July 25, 2006</first_received>
    <start_date>October 2005</start_date>
    <completion_date>March 2009</completion_date>
    <last_updated>September 2, 2009</last_updated>
    <last_verified>September 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of patients with undetectable RNA-HCV</outcome_measure>
      <outcome_measure>Variations of the levels of RNA-HCV</outcome_measure>
      <outcome_measure>Percentage of patients with undetectable HCV RNA</outcome_measure>
      <outcome_measure>Levels of ALT</outcome_measure>
      <outcome_measure>Percentage of patients that must reduce the dose of peginterferon alpha-2a (40 KD) and ribavirin.</outcome_measure>
      <outcome_measure>Percentage of patients that drop out of the study for adverse effects or intolerance</outcome_measure>
      <outcome_measure>Variations in levels of haemoglobin, neutrophil, and platelet count</outcome_measure>
      <outcome_measure>AIDS-defining events or death</outcome_measure>
      <outcome_measure>Changes in the CD4/CD8 cell count</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00356486</url>
  </study>
  <study rank="88">
    <nct_id>NCT01467492</nct_id>
    <title>Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Biological">Pegylated Interferon Alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>121</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX11-950-116</other_id>
    </other_ids>
    <first_received>November 3, 2011</first_received>
    <start_date>January 2012</start_date>
    <completion_date>May 2014</completion_date>
    <last_updated>July 13, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>June 1, 2015</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Viral Response 12 Weeks After Last Actual Dose of Study Drug (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Viral Response 24 Weeks After Last Actual Dose of Study Drug (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With Extended Rapid Viral Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With On Treatment Virologic Failure</outcome_measure>
      <outcome_measure>Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01467492</url>
  </study>
  <study rank="89">
    <nct_id>NCT01684787</nct_id>
    <title>Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a + ribavirin in normal ALT</intervention>
      <intervention type="Drug">Peginterferon alfa-2a + ribavirin in elevated ALT</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Miguel Santin</lead_sponsor>
      <collaborator>Hospital Universitari de Bellvitge</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Miguel SantÃ­n</other_id>
    </other_ids>
    <first_received>June 11, 2010</first_received>
    <start_date>September 2006</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>September 12, 2012</last_updated>
    <last_verified>September 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>CONTRA</acronym>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>% patients with RNA-HCV negative</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01684787</url>
  </study>
  <study rank="90">
    <nct_id>NCT00245414</nct_id>
    <title>Trial of PegasysÂ® in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PegasysÂ®</intervention>
      <intervention type="Drug">PegasysÂ®</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chugai Pharmaceutical</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>108</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML18501</other_id>
    </other_ids>
    <first_received>October 27, 2005</first_received>
    <start_date>October 2005</start_date>
    <completion_date>July 2010</completion_date>
    <last_updated>November 16, 2010</last_updated>
    <last_verified>November 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained viral response as undetectable level of HCV-RNA</outcome_measure>
      <outcome_measure>Biochemical response as normal level of ALT</outcome_measure>
      <outcome_measure>Viral response as undetectable level of HCV-RNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00245414</url>
  </study>
  <study rank="91">
    <nct_id>NCT01369212</nct_id>
    <title>Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tenofovir</intervention>
      <intervention type="Drug">Peginterferon-alfa 2a and tenofovir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>University of Pittsburgh</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>376</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>DK082864 HBRN Immune Active</other_id>
    </other_ids>
    <first_received>June 6, 2011</first_received>
    <start_date>November 2012</start_date>
    <completion_date>October 2020</completion_date>
    <last_updated>October 28, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HBRN</acronym>
    <primary_completion_date>October 2019</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Hepatitis B surface antigen (HBsAg) loss</outcome_measure>
      <outcome_measure>Cumulative HBsAg loss</outcome_measure>
      <outcome_measure>Serious Adverse Events</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Hepatitis B e antigen (HBeAg) loss</outcome_measure>
      <outcome_measure>HBeAg loss</outcome_measure>
      <outcome_measure>HBsAg seroconversion</outcome_measure>
      <outcome_measure>HBeAg seroconversion</outcome_measure>
      <outcome_measure>Normalization of Alanine Transaminase(ALT) levels</outcome_measure>
      <outcome_measure>HBV DNA &lt;1000 IU/mL</outcome_measure>
      <outcome_measure>HBV DNA &lt;20 IU/mL(Lower limit of quantification [LLOQ]) of COBAS Ampliprep/COBAS TaqMan HBV v2.0 test)</outcome_measure>
      <outcome_measure>Absence of detectable antiviral drug-resistance HBV mutations</outcome_measure>
      <outcome_measure>Sustained HBV DNA &lt;1000 IU/mL</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Hawaii</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01369212</url>
  </study>
  <study rank="92">
    <nct_id>NCT01519921</nct_id>
    <title>A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML18495</other_id>
    </other_ids>
    <first_received>January 5, 2012</first_received>
    <start_date>October 2005</start_date>
    <completion_date>October 2008</completion_date>
    <last_updated>November 2, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of patients with hepatitis B virus DNA &lt;100,000 copies/mL</outcome_measure>
      <outcome_measure>Percentage of patients with hepatitis B virus HBeAg loss rate</outcome_measure>
      <outcome_measure>Percentage of patients with alanine aminotransferase (ALT) normalization</outcome_measure>
      <outcome_measure>Percentage of patients with hepatitis B virus (HBV) DNA below limit of detection</outcome_measure>
      <outcome_measure>Percentage of patients with a combined response of HBeAg seroconversion, loss of HBeAg, and alanine aminotransferase normalization</outcome_measure>
      <outcome_measure>Percentage of patients with HBeAg seroconversion</outcome_measure>
      <outcome_measure>Percentage of patients with loss of HBsAg</outcome_measure>
      <outcome_measure>Percentage of patients with loss of HBsAg and presence of anti-HBs</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Korea, Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01519921</url>
  </study>
  <study rank="93">
    <nct_id>NCT01033448</nct_id>
    <title>A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">COPEGUS</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>59</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML21778</other_id>
    </other_ids>
    <first_received>December 15, 2009</first_received>
    <start_date>December 2009</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy: end of treatment response rate (virological), sustained viral response</outcome_measure>
      <outcome_measure>Safety and Tolerability: AEs, laboratory parameters</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Israel</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01033448</url>
  </study>
  <study rank="94">
    <nct_id>NCT01030432</nct_id>
    <title>Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-650032</intervention>
      <intervention type="Drug">BMS-650032</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Peginterferon Alfa-2a</intervention>
      <intervention type="Drug">Peginterferon Alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>285</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI447-016</other_id>
      <other_id>2009-013652-69</other_id>
    </other_ids>
    <first_received>December 10, 2009</first_received>
    <start_date>February 2010</start_date>
    <completion_date>October 2012</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Phase 2a and Phase 2b: Safety, as measured by the frequency of SAEs and discontinuations due to AEs</outcome_measure>
      <outcome_measure>Antiviral activity as determined by proportion of HCV genotype 1 subjects with extended rapid virologic response (eRVR), defined as undetectable HCV RNA</outcome_measure>
      <outcome_measure>Phase 2b only: Antiviral activity, as determined by the proportion of HCV genotype 1 subjects with 24-week sustained virologic response (SVR24), defined as undetectable HCV RNA</outcome_measure>
      <outcome_measure>Proportion of HCV genotype 1 subjects with rapid virologic response (RVR), defined as undetectable HCV RNA at Week 4</outcome_measure>
      <outcome_measure>Proportion of HCV genotype 1 subjects with complete early rapid virologic response (eEVR), defined as undetectable HCV RNA at Week 12 (Stage 2 only)</outcome_measure>
      <outcome_measure>Proportion of HCV genotype 1 subjects with early virologic response (EVR) defined as â¥2 log10 decrease in HCV RNA from baseline at Week 12 (Stage 1 only)</outcome_measure>
      <outcome_measure>Proportion of HCV genotype 1 subjects with 12-week sustained virologic response (SVR12), defined as undetectable HCV RNA at follow-up Week 12</outcome_measure>
      <outcome_measure>Proportion of HCV genotype 1 subjects with 24-week sustained virologic response (SVR24) defined as undetectable HCV RNA at follow-up Week 24 (Stage 1 only)</outcome_measure>
      <outcome_measure>Resistant variants associated with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Argentina</country>
      <country>France</country>
      <country>Germany</country>
      <country>Ireland</country>
      <country>Italy</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01030432</url>
  </study>
  <study rank="95">
    <nct_id>NCT00869661</nct_id>
    <title>A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">RO5024048</intervention>
      <intervention type="Drug">RO5024048</intervention>
      <intervention type="Drug">RO5024048</intervention>
      <intervention type="Drug">RO5024048</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>413</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV20536</other_id>
      <other_id>2008-008258-21</other_id>
    </other_ids>
    <first_received>March 25, 2009</first_received>
    <start_date>February 2001</start_date>
    <completion_date>February 2012</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response: Percentage of patients with undetectable Hepatitis C RNA level</outcome_measure>
      <outcome_measure>Virologic response: Percentage of patients with undetectable Hepatitis C RNA level</outcome_measure>
      <outcome_measure>Relapse rate: Percentage of patients who achieved a virologic response at the end of treatment but had detectable Hepatitis C RNA level at the last assessment post treatment</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00869661</url>
  </study>
  <study rank="96">
    <nct_id>NCT02594293</nct_id>
    <title>Pegylated Interferon(Peg-IFN) in Reducing Relapse Rate in Patients After Discontinuation of NUC Therapy</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PegIFN alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Huashan Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>354</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CEASE</other_id>
    </other_ids>
    <first_received>October 11, 2015</first_received>
    <start_date>October 2015</start_date>
    <completion_date>May 2018</completion_date>
    <last_updated>November 3, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants who relapse</outcome_measure>
      <outcome_measure>Number of participants who achieve HBsAg seroconversion</outcome_measure>
      <outcome_measure>HBsAg changes from Baseline</outcome_measure>
      <outcome_measure>Predictive value of other markers for recurrence after NUC withdrawal</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02594293</url>
  </study>
  <study rank="97">
    <nct_id>NCT01464281</nct_id>
    <title>A Study of Switch From Nucleotide to Peginterferon Alfa-2a in CHB Patients Achieving HBeAg Loss and HBV DNA &lt;200IU/ml</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa 2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>The Second Affiliated Hospital of Chongqing Medical University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML27928</other_id>
    </other_ids>
    <first_received>October 19, 2011</first_received>
    <start_date>October 2011</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>November 1, 2011</last_updated>
    <last_verified>November 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>New Switch</acronym>
    <primary_completion_date>June 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>determine the response rate (HBsAg clearance at Week 48 and 96)</outcome_measure>
      <outcome_measure>HBsAg/HBeAg/HBV DNA changes/ALT normalization /HBsAg seroconversion at EOT and EOF</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01464281</url>
  </study>
  <study rank="98">
    <nct_id>NCT00502099</nct_id>
    <title>Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alpha 2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon alpha 2 b plus ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Amr Hafez</lead_sponsor>
      <collaborator>Ain Shams University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>217</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>LG161190-06</other_id>
    </other_ids>
    <first_received>July 15, 2007</first_received>
    <start_date>January 2006</start_date>
    <completion_date>May 2009</completion_date>
    <last_updated>October 21, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR, defined as undetectable serum HCV RNA</outcome_measure>
      <outcome_measure>histological response</outcome_measure>
      <outcome_measure>biochemical response</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00502099</url>
  </study>
  <study rank="99">
    <nct_id>NCT01057667</nct_id>
    <title>A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">RO5024048</intervention>
      <intervention type="Drug">Ribavirin [Copegus]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>168</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV22621</other_id>
    </other_ids>
    <first_received>January 26, 2010</first_received>
    <start_date>February 2010</start_date>
    <completion_date>April 2012</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (undetectable HCV DNA as measured by Roche COBAS TaqMan HCV test)</outcome_measure>
      <outcome_measure>Virologic response over time</outcome_measure>
      <outcome_measure>Pharmacokinetics of RO4995855 when RO5024048 is administered with peginterferon alfa-2a and ribavirin</outcome_measure>
      <outcome_measure>Resistance profile of RO5024048</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Kansas</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01057667</url>
  </study>
  <study rank="100">
    <nct_id>NCT01492426</nct_id>
    <title>Study Comparing BMS-790052 (Daclatasvir) to Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Untreated Hepatitis C Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-790052 (Daclatasvir)</intervention>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>605</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-052</other_id>
      <other_id>2011-004237-14</other_id>
    </other_ids>
    <first_received>December 13, 2011</first_received>
    <start_date>January 2012</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>May 5, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>COMMAND-3</acronym>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of genotype 1b patients with SVR12, defined as HCV RNA less than limit of quantitation at follow-up Week 12 in each group</outcome_measure>
      <outcome_measure>Proportion of genotype 1b patients with hemoglobin value less than 10 g/dL</outcome_measure>
      <outcome_measure>Proportion of genotype 1b patients with rash events</outcome_measure>
      <outcome_measure>Proportion of genotype1b patients with HCV RNA undetectable Week 12</outcome_measure>
      <outcome_measure>Proportion of genotype 1b patients with HCV RNA undetectable Week 4</outcome_measure>
      <outcome_measure>Proportion of genotype 1b patients with HCV RNA undetectable Weeks 4 and 12</outcome_measure>
      <outcome_measure>Proportion of genotype 1b patients with SVR24, defined as HCV RNA &lt; Limit of Quantification (LOQ) at follow-up Week 24 for each cohort</outcome_measure>
      <outcome_measure>Proportion of genotype 1b patients with SVR12 based on IL28B rs12979860 Single nucleotide polymorphism (SNP) genotype (CC or non-CC)</outcome_measure>
      <outcome_measure>Proportion of genotype 1a patients with SVR12 defined as HCV RNA &lt; LOQ at follow-up Week 12 for each cohort</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>Brazil</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01492426</url>
  </study>
  <study rank="101">
    <nct_id>NCT01524679</nct_id>
    <title>Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa-2a plus nucleos(t)ide(s)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Johannes Gutenberg University Mainz</lead_sponsor>
      <collaborator>Roche Pharma AG</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>170</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML 27787</other_id>
    </other_ids>
    <first_received>January 31, 2012</first_received>
    <start_date>August 2012</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>November 30, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PADD-ON</acronym>
    <primary_completion_date>July 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Difference in percentage of patients between treatment and comparator arm reaching a â¥ 1log10 decline of quantitative HBsAg after 48 weeks</outcome_measure>
      <outcome_measure>Decline of quantitative HBs antigen at week 12 and 24</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01524679</url>
  </study>
  <study rank="102">
    <nct_id>NCT00517439</nct_id>
    <title>A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">RO4588161</intervention>
      <intervention type="Drug">RO4588161</intervention>
      <intervention type="Drug">RO4588161</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>516</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV19865</other_id>
    </other_ids>
    <first_received>August 16, 2007</first_received>
    <start_date>December 2007</start_date>
    <completion_date>January 2010</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR)</outcome_measure>
      <outcome_measure>Virological response over time</outcome_measure>
      <outcome_measure>SVR</outcome_measure>
      <outcome_measure>Relapse rate</outcome_measure>
      <outcome_measure>AEs, laboratory parameters.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Minnesota</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00517439</url>
  </study>
  <study rank="103">
    <nct_id>NCT01296971</nct_id>
    <title>A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML25246</other_id>
    </other_ids>
    <first_received>December 21, 2010</first_received>
    <start_date>December 2009</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety of individualized Copegus treatment in combination with Pegasys: Adverse events</outcome_measure>
      <outcome_measure>Influence of dose reductions in case of adverse events on sustained virological response (HCV-RNA)</outcome_measure>
      <outcome_measure>Virological response/sustained virological response (serum HCV RNA levels)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01296971</url>
  </study>
  <study rank="104">
    <nct_id>NCT01373684</nct_id>
    <title>PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Nucleos(t)ide analogue</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Foundation for Liver Research</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HBV11-01</other_id>
    </other_ids>
    <first_received>June 14, 2011</first_received>
    <start_date>March 2012</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>October 16, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PAS</acronym>
    <primary_completion_date>October 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HBsAg decline</outcome_measure>
      <outcome_measure>HBsAg loss</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01373684</url>
  </study>
  <study rank="105">
    <nct_id>NCT00087646</nct_id>
    <title>REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>948</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MV17150</other_id>
    </other_ids>
    <first_received>July 12, 2004</first_received>
    <start_date>September 2003</start_date>
    <completion_date>May 2008</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response rate</outcome_measure>
      <outcome_measure>Percentage of patients with &gt;=2log drop in HCV-RNA</outcome_measure>
      <outcome_measure>Percentage of patients with undetectable HCV-RNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>Italy</country>
      <country>Portugal</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>Switzerland</country>
      <country>Turkey</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Iowa</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Vermont</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00087646</url>
  </study>
  <study rank="106">
    <nct_id>NCT01017575</nct_id>
    <title>Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>55</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-022</other_id>
    </other_ids>
    <first_received>November 19, 2009</first_received>
    <start_date>December 2009</start_date>
    <completion_date>October 2011</completion_date>
    <last_updated>August 13, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>August 13, 2015</firstreceived_results_date>
    <primary_completion_date>October 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With a Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With a Sustained Virologic Response (SVR) at Follow-up Week 12 and Follow-up Week 24</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01017575</url>
  </study>
  <study rank="107">
    <nct_id>NCT01482390</nct_id>
    <title>A Study of Mericitabine in Combination With Telaprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">mericitabine</intervention>
      <intervention type="Drug">mericitabine</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV27779</other_id>
      <other_id>2011-002715-28</other_id>
    </other_ids>
    <first_received>November 28, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>March 9, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response 12 weeks after treatment (SVR-12)</outcome_measure>
      <outcome_measure>Sustained virological response 4 weeks after treatment (SVR-4)</outcome_measure>
      <outcome_measure>Virologic response over time</outcome_measure>
      <outcome_measure>Proportion of patients who develop treatment resistance</outcome_measure>
      <outcome_measure>Safety (incidence of adverse events)</outcome_measure>
      <outcome_measure>Pharmacokinetics: trough concentration of RO4995855</outcome_measure>
      <outcome_measure>Pharmacokinetics: trough concentration of RO5012433</outcome_measure>
      <outcome_measure>Pharmacokinetics: trough concentration of telaprevir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01482390</url>
  </study>
  <study rank="108">
    <nct_id>NCT01482403</nct_id>
    <title>A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">boceprevir</intervention>
      <intervention type="Drug">boceprevir</intervention>
      <intervention type="Drug">mericitabine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV27780</other_id>
      <other_id>2011-002714-37</other_id>
    </other_ids>
    <first_received>November 28, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response 12 weeks after treatment (SVR-12)</outcome_measure>
      <outcome_measure>Sustained virological response 4 weeks after treatment</outcome_measure>
      <outcome_measure>Virologic response over time</outcome_measure>
      <outcome_measure>Proportion of patients who develop treatment resistance</outcome_measure>
      <outcome_measure>Safety (incidence of adverse events)</outcome_measure>
      <outcome_measure>Pharmacokinetics: trough concentration of RO4995855</outcome_measure>
      <outcome_measure>Pharmacokinetics: trough concentration of RO5012433</outcome_measure>
      <outcome_measure>Pharmacokinetics: trough concentration of boceprevir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Colorado</state>
      <state>Illinois</state>
      <state>Louisiana</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01482403</url>
  </study>
  <study rank="109">
    <nct_id>NCT00412334</nct_id>
    <title>SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>104</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML20399</other_id>
    </other_ids>
    <first_received>December 15, 2006</first_received>
    <start_date>January 2007</start_date>
    <completion_date>September 2010</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained viral response</outcome_measure>
      <outcome_measure>Percentage of patients with &gt;=2log drop of HCV-RNA</outcome_measure>
      <outcome_measure>Percentage of patients with non-detectable HCV-RNA</outcome_measure>
      <outcome_measure>Relapse rate</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00412334</url>
  </study>
  <study rank="110">
    <nct_id>NCT00948220</nct_id>
    <title>Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Liver Diseases</condition>
      <condition>Virus Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Ulm</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>26</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>OSTEO</other_id>
    </other_ids>
    <first_received>July 24, 2009</first_received>
    <start_date>July 2003</start_date>
    <completion_date>March 2008</completion_date>
    <last_updated>June 6, 2011</last_updated>
    <last_verified>May 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change of the bone mineral density of the lumbar spine and right hip measured by DEXA in patients with chronic hepatitis C with or without antiviral combination treatment with peginterferon and ribavirin</outcome_measure>
      <outcome_measure>Change in markers of bone formation and resorption over time during antiviral therapy and after cessation of therapy.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00948220</url>
  </study>
  <study rank="111">
    <nct_id>NCT00483938</nct_id>
    <title>IMPROVE Study(The Individualized Management With PEGASYS and Ribavirin Offering Viral Eradication): A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Non-Genotype 2/3.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>226</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML21035</other_id>
    </other_ids>
    <first_received>June 7, 2007</first_received>
    <start_date>June 2007</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response</outcome_measure>
      <outcome_measure>SVR</outcome_measure>
      <outcome_measure>Viral kinetics</outcome_measure>
      <outcome_measure>AEs, laboratory parameters</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00483938</url>
  </study>
  <study rank="112">
    <nct_id>NCT01471535</nct_id>
    <title>HBsAg Clearance in Inactive Chronic HBsAg Carriers After Interferon Treated</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Beijing Ditan Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>DTH-XY002</other_id>
    </other_ids>
    <first_received>October 31, 2011</first_received>
    <start_date>May 2008</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>March 8, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HBsAg loss/seroconversion</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01471535</url>
  </study>
  <study rank="113">
    <nct_id>NCT01290679</nct_id>
    <title>An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNÎ±-2a/b)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>393</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017380</other_id>
      <other_id>TMC435-TiDP16-C216</other_id>
      <other_id>2010-021174-11</other_id>
    </other_ids>
    <first_received>January 7, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>February 2013</completion_date>
    <last_updated>June 10, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>February 3, 2014</firstreceived_results_date>
    <acronym>QUEST-2</acronym>
    <primary_completion_date>February 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Sustained Virologic Response 4 Weeks After the Planned End of Treatment (SVR4)</outcome_measure>
      <outcome_measure>Change From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Actual Values of log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Virologic Response at All Time Points</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants With &lt;1 log10 Decrease in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) From Baseline at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels &gt;1000 IU/mL at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Null Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Partial Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants Who Completed All Study Treatment at Week 24 Because of the Treatment Duration Rule</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Failure</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Undetectable or Detectable</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Undetectable</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;100 IU/mL</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;1000 IU/mL</outcome_measure>
      <outcome_measure>The Percentage of Participants With Viral Breakthrough at Different Time Points</outcome_measure>
      <outcome_measure>Time From End-of-treatment to Viral Relapse</outcome_measure>
      <outcome_measure>The Percentage of Participants With Normalization of Alanine Aminotransferase (ALT)</outcome_measure>
      <outcome_measure>Median Time to Normalization of Alanine Aminotransferase (ALT) Levels</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h)</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Predose Plasma Concentration (C0h)</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Systemic Clearance (CL)</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for the Fatigue Severity Scale (FSS) Total Scores</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Impairment in Overall Work Productivity Due to Hepatitis C Virus (HCV) Infection and Its Treatment</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Impairment in Daily Activities Due to Hepatitis C Virus (HCV) Infection and Its Treatment</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Time Missed From Work Due to Hepatitis C Virus (HCV) Infection and Its Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>Bulgaria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>Portugal</country>
      <country>Puerto Rico</country>
      <country>Slovakia</country>
      <country>Spain</country>
      <country>Turkey</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Minnesota</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01290679</url>
  </study>
  <study rank="114">
    <nct_id>NCT01178996</nct_id>
    <title>Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Thymosin alpha 1</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Biological">PEGinterferon alfa2a</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>sigma-tau i.f.r. S.p.A.</lead_sponsor>
      <collaborator>SciClone Pharmaceuticals</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>552</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>ST1472-DM-03-004</other_id>
      <other_id>2004-001277-25</other_id>
    </other_ids>
    <first_received>August 9, 2010</first_received>
    <start_date>December 2004</start_date>
    <completion_date>July 2009</completion_date>
    <last_updated>August 9, 2010</last_updated>
    <last_verified>August 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virological Response (SVR)</outcome_measure>
      <outcome_measure>Sustained Biochemical Response (SBR)</outcome_measure>
      <outcome_measure>End of Treatment Biochemical Response (EBR)</outcome_measure>
      <outcome_measure>End of Treatment Virological Response [EVR]</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>Italy</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01178996</url>
  </study>
  <study rank="115">
    <nct_id>NCT01471574</nct_id>
    <title>Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Genotype 1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-790052 (Daclatasvir)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peg-Interferon alfa 2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>301</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-043</other_id>
      <other_id>2011-003067-30</other_id>
    </other_ids>
    <first_received>November 4, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>February 6, 2015</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects with SVR12, defined as HCV RNA &lt; LLOQ, target detected or not detected at post-treatment Week 12</outcome_measure>
      <outcome_measure>Proportion of subjects with Genotype 1 infection who achieve HCV RNA &lt; LLOQ , target detected or not detected</outcome_measure>
      <outcome_measure>Proportion of subjects with Genotype 1 infection who achieve HCV RNA &lt; LLOQ, target not detected</outcome_measure>
      <outcome_measure>Safety, as measured by the frequency of SAEs and discontinuations due to AEs</outcome_measure>
      <outcome_measure>Proportion of subjects who are receiving HAART and who maintain their HIV RNA &lt; 40 copies/mL and the proportion of subjects who experience confirmed HIV RNA â¥ 400 copies/mL at end of treatment for subjects who are receiving HAART</outcome_measure>
      <outcome_measure>Proportion of subjects with SVR12 by rs12979860 Single nucleotide polymorphism (SNP) in the IL28B gene</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Puerto Rico</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01471574</url>
  </study>
  <study rank="116">
    <nct_id>NCT02589652</nct_id>
    <title>Switch or Sequential Combination Therapy of Peginterferon in Hepatitis B Patients With Longterm Entecavir Therapy</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa-2a</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a plus Entecavir</intervention>
      <intervention type="Drug">Entecavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Huashan Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>294</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>81271833</other_id>
    </other_ids>
    <first_received>October 25, 2015</first_received>
    <start_date>October 2015</start_date>
    <completion_date>October 2017</completion_date>
    <last_updated>October 27, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rate of HBeAg seroconversion</outcome_measure>
      <outcome_measure>Rate of HBsAg loss</outcome_measure>
      <outcome_measure>Rate of HBV DNA &lt;20IU/mL</outcome_measure>
      <outcome_measure>Rate of HBsAg seroconversion</outcome_measure>
      <outcome_measure>Percentage of patients reaching a â¥ 1log10 decline of quantitative HBsAg</outcome_measure>
      <outcome_measure>Decline of quantitative HBsAg from baseline</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02589652</url>
  </study>
  <study rank="117">
    <nct_id>NCT00154869</nct_id>
    <title>Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon Alfa-2a plus Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>320</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>921003</other_id>
      <other_id>ML17862</other_id>
    </other_ids>
    <first_received>September 8, 2005</first_received>
    <start_date>June 2004</start_date>
    <completion_date>August 2007</completion_date>
    <last_updated>August 10, 2007</last_updated>
    <last_verified>August 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>To demonstrate the efficacy of peginterferon alfa-2a (PEG-IFN alfa-2a) (PegasysÂ®) plus ribavirin (RBV) for sustained virological response (SVR) in HBV-coinfected versus monoinfected chronic hepatitis C (CHC) patients</outcome_measure>
      <outcome_measure>To demonstrate the efficacy of peginterferon alfa-2a (PEG-IFN alfa-2a) (PegasysÂ®) plus ribavirin (RBV) on the reduction of HCV viremia after 24 and 48 weeks of treatment (depending on genotype) in coinfected versus monoinfected CHC patients</outcome_measure>
      <outcome_measure>To demonstrate the efficacy of PEG-IFN alfa-2a plus RBV in dual chronic hepatitis C and B on:</outcome_measure>
      <outcome_measure>1) the biochemical response rate</outcome_measure>
      <outcome_measure>2) the score of histologic change</outcome_measure>
      <outcome_measure>3) serum HBV DNA disappearance</outcome_measure>
      <outcome_measure>4) HBsAg disappearance</outcome_measure>
      <outcome_measure>5) combined response of HBV DNA disappearance and normalization of ALT</outcome_measure>
      <outcome_measure>6) end of treatment virological response</outcome_measure>
      <outcome_measure>To assess the influence of serum HBV load on the clearance of serum HCV RNA, the loss of serum HBV DNA, and normalization of serum ALT</outcome_measure>
      <outcome_measure>To assess the influence of HBV genotype on the clearance of serum HCV RNA, the loss of serum HBV DNA, and normalization of serum ALT</outcome_measure>
      <outcome_measure>To assess the safety profile of the PEG-IFN alfa-2a plus RBV combination therapy in dual chronic hepatitis C and B</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00154869</url>
  </study>
  <study rank="118">
    <nct_id>NCT01086085</nct_id>
    <title>A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Adefovir</intervention>
      <intervention type="Drug">peginterferon alfa-2a [PEGASYS]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [PEGASYS]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [PEGASYS]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
      <collaborator>Major Science and Technology Special Project of China Eleventh Five-year</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>265</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML22266</other_id>
    </other_ids>
    <first_received>March 11, 2010</first_received>
    <start_date>April 2010</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy: Quantitative HBsAG reduction (proportion of patients with HBsAG reduction)</outcome_measure>
      <outcome_measure>Proportion of patients achieving HBeAG seroconversion and HBV DNA &lt;/=100000 copies/ml</outcome_measure>
      <outcome_measure>Safety: Adverse Events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01086085</url>
  </study>
  <study rank="119">
    <nct_id>NCT00614471</nct_id>
    <title>A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Entecavir</intervention>
      <intervention type="Drug">Entecavir</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>219</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML20742</other_id>
    </other_ids>
    <first_received>January 30, 2008</first_received>
    <start_date>August 2007</start_date>
    <completion_date>October 2009</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Log change in quantitative HBeAg from baseline to 24 weeks after end of treatment.</outcome_measure>
      <outcome_measure>HBeAg seroconversion, HBV-DNA &lt;1000 copies/mL, loss of HBeAg, HBV DNA reduction, ALT normalization, loss of HBsAg seroconversion, reduction of HBsAg 24 weeks after end of treatment.</outcome_measure>
      <outcome_measure>AEs, laboratory parameters.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
      <country>Hong Kong</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00614471</url>
  </study>
  <study rank="120">
    <nct_id>NCT00763568</nct_id>
    <title>4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitazoxanide</intervention>
      <intervention type="Biological">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Romark Laboratories L.C.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>RM01-3037</other_id>
    </other_ids>
    <first_received>September 26, 2008</first_received>
    <start_date>August 2006</start_date>
    <completion_date>September 2008</completion_date>
    <last_updated>September 26, 2008</last_updated>
    <last_verified>September 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response</outcome_measure>
      <outcome_measure>End of treatment virologic response</outcome_measure>
      <outcome_measure>Early virologic response</outcome_measure>
      <outcome_measure>Rapid virologic response</outcome_measure>
      <outcome_measure>ALT normalization</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00763568</url>
  </study>
  <study rank="121">
    <nct_id>NCT00077636</nct_id>
    <title>ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>1469</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV17317</other_id>
    </other_ids>
    <first_received>February 10, 2004</first_received>
    <start_date>December 2003</start_date>
    <completion_date>March 2006</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR</outcome_measure>
      <outcome_measure>Virological response</outcome_measure>
      <outcome_measure>AEs, laboratory parameters, vital signs.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Alaska</state>
      <state>Arizona</state>
      <state>Arkansas</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Idaho</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Iowa</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Vermont</state>
      <state>Virginia</state>
      <state>Washington</state>
      <state>Wisconsin</state>
      <state>Wyoming</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00077636</url>
  </study>
  <study rank="122">
    <nct_id>NCT01179594</nct_id>
    <title>A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">entecavir</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>MV22597</other_id>
      <other_id>2009-017602-36</other_id>
    </other_ids>
    <first_received>August 10, 2010</first_received>
    <completion_date>November 2014</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Efficacy: HBV-DNA reduction to &lt;10,000 copies/ml (&lt;2,000 IU/ml)</outcome_measure>
      <outcome_measure>Correlation early HBsAg response - response end of treatment/follow-up</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01179594</url>
  </study>
  <study rank="123">
    <nct_id>NCT01544920</nct_id>
    <title>Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">peginterferon alfa-2a</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>737</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P07755</other_id>
      <other_id>2011-001345-32</other_id>
      <other_id>MK-3034-040</other_id>
      <other_id>CTRI/2012/12/003200</other_id>
      <other_id>PHRR131022-000133</other_id>
    </other_ids>
    <first_received>February 28, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>May 2015</completion_date>
    <last_updated>June 18, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Overall Number of Participants Achieving Sustained Viral Response (SVR) at Follow-up Week 24</outcome_measure>
      <outcome_measure>Number of Participants Achieving SVR at Follow-up Week 24 Among Those Participants Who Had Achieved Rapid Virologic Response (RVR)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01544920</url>
  </study>
  <study rank="124">
    <nct_id>NCT00262483</nct_id>
    <title>Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">VX-950</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX05-950-102</other_id>
    </other_ids>
    <first_received>December 2, 2005</first_received>
    <start_date>December 2005</start_date>
    <completion_date>April 2006</completion_date>
    <last_updated>December 17, 2007</last_updated>
    <last_verified>December 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Safety of triple combination therapy.</outcome_measure>
      <outcome_measure>Pharmacokinetics of VX-950, peginterferon alfa-2a and ribavirin.</outcome_measure>
      <outcome_measure>Plasma HCV RNA levels</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00262483</url>
  </study>
  <study rank="125">
    <nct_id>NCT00377182</nct_id>
    <title>A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">PEGASYS</intervention>
      <intervention type="Drug">RO5024048</intervention>
      <intervention type="Drug">RO5024048</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>107</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>PV18369</other_id>
    </other_ids>
    <first_received>September 15, 2006</first_received>
    <start_date>September 2006</start_date>
    <completion_date>August 2008</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>AEs and laboratory parameters.</outcome_measure>
      <outcome_measure>Plasma concentration of HCV polymerase inhibitor</outcome_measure>
      <outcome_measure>Antiviral activity</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00377182</url>
  </study>
  <study rank="126">
    <nct_id>NCT01183169</nct_id>
    <title>Efficacy and Safety of DEB025 Combined With Peg-IFN Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Relapsers and Non-responders</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DEB025 600 mg QD + PegIFN + RBV</intervention>
      <intervention type="Drug">DEB025 800 mg QD + PegIFN + RBV</intervention>
      <intervention type="Drug">placebo + PegIFN + RBV</intervention>
      <intervention type="Drug">placebo + PegIFN + RBV</intervention>
      <intervention type="Drug">DEB025 400 mg BID + PegIFN + RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>459</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CDEB025A2210</other_id>
      <other_id>2010-020033-14</other_id>
    </other_ids>
    <first_received>August 16, 2010</first_received>
    <start_date>August 2010</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>March 19, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>cEVR (complete early virologic response) i.e. HCV RNA &lt; 25 IU/mL (by Limit of Quantitation, LOQ) ; the primary efficacy comparison is between DEB025 active plus peg-IFNÎ±2a once weekly + RBV BID and DEB025 placebo plus peg-IFNÎ±2a once weekly + RBV BID</outcome_measure>
      <outcome_measure>SVR12: sustained virologic response 12 weeks following cessation of therapy, defined as HCV RNA negative (by LOQ)</outcome_measure>
      <outcome_measure>cEVR after 12 week triple therapy with 600 mg DEB025 daily plus peg-IFNÎ±2a once weekly + RBV BID versus 800 mg daily plus peg-IFNÎ±2a once weekly + RBV BID versus 400 mg BID plus peg-IFNÎ±2a once weekly + RBV BID.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Hungary</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Spain</country>
      <country>Taiwan</country>
      <country>Turkey</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Kansas</state>
      <state>Massachusetts</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01183169</url>
  </study>
  <study rank="127">
    <nct_id>NCT02560649</nct_id>
    <title>An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a plus Entecavir</intervention>
      <intervention type="Drug">Peginterferon alfa-2a plus Lamivudine</intervention>
      <intervention type="Drug">Peginterferon alfa-2a plus Adefovir</intervention>
      <intervention type="Drug">Peginterferon alfa-2a plus Tenofovir</intervention>
      <intervention type="Drug">Entecavir</intervention>
      <intervention type="Drug">Lamivudine</intervention>
      <intervention type="Drug">Adefovir</intervention>
      <intervention type="Drug">Tenofovir disoproxil</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ruijin Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>324</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PYRAMID</other_id>
    </other_ids>
    <first_received>September 22, 2015</first_received>
    <start_date>May 2015</start_date>
    <completion_date>February 2017</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants who achieve HBsAg clearance</outcome_measure>
      <outcome_measure>Number of participants who achieve HBsAg seroconversion</outcome_measure>
      <outcome_measure>Number of participants who achieve HBeAg loss</outcome_measure>
      <outcome_measure>Number of participants who achieve HBeAg seroconversion</outcome_measure>
      <outcome_measure>Percentage of of participants who achieve HBsAg decline &gt;2log from baseline(0 week)</outcome_measure>
      <outcome_measure>Percentage of of participants who achieve HBsAg &lt;10IU/mL</outcome_measure>
      <outcome_measure>Percentage of of participants who achieve combined response(defined as HBeAg seroconversion and HBVDNA&lt;300copies/mL)</outcome_measure>
      <outcome_measure>Percentage of of participants who achieve dural response I (defined as HBeAg seroconversion and HBsAg&lt;100IU/mL)</outcome_measure>
      <outcome_measure>Percentage of of participants who achieve dural response II (defined as HBeAg seroconversion and HBsAg&lt;10IU/mL)</outcome_measure>
      <outcome_measure>Number of participants who relapses (HBVDNA&gt;1000copies/ml)</outcome_measure>
      <outcome_measure>Number of Participants with AE</outcome_measure>
      <outcome_measure>Number of Participants with SAE</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02560649</url>
  </study>
  <study rank="128">
    <nct_id>NCT01596517</nct_id>
    <title>Efficacy and Effectiveness of PegInterferon and Ribavirin in Korean Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a plus ribavirin for HCV genotype 1</intervention>
      <intervention type="Drug">Peginterferon alfa-2a plus ribavirin for HCV genotype 2/3</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Asan Medical Center</lead_sponsor>
      <collaborator>Samsung Medical Center</collaborator>
      <collaborator>Severance Hospital</collaborator>
      <collaborator>Gangnam Severance Hospital</collaborator>
      <collaborator>Seoul St. Mary's Hospital</collaborator>
      <collaborator>Korea University Guro Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>272</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AMC2003-0059</other_id>
    </other_ids>
    <first_received>May 7, 2012</first_received>
    <start_date>June 2003</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>May 12, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The proportion of patients achieving sustained virological response (SVR)</outcome_measure>
      <outcome_measure>The proportion of patients achieving early virological response (EVR)</outcome_measure>
      <outcome_measure>the proportion of patients achieving complete EVR (cEVR)</outcome_measure>
      <outcome_measure>The proportion of patients achieving end-of-treatment response (ETR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Korea, Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01596517</url>
  </study>
  <study rank="129">
    <nct_id>NCT00487747</nct_id>
    <title>A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>19</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML20003</other_id>
    </other_ids>
    <first_received>June 18, 2007</first_received>
    <completion_date>October 2009</completion_date>
    <last_updated>February 15, 2010</last_updated>
    <last_verified>February 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>HBV DNA &lt;100,000 copies/mL (HBeAg positive patients)</outcome_measure>
      <outcome_measure>HBV DNA &lt;20,000 copies/mL (HBeAg negative patients)</outcome_measure>
      <outcome_measure>HBV DNA &lt;400 copies/mL, HbsAg seroconversion, ALT normalization, sustained HBe seroconversion in HBeAg positive patients.</outcome_measure>
      <outcome_measure>AEs and laboratory parameters</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Russian Federation</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00487747</url>
  </study>
  <study rank="130">
    <nct_id>NCT00275548</nct_id>
    <title>Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Liver Transplant</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Copegus</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
      <collaborator>Roche Pharma AG</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1404-04</other_id>
    </other_ids>
    <first_received>January 10, 2006</first_received>
    <start_date>July 2004</start_date>
    <completion_date>April 2009</completion_date>
    <last_updated>November 9, 2011</last_updated>
    <last_verified>November 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The proportion of patients in each group who experienced histologically confirmed recurrence of HCV at 120 weeks post randomization.</outcome_measure>
      <outcome_measure>The proportion of patients who have non-detectable serum HCV-RNA measured by Quanta Sure plus HCV test and HCV RNA negative by quantitative PCR at week 12, 24, and 48 following initiation of treatment or on observation.</outcome_measure>
      <outcome_measure>Virological response rate to antiviral therapy at week 12, week 24, and week 48 of therapy among patients who received antiviral therapy in either study arm.</outcome_measure>
      <outcome_measure>Sustained virological response rate: the virological response at the conclusion of the 24 weeks treatment free follow-up period or 72 weeks on observation (for patients who received no treatment).</outcome_measure>
      <outcome_measure>The virological response at the conclusion of the 24 weeks treatment-free follow-up period among patients who received antiviral therapy in either arm of the study.</outcome_measure>
      <outcome_measure>Patient death or graft failure (as indicated by retransplantation).</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Minnesota</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00275548</url>
  </study>
  <study rank="131">
    <nct_id>NCT01787279</nct_id>
    <title>An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>59</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML19522</other_id>
    </other_ids>
    <first_received>February 6, 2013</first_received>
    <start_date>January 2006</start_date>
    <completion_date>April 2012</completion_date>
    <last_updated>November 2, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of patients achieving HCV DNA &lt;10'000 copies/ml (Roche PCR or Taqman tests)</outcome_measure>
      <outcome_measure>Percentage of patients achieving normalization of alanine aminotransferase (ALT)</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
      <outcome_measure>Percentage of patients achieving HBV DNA &lt; 400 copies/ml (Roche PCR or Taqman tests)</outcome_measure>
      <outcome_measure>Percentage of patients achieving HBsAg seroconversion (HBsAg-negative, anti-HBs positive)</outcome_measure>
      <outcome_measure>Percentage of patients achieving combined response (HBV DNA &lt; 10'000 copies/ml and normal ALT)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Morocco</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01787279</url>
  </study>
  <study rank="132">
    <nct_id>NCT00963885</nct_id>
    <title>A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">danoprevir</intervention>
      <intervention type="Drug">danoprevir</intervention>
      <intervention type="Drug">danoprevir</intervention>
      <intervention type="Drug">danoprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>229</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV21075</other_id>
      <other_id>2009-009608-38</other_id>
    </other_ids>
    <first_received>August 18, 2009</first_received>
    <start_date>August 2009</start_date>
    <completion_date>January 2012</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response</outcome_measure>
      <outcome_measure>Virological response over time</outcome_measure>
      <outcome_measure>Adverse events; laboratory parameters</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Louisiana</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Washington</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00963885</url>
  </study>
  <study rank="133">
    <nct_id>NCT01467479</nct_id>
    <title>A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Biological">Pegylated Interferon Alfa-2a</intervention>
      <intervention type="Drug">Highly Active Antiretroviral Therapy (HAART)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>185</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX11-950-115</other_id>
    </other_ids>
    <first_received>November 3, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>March 3, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>March 3, 2015</firstreceived_results_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR 24)</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Viral Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Extended Rapid Viral Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Undetectable HCV RNA at End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Maximum (Cmax), Minimum (Cmin), and Average Plasma Concentration (Cavg)</outcome_measure>
      <outcome_measure>Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Germany</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maine</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>South Carolina</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01467479</url>
  </study>
  <study rank="134">
    <nct_id>NCT01753557</nct_id>
    <title>Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-NaÃ¯ve or Relapsed Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C (CHC)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MP-424</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">PEG-IFN alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mitsubishi Tanabe Pharma Corporation</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>54</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>G060-A12</other_id>
    </other_ids>
    <first_received>December 13, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>November 2014</completion_date>
    <last_updated>August 17, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Undetectable HCV (Hepatitis C Virus) RNA (Ribonucleic Acid) at 24 weeks after completion of drug administration (SVR, sustained viral response)</outcome_measure>
      <outcome_measure>Undetectable HCV RNA at 4 weeks after beginning of drug administration (RVR, rapid viral response)</outcome_measure>
      <outcome_measure>Undetectable HCV RNA at completion of drug administration (ETR, end-of-treatment response)</outcome_measure>
      <outcome_measure>Undetectable HCV RNA at 12 weeks after completion of drug administration</outcome_measure>
      <outcome_measure>Transition of serum HCV RNA levels</outcome_measure>
      <outcome_measure>Viral sequencing at the NS3 protease region of HCV virus</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01753557</url>
  </study>
  <study rank="135">
    <nct_id>NCT00436163</nct_id>
    <title>A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B (CHB).</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>38</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML20601</other_id>
    </other_ids>
    <first_received>February 15, 2007</first_received>
    <start_date>March 2007</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients with HBV DNA &lt;100,000 copies/mL</outcome_measure>
      <outcome_measure>HBV DNA &lt;400 copies/mL, HBsAg seroconversion, ALT normalization, sustained HBe seroconversion.</outcome_measure>
      <outcome_measure>AEs, laboratory parameters.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Estonia</country>
      <country>Latvia</country>
      <country>Lithuania</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00436163</url>
  </study>
  <study rank="136">
    <nct_id>NCT01641640</nct_id>
    <title>Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">PEG</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>328</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0110</other_id>
    </other_ids>
    <first_received>July 9, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>April 2013</completion_date>
    <last_updated>April 8, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>February 25, 2014</firstreceived_results_date>
    <acronym>NEUTRINO</acronym>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response (SVR)12</outcome_measure>
      <outcome_measure>Number of Participants Experiencing Adverse Events Leading to Permanent Discontinuation of Study Drug</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR4</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR24</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01641640</url>
  </study>
  <study rank="137">
    <nct_id>NCT01095835</nct_id>
    <title>A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>131</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML18253</other_id>
    </other_ids>
    <first_received>March 26, 2010</first_received>
    <start_date>February 2005</start_date>
    <completion_date>January 2010</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy: Alanine aminotransferase normalization plus lowering of HBV-DNA levels to &lt;20,000 copies/mL at end of follow-up period\n</outcome_measure>
      <outcome_measure>Efficacy: ALT normalization plus lowering of HBV-DNA levels to &lt;20,000 copies/mL, HBV-DNA below limit of quantification, and HBsAg loss and anti-HBs seroconversion at EoT, end of follow-up, and 24 weeks' follow-up\nSafety: AEs, vital signs, lab values\n</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01095835</url>
  </study>
  <study rank="138">
    <nct_id>NCT00474955</nct_id>
    <title>A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>27</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML20434</other_id>
    </other_ids>
    <first_received>May 16, 2007</first_received>
    <start_date>July 2007</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of patients with SVR</outcome_measure>
      <outcome_measure>Percentage of patients with undetectable HCV-RNA</outcome_measure>
      <outcome_measure>Percentage of patients with a 2log10 drop in HCV-RNA</outcome_measure>
      <outcome_measure>SAEs, premature withdrawals, AEs and laboratory parameters.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Russian Federation</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00474955</url>
  </study>
  <study rank="139">
    <nct_id>NCT00540345</nct_id>
    <title>Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon alpha 2a and plus ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a and ribavirin</intervention>
      <intervention type="Drug">pegylated interferon alpha 2a and ribavirin</intervention>
      <intervention type="Drug">pegylated interferon alpha 2a and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kaohsiung Medical University Chung-Ho Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KMUH-IRB-960057</other_id>
    </other_ids>
    <first_received>October 5, 2007</first_received>
    <start_date>October 2006</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>December 24, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy - Rapid virologic response (RVR), HCV RNA seronegative by PCR at week 4 Sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period</outcome_measure>
      <outcome_measure>Safety - adverse event rate and profile</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00540345</url>
  </study>
  <study rank="140">
    <nct_id>NCT00532701</nct_id>
    <title>Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-IFN + WB RBV for 16 weeks</intervention>
      <intervention type="Drug">Peg-IFN + LD RBV for 16 weeks</intervention>
      <intervention type="Drug">Peg-IFN + WB RBV for 24 weeks</intervention>
      <intervention type="Drug">Peg-IFN + WB RBV for 48 weeks</intervention>
      <intervention type="Drug">Peg-IFN + LD RBV for 24 weeks</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>National Science Council, Taiwan</collaborator>
      <collaborator>Department of Health, Executive Yuan, R.O.C. (Taiwan)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>880</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>200709014M</other_id>
    </other_ids>
    <first_received>September 18, 2007</first_received>
    <start_date>November 2007</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>June 3, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR)</outcome_measure>
      <outcome_measure>Histologic response (HR)</outcome_measure>
      <outcome_measure>Biochemical response (BR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00532701</url>
  </study>
  <study rank="141">
    <nct_id>NCT00962871</nct_id>
    <title>A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">tenofovir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PP22512</other_id>
    </other_ids>
    <first_received>August 19, 2009</first_received>
    <start_date>August 2009</start_date>
    <completion_date>February 2012</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Acute immunologic response</outcome_measure>
      <outcome_measure>Early kinetics of viral suppression</outcome_measure>
      <outcome_measure>Early changes in viral sequence associated with viral suppression</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>New Zealand</country>
      <country>Singapore</country>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00962871</url>
  </study>
  <study rank="142">
    <nct_id>NCT01591460</nct_id>
    <title>A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">boceprevir</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin (Copegus]</intervention>
      <intervention type="Drug">ribavirin (Copegus]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>165</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MV28073</other_id>
      <other_id>2011-004810-41</other_id>
    </other_ids>
    <first_received>May 2, 2012</first_received>
    <start_date>August 2012</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>July 10, 2015</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virological Response (SVR) at 12 Weeks After End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Percentage of Participants With SVR at 24 Weeks After EOT</outcome_measure>
      <outcome_measure>HCV RNA Levels</outcome_measure>
      <outcome_measure>Percentage of Participants With Virological Response</outcome_measure>
      <outcome_measure>Percentage of Participants With at Least a 1-Log, 2-Log, or 3-Log Reduction in HCV RNA</outcome_measure>
      <outcome_measure>Percentage of Participants With Virological Relapse Following EOT Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Virological Breakthrough Following On-Treatment Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Virological Rebound Following On-Treatment Decline in HCV RNA</outcome_measure>
      <outcome_measure>Percentage of Participants With Treatment Discontinued Based Upon Elevated (Week 12) or Detectable (Week 24) HCV RNA</outcome_measure>
      <outcome_measure>Duration of Treatment With PEG-IFN, RBV, and Boceprevir</outcome_measure>
      <outcome_measure>Percentage of Participants With a Dose Modification of PEG-IFN, RBV, or Boceprevir By Reason</outcome_measure>
      <outcome_measure>Percentage of Participants Receiving Target Administrations of PEG-IFN, RBV, and Boceprevir</outcome_measure>
      <outcome_measure>Number of Participants With a Safety-Related Dose Modification</outcome_measure>
      <outcome_measure>Time to Safety-Related Dose Modification</outcome_measure>
      <outcome_measure>Percentage of Participants Using Concomitant Hematopoietic Stimulants During Treatment and Follow-Up</outcome_measure>
      <outcome_measure>Percentage of Participants With a Concomitant Disease Prior to or During the Study</outcome_measure>
      <outcome_measure>Percentage of Participants Using Concomitant Medications During Treatment and Follow-Up</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>Germany</country>
      <country>Hungary</country>
      <country>Poland</country>
      <country>Romania</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01591460</url>
  </study>
  <study rank="143">
    <nct_id>NCT00700401</nct_id>
    <title>POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>266</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML21543</other_id>
    </other_ids>
    <first_received>June 17, 2008</first_received>
    <start_date>November 2008</start_date>
    <completion_date>November 2010</completion_date>
    <last_updated>January 12, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response</outcome_measure>
      <outcome_measure>Sustained virological response 24 weeks after treatment completion</outcome_measure>
      <outcome_measure>Virological response at end of treatment</outcome_measure>
      <outcome_measure>Virological relapse</outcome_measure>
      <outcome_measure>AEs, laboratory parameters.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Brazil</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00700401</url>
  </study>
  <study rank="144">
    <nct_id>NCT01288209</nct_id>
    <title>A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Peginterferon alfa-2a (PegIFNÎ±-2a )</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Pharmaceutical K.K.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>106</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017689</other_id>
      <other_id>TMC435HPC3004</other_id>
    </other_ids>
    <first_received>February 1, 2011</first_received>
    <start_date>February 2011</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>December 18, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>October 15, 2013</firstreceived_results_date>
    <primary_completion_date>September 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants With a Sustained Virologic Response at the End of Treatment (EOT) and 12 Weeks After the Last Dose of Treatment (SVR12)</outcome_measure>
      <outcome_measure>The Percentage of Participants With a Sustained Virologic Response 24 Weeks After the End of Treatment (EOT) and 24 Weeks After the Last Dose of Treatment (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up</outcome_measure>
      <outcome_measure>The Percentage of Participants With Undetectable Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) During Treatment and at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels During Treatment for Participants Who Did Not Achieve Undetectable Plasma HCV RNA Levels at Week 12</outcome_measure>
      <outcome_measure>The Number of Participants With Viral Breakthrough During the Study</outcome_measure>
      <outcome_measure>The Number of Participants Demonstrating Viral Relapse During the Study</outcome_measure>
      <outcome_measure>The Number Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal ALT Levels at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Met Response Guided Treatment (RGT) Criteria and Completed Treatment With Peginterferon Alpha-2a (PegIFNÎ±-2a) and Ribavirin (RBV) at Week 24</outcome_measure>
      <outcome_measure>Plasma Concentrations of TMC435</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24h) for TMC435</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01288209</url>
  </study>
  <study rank="145">
    <nct_id>NCT01193361</nct_id>
    <title>Ph IIA Study (SOC +/- NS5B)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-791325</intervention>
      <intervention type="Drug">BMS-791325</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Peg-interferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>39</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI443-012</other_id>
    </other_ids>
    <first_received>August 25, 2010</first_received>
    <start_date>October 2010</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HEPCAT</acronym>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety, as measured by the frequency of serious adverse events (SAEs) and discontinuations due to adverse events (AEs)</outcome_measure>
      <outcome_measure>Antiviral activity, as determined by the proportion subjects with eRVR</outcome_measure>
      <outcome_measure>Proportion of subjects with rapid virologic response (RVR), defined as undetectable HCV RNA</outcome_measure>
      <outcome_measure>Proportion of subjects with complete early virologic response (cEVR), defined as undetectable HCV RNA</outcome_measure>
      <outcome_measure>Proportions of subjects with a 12-week SVR (SVR12) and 24-week SVR (SVR24), defined as undetectable HCV RNA at off treatment follow-up</outcome_measure>
      <outcome_measure>Resistant HCV variants associated with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01193361</url>
  </study>
  <study rank="146">
    <nct_id>NCT00442572</nct_id>
    <title>SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML20020</other_id>
    </other_ids>
    <first_received>February 15, 2007</first_received>
    <start_date>July 2006</start_date>
    <completion_date>April 2012</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Duration of treatment response (Serum HBV DNA &lt;100,000 copies/mL)</outcome_measure>
      <outcome_measure>Duration of treatment response</outcome_measure>
      <outcome_measure>Loss of HbsAg and seroconversion, and HBV DNA BLQ.</outcome_measure>
      <outcome_measure>Changes in liver fibrosis, AEs, lab parameters.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Bulgaria</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00442572</url>
  </study>
  <study rank="147">
    <nct_id>NCT01292239</nct_id>
    <title>A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Peginterferon alfa-2a (pegIFN alfa-2a)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Pharmaceutical K.K.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>183</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017686</other_id>
      <other_id>TMC435HPC3003</other_id>
    </other_ids>
    <first_received>February 1, 2011</first_received>
    <start_date>February 2011</start_date>
    <completion_date>October 2012</completion_date>
    <last_updated>December 16, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>October 15, 2013</firstreceived_results_date>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants With a Sustained Virologic Response at the End of Treatment (EOT) and 12 Weeks After the Last Dose of Treatment (SVR12)</outcome_measure>
      <outcome_measure>The Percentage of Participants With a Sustained Virologic Response at the End of Treatment (EOT) and 24 Weeks After the Last Dose of Treatment (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up</outcome_measure>
      <outcome_measure>The Percentage of Participants With Undetectable Plasma Levels of Hepatitis C Virus Ribonucleic Acid (HCV RNA) During Treatment and at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>The Number of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>The Number of Participants Demonstrating Viral Relapse</outcome_measure>
      <outcome_measure>The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal ALT Levels at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>The Percentage of Participants in the TMC435 Treatment Group Who Met Response Guided Treatment (RGT) Criteria and Completed Treatment With Peginterferon Alpha-2a (PegIFN Alpha-2a) and Ribavirin (RBV) at Week 24</outcome_measure>
      <outcome_measure>Plasma Concentrations of TMC435</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24h) for TMC435</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01292239</url>
  </study>
  <study rank="148">
    <nct_id>NCT01749150</nct_id>
    <title>A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">danoprevir + ritonavir</intervention>
      <intervention type="Drug">danoprevir + ritonavir</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>61</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>YV28218</other_id>
    </other_ids>
    <first_received>December 11, 2012</first_received>
    <start_date>April 2013</start_date>
    <completion_date>February 2015</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
      <outcome_measure>Pharmacokinetics: Area under the concentration-time curve (AUC) for danoprevir/ritonavir</outcome_measure>
      <outcome_measure>Antiviral activity: Change in HCV RNA levels, measured using Roche COBAS TaqMan HCV Test v2.0 for High Pure System</outcome_measure>
      <outcome_measure>Antiviral activity: Proportion of patients with unquantifiable/undetectable HCV RNA during the study</outcome_measure>
      <outcome_measure>Incidence of viral resistance to danoprevir</outcome_measure>
      <outcome_measure>Rapid virological response (RVR): Proportion of patients with undetectable HCV RNA at Week 4</outcome_measure>
      <outcome_measure>Complete early virological response (cEVR): Proportion of patients with undetectable HCV RNA at Week 12</outcome_measure>
      <outcome_measure>Sustained virological response 12 weeks after end of treatment (SVR-12), defined as unquantifiable HCV RNA 8-20 weeks after the last day of study drug administration</outcome_measure>
      <outcome_measure>Sustained virological response 24 weeks after end of treatment (SVR-24), defined as unquantifiable HCV RNA &gt; 20 weeks after the last day of study drug administration</outcome_measure>
      <outcome_measure>SVR measured as HCV RNA log10 IU/mL change from baseline to Week 12</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Korea, Republic of</country>
      <country>Taiwan</country>
      <country>Thailand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01749150</url>
  </study>
  <study rank="149">
    <nct_id>NCT01237496</nct_id>
    <title>Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a (40KD)) - Immunology Sub-Study of ML18253</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>17</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacodynamics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML18675</other_id>
    </other_ids>
    <first_received>November 8, 2010</first_received>
    <start_date>July 2005</start_date>
    <completion_date>September 2009</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>CD4 and CD8 mediated immune response: Interferon-y (ELISPOT analysis, flow cytometry)</outcome_measure>
      <outcome_measure>CD4 and CD8 mediated immune response: Interleukin-2 production (Flow cytometry)</outcome_measure>
      <outcome_measure>CD4 and CD8 mediated immune response: Cytokine profile analysis by supernatant culture</outcome_measure>
      <outcome_measure>CD4 and CD8 mediated immune response: Proliferative response upon T-cell stimulation</outcome_measure>
      <outcome_measure>CD8 response in HLA-A2 positive patients</outcome_measure>
      <outcome_measure>Profile of proinflammatory cytokines: analysis of cytokines in serum</outcome_measure>
      <outcome_measure>HBV viremia (HBV RNA assessed by COBAS PaqMan HCV test)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01237496</url>
  </study>
  <study rank="150">
    <nct_id>NCT01429792</nct_id>
    <title>A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 &amp; 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>940</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML21779</other_id>
    </other_ids>
    <first_received>September 5, 2011</first_received>
    <start_date>September 2008</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rate of genotype 1 patients with partial early viral response (pEVR, a 2-log decrement but with detectable HCV RNA at Week 12 of standard treatment)</outcome_measure>
      <outcome_measure>Rate of genotype 1 patients with complete early viral response (cEVR, undetectable HCV RNA at Week 12 of standard treatment)</outcome_measure>
      <outcome_measure>Rate of genotype 1 patients with pEVR at Week 12 and undetectable HCV RNA at Week 24</outcome_measure>
      <outcome_measure>Rate of genotype 2 &amp; 3 patients not achieving rapid viral response (RVR, defined as undetectable HCV RNA at Week 4 of standard treatment)</outcome_measure>
      <outcome_measure>Rate of genotype 2 &amp; 3 patients achieving virological response at Week 24 (EOT - end of treatment, defined as undetectable HVC RNA)</outcome_measure>
      <outcome_measure>Rate of genotype 4 patients with partial EVR</outcome_measure>
      <outcome_measure>Rate of genotype 4 patients with complete EVR</outcome_measure>
      <outcome_measure>Rate of genotype 4 patients with pEVR at Week 12 and undetectable HCV RNA at Week 24</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Israel</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01429792</url>
  </study>
  <study rank="151">
    <nct_id>NCT00575224</nct_id>
    <title>Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Asian Americans</condition>
      <condition>Novel Genotypes</condition>
      <condition>Treatment</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pacific Health Foundation</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PEG-183</other_id>
      <other_id>IRB Protocol #20041038</other_id>
      <other_id>IRB Study #1059635</other_id>
    </other_ids>
    <first_received>December 15, 2007</first_received>
    <start_date>October 2004</start_date>
    <completion_date>September 2009</completion_date>
    <last_updated>November 23, 2009</last_updated>
    <last_verified>November 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00575224</url>
  </study>
  <study rank="152">
    <nct_id>NCT01143662</nct_id>
    <title>Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ypeginterferon alfa-2b</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Xiamen Amoytop Biotech Co., Ltd.</lead_sponsor>
      <collaborator>Peking University First Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>205</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TB1007IFN</other_id>
    </other_ids>
    <first_received>June 11, 2010</first_received>
    <start_date>July 2010</start_date>
    <completion_date>April 2012</completion_date>
    <last_updated>January 31, 2013</last_updated>
    <last_verified>June 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01143662</url>
  </study>
  <study rank="153">
    <nct_id>NCT00475072</nct_id>
    <title>A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>14</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML16814</other_id>
    </other_ids>
    <first_received>May 16, 2007</first_received>
    <start_date>June 2003</start_date>
    <completion_date>July 2006</completion_date>
    <last_updated>November 2, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR</outcome_measure>
      <outcome_measure>AEs, laboratory parameters.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Mexico</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00475072</url>
  </study>
  <study rank="154">
    <nct_id>NCT00460850</nct_id>
    <title>A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a (40KD) [PEGASYS]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML20135</other_id>
    </other_ids>
    <first_received>April 16, 2007</first_received>
    <start_date>September 2007</start_date>
    <completion_date>June 2008</completion_date>
    <last_updated>June 27, 2008</last_updated>
    <last_verified>June 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Normalization of ALT, and HBV-DNA &lt;10,000 copies/mL</outcome_measure>
      <outcome_measure>HBsAg loss and anti-HBs seroconversion</outcome_measure>
      <outcome_measure>AEs and lab parameters</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Turkey</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00460850</url>
  </study>
  <study rank="155">
    <nct_id>NCT00962715</nct_id>
    <title>Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Lymphocytic Leukemia</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Influenza Vaccine Trivalent Inactivated (TIV)</intervention>
      <intervention type="Drug">Pegylated interferon (PEGrIFN-Î±, Pegasys)</intervention>
      <intervention type="Drug">Interferon (IFNÎ±, Roferon-A)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>M.D. Anderson Cancer Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2007-0145</other_id>
    </other_ids>
    <first_received>August 19, 2009</first_received>
    <start_date>April 2011</start_date>
    <last_updated>August 2, 2012</last_updated>
    <last_verified>August 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Immunogenicity rate</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00962715</url>
  </study>
  <study rank="156">
    <nct_id>NCT00830609</nct_id>
    <title>High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa 2 A</intervention>
      <intervention type="Drug">Peginterferon alfa 2 A, ribavirin + Epo Beta</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa 2</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Dr. Conrado Fernandez</lead_sponsor>
      <collaborator>Hospital Universitario FundaciÃ³n AlcorcÃ³n</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>101</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ROCHE FARMA S.A.</other_id>
    </other_ids>
    <first_received>January 27, 2009</first_received>
    <start_date>November 2008</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>March 12, 2012</last_updated>
    <last_verified>March 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>DARGEN-3</acronym>
    <primary_completion_date>September 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rate of patients with RNA-HCV negative in each arm at week 24 after the end of treatment.</outcome_measure>
      <outcome_measure>Rate of patients with undetectable RNA-HCV in each arm at week 4 and 24 of treatment. Rate of adverse effects in each arm.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00830609</url>
  </study>
  <study rank="157">
    <nct_id>NCT00637923</nct_id>
    <title>Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitazoxanide</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Biological">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Romark Laboratories L.C.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>112</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>RM01-2026</other_id>
    </other_ids>
    <first_received>March 11, 2008</first_received>
    <start_date>March 2008</start_date>
    <completion_date>April 2010</completion_date>
    <last_updated>January 9, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>November 18, 2013</firstreceived_results_date>
    <acronym>STEALTHC-3</acronym>
    <primary_completion_date>April 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (HCV RNA Below Lower Limit of Detection)</outcome_measure>
      <outcome_measure>End of Treatment Response (HCV RNA Below Lower Limit of Detection)</outcome_measure>
      <outcome_measure>Early Virologic Response (HCV RNA Below Lower Limit of Detection)</outcome_measure>
      <outcome_measure>Rapid Virologic Response (HCV RNA Below Lower Limit of Detection)</outcome_measure>
      <outcome_measure>Changes in ALT</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Massachusetts</state>
      <state>New York</state>
      <state>Tennessee</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00637923</url>
  </study>
  <study rank="158">
    <nct_id>NCT00087633</nct_id>
    <title>PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">Copegus</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>115</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML18124</other_id>
    </other_ids>
    <first_received>July 12, 2004</first_received>
    <start_date>October 2004</start_date>
    <completion_date>October 2008</completion_date>
    <last_updated>December 22, 2010</last_updated>
    <last_verified>December 2010</last_verified>
    <firstreceived_results_date>October 14, 2009</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Percentage of Patients With Histologically-confirmed Recurrence of Hepatitis C Virus (HCV)</outcome_measure>
      <outcome_measure>Summary of Virologic Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Washington</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00087633</url>
  </study>
  <study rank="159">
    <nct_id>NCT00922207</nct_id>
    <title>A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Adefovir</intervention>
      <intervention type="Drug">Entecavir</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>280</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML21827</other_id>
    </other_ids>
    <first_received>June 16, 2009</first_received>
    <start_date>May 2010</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>October 20, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>October 20, 2015</firstreceived_results_date>
    <primary_completion_date>September 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Hepatitis B e-Antigen (HBeAg) Seroconversion at 100 Weeks After Start of Treatment</outcome_measure>
      <outcome_measure>Change From Baseline in Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Levels at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100</outcome_measure>
      <outcome_measure>Percentage of Participants Who Were HBeAg Negative</outcome_measure>
      <outcome_measure>Percentage of Participant Who Were Both Hepatitis B Surface Antigen (HBsAg) Negative and Hepatitis B Surface Antibody (Anti-HBs/HBsAb) Positive</outcome_measure>
      <outcome_measure>Percentage of Participant With Normal Alanine Aminotransferase (ALT) Levels</outcome_measure>
      <outcome_measure>Change From Baseline in HBsAg Levels at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100</outcome_measure>
      <outcome_measure>Percentage of Participants With Combined Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00922207</url>
  </study>
  <study rank="160">
    <nct_id>NCT01448044</nct_id>
    <title>Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-790052 (NS5A Replication Complex Inhibitor)</intervention>
      <intervention type="Drug">Placebo matching BMS-790052</intervention>
      <intervention type="Drug">Pegylated-interferon alfa 2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>152</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-042</other_id>
      <other_id>2011-002793-23</other_id>
    </other_ids>
    <first_received>October 5, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>September 11, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 7, 2015</firstreceived_results_date>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With 12 Week Sustained Virologic Response (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieve HCV Ribonucleic Acid (RNA) &lt; Limit of Quantification (LLOQ)</outcome_measure>
      <outcome_measure>Percentage of Participants With Undetectable Hepatitis C Virus (HCV) RNA Levels</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) or Sustained Virologic Response at Follow-up Week 24 (SVR24) by rs12979860 Single Nucleotide Polymorphism (SNP) in the IL28B Gene</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs) and Who Died</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
      <country>Greece</country>
      <country>Italy</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Massachusetts</state>
      <state>Rhode Island</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01448044</url>
  </study>
  <study rank="161">
    <nct_id>NCT00087607</nct_id>
    <title>PEAK Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">PEG-Intron</intervention>
      <intervention type="Drug">Rebetol</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>385</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacodynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML17756</other_id>
    </other_ids>
    <first_received>July 12, 2004</first_received>
    <start_date>December 2003</start_date>
    <completion_date>May 2006</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Viral load reduction from baseline.</outcome_measure>
      <outcome_measure>Viral load reduction</outcome_measure>
      <outcome_measure>Viral AUC and AAUCMB.</outcome_measure>
      <outcome_measure>AEs, laboratory parameters.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arkansas</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Kansas</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>Nevada</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00087607</url>
  </study>
  <study rank="162">
    <nct_id>NCT00107653</nct_id>
    <title>Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>569</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML18179</other_id>
    </other_ids>
    <first_received>April 6, 2005</first_received>
    <start_date>August 2004</start_date>
    <completion_date>February 2008</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of patients with sustained virologic response</outcome_measure>
      <outcome_measure>Percentage of patients with early virologic response</outcome_measure>
      <outcome_measure>Percentage of patients with virologic response</outcome_measure>
      <outcome_measure>AEs, laboratory parameters, premature withdrawals</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00107653</url>
  </study>
  <study rank="163">
    <nct_id>NCT01581398</nct_id>
    <title>Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ypeginterferon alfa-2b</intervention>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Ypeginterferon alfa-2b</intervention>
      <intervention type="Drug">Pegasys</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Xiamen Amoytop Biotech Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>770</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TB1203IFN</other_id>
    </other_ids>
    <first_received>February 16, 2012</first_received>
    <start_date>April 2012</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>October 6, 2014</last_updated>
    <last_verified>April 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients with sustained virologic response (defined as HCV RNA&lt;15IU/ml at 24 weeks after the end of therapy)</outcome_measure>
      <outcome_measure>Proportion of patients with HCV RNA undetectable (defined as HCV RNA &lt;15IU/ml)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01581398</url>
  </study>
  <study rank="164">
    <nct_id>NCT00087594</nct_id>
    <title>A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML17251</other_id>
    </other_ids>
    <first_received>July 12, 2004</first_received>
    <start_date>November 2003</start_date>
    <completion_date>October 2006</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Treatment completion rate\n</outcome_measure>
      <outcome_measure>AEs, laboratory parameters.</outcome_measure>
      <outcome_measure>Beck Depression Inventory, HQLQ, SVR, biochemical response.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Connecticut</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>New York</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00087594</url>
  </study>
  <study rank="165">
    <nct_id>NCT00580801</nct_id>
    <title>An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Pegylated-interferon-alfa-2a</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec BVBA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR013714</other_id>
      <other_id>VX-950-TiDP24-C210</other_id>
    </other_ids>
    <first_received>December 20, 2007</first_received>
    <start_date>January 2008</start_date>
    <completion_date>January 2010</completion_date>
    <last_updated>August 27, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>March 7, 2013</firstreceived_results_date>
    <primary_completion_date>January 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Day 15</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Response (Undetectable HCV RNA)</outcome_measure>
      <outcome_measure>Median Time to First Viral Response (Undetectable HCV RNA)</outcome_measure>
      <outcome_measure>Number of Participants With Viral Breakthrough (Detectable HCV RNA)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Viral Response (SVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Relapse</outcome_measure>
      <outcome_measure>Area Under the Serum Concentration-Time Curve (AUC)</outcome_measure>
      <outcome_measure>Maximum Serum Concentration (Cmax) of Telaprevir</outcome_measure>
      <outcome_measure>Pre-Dose Serum Concentration (C[0h]) of Telaprevir</outcome_measure>
      <outcome_measure>Minimum Serum Concentration (Cmin) of Telaprevir on Day 15</outcome_measure>
      <outcome_measure>Time to Reach the Maximum Serum Concentration (Tmax) of Telaprevir</outcome_measure>
      <outcome_measure>Average Steady-State Serum Concentration (Css,av) of Telaprevir</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00580801</url>
  </study>
  <study rank="166">
    <nct_id>NCT00758043</nct_id>
    <title>A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment NaÃ¯ve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">telaprevir</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Biological">peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
      <collaborator>Tibotec Pharmaceutical Limited</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>540</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX08-950-111</other_id>
      <other_id>EudraCT 2008-003836-39</other_id>
    </other_ids>
    <first_received>September 19, 2008</first_received>
    <start_date>October 2008</start_date>
    <completion_date>July 2010</completion_date>
    <last_updated>September 30, 2013</last_updated>
    <last_verified>June 2011</last_verified>
    <firstreceived_results_date>June 22, 2011</firstreceived_results_date>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of Randomized Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable HCV RNA 24 Weeks After Last Dose of Study Treatment (SVR24)</outcome_measure>
      <outcome_measure>Proportion of Subjects Who Have Undetectable HCV RNA at Week 72</outcome_measure>
      <outcome_measure>Proportion of Subjects Achieving eRVR (Extended RVR), Demonstrated by Achieving Undetectable HCV RNA at Week 4 and at Week 12</outcome_measure>
      <outcome_measure>Proportion of Randomized Subjects Who Have Undetectable HCV RNA 12 Weeks After Last Dose of Study Treatment</outcome_measure>
      <outcome_measure>Proportion of Randomized Subjects Who Relapse, Defined as Those Who Complete Treatment, Have Undetectable HCV RNA at End of Treatment (EOT; Week 24 or Week 48 Respectively), and Become HCV RNA Detectable During Antiviral Follow-up</outcome_measure>
      <outcome_measure>Proportion of Enrolled Subjects Who Relapse, Defined as Those Who Have Undetectable HCV RNA at the EOT, and Become HCV RNA Detectable During Antiviral Follow-up</outcome_measure>
      <outcome_measure>Proportion of Subjects Who Have Undetectable HCV RNA at the EOT (Week 24 or Week 48 Respectively).</outcome_measure>
      <outcome_measure>Adverse Events, Physical Examination Findings, and Clinical Laboratory, Vital Sign, and Electrocardiogram (ECG) Assessments</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Belgium</country>
      <country>Netherlands</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00758043</url>
  </study>
  <study rank="167">
    <nct_id>NCT01609933</nct_id>
    <title>A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hepatitis C (HCV)</condition>
      <condition>Hepatitis C Genotype 1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450/r</intervention>
      <intervention type="Drug">ABT-267</intervention>
      <intervention type="Drug">pegylated interferon alpha-2a (pegIFN)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>93</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M13-101</other_id>
      <other_id>2011-005393-32</other_id>
    </other_ids>
    <first_received>May 30, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>May 2017</completion_date>
    <last_updated>October 10, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of subjects achieving 12-week sustained virologic response following treatment with 2 direct acting anti-virals and peginterferon alpha-2a and ribavirin in Hepatitis C infected adults.</outcome_measure>
      <outcome_measure>Percentage of subjects achieving 24-week sustained virologic response following treatment with 2 direct acting anti-viral and peginterferon alpha-2a and ribavirin in Hepatitis C infected adults.</outcome_measure>
      <outcome_measure>Percentage of subjects with extended rapid virologic response (Hepatitis C ribonucleic acid less than lower limit of quantitation at Weeks 4 through 12 of therapy with ABT 450/r plus ABT-267 plus peginterferon alpha-2a plus ribavirin)</outcome_measure>
      <outcome_measure>Number and percentage of subjects having treatment-emergent adverse events.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Germany</country>
      <country>Hungary</country>
      <country>Italy</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Slovakia</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oregon</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01609933</url>
  </study>
  <study rank="168">
    <nct_id>NCT00661076</nct_id>
    <title>ADVANCE Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) + Adefovir Dipivoxil in Patients With Hbe(-) Chronic Hepatitis B</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">adefovir dipivoxil</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML20622</other_id>
    </other_ids>
    <first_received>April 16, 2008</first_received>
    <start_date>August 2008</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Normalization of ALT, and HBV-DNA &lt;400 copies/mL</outcome_measure>
      <outcome_measure>HBsAg quantitative loss and anti-HBs seroconversion</outcome_measure>
      <outcome_measure>AEs, lab parameters, vital signs</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Turkey</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00661076</url>
  </study>
  <study rank="169">
    <nct_id>NCT00491179</nct_id>
    <title>Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hemodialysis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa-2a and ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>National Science Council, Taiwan</collaborator>
      <collaborator>Department of Health, Executive Yuan, R.O.C. (Taiwan)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>35</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>200703032M</other_id>
    </other_ids>
    <first_received>June 23, 2007</first_received>
    <start_date>June 2006</start_date>
    <completion_date>July 2008</completion_date>
    <last_updated>October 7, 2009</last_updated>
    <last_verified>October 2009</last_verified>
    <firstreceived_results_date>December 21, 2008</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>1.Number of Participants With Sustained Virologic Response (SVR) 2.Number of Participants Who Droppoed Out of the Study Prematurely Due to Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Number of Participants With Histologic Response(HR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00491179</url>
  </study>
  <study rank="170">
    <nct_id>NCT00006164</nct_id>
    <title>Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Cirrhosis, Liver</condition>
      <condition>Fibrosis, Liver</condition>
      <condition>Hepatic Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a + Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>National Institute of Allergy and Infectious Diseases (NIAID)</collaborator>
      <collaborator>National Institute on Minority Health and Health Disparities (NIMHD)</collaborator>
      <collaborator>National Cancer Institute (NCI)</collaborator>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1050</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HALT C</other_id>
      <other_id>N01-DK-9-2328</other_id>
      <other_id>N01-DK-9-2323</other_id>
      <other_id>N01-DK-9-2324</other_id>
      <other_id>N01-DK-9-2325</other_id>
      <other_id>N01-DK-9-2326</other_id>
      <other_id>N01-DK-9-2321</other_id>
      <other_id>N01-DK-9-2327</other_id>
      <other_id>N01-DK-9-2319</other_id>
      <other_id>N01-DK-9-2318</other_id>
      <other_id>N01-DK-9-2320</other_id>
      <other_id>N01-DK-9-2322</other_id>
    </other_ids>
    <first_received>August 8, 2000</first_received>
    <start_date>June 2000</start_date>
    <completion_date>October 2009</completion_date>
    <last_updated>January 12, 2010</last_updated>
    <last_verified>January 2010</last_verified>
    <firstreceived_results_date>June 9, 2009</firstreceived_results_date>
    <acronym>HALT-C</acronym>
    <primary_completion_date>April 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Progression of Liver Disease as Indicated by Death, Hepatic Decompensation, Hepatocellular Carcinoma, or for Patients With Noncirrhotic Fibrosis at Baseline, an Increase in the Ishak Hepatic Fibrosis Score of 2 or More Points</outcome_measure>
      <outcome_measure>Increase in Ishak Fibrosis Score by 2 Points or More at 2 or 4 Year Biopsies</outcome_measure>
      <outcome_measure>Death From Any Cause</outcome_measure>
      <outcome_measure>Development of Hepatocellular Carcinoma (HCC)</outcome_measure>
      <outcome_measure>Child-Turcotte-Pugh (CTP) Score of 7 or Higher at Two Consecutive Study Visits</outcome_measure>
      <outcome_measure>Variceal Hemorrhage</outcome_measure>
      <outcome_measure>Ascites</outcome_measure>
      <outcome_measure>Spontaneous Bacterial Peritonitis</outcome_measure>
      <outcome_measure>Hepatic Encephalopathy</outcome_measure>
      <outcome_measure>Serious Adverse Events</outcome_measure>
      <outcome_measure>Events Requiring Dose Reductions (in Both Treatment Groups).</outcome_measure>
      <outcome_measure>Changes in Fibrosis From Baseline at Year 2 or Year 4 Biopsy.</outcome_measure>
      <outcome_measure>Presumed Hepatocellular Carcinoma (HCC)</outcome_measure>
      <outcome_measure>Quality of Life</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00006164</url>
  </study>
  <study rank="171">
    <nct_id>NCT01769833</nct_id>
    <title>HBsAg Decline After Pegylated-interferon-Î± in e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-interferon-Alfa-2A</intervention>
      <intervention type="Drug">Nucleosides</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pusan National University Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>144</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML25659</other_id>
    </other_ids>
    <first_received>January 15, 2013</first_received>
    <start_date>May 2013</start_date>
    <completion_date>May 2016</completion_date>
    <last_updated>November 3, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in log10 HBsAg titer during antiviral therapy</outcome_measure>
      <outcome_measure>HBV DNA undetectability and below 400 IU/mL during antiviral therapy and follow-up</outcome_measure>
      <outcome_measure>HBeAg seroconversion and loss during antiviral therapy and at end of treatment and 1 and 2 years following end of treatment</outcome_measure>
      <outcome_measure>HBsAg loss and HBsAg seroconversion at end of treatment and 1 and 2 years following end of treatment</outcome_measure>
      <outcome_measure>Change in log10 HBsAg titer during follow-up</outcome_measure>
      <outcome_measure>Mean change in log10 HBsAg titre over time, as estimated from the area between the baseline value and the curve of log10 HBsAg titre divided by the duration of treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Korea, Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01769833</url>
  </study>
  <study rank="172">
    <nct_id>NCT01718158</nct_id>
    <title>Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naÃ¯ve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon Lambda-1a</intervention>
      <intervention type="Biological">Peginterferon Alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>444</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI452-021</other_id>
      <other_id>2011â005409â65</other_id>
    </other_ids>
    <first_received>October 29, 2012</first_received>
    <start_date>January 2013</start_date>
    <completion_date>October 2014</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>STRUCTURE</acronym>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects with Sustained Virologic Response at post-treatment follow-up Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve SVR12 in treatment-naive subjects</outcome_measure>
      <outcome_measure>Proportion of subjects with rash related dermatologic events</outcome_measure>
      <outcome_measure>Proportion of subjects who develop treatment emergent cytopenic abnormalities</outcome_measure>
      <outcome_measure>Proportion of subjects with on-treatment interferon (IFN) associated flu like/musculoskeletal symptoms</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve SVR24 [Hepatitis C virus (HCV) Ribonucleic acid (RNA) &lt; Lower limit of quantitation (LLOQ)] at post-treatment follow-up Week 24</outcome_measure>
      <outcome_measure>Proportion of subjects with adverse events (AEs), Serious adverse events (SAEs), dose reductions, and discontinuations due to AEs through end of follow-up</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve SVR12 with a 24-week treatment regimen</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve Extended rapid virologic response (eRVR) (HCV RNA &lt; LLOQ target not detected at Weeks 4 and 12 of treatment)</outcome_measure>
      <outcome_measure>Patient Health Questionnaire-9 (PHQ-9) score through end of follow-up</outcome_measure>
      <outcome_measure>Proportion of subjects with treatment emergent laboratory abnormalities by toxicity grade through End of treatment (EOT)</outcome_measure>
      <outcome_measure>Proportion of subjects with the following on-treatment interferon-associated neuropsychiatric symptoms through EOT</outcome_measure>
      <outcome_measure>Association of Single nucleotide polymorphism (SNPs) in Interleukin 28B (IL28B) (including rs12979860) or equilibrative nucleoside transporter 1 (ENT1) with clinical responses</outcome_measure>
      <outcome_measure>Resistant variants associated with virologic failure through end of follow-up</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Argentina</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Japan</country>
      <country>Korea, Republic of</country>
      <country>Poland</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Taiwan</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Georgia</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01718158</url>
  </study>
  <study rank="173">
    <nct_id>NCT01892241</nct_id>
    <title>Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Antiviral Treatment of Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegasys(Roche)</intervention>
      <intervention type="Drug">Entecavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Third Affiliated Hospital, Sun Yat-Sen University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>74</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ATFSHBVD</other_id>
    </other_ids>
    <first_received>August 22, 2012</first_received>
    <start_date>January 2010</start_date>
    <completion_date>February 2013</completion_date>
    <last_updated>September 28, 2013</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Complete viralogic response</outcome_measure>
      <outcome_measure>HBsAg loss and seroconversion</outcome_measure>
      <outcome_measure>ALT normalization</outcome_measure>
      <outcome_measure>Sick leave in patients in different groups</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01892241</url>
  </study>
  <study rank="174">
    <nct_id>NCT01389323</nct_id>
    <title>BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Peg-Interferon Alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>448</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-038</other_id>
    </other_ids>
    <first_received>July 6, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>September 19, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 17, 2015</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response at Post-treatment Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response at Post-treatment Week 12 (SVR12) With rs12979860 Single Nucleotide Polymorphisms at Baseline in the Interleukin-28B Gene</outcome_measure>
      <outcome_measure>Percentage of Participants With Hepatitis C Virus (HCV) RNA Levels &lt;Lower Limit of Quantitation (LLOQ), Target Detected or Target Not Detected, at Specified Time Points</outcome_measure>
      <outcome_measure>Percentage of Participants With Hepatitis C Virus (HCV) RNA Levels &lt;Lower Limit of Quantitation (LLOQ), Target Not Detected, at Specified Time Points</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Treatment-related AEs, and Who Died</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Mississippi</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oregon</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01389323</url>
  </study>
  <study rank="175">
    <nct_id>NCT01513941</nct_id>
    <title>An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated-Interferon-alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen-Cilag International NV</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>163</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100778</other_id>
      <other_id>VX-950HPC3008</other_id>
      <other_id>2011-004928-35</other_id>
    </other_ids>
    <first_received>January 16, 2012</first_received>
    <start_date>April 2012</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>May 22, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>INSIGHT</acronym>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients achieving undetectable plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels</outcome_measure>
      <outcome_measure>Change from baseline in log HCV RNA values</outcome_measure>
      <outcome_measure>Proportiond of patients achieving undetectable HCV RNA levels</outcome_measure>
      <outcome_measure>Proportion of patients achieving undetectable HCV RNA levels at Week 4</outcome_measure>
      <outcome_measure>Proportion of patients achieving undetectable HCV RNA levels at Week 12</outcome_measure>
      <outcome_measure>Proportion of patients achieving undetectable HCV RNA levels at Week 4 and Week 12 (eRVR)</outcome_measure>
      <outcome_measure>Proportion of patients achieving undetectable HCV RNA at the actual end of treatment</outcome_measure>
      <outcome_measure>Proportion of patients achieving less than 25 IU/mL</outcome_measure>
      <outcome_measure>Proportion of patients with on-treatment virologic failure</outcome_measure>
      <outcome_measure>Proportion of patients with relapse achieving detectable HCV RNA levels after previously undetectable HCV RNA levels</outcome_measure>
      <outcome_measure>Proportion of patients with relapse achieving detectable HCV RNA levels after previous HCV RNA levels</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Poland</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01513941</url>
  </study>
  <study rank="176">
    <nct_id>NCT02601976</nct_id>
    <title>Evaluation of UnipegÂ® for Response and Ongoing Safety in Pakistani Population</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Getz Pharma</lead_sponsor>
      <collaborator>Dimension Research</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>64</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GETZ-UNIP- 4010810</other_id>
    </other_ids>
    <first_received>November 2, 2015</first_received>
    <start_date>August 2010</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>November 9, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>EUROP</acronym>
    <primary_completion_date>September 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virological Response (SVR)</outcome_measure>
      <outcome_measure>End Treatment Response</outcome_measure>
      <outcome_measure>Reporting And Assessment of Adverse Events through CRF</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02601976</url>
  </study>
  <study rank="177">
    <nct_id>NCT01467505</nct_id>
    <title>An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated Interferon Alfa-2a</intervention>
      <intervention type="Drug">Immunosuppressant Regimen</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>61</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX11-950-117</other_id>
    </other_ids>
    <first_received>November 3, 2011</first_received>
    <start_date>February 2012</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>June 1, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>May 2, 2015</firstreceived_results_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Viral Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Extended Rapid Viral Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With On-Treatment Virologic Failure</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Pharmacokinetics of Telaprevir, Peg-IFN, RBV , and Selected Immunosuppressant Medications (Tacrolimus and Cyclosporine)</outcome_measure>
      <outcome_measure>Percentage of Participants Requiring Dose Titration of Immunosuppressant Medications</outcome_measure>
      <outcome_measure>Percentage of Participants With Biopsy Confirmed and Treated Rejection</outcome_measure>
      <outcome_measure>Percentage of Participants With Histological Evidence of Stabilization or Improvement in Inflammation Grade or Fibrosis Stage</outcome_measure>
      <outcome_measure>Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01467505</url>
  </study>
  <study rank="178">
    <nct_id>NCT00980330</nct_id>
    <title>A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Peg-IFN-alfa-2a (P)</intervention>
      <intervention type="Drug">Ribavirin (R)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>463</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR016063</other_id>
      <other_id>TMC435-TiDP16-C206</other_id>
      <other_id>2009-010590-20</other_id>
    </other_ids>
    <first_received>September 10, 2009</first_received>
    <start_date>October 2009</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>May 30, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>December 18, 2013</firstreceived_results_date>
    <acronym>ASPIRE</acronym>
    <primary_completion_date>August 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response at the End of Treatment (EOT) and 24 Weeks After the EOT (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants With a Greater Than 2 log10 Drop in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Time Points During Treatment</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving Plasma Levels of Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Undetectable During Treatment and Follow-up</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving Plasma Levels of Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Detectable or Undetectable During Treatment and Follow-up</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving an Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>The Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>The Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>The Number of Participants Who Achieved Normalized Alanine Aminotransferase (ALT) Levels at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Plasma Concentrations of TMC435</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24h) for TMC435</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>New Zealand</country>
      <country>Norway</country>
      <country>Poland</country>
      <country>Portugal</country>
      <country>Russian Federation</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Mississippi</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00980330</url>
  </study>
  <study rank="179">
    <nct_id>NCT01170962</nct_id>
    <title>Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-790052</intervention>
      <intervention type="Drug">BMS-790052</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">peginterferon alfa-2a</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>512</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-011</other_id>
      <other_id>2010-019378-34</other_id>
    </other_ids>
    <first_received>July 16, 2010</first_received>
    <start_date>August 2010</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>September 11, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 10, 2015</firstreceived_results_date>
    <acronym>HEPCAT</acronym>
    <primary_completion_date>June 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With 24-week Sustained Virologic Response (SVR24)</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs) and Who Died On-treatment</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs) and Who Died During Follow-up Period</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 12 (SVR12)</outcome_measure>
      <outcome_measure>Number of Participants With Genotypic-1A Substitution at Baseline, On-treatment and During Follow-up Associated With Virologic Failures</outcome_measure>
      <outcome_measure>Number of Participants With Genotypic-1B Substitution at Baseline, On-treatment and During Follow-up Associated With Virologic Failures</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Mexico</country>
      <country>Puerto Rico</country>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01170962</url>
  </study>
  <study rank="180">
    <nct_id>NCT01447420</nct_id>
    <title>A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-NaÃ¯ve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>129</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML25592</other_id>
    </other_ids>
    <first_received>October 4, 2011</first_received>
    <start_date>February 2011</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rate of sustained virological response (undetectable HCV RNA 24 weeks after end of treatment) in relation to Interleukin 28B (IL28-b) expression</outcome_measure>
      <outcome_measure>Incidence of anemia</outcome_measure>
      <outcome_measure>Response rate (rapid/early/end of treatment) in relation to IL28-b expression</outcome_measure>
      <outcome_measure>Correlation between sustained virological response and anemia (Hb levels) during the first month of treatment</outcome_measure>
      <outcome_measure>Correlation between sustained virological response and anemia (Hb levels) after the first month of treatment</outcome_measure>
      <outcome_measure>Correlation between viral load (HCV RNA levels) 12 weeks after the end of treatment and sustained virological response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Brazil</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01447420</url>
  </study>
  <study rank="181">
    <nct_id>NCT00423397</nct_id>
    <title>Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Non-melanomatous Skin Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PEG-interferon alfa-2a</intervention>
      <intervention type="Drug">gefitinib</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of California, San Diego</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CDR0000521454</other_id>
      <other_id>UCSD-051205</other_id>
      <other_id>ZENECA-IRUSIRES0488</other_id>
    </other_ids>
    <first_received>January 16, 2007</first_received>
    <start_date>September 2006</start_date>
    <last_updated>December 18, 2013</last_updated>
    <last_verified>March 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Tolerability</outcome_measure>
      <outcome_measure>Response rate to treatment with gefitinib alone for 1 month</outcome_measure>
      <outcome_measure>Response rate to treatment with gefitinib in combination with PEG-interferon alfa-2a</outcome_measure>
      <outcome_measure>Toxicity</outcome_measure>
      <outcome_measure>Quantification of rash after treatment with gefitinib for 1 month and after the addition of PEG-interferon alfa-2a to gefitinib</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00423397</url>
  </study>
  <study rank="182">
    <nct_id>NCT01289496</nct_id>
    <title>Ribavirin Dose Optimization for the Treatment of Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-interferon alpha-2a, Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Centre hospitalier de l'UniversitÃ© de MontrÃ©al (CHUM)</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
      <collaborator>Centre de Recherche du Centre Hospitalier de l'UniversitÃ© de MontrÃ©al</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>13</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML25553</other_id>
      <other_id>Control Number: 143155</other_id>
    </other_ids>
    <first_received>January 25, 2011</first_received>
    <start_date>February 2011</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>February 24, 2014</last_updated>
    <last_verified>August 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Hepatitis C Virus-Ribonucleic Acid (HCV-RNA) analysis assay</outcome_measure>
      <outcome_measure>Viral Kinetics</outcome_measure>
      <outcome_measure>Neutrophils</outcome_measure>
      <outcome_measure>Hemoglobin</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01289496</url>
  </study>
  <study rank="183">
    <nct_id>NCT01456312</nct_id>
    <title>HBsAg Related Response Guided Therapy</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Entecavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gangnam Severance Hospital</lead_sponsor>
      <collaborator>Roche Pharma AG</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML25588</other_id>
    </other_ids>
    <first_received>October 15, 2011</first_received>
    <start_date>September 2012</start_date>
    <completion_date>August 2016</completion_date>
    <last_updated>October 29, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>S-RGT</acronym>
    <primary_completion_date>February 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HBeAg seroconversion</outcome_measure>
      <outcome_measure>The changes of HBsAg titer</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Korea, Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01456312</url>
  </study>
  <study rank="184">
    <nct_id>NCT01425970</nct_id>
    <title>Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">INX-08189</intervention>
      <intervention type="Drug">INX-08189</intervention>
      <intervention type="Drug">INX-08189</intervention>
      <intervention type="Drug">Placebo matching with INX-08189</intervention>
      <intervention type="Biological">Pegylated interferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">INX-08189</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>210</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI472-003</other_id>
      <other_id>INH-189-003</other_id>
    </other_ids>
    <first_received>August 25, 2011</first_received>
    <start_date>May 2012</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>October 12, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Part A: Change in Hepatitis C Viral Load Measurements at protocol specific timepoints</outcome_measure>
      <outcome_measure>Part B: proportion of subjects with SVR defined as HCV RNA â¤ LOQ (Limit of Quantitation)</outcome_measure>
      <outcome_measure>Part B: proportion of subjects with SVR defined as HCV RNA â¤ LOQ</outcome_measure>
      <outcome_measure>Safety assessments is measured by Physical Exams, vital signs, laboratory assessments, ECGs, pregnancy test, viral resistance testing, adverse event assessment</outcome_measure>
      <outcome_measure>Proportion of subjects with RVR (Rapid Virologic Response), undetectable HCV RNA</outcome_measure>
      <outcome_measure>Proportion of subjects with Complete EVR (Early Virologic Response), undetectable HCV RNA</outcome_measure>
      <outcome_measure>Proportion of subjects with Extended RVR</outcome_measure>
      <outcome_measure>Proportion of subjects with SVR24</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Missouri</state>
      <state>Oklahoma</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01425970</url>
  </study>
  <study rank="185">
    <nct_id>NCT01185860</nct_id>
    <title>A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">danoprevir</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">placebo</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">ritonavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>59</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Single Blind (Subject)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NP22660</other_id>
      <other_id>2009-012426-36</other_id>
    </other_ids>
    <first_received>August 19, 2010</first_received>
    <start_date>August 2009</start_date>
    <completion_date>January 2012</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and tolerability: Adverse events, ECG, laboratory parameters</outcome_measure>
      <outcome_measure>Pharmacokinetics: Cmax, AUC, Cmin, Tmax, Cl, T1/2</outcome_measure>
      <outcome_measure>Antiviral activity: HCV RNA (COBAS Taqman HCV Test)</outcome_measure>
      <outcome_measure>Viral resistance development</outcome_measure>
      <outcome_measure>Effects on cytochrome P450(CYP)2C9 and 3A isozymes</outcome_measure>
      <outcome_measure>Virological response in prior null-responders</outcome_measure>
      <outcome_measure>Comparison of pharmacokinetics and antiviral activity between treatment-naÃ¯ve patients and prior null-responders to standard of care treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
      <country>New Zealand</country>
      <country>Poland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01185860</url>
  </study>
  <study rank="186">
    <nct_id>NCT02557646</nct_id>
    <title>An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>697</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML22453</other_id>
    </other_ids>
    <first_received>September 22, 2015</first_received>
    <start_date>May 2009</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>September 22, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virological Response (SVR) According to Cumulative Dose of Ribavirin</outcome_measure>
      <outcome_measure>Percentage of Participants with Virologic Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Response According to Starting Dose of Ribavirin</outcome_measure>
      <outcome_measure>Percentage of Participants With SVR According to Starting Dose of Ribavirin</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Response According to Body Weight-normalized Dose of Ribavirin</outcome_measure>
      <outcome_measure>Percentage of Participants With SVR According to Body Weight-normalized Dose of Ribavirin</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Response According to Dose Reduction of Ribavirin</outcome_measure>
      <outcome_measure>Percentage of Participants With SVR According to Dose Reduction of Ribavirin</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Response According to interleukin-28B (IL-28B) Polymorphism</outcome_measure>
      <outcome_measure>Percentage of Participants With SVR According to IL-28B Polymorphism</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse or Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse or Breakthrough According to Cumulative Dose of Ribavirin</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse or Breakthrough According to Starting Dose of Ribavirin</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse or Breakthrough According to Body Weight-normalized Dose of Ribavirin</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse or Breakthrough According to Dose Reduction of Ribavirin</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Hungary</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02557646</url>
  </study>
  <study rank="187">
    <nct_id>NCT01257204</nct_id>
    <title>Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>196</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-031</other_id>
      <other_id>2010-022408-28</other_id>
    </other_ids>
    <first_received>December 1, 2010</first_received>
    <start_date>December 2010</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>November 10, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>August 5, 2015</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response at Follow-up Week 24 (SVR24) for Hepatitis C Virus (HCV) Genotype 2</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response at Follow-up Week 24 (SVR24) for Hepatitis C Virus (HCV) Genotype 3</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Rapid Virologic Response (RVR) at Week 4 for Hepatitis C Virus (HCV) Genotype 2</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Rapid Virologic Response (RVR) at Week 4 for Hepatitis C Virus (HCV) Genotype 3</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Complete Early Virologic Response (cEVR) at Week 12 for Hepatitis C Virus (HCV) Genotype 2</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Complete Early Virologic Response (cEVR) at Week 12 for Hepatitis C Virus (HCV) Genotype 3</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response at Follow-up Week 12 (SVR12) for Hepatitis C Virus (HCV) Genotype 2</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Sustained Virologic Response at Follow-up Week 12 (SVR12) for Hepatitis C Virus (HCV) Genotype 3</outcome_measure>
      <outcome_measure>Number of Participants With Virologic Failure for Hepatitis C Virus (HCV) Genotype 2</outcome_measure>
      <outcome_measure>Number of Participants With Virologic Failure for Hepatitis C Virus (HCV) Genotype 3</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations Due to AEs, and Treatment-related AEs and Who Died During Treatment Period</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Who Died During Follow-up Period</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Maryland</state>
      <state>Oklahoma</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01257204</url>
  </study>
  <study rank="188">
    <nct_id>NCT01573351</nct_id>
    <title>Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Asunaprevir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Peg-interferon Alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>398</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI447-029</other_id>
      <other_id>2011-005422-21</other_id>
    </other_ids>
    <first_received>April 5, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Hallmark QUAD</acronym>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of genotype 1 subjects with SVR12, defined as HCV RNA &lt; LOQ at post-treatment Week 12, for all subjects infected with HCV genotype 1</outcome_measure>
      <outcome_measure>On-treatment safety, as measured by frequency of Serious Adverse Events (SAEs) and discontinuations due to Adverse Events (AEs) through the end of treatment</outcome_measure>
      <outcome_measure>Proportion of subjects with SVR12 (HCV RNA &lt; LOQ at post-treatment Week 12) by the rs12979860 single nucleotide polymorphisms (SNP) in the IL28 gene</outcome_measure>
      <outcome_measure>Proportion of subjects with HCV RNA undetectable</outcome_measure>
      <outcome_measure>Proportion of subjects with HCV RNA &lt; LOQ</outcome_measure>
      <outcome_measure>Proportion of patients with SVR12 (HCV RNA &lt; LOQ at post-treatment Week 12) for HCV genotype 4 subjects</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Argentina</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>Mexico</country>
      <country>Netherlands</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>Switzerland</country>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01573351</url>
  </study>
  <study rank="189">
    <nct_id>NCT00874770</nct_id>
    <title>Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Peginterferon alpha-2a</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>74</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-014</other_id>
      <other_id>EUDRACT# 2009-010149-29</other_id>
    </other_ids>
    <first_received>April 2, 2009</first_received>
    <start_date>June 2009</start_date>
    <completion_date>January 2011</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 6, 2015</firstreceived_results_date>
    <primary_completion_date>November 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Extended Rapid Virologic Response (eRVR) at Weeks 4 and 12</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response (RVR) at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Early Virologic Response (EVR) at Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With a Complete Early Virologic Response (cEVR) at Week 12</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00874770</url>
  </study>
  <study rank="190">
    <nct_id>NCT01088659</nct_id>
    <title>A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis D, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">placebo</intervention>
      <intervention type="Drug">tenofovir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML22364</other_id>
    </other_ids>
    <first_received>March 16, 2010</first_received>
    <start_date>February 2010</start_date>
    <completion_date>November 2017</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>proportion of patients becoming HDV-RNA negative</outcome_measure>
      <outcome_measure>HDV-RNA levels, HBsAg levels, HBV DNA, biochemical disease activity, liver histology</outcome_measure>
      <outcome_measure>Safety and tolerability: adverse events, laboratory parameters, vital signs</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Turkey</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01088659</url>
  </study>
  <study rank="191">
    <nct_id>NCT00922779</nct_id>
    <title>A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>7755</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML16709</other_id>
    </other_ids>
    <first_received>June 16, 2009</first_received>
    <start_date>June 2002</start_date>
    <completion_date>June 2012</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Adverse events; laboratory parameters</outcome_measure>
      <outcome_measure>Sustained viral response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Russian Federation</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00922779</url>
  </study>
  <study rank="192">
    <nct_id>NCT00977054</nct_id>
    <title>Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DFPP + Peg-IFN + RBV</intervention>
      <intervention type="Drug">Peg-IFN + RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>National Science Council, Taiwan</collaborator>
      <collaborator>Department of Health, Executive Yuan, R.O.C. (Taiwan)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>59</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>200904053D</other_id>
    </other_ids>
    <first_received>September 13, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>December 19, 2012</last_updated>
    <last_verified>December 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR)</outcome_measure>
      <outcome_measure>Rapid virologic response (RVR)</outcome_measure>
      <outcome_measure>Treatment-related withdrawal rate</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00977054</url>
  </study>
  <study rank="193">
    <nct_id>NCT01371578</nct_id>
    <title>Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GS-5885 tablet</intervention>
      <intervention type="Drug">GS-9451 tablet</intervention>
      <intervention type="Biological">peginterferon alfa-2a</intervention>
      <intervention type="Drug">ribavirin tablet</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>163</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-256-0124</other_id>
    </other_ids>
    <first_received>June 9, 2011</first_received>
    <start_date>July 2011</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>January 14, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Sustained Virologic Response(SVR) of each regimen administered for 24 to 48 weeks</outcome_measure>
      <outcome_measure>Safety and Tolerability</outcome_measure>
      <outcome_measure>Characterize the viral dynamics of GS-5885, GS-9451 when administered in combination with PEG and RBV</outcome_measure>
      <outcome_measure>Characterize the pharmacokinetics of GS-5885 and GS-9451 when administered in combination with PEG and RBV</outcome_measure>
      <outcome_measure>Emergence of Viral Resistance</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Mississippi</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01371578</url>
  </study>
  <study rank="194">
    <nct_id>NCT00940485</nct_id>
    <title>A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">entecavir</intervention>
      <intervention type="Drug">entecavir</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML22265</other_id>
    </other_ids>
    <first_received>June 16, 2009</first_received>
    <start_date>April 2009</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>November 2, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HBeAg seroconversion</outcome_measure>
      <outcome_measure>Loss of HBeAg; proportion of patients who achieve HBV DNA &lt;1000 copies/mL;ALT normalization; quantitative HBeAg and HBsAg measurement;HBsAg loss/seroconversion</outcome_measure>
      <outcome_measure>Adverse events, laboratory parameters, vital signs</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00940485</url>
  </study>
  <study rank="195">
    <nct_id>NCT00553930</nct_id>
    <title>Low Dose Peginterferon-Î± 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa-2a and Ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon alfa 2a and Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Sociedad Andaluza de Enfermedades Infecciosas</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>71</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>SAEI_IFN_1</other_id>
    </other_ids>
    <first_received>November 3, 2007</first_received>
    <start_date>November 2007</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>May 16, 2010</last_updated>
    <last_verified>May 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>SAEI_IFN_1</acronym>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained viral response(undetectable serum HCV-RNA)</outcome_measure>
      <outcome_measure>Relationships between the plasma interferon an ribavirin concentrations and efficacy. The safety and tolerability of the studied medications will be evaluated by means of clinical adverse events, physical examination and laboratory results.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00553930</url>
  </study>
  <study rank="196">
    <nct_id>NCT00927082</nct_id>
    <title>A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>383</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MV22430</other_id>
    </other_ids>
    <first_received>June 16, 2009</first_received>
    <start_date>April 2009</start_date>
    <completion_date>November 2014</completion_date>
    <last_updated>November 2, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HBV DNA, ALT, HBsAg, anti-HBs, HBeAg, anti-HBe, quantitative HBsAg</outcome_measure>
      <outcome_measure>Clinical events related to chronic hepatitis B; laboratory parameters; concomitant medications; adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
      <country>Brazil</country>
      <country>China</country>
      <country>Hong Kong</country>
      <country>Korea, Republic of</country>
      <country>New Zealand</country>
      <country>Russian Federation</country>
      <country>Singapore</country>
      <country>Taiwan</country>
      <country>Thailand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00927082</url>
  </study>
  <study rank="197">
    <nct_id>NCT00421434</nct_id>
    <title>Study of Nitazoxanide, Peginterferon, and Ribavirin Combination Therapies in the Treatment of Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitazoxanide</intervention>
      <intervention type="Biological">Peginterferon alfa-2a</intervention>
      <intervention type="Biological">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Romark Laboratories L.C.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>121</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>RM01-3036</other_id>
    </other_ids>
    <first_received>January 10, 2007</first_received>
    <start_date>June 2006</start_date>
    <completion_date>September 2008</completion_date>
    <last_updated>September 23, 2008</last_updated>
    <last_verified>September 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>STEALTHC-1</acronym>
    <primary_completion_date>September 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response</outcome_measure>
      <outcome_measure>End of treatment virologic response</outcome_measure>
      <outcome_measure>Early virologic response</outcome_measure>
      <outcome_measure>Rapid virologic response</outcome_measure>
      <outcome_measure>ALT normalization</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00421434</url>
  </study>
  <study rank="198">
    <nct_id>NCT00630084</nct_id>
    <title>Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Neoplasms</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon alpha 2a and plus ribavirin</intervention>
      <intervention type="Drug">pegylated interferon alpha 2a and plus ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kaohsiung Medical University Chung-Ho Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KMUH-IRB-960044</other_id>
    </other_ids>
    <first_received>February 26, 2008</first_received>
    <start_date>August 2006</start_date>
    <completion_date>October 2008</completion_date>
    <last_updated>September 3, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy - Sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.</outcome_measure>
      <outcome_measure>Rapid virologic response (RVR), HCV RNA seronegative by PCR at week 4.</outcome_measure>
      <outcome_measure>Early virological response (EVR), by PCR-negative or at least 2 logs decline from baseline of serum HCV RNA at 12 weeks of treatment.</outcome_measure>
      <outcome_measure>Safety - adverse event rate and profile</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00630084</url>
  </study>
  <study rank="199">
    <nct_id>NCT01337375</nct_id>
    <title>A Study of the Pharmacokinetics And Pharmacodynamics of Intravenously Administered Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C And Previous Non-Response to Pegylated Interferon And Ribavirin Combination Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa 2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>31</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML22936</other_id>
    </other_ids>
    <first_received>March 29, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>April 2012</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV RNA levels (IU/ml, COBAS TaqMan HCV Test) in correlation with area under the plasma concentration-time curve (AUC) after sc and iv administration</outcome_measure>
      <outcome_measure>Evaluation of predictors of response to i.v. treatment</outcome_measure>
      <outcome_measure>Effect of waist to hip ratio on pharmacokinetics</outcome_measure>
      <outcome_measure>Effect of waist to hip ratio on viral response</outcome_measure>
      <outcome_measure>Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01337375</url>
  </study>
  <study rank="200">
    <nct_id>NCT02107365</nct_id>
    <title>Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Genotype 4 Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Asunaprevir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated Interferon alpha-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
      <collaborator>Bristol-Myers Squibb</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS HC32 QUATTRO</other_id>
    </other_ids>
    <first_received>March 31, 2014</first_received>
    <start_date>November 2013</start_date>
    <completion_date>September 2015</completion_date>
    <last_updated>August 25, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR12 Rate</outcome_measure>
      <outcome_measure>Number of patients with adverse events</outcome_measure>
      <outcome_measure>Treatment discontinuations</outcome_measure>
      <outcome_measure>Self-reported symptoms</outcome_measure>
      <outcome_measure>Patients' adherence</outcome_measure>
      <outcome_measure>SVR 24 rate</outcome_measure>
      <outcome_measure>HCV viral load</outcome_measure>
      <outcome_measure>Number of patients with virological failure under treatment</outcome_measure>
      <outcome_measure>HCV subtypic distribution</outcome_measure>
      <outcome_measure>Proportion of patients with resistance mutations to Asunaprevir and/or Daclatasvir in case of virological failure</outcome_measure>
      <outcome_measure>Cirrhosis evaluation</outcome_measure>
      <outcome_measure>Insulin resistance : HOMA-IR score</outcome_measure>
      <outcome_measure>Metabolic syndrome parameters</outcome_measure>
      <outcome_measure>Liver fibrosis</outcome_measure>
      <outcome_measure>Polymorphism of the gene of IL28B</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02107365</url>
  </study>
  <study rank="201">
    <nct_id>NCT00561353</nct_id>
    <title>A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Peginterferon (PegIFNÎ±-2a)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>121</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR012607</other_id>
      <other_id>TMC435350-TiDP16-C201</other_id>
    </other_ids>
    <first_received>November 19, 2007</first_received>
    <start_date>January 2008</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>May 14, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>December 18, 2013</firstreceived_results_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-NaÃ¯ve HCV-Infected Participants (Cohort 1 and 2, Panel A)</outcome_measure>
      <outcome_measure>Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-NaÃ¯ve HCV-Infected Participants (Cohort 1 and 2, Panel B)</outcome_measure>
      <outcome_measure>Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-Experienced HCV-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-NaÃ¯ve HCV-Infected Participants (Cohort 1 and 2, Panel A)</outcome_measure>
      <outcome_measure>Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-NaÃ¯ve HCV-Infected Participants (Cohort 1 and 2, Panel B)</outcome_measure>
      <outcome_measure>Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-Experienced HCV-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Virologic Responses Following Treatment With TMC435 in Treatment-Naive Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A)</outcome_measure>
      <outcome_measure>Virologic Responses Following Treatment With TMC435 in Treatment-Naive Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel B)</outcome_measure>
      <outcome_measure>Virologic Responses Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Virologic Response Parameters in Treatment-NaÃ¯ve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined)</outcome_measure>
      <outcome_measure>Virologic Response Parameters Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-NaÃ¯ve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A)</outcome_measure>
      <outcome_measure>Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-NaÃ¯ve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel B)</outcome_measure>
      <outcome_measure>Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Viral Breakthrough in Treatment-NaÃ¯ve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1, Panel A and B)</outcome_measure>
      <outcome_measure>Viral Breakthrough in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Viral Relapse in Treatment-NaÃ¯ve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined)</outcome_measure>
      <outcome_measure>Viral Relapse in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Sustained Virologic Response (SVR) in Treatment-NaÃ¯ve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined)</outcome_measure>
      <outcome_measure>Sustained Virologic Response (SVR) in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of TMC435 in Treatment-NaÃ¯ve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B)</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Predose Plasma Concentration (C0h) of TMC435 in Treatment-NaÃ¯ve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B)</outcome_measure>
      <outcome_measure>Predose Plasma Concentration (C0h) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Average Steady-state Plasma Concentration (Css,av) of TMC435 in Treatment-NaÃ¯ve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B)</outcome_measure>
      <outcome_measure>Average Steady-state Plasma Concentration (Css,av) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h) of TMC435 in Treatment-NaÃ¯ve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B)</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h) of TMC435 in Treatment-NaÃ¯ve Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00561353</url>
  </study>
  <study rank="202">
    <nct_id>NCT01446250</nct_id>
    <title>Study of DEB025/Alisporivir Plus Pegylated Interferon alfa2a and Ribavirin and Boceprevir Plus Pegylated Interferon alfa2a and Ribavirin in African American Chronic Hepatitis C Genotype 1 Patients That Have Never Received Treatment for Their Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Liver Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DEB025 plus peg-IFN alpha 2a and ribavirin fixed duration treatment</intervention>
      <intervention type="Drug">DEB025 plus peg-IFN alpha 2a and ribavirin response guided treatment duration</intervention>
      <intervention type="Drug">Boceprevir plus peg-IFN alpha 2a and ribavirin per label response guided treatment</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>210</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CDEB025A2307</other_id>
    </other_ids>
    <first_received>September 26, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>October 12, 2013</last_updated>
    <last_verified>October 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients that discontinue study drug or require dose reduction or dose interruption due to treatment-emergent Adverse Events.</outcome_measure>
      <outcome_measure>Proportion of patients with emergence of resistant mutations in each treatment arm.</outcome_measure>
      <outcome_measure>Proportion of patients that achieve Sustained Viral Response Week 24 (SVR24) defined as serum HCV RNA undetectable by limit of detection (LOD) 24 weeks after end of treatment.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01446250</url>
  </study>
  <study rank="203">
    <nct_id>NCT01195181</nct_id>
    <title>Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
      <condition>Chronic Liver Disease</condition>
      <condition>Viral Hepatitis</condition>
      <condition>Therapeutic Uses</condition>
      <condition>Antiviral Agents</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon plus ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Azienda Ospedaliera di Padova</lead_sponsor>
      <collaborator>Regione Veneto</collaborator>
      <collaborator>University of Padua</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>506</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HEPCOVE protocol</other_id>
      <other_id>DRG N.2920/2002</other_id>
    </other_ids>
    <first_received>August 31, 2010</first_received>
    <start_date>September 2005</start_date>
    <completion_date>August 2010</completion_date>
    <last_updated>September 3, 2010</last_updated>
    <last_verified>September 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluation of real dose drugs intake in relation to sustained virological response (SVR).</outcome_measure>
      <outcome_measure>Description of the profile of the virus decay during antiviral therapy in relation to virological response.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01195181</url>
  </study>
  <study rank="204">
    <nct_id>NCT02401737</nct_id>
    <title>Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">NVR 3-778</intervention>
      <intervention type="Drug">Placebo for NVR 3-778</intervention>
      <intervention type="Drug">Pegasys</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novira Therapeutics, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>84</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NVR3-778-101B</other_id>
    </other_ids>
    <first_received>March 11, 2015</first_received>
    <start_date>January 2015</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Compared with baseline, decline of serum HBV-DNA in the value</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>China</country>
      <country>Korea, Republic of</country>
      <country>Singapore</country>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02401737</url>
  </study>
  <study rank="205">
    <nct_id>NCT02112799</nct_id>
    <title>Safety and Efficacy Study of NVR 3-778 in Healthy Volunteers and Hepatitis B Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">NVR 3-778</intervention>
      <intervention type="Drug">Placebo for NVR 3-778</intervention>
      <intervention type="Drug">Pegasys</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novira Therapeutics, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>84</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NVR3-778-101</other_id>
    </other_ids>
    <first_received>April 9, 2014</first_received>
    <start_date>April 2014</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To assess the dose-related safety and tolerability of NVR 3-778 in healthy volunteers and hepatitis B patients</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>New Zealand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02112799</url>
  </study>
  <study rank="206">
    <nct_id>NCT00882193</nct_id>
    <title>Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Genotype 1</condition>
      <condition>Relapse</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Betaine</intervention>
      <intervention type="Drug">Peginterferon alpha 2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Nebraska</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 0</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>133-09</other_id>
    </other_ids>
    <first_received>April 15, 2009</first_received>
    <start_date>May 2009</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>August 8, 2011</last_updated>
    <last_verified>August 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To examine the safety and efficacy of betaine when combined with standard antiviral therapy in previously teated subjects with chronic hepatitis c genotype 1</outcome_measure>
      <outcome_measure>The effect on interferon gene signaling in peripheral blood mononuclear cells in the first 12 weeks of treatment and 6 months following the end of therapy.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Nebraska</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00882193</url>
  </study>
  <study rank="207">
    <nct_id>NCT00056862</nct_id>
    <title>Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>030136</other_id>
      <other_id>03-DK-0136</other_id>
    </other_ids>
    <first_received>March 25, 2003</first_received>
    <start_date>March 2003</start_date>
    <completion_date>June 2010</completion_date>
    <last_updated>November 13, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>November 12, 2010</firstreceived_results_date>
    <primary_completion_date>January 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Virological Response (Intention to Treat)</outcome_measure>
      <outcome_measure>Virological Response Category (Per Protocol)</outcome_measure>
      <outcome_measure>First Phase Decline in Logarithm of HCV RNA Level</outcome_measure>
      <outcome_measure>Slope of Second Phase Decline in HCV Levels</outcome_measure>
      <outcome_measure>Time to Negativity</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00056862</url>
  </study>
  <study rank="208">
    <nct_id>NCT01648140</nct_id>
    <title>Dose Ranging of GSK2336805 in Combination Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GSK2336805 40 mg</intervention>
      <intervention type="Drug">GSK2336805 60 mg</intervention>
      <intervention type="Drug">Pegylated interferon alpha-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
      <collaborator>PPD</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>286</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>115879</other_id>
    </other_ids>
    <first_received>July 12, 2012</first_received>
    <start_date>August 2012</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>September 10, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HAI115879</acronym>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Frequency of adverse events and absolute values.</outcome_measure>
      <outcome_measure>Antiviral activity of 40 and 60 mg of GSK2336805 when given in combination with pegylated interferon alpha-2a and ribavirin.</outcome_measure>
      <outcome_measure>Changes over time from predose values for hematology, clinical chemistry, urinalysis, vital sign measurements and electrocardiograms.</outcome_measure>
      <outcome_measure>GSK2336805 plasma pharmacokinetics</outcome_measure>
      <outcome_measure>Very rapid virologic response (vRVR)</outcome_measure>
      <outcome_measure>Rapid virologic response (RVR)</outcome_measure>
      <outcome_measure>Complete early virologic response (cEVR)</outcome_measure>
      <outcome_measure>Sustained virologic response (SVR12)</outcome_measure>
      <outcome_measure>Sustained virologic response (SVR24)</outcome_measure>
      <outcome_measure>Sustained virologic response rates between GSK2336805 and standard of care</outcome_measure>
      <outcome_measure>Resistance against GSK2336805</outcome_measure>
      <outcome_measure>Antiviral activity and safety of 60 mg of GSK2336805 in subjects with genotype 4 hepatitis C virus (HCV) infection</outcome_measure>
      <outcome_measure>GSK2336805 exposure-response relationships</outcome_measure>
      <outcome_measure>Frequency of adverse events and absolute values</outcome_measure>
      <outcome_measure>Changes over time from predose values for hematology, clinical chemistry, urinalysis, vital sign measurements and electrocardiograms</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Belgium</country>
      <country>Bulgaria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Nevada</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01648140</url>
  </study>
  <study rank="209">
    <nct_id>NCT00703118</nct_id>
    <title>A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Peg-IFN-alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec BVBA</lead_sponsor>
      <collaborator>Tibotec Pharmaceutical Limited</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>663</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR014842</other_id>
      <other_id>VX-950-TIDP24-C216</other_id>
    </other_ids>
    <first_received>June 19, 2008</first_received>
    <start_date>October 2008</start_date>
    <completion_date>July 2010</completion_date>
    <last_updated>December 5, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>July 18, 2011</firstreceived_results_date>
    <primary_completion_date>July 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Sustained Virologic Response (SVR) 24 Weeks After the Last Planned Dose of Study Medication - SVR24 Planned</outcome_measure>
      <outcome_measure>Number of Participants Acheiving Rapid Virologic Response (RVR) at Week 4</outcome_measure>
      <outcome_measure>Number of Participants Acheiving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Week 48 (End of Treatment)</outcome_measure>
      <outcome_measure>Number of Participants With Sustained Virologic Response (SVR) 12 Weeks After the Last Planned Dose of Study Medication - SVR12 Planned</outcome_measure>
      <outcome_measure>Number of Participants Who Meet the Telaprevir Stopping Rule at Week 4, Week 6, or Week 8</outcome_measure>
      <outcome_measure>Number of Participants Who Have Viral Relapse During Entire Follow-up Period (up to Week 72)</outcome_measure>
      <outcome_measure>Change From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 4</outcome_measure>
      <outcome_measure>Number of Participants Acheiving Extended Rapid Virologic Response at Week 4 and Week 12</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00703118</url>
  </study>
  <study rank="210">
    <nct_id>NCT01258101</nct_id>
    <title>A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>393</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML17087</other_id>
    </other_ids>
    <first_received>November 29, 2010</first_received>
    <start_date>May 2003</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response rate (Hepatitis C Virus-RNA determined by AMPLICOR HCV test)</outcome_measure>
      <outcome_measure>Hepatitis C Virus-RNA determined by AMPLICOR HCV test)</outcome_measure>
      <outcome_measure>Virologic response rates (Hepatitis C Virus-RNA determined by AMPLICOR HCV test)</outcome_measure>
      <outcome_measure>Safety: incidence of adverse events</outcome_measure>
      <outcome_measure>Hemoglobin levels at end of treatment</outcome_measure>
      <outcome_measure>Health Survey (Short Form 36)</outcome_measure>
      <outcome_measure>Fatigue Severity Scale</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01258101</url>
  </study>
  <study rank="211">
    <nct_id>NCT01571583</nct_id>
    <title>An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus (HCV) Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen-Cilag International NV</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>74</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR018721</other_id>
      <other_id>VX-950HPC3006</other_id>
      <other_id>2011-004724-35</other_id>
    </other_ids>
    <first_received>December 16, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>July 14, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>REPLACE</acronym>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients achieving sustained virologic response (SVR) 12 planned</outcome_measure>
      <outcome_measure>Number of patients achieving SVR12 planned(c)</outcome_measure>
      <outcome_measure>Number of patients achieving SVR24 planned</outcome_measure>
      <outcome_measure>Number of patients achieving SVR24 planned(c)</outcome_measure>
      <outcome_measure>Number of patients having an undetectable HCV RNA level at Week 4 of treatment</outcome_measure>
      <outcome_measure>Number of patients having an undetectable HCV RNA level at Week 12 of treatment</outcome_measure>
      <outcome_measure>Number of patients having undetectable HCV RNA levels at Week 4 and Week 12 of treatment</outcome_measure>
      <outcome_measure>Number of patients having an undetectable HCV RNA level at the actual end of treatment</outcome_measure>
      <outcome_measure>Number of patients having an undetectable HCV RNA level at the planned end of treatment</outcome_measure>
      <outcome_measure>Number of patients having less than 25 IU/mL at the planned end of treatment</outcome_measure>
      <outcome_measure>Number of patients with on-treatment virologic failure</outcome_measure>
      <outcome_measure>Number of patients with relapse after undetectable HCV RNA at actual end of treatment</outcome_measure>
      <outcome_measure>Number of patients with relapse after undetectable HCV RNA at planned end of treatment</outcome_measure>
      <outcome_measure>Number of patients with relapse after previous HCV RNA less than 25 IU/mL at planned end of treatment</outcome_measure>
      <outcome_measure>Number of patients with viral breakthrough</outcome_measure>
      <outcome_measure>Change from baseline in log HCV RNA values</outcome_measure>
      <outcome_measure>Number of patients who have changes in liver graft biopsy histology</outcome_measure>
      <outcome_measure>Number of patients with adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01571583</url>
  </study>
  <study rank="212">
    <nct_id>NCT00252642</nct_id>
    <title>Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Cirrhosis</condition>
      <condition>Fibrosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon Alpha-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Virginia Commonwealth University</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PH-VCU-05</other_id>
    </other_ids>
    <first_received>November 9, 2005</first_received>
    <start_date>November 2005</start_date>
    <completion_date>September 2007</completion_date>
    <last_updated>December 14, 2007</last_updated>
    <last_verified>August 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Changes in portal pressure after 6 moths of treatment with peginterferon alfa-2a will be calculated by comparing portal pressure at the end of HALT-C to values obtained after 6 months of peginterferon.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00252642</url>
  </study>
  <study rank="213">
    <nct_id>NCT01220947</nct_id>
    <title>A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">Copegus</intervention>
      <intervention type="Drug">daneprovir</intervention>
      <intervention type="Drug">danoprevir</intervention>
      <intervention type="Drug">danoprevir</intervention>
      <intervention type="Drug">danoprevir</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ritonavir</intervention>
      <intervention type="Drug">ritonavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>421</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV22776</other_id>
      <other_id>2010-019584-10</other_id>
    </other_ids>
    <first_received>October 7, 2010</first_received>
    <start_date>November 2010</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (HCV RNA measured by Roche COBAS TaqMan HCV test)</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
      <outcome_measure>Evaluation of relapse rate</outcome_measure>
      <outcome_measure>Characterization of resistance profile (HCV RNA sequencing and/or phenotypic analyses)</outcome_measure>
      <outcome_measure>Virological response at scheduled visits over time (HCV RNA measured by Roche COBAS TaqMan HCV test)</outcome_measure>
      <outcome_measure>Evaluation of virological breakthrough (viral load rebound) rate</outcome_measure>
      <outcome_measure>Evaluation of pharmacokinetics (serum concentrations assessed by validated methods)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Austria</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Mexico</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oregon</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01220947</url>
  </study>
  <study rank="214">
    <nct_id>NCT02027493</nct_id>
    <title>Hansenula-Derived Pegylated-Interferon Alpha-2a in Egyptian Children With Chronic HCV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Reiferon R</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Liver Institute, Egypt</lead_sponsor>
      <collaborator>Yassin Abdel Ghaffar Charity Center for Liver Disease and Research, Cairo, Egypt</collaborator>
      <collaborator>National Hepatology &amp; Tropical Medicine Research Institute</collaborator>
      <collaborator>Ain Shams University</collaborator>
      <collaborator>Cairo University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>46</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NLI-YAGCC-CUPH-HCV-PEG-PED</other_id>
    </other_ids>
    <first_received>January 1, 2014</first_received>
    <start_date>February 2009</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>January 3, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To study the safety of Hansenula-Derived Pegylated-Interferon Alpha-2a (Reiferon retard) in attaining sustained virological response in children with chronic hepatitis C virus infection</outcome_measure>
      <outcome_measure>Efficacy of treatment customization on the outcome</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02027493</url>
  </study>
  <study rank="215">
    <nct_id>NCT01592006</nct_id>
    <title>Pegylated Interferon, Ribavirin, Telaprevir in Hepatitis C Virus Infection in Orthotopic Liver Transplant Recipients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>3</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>12-0156</other_id>
    </other_ids>
    <first_received>April 27, 2012</first_received>
    <start_date>April 2012</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>January 5, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>January 5, 2015</firstreceived_results_date>
    <primary_completion_date>September 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Efficacy of Triple Antiviral Therapy</outcome_measure>
      <outcome_measure>Safety of Triple Antiviral Therapy in HCV Infected OLT Recipients</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Illinois</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01592006</url>
  </study>
  <study rank="216">
    <nct_id>NCT00196586</nct_id>
    <title>Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Interleukin 2</intervention>
      <intervention type="Drug">pegylated interferon alpha 2a</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Agency for Research on AIDS and Viral Hepatitis</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS HC09 SECOIIA</other_id>
    </other_ids>
    <first_received>September 12, 2005</first_received>
    <start_date>April 2003</start_date>
    <completion_date>November 2006</completion_date>
    <last_updated>November 15, 2007</last_updated>
    <last_verified>November 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response, defined by undetectable serum HCV-RNA at week 72, six months after the end of treatment; Safety of IL-2 in combination with pegylated interferon and ribavirin</outcome_measure>
      <outcome_measure>Virologic response at the end of treatment at week 48, Biochemical response, CD4 cell counts and HIV-RNA plasma levels from baseline to week 72</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00196586</url>
  </study>
  <study rank="217">
    <nct_id>NCT00470210</nct_id>
    <title>Peginterferon Alfa-2a, Ribavirin and Epoetin Î² in Coinfected Patients HCV/HIV Not Responding to Previous Treatment Regimens</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PeginterferÃ³n alfa-2a (40 KD) (PegasysÂ®) 180 ug/week</intervention>
      <intervention type="Drug">Ribavirin (CopegusÂ®) 1600 mg/day</intervention>
      <intervention type="Drug">Epoetin Î² (450 UI/kg/week)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Germans Trias i Pujol Hospital</lead_sponsor>
      <collaborator>Fundacio Lluita Contra la SIDA</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MORE</other_id>
      <other_id>2006-005554-74</other_id>
    </other_ids>
    <first_received>May 4, 2007</first_received>
    <start_date>May 2007</start_date>
    <completion_date>June 2009</completion_date>
    <last_updated>April 15, 2010</last_updated>
    <last_verified>April 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rate of sustained virologic response measured as serum HCV-RNA loads of &lt; 50 IU/mL</outcome_measure>
      <outcome_measure>Changes in serum HCV-RNA titers</outcome_measure>
      <outcome_measure>Percentage of patients with serum HCV-RNA loads of &lt; 50 IU/mL</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00470210</url>
  </study>
  <study rank="218">
    <nct_id>NCT01281839</nct_id>
    <title>An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Peginterferon alpha-2a (PegIFN alpha-2a)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>394</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017371</other_id>
      <other_id>TMC435HPC3007</other_id>
      <other_id>2010-021113-23</other_id>
    </other_ids>
    <first_received>January 7, 2011</first_received>
    <start_date>February 2011</start_date>
    <completion_date>February 2013</completion_date>
    <last_updated>March 26, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>February 3, 2014</firstreceived_results_date>
    <acronym>PROMISE</acronym>
    <primary_completion_date>February 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Sustained Virologic Response 4 Weeks After the Planned End of Treatment (SVR4)</outcome_measure>
      <outcome_measure>Change From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Actual Values of log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>The Percentage of Participants With On-treatment Virologic Response at All Time Points</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants With &lt;1 log10 Decrease in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) From Baseline at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels &gt;1000 IU/mL at Week 4</outcome_measure>
      <outcome_measure>The Percentage of Participants With Null Response</outcome_measure>
      <outcome_measure>The Percentage of Participants With Partial Response</outcome_measure>
      <outcome_measure>The Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>The Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Completed All Study Treatment at Week 24 Because of the Treatment Duration Rule</outcome_measure>
      <outcome_measure>The Percentage of Participants With On-treatment Failure</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Undetectable</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Undetectable or Detectable</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;100 IU/mL</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;1000 IU/mL</outcome_measure>
      <outcome_measure>The Percentage of Participants With Viral Breakthrough at Different Time Points</outcome_measure>
      <outcome_measure>Time From End-of-treatment to Viral Relapse</outcome_measure>
      <outcome_measure>The Percentage of Participants With Normalization of Alanine Aminotransferase (ALT)</outcome_measure>
      <outcome_measure>Median Time to Normalization of Alanine Aminotransferase (ALT) Levels</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h)</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Predose Plasma Concentration (C0h)</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Systemic Clearance (CL)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>New Zealand</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Kentucky</state>
      <state>Minnesota</state>
      <state>Mississippi</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01281839</url>
  </study>
  <study rank="219">
    <nct_id>NCT00973219</nct_id>
    <title>Hepatitis B Surface Antigen(HBsAg) Loss in Chronic Hepatitis B Patients With Low Viral Load</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-Interferon alfa 2a + Adefovir dipivoxil, Peg-Interferon alfa 2a + Tenofovir disoproxil fumarate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TTM16002</other_id>
      <other_id>EudraCT number: 2009-013117-94</other_id>
      <other_id>ABR number: 28338</other_id>
    </other_ids>
    <first_received>September 8, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>November 2018</completion_date>
    <last_updated>January 19, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>LVL</acronym>
    <primary_completion_date>April 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The primary objective is to demonstrate the efficacy of combination therapy (Peg-IFN and adefovir or Peg-IFN and tenofovir) for inducing loss of HBsAg compared to no-treatment in HBeAg negative chronic hepatitis B patients with low viral load.</outcome_measure>
      <outcome_measure>The secondary objectives are to evaluate: a. the rate of HBsAg loss and anti-HBs seroconversion, b. To establish predictive markers at baseline and during the first 12 weeks of treatment for response of primary and secondary endpoints.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00973219</url>
  </study>
  <study rank="220">
    <nct_id>NCT02328755</nct_id>
    <title>Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Myeloid Leukemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peg-IFN-Î±</intervention>
      <intervention type="Procedure">Hematopoietic Cell Transplant (HCT)</intervention>
      <intervention type="Drug">Calcineurin Inhibitor</intervention>
      <intervention type="Drug">Methotrexate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Michigan Cancer Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>35</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>UMCC 2014.107</other_id>
      <other_id>HUM00093471</other_id>
    </other_ids>
    <first_received>November 11, 2014</first_received>
    <start_date>January 2015</start_date>
    <completion_date>January 2019</completion_date>
    <last_updated>December 9, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maximum Tolerated Dose (MTD) of peg-IFN-Î±</outcome_measure>
      <outcome_measure>Number of Patients that Relapse</outcome_measure>
      <outcome_measure>Overall Survival Time</outcome_measure>
      <outcome_measure>Event Free Survival Time</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Michigan</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02328755</url>
  </study>
  <study rank="221">
    <nct_id>NCT01309932</nct_id>
    <title>Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated Interferon Lambda (pegIFNÎ»)</intervention>
      <intervention type="Drug">BMS-790052 (NS5A Inhibitor)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">BMS-650032 (NS3 Protease Inhibitor)</intervention>
      <intervention type="Biological">Pegylated Interferon Alfa-2a (pegIFNÎ±-2a)</intervention>
      <intervention type="Biological">Pegylated Interferon Lambda (pegIFNÎ»)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Biological">Pegylated Interferon Lambda (pegIFNÎ»)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">BMS-790052 (NS5A Inhibitor)</intervention>
      <intervention type="Drug">BMS-650032 (NS3 Protease Inhibitor)</intervention>
      <intervention type="Drug">Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor)</intervention>
      <intervention type="Drug">Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor)</intervention>
      <intervention type="Drug">Placebo for Ribavirin (RBV)</intervention>
      <intervention type="Drug">Placebo for Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>165</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI452-008</other_id>
      <other_id>2010-022568-11</other_id>
    </other_ids>
    <first_received>March 4, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>D-LITE</acronym>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and tolerability (as measured by the frequency of serious adverse events (SAEs), dose reductions and discontinuations due to adverse events (AEs)</outcome_measure>
      <outcome_measure>Antiviral activity as determined by the proportion of Hepatitis C virus (HCV) genotype 1 subjects with 24-week sustained virologic response (SVR24)</outcome_measure>
      <outcome_measure>Proportion of HCV genotype 1 subjects with Protocol definition of virologic response (PDR) for Part A and Part B</outcome_measure>
      <outcome_measure>Proportion of subjects with either a 2-log or greater decrease in Hepatitis C virus (HCV) Ribonucleic acid (RNA) levels from baseline or undetectable levels of HCV RNA</outcome_measure>
      <outcome_measure>Proportion of subjects with viral breakthrough, defined as confirmed &gt; 1 log10 increase in HCV RNA over nadir or confirmed HCV RNA â¥ Lower limit of quantitation (LLOQ) after confirmed undetectable HCV RNA while on treatment</outcome_measure>
      <outcome_measure>Proportion of subjects with undetectable HCV RNA at the end of treatment that develop detectable levels of HCV RNA in the post-treatment follow-up period</outcome_measure>
      <outcome_measure>Serum HCV Ribonucleic acid (RNA) levels over time</outcome_measure>
      <outcome_measure>Proportion of subjects with undetectable HCV RNA over time</outcome_measure>
      <outcome_measure>Time to viral clearance, defined as an absence of detectable HCV RNA</outcome_measure>
      <outcome_measure>Serum levels of pegIFNÎ» and pegIFNÎ±-2a and plasma levels of BMS-790052 and BMS-650032: In PK sub-study group Maximum observed serum/plasma concentration (Cmax)</outcome_measure>
      <outcome_measure>Serum levels of pegIFNÎ» and pegIFNÎ±-2a and plasma levels of BMS-790052 and BMS-650032: In PK sub-study group Time to maximum concentration (Tmax)</outcome_measure>
      <outcome_measure>Serum levels of pegIFNÎ» and pegIFNÎ±-2a and plasma levels of BMS-790052 and BMS-650032: In PK sub-study group Minimal observed serum/plasma concentration (Cmin)</outcome_measure>
      <outcome_measure>Serum levels of pegIFNÎ» and pegIFNÎ±-2a and plasma levels of BMS-790052 and BMS-650032: In PK sub-study group Area under the serum/plasma concentration-time curve during one dose interval AUC(TAU)</outcome_measure>
      <outcome_measure>Serum levels of pegIFNÎ» and pegIFNÎ±-2a and plasma levels of BMS-790052 and BMS-650032: In all subjects, trough concentrations will be assessed (Ctrough)</outcome_measure>
      <outcome_measure>Proportion of subjects with 12-week sustained virologic response (SVR12), defined as undetectable HCV RNA</outcome_measure>
      <outcome_measure>Proportion of subjects with 4-week sustained virologic response (SVR4), defined as undetectable HCV RNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Japan</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01309932</url>
  </study>
  <study rank="222">
    <nct_id>NCT01125189</nct_id>
    <title>Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naÃ¯ve Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">peg-interferon alfa-2a</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>558</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-010</other_id>
      <other_id>2010-018295-24</other_id>
    </other_ids>
    <first_received>May 17, 2010</first_received>
    <start_date>July 2010</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 13, 2015</firstreceived_results_date>
    <acronym>HEPCAT</acronym>
    <primary_completion_date>April 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With Sustained Virologic Response (SVR24)</outcome_measure>
      <outcome_measure>Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), and Who Died</outcome_measure>
      <outcome_measure>Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With 12-week Sustained Virologic Response (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Resistant Variants Associated With Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Denmark</country>
      <country>Egypt</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Mexico</country>
      <country>Puerto Rico</country>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01125189</url>
  </study>
  <study rank="223">
    <nct_id>NCT01609049</nct_id>
    <title>An Observational Study of Pegasys (Peginterferon Alfa-2a) in Combination With Ribavirin in Patients With Chronic Hepatitis C and Compensated Liver Cirrhosis (STANDART)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1496</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML27851</other_id>
    </other_ids>
    <first_received>May 29, 2012</first_received>
    <start_date>December 2011</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR) rate: Percentage of patients with undetectable HCV RNA 24 weeks after therapy completion</outcome_measure>
      <outcome_measure>Virologic response rate: Percentage of patients with SVR and negative HCV RNA at Week 4 and 12 (naÃ¯ve patients)</outcome_measure>
      <outcome_measure>Virologic response rate: Percentage of patients with SVR and negative HCV RNA at Week 12 (previously treated patients)</outcome_measure>
      <outcome_measure>Virologic response rate: Percentage of patients with SVR and decrease in HCV RNA by &gt;/= log 10 from baseline (previously treated and naÃ¯ve patients)</outcome_measure>
      <outcome_measure>Virologic response rate: Percentage of patients with SVR who had dose reduction of any drug (ribavirin or Pegasys) due to adverse events</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Korea, Republic of</country>
      <country>Russian Federation</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01609049</url>
  </study>
  <study rank="224">
    <nct_id>NCT00909129</nct_id>
    <title>Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Human Immunodeficiency Virus</condition>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon-alpha (Pegasys)</intervention>
      <intervention type="Drug">ribavirin (COPEGUS)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Karolinska Institutet</lead_sponsor>
      <collaborator>The Swedish Research Council</collaborator>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>03-541</other_id>
    </other_ids>
    <first_received>May 15, 2009</first_received>
    <last_updated>May 26, 2009</last_updated>
    <last_verified>May 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>DICO</acronym>
    <outcome_measures>
      <outcome_measure>Sustained virological response</outcome_measure>
      <outcome_measure>T-cell mediated immune responses</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00909129</url>
  </study>
  <study rank="225">
    <nct_id>NCT00304551</nct_id>
    <title>A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Liver Cirrhosis</condition>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a 180Î¼g</intervention>
      <intervention type="Drug">peginterferon alfa-2a 90Î¼g</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chugai Pharmaceutical</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>180</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>JV19595</other_id>
    </other_ids>
    <first_received>March 5, 2006</first_received>
    <start_date>June 2006</start_date>
    <completion_date>June 2010</completion_date>
    <last_updated>June 1, 2010</last_updated>
    <last_verified>June 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response, defined as undetectable hepatitis C virus (HCV)-RNA (&lt; 50 IU per milliliter [IU/mL])</outcome_measure>
      <outcome_measure>Biochemical response (normalization of serum alanine aminotransferase activity)</outcome_measure>
      <outcome_measure>Virological response (HCV-RNA &lt; 50 IU per milliliter)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00304551</url>
  </study>
  <study rank="226">
    <nct_id>NCT01289782</nct_id>
    <title>An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Peginterferon alpha-2a (PegIFN alpha-2a)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>395</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017386</other_id>
      <other_id>TMC435-TiDP16-C208</other_id>
    </other_ids>
    <first_received>January 7, 2011</first_received>
    <start_date>February 2011</start_date>
    <completion_date>January 2013</completion_date>
    <last_updated>May 20, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>January 27, 2014</firstreceived_results_date>
    <acronym>QUEST-1</acronym>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Sustained Virologic Response 4 Weeks After the Planned End of Treatment (SVR4)</outcome_measure>
      <outcome_measure>Change From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Actual Values of log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Virologic Response at All Time Points</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants With &lt;1 log10 Decrease in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) From Baseline at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels &gt;1000 IU/mL at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Null Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Partial Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants Who Completed All Study Treatment at Week 24 Because of the Treatment Duration Rule</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Failure</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Undetectable or Detectable</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;25 IU/mL Undetectable</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;100 IU/mL</outcome_measure>
      <outcome_measure>Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) &lt;1000 IU/mL</outcome_measure>
      <outcome_measure>The Percentage of Participants With Viral Breakthrough at Different Time Points</outcome_measure>
      <outcome_measure>Time From End-of-treatment to Viral Relapse</outcome_measure>
      <outcome_measure>The Percentage of Participants With Normalization of Alanine Aminotransferase (ALT)</outcome_measure>
      <outcome_measure>Median Time to Normalization of Alanine Aminotransferase (ALT) Levels</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h)</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Predose Plasma Concentration (C0h)</outcome_measure>
      <outcome_measure>Plasma Concentration of TMC435: Systemic Clearance (CL)</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for the Fatigue Severity Scale (FSS) Total Scores</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Impairment in Overall Work Productivity Scores Due to Hepatitis C Virus (HCV) Infection and Its Treatment</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Impairment in Daily Activity Scores Due to Hepatitis C Virus (HCV) Infection and Its Treatment</outcome_measure>
      <outcome_measure>Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) in Work Productivity and Activity (WPAI) Absenteeism Scores Due to Hepatitis C Virus (HCV) Infection and Its Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Germany</country>
      <country>Mexico</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Ukraine</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01289782</url>
  </study>
  <study rank="227">
    <nct_id>NCT00612755</nct_id>
    <title>Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a + ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hospital Clinico Universitario San Cecilio</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>43</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Extrados</other_id>
      <other_id>2004-004948-45</other_id>
    </other_ids>
    <first_received>January 29, 2008</first_received>
    <start_date>October 2005</start_date>
    <completion_date>January 2008</completion_date>
    <last_updated>January 29, 2008</last_updated>
    <last_verified>January 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>% of patients with RNA-HCV undetectable</outcome_measure>
      <outcome_measure>% of percentage of patients with RNA-HCV undetectable</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00612755</url>
  </study>
  <study rank="228">
    <nct_id>NCT01890772</nct_id>
    <title>Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Dietary Supplement">Vitamin D</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Timothy Morgan, MD</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
      <collaborator>Southern California Institute for Research and Education</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1217</other_id>
    </other_ids>
    <first_received>May 31, 2013</first_received>
    <start_date>August 2013</start_date>
    <last_updated>May 13, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV RNA</outcome_measure>
      <outcome_measure>adverse event profile</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>Pennsylvania</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01890772</url>
  </study>
  <study rank="229">
    <nct_id>NCT00940420</nct_id>
    <title>A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus (ribavirin)</intervention>
      <intervention type="Drug">Copegus (ribavirin)</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>2695</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML16837</other_id>
    </other_ids>
    <first_received>July 6, 2009</first_received>
    <start_date>October 2002</start_date>
    <completion_date>November 2009</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>safety and tolerability with regard to clinical AEs and laboratory parameters</outcome_measure>
      <outcome_measure>safety with regard to hematological parameters</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Israel</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00940420</url>
  </study>
  <study rank="230">
    <nct_id>NCT00901524</nct_id>
    <title>ANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-interfÃ©ron alpha 2a + ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
      <collaborator>Roche Pharma AG</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2008-000859-10</other_id>
      <other_id>ANRS HC 20</other_id>
    </other_ids>
    <first_received>April 28, 2009</first_received>
    <start_date>June 2009</start_date>
    <completion_date>June 2012</completion_date>
    <last_updated>March 28, 2013</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ETOC</acronym>
    <primary_completion_date>June 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Study the proportion of patients co-infected HIV-HCV, non-responders to treatment for HCV (genotype 1 and 4), with a sustained virological response (6 months after stopping treatment (W72 or W96)) at a re-optimized treatment of hepatitis C.</outcome_measure>
      <outcome_measure>Analyze rapid virological response (W4) and early (W12).</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00901524</url>
  </study>
  <study rank="231">
    <nct_id>NCT01215643</nct_id>
    <title>Efficacy and Safety of DEB025 Alone or Combined With Either Ribavirin or Peg-IFN Î±2a in Chronic Hepatitis C Genotype 2 and 3 naÃ¯ve Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Chronic Pain</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DEB025 1000 mg QD</intervention>
      <intervention type="Drug">DEB025 600 mg QD + RBV 400 mg BID</intervention>
      <intervention type="Drug">DEB025 800 mg QD + RBV 400 mg BID</intervention>
      <intervention type="Drug">DEB025 600 mg QD + peg-IFNÎ±2a once weekly</intervention>
      <intervention type="Drug">SOC (peg-IFNÎ±2a once weekly + RBV 400 mg BID)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>340</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CDEB025A2211</other_id>
      <other_id>2010-020034-26</other_id>
    </other_ids>
    <first_received>October 5, 2010</first_received>
    <start_date>October 2010</start_date>
    <last_updated>June 5, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Measure: RVR : Rapid Viral Response : defined as serum HCV RNA undetectable (by LOQ) after 4 weeks of treatment.</outcome_measure>
      <outcome_measure>Measure: SVR24 : Sustained Viral Response Week 24 : defined as serum HCV RNA undetectable (by LOD) after 24 weeks of treatment.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>India</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Taiwan</country>
      <country>Thailand</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Hawaii</state>
      <state>Kansas</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New York</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01215643</url>
  </study>
  <study rank="232">
    <nct_id>NCT02515279</nct_id>
    <title>An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>463</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML22273</other_id>
    </other_ids>
    <first_received>July 29, 2015</first_received>
    <start_date>November 2008</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>July 31, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Incidence of adverse events</outcome_measure>
      <outcome_measure>Sustained virologic response (SVR) rate</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02515279</url>
  </study>
  <study rank="233">
    <nct_id>NCT01889849</nct_id>
    <title>Comparative Pharmacokinetics and Pharmacodynamics of Peginterferon BIP48 and 40kDa in Healthy Volunteers</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Viral Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BIP 48</intervention>
      <intervention type="Drug">Pegasys</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>ASCLIN 003/2009</other_id>
    </other_ids>
    <first_received>June 19, 2013</first_received>
    <start_date>October 2010</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>June 28, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety Assessment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Brazil</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01889849</url>
  </study>
  <study rank="234">
    <nct_id>NCT00910975</nct_id>
    <title>Individualized Duration of Peg-interferon/Ribavirin Treatment of Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C, Genotype 1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-interferon-alfa2a (Pegasys)</intervention>
      <intervention type="Drug">Ribavirin (Copegus)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GÃ¶teborg University</lead_sponsor>
      <collaborator>Sahlgrenska University Hospital, Sweden</collaborator>
      <collaborator>Sodra Alvsborgs Hospital</collaborator>
      <collaborator>Skaraborg Hospital</collaborator>
      <collaborator>Uddevalla Hospital</collaborator>
      <collaborator>Skane University Hospital</collaborator>
      <collaborator>Lund University Hospital</collaborator>
      <collaborator>Karolinska University Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TTG1_081119</other_id>
    </other_ids>
    <first_received>May 28, 2009</first_received>
    <start_date>November 2007</start_date>
    <completion_date>September 2011</completion_date>
    <last_updated>September 3, 2012</last_updated>
    <last_verified>September 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>TTG1</acronym>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Medication dose per cured patient</outcome_measure>
      <outcome_measure>Sustained virological response and relapse rate</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00910975</url>
  </study>
  <study rank="235">
    <nct_id>NCT00127777</nct_id>
    <title>Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Amantadine sulphate (in addition to standard treatment)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Saarland</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>700</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML17002</other_id>
    </other_ids>
    <first_received>August 4, 2005</first_received>
    <start_date>July 2002</start_date>
    <completion_date>December 2006</completion_date>
    <last_updated>August 24, 2005</last_updated>
    <last_verified>August 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Proof that peginterferon alfa-2a, ribavirin and amantadine sulphate over a period of 50 weeks improves the permanent virological efficacy by more than 10% compared to peginterferon alfa-2a and ribavirin</outcome_measure>
      <outcome_measure>Verification of the initial virological efficacy up to week 12, defined as negative HCV-RNA test results by means of quantitative proof methods, e.g. Roche AmplicorTM HCV Monitor v.2.0 (sensitivity &lt;600 IE/ml)</outcome_measure>
      <outcome_measure>Biochemical efficacy, defined by the serum GPT values 24 weeks after the end of the therapy</outcome_measure>
      <outcome_measure>Virological efficacy, measured on the basis of the HCV-RNA values at the end of the therapy</outcome_measure>
      <outcome_measure>Biochemical efficacy defined by the serum GPT values at the end of the therapy</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00127777</url>
  </study>
  <study rank="236">
    <nct_id>NCT00814606</nct_id>
    <title>A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Fluvastatin</intervention>
      <intervention type="Drug">Peginterferon alfa2a</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>16336A</other_id>
    </other_ids>
    <first_received>December 23, 2008</first_received>
    <start_date>February 2010</start_date>
    <completion_date>October 2010</completion_date>
    <last_updated>June 28, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy of adding fluvastatin to pegylated interferon alfa-2a and ribavirin in patients infected with genotype 1 HCV who are previous partial responders to standard treatment.</outcome_measure>
      <outcome_measure>Safety of adding fluvastatin to pegylated interferon alfa-2a and ribavirin in patients infected with genotype 1 HCV who are previous partial responders to standard treatment.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00814606</url>
  </study>
  <study rank="237">
    <nct_id>NCT01705704</nct_id>
    <title>A Retrospective Biomarker Study of Stored Samples Obtained From Patients With Chronic Hepatitis B</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>269</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>BV28333</other_id>
    </other_ids>
    <first_received>October 9, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>February 2013</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Interleukin-28B (IL-28B) genotype in stored serum samples of patients with chronic hepatitis B, who have completed therapy with Pegasys +/- lamivudine</outcome_measure>
      <outcome_measure>Single nucleotide polymorphisms (SNP) of rs12356193 in stored serum samples of patients with chronic hepatitis B, who have completed therapy with Pegasys +/- lamivudine</outcome_measure>
      <outcome_measure>IL-28B concentration at baseline and during treatment with Pegasys +/- lamivudine from stored serum samples of patients with chronic hepatitis B</outcome_measure>
      <outcome_measure>Protein/RNA biomarker evaluation from stored serum samples of patients with chronic hepatitis B, who have completed therapy with Pegasys +/- lamivudine</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
      <country>France</country>
      <country>Hong Kong</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>New Zealand</country>
      <country>Russian Federation</country>
      <country>Singapore</country>
      <country>Taiwan</country>
      <country>Thailand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01705704</url>
  </study>
  <study rank="238">
    <nct_id>NCT02577029</nct_id>
    <title>Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic HBV</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ARC-520</intervention>
      <intervention type="Drug">Entecavir</intervention>
      <intervention type="Biological">Pegylated Interferon alpha 2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Arrowhead Research Corporation</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>72</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Heparc-2008</other_id>
    </other_ids>
    <first_received>October 14, 2015</first_received>
    <start_date>October 2015</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>October 30, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Monarch</acronym>
    <primary_completion_date>December 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of patients achieving a 1-log reduction in Hepatitis B Surface Antigen (HBsAg) compared to baseline</outcome_measure>
      <outcome_measure>Percentage of patients with HBsAg loss (based on qualitative assay) compared to baseline</outcome_measure>
      <outcome_measure>Percentage of patients achieving a 1-log reduction in HBsAg and achieving a HBsAg level &lt; 100 IU/L compared to baseline</outcome_measure>
      <outcome_measure>Time to HBsAg loss</outcome_measure>
      <outcome_measure>Time to anti-HBs (antibody to Hepatitis B Surface Antigen) seroconversion</outcome_measure>
      <outcome_measure>Percentage of patients with anti-HBs seroconversion compared to baseline</outcome_measure>
      <outcome_measure>Percentage of patients with Hepatitis B e Antigen (HBeAg) loss and Anti Hepatitis B e Antigen (Anti-HBe) seroconversion compared to baseline (if HBeAg positive at study entry)</outcome_measure>
      <outcome_measure>Percentage of patients with resistance to ARC-520 compared from baseline to Week 52</outcome_measure>
      <outcome_measure>Percentage of patients with resistance to the combination therapy from baseline to Week 60</outcome_measure>
      <outcome_measure>Incidence and frequency of adverse events as a measure of safety and tolerability of ARC-520 alone or when coadministered with combination therapy</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02577029</url>
  </study>
  <study rank="239">
    <nct_id>NCT00528528</nct_id>
    <title>An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Peg-IFN-alfa-2a</intervention>
      <intervention type="Drug">Peg-IFN-alfa-2b</intervention>
      <intervention type="Drug">Ribavirin (RBV) tablet</intervention>
      <intervention type="Drug">Ribavirin (RBV) capsule</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec BVBA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>166</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR013516</other_id>
      <other_id>VX-950-TIDP24-C208</other_id>
      <other_id>2007-001044-44</other_id>
    </other_ids>
    <first_received>September 10, 2007</first_received>
    <start_date>October 2007</start_date>
    <completion_date>August 2009</completion_date>
    <last_updated>June 13, 2014</last_updated>
    <last_verified>June 2014</last_verified>
    <firstreceived_results_date>March 18, 2013</firstreceived_results_date>
    <primary_completion_date>July 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Virologic Response at Week 12</outcome_measure>
      <outcome_measure>Time to First Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level</outcome_measure>
      <outcome_measure>Number of Participants With Viral Breakthrough at End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Percentage of Participants With Partial Response</outcome_measure>
      <outcome_measure>Change From Baseline in Log 10-Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values at Week 12</outcome_measure>
      <outcome_measure>Change From Baseline in Log 10-Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values at End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Viral Response 24 Weeks After End of Treatment (SVR24)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Netherlands</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00528528</url>
  </study>
  <study rank="240">
    <nct_id>NCT00291616</nct_id>
    <title>Efficacy Study of Thymosin alpha1 &amp; Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon-alpha2a</intervention>
      <intervention type="Drug">Thymosin alpha1 &amp; Pegylated Interferon-alpha2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Seoul National University Hospital</lead_sponsor>
      <collaborator>Roche Pharma AG</collaborator>
      <collaborator>SciClone Pharmaceuticals</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>12-05-008</other_id>
    </other_ids>
    <first_received>February 13, 2006</first_received>
    <start_date>December 2005</start_date>
    <completion_date>August 2008</completion_date>
    <last_updated>July 20, 2011</last_updated>
    <last_verified>July 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HBeAg seroconversion, HBV DNA titer&lt;20,000 IU/mL</outcome_measure>
      <outcome_measure>Normalization of serum ALT, loss of HBeAg and HBsAg, production of anti-HBs</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Korea, Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00291616</url>
  </study>
  <study rank="241">
    <nct_id>NCT00845676</nct_id>
    <title>Treatment of Acute Hepatitis C Virus in HIV Co-Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Human Immunodeficiency Virus</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa-2a + Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of California, San Francisco</lead_sponsor>
      <collaborator>California HIV/AIDS Research Program</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CHRP ID06-SF-218</other_id>
    </other_ids>
    <first_received>February 17, 2009</first_received>
    <start_date>March 2008</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>April 10, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>August 13, 2013</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Safety and Tolerability of Treatment</outcome_measure>
      <outcome_measure>Association of SVR With Entry HCV RNA, Entry ALT, Entry CD4, and IL28B Genotype</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00845676</url>
  </study>
  <study rank="242">
    <nct_id>NCT01392742</nct_id>
    <title>An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>443</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML25670</other_id>
    </other_ids>
    <first_received>July 11, 2011</first_received>
    <start_date>May 2011</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>November 9, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>November 9, 2015</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virological Response (SVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants Who Were Non-Responders</outcome_measure>
      <outcome_measure>Percentage of Participants With Positive Predictive Value on SVR at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Positive Predictive Value on SVR at Week 12</outcome_measure>
      <outcome_measure>Correlation of SVR With Rapid Virological Response (RVR)</outcome_measure>
      <outcome_measure>Correlation of SVR With Early Virological Response (EVR)</outcome_measure>
      <outcome_measure>Predictive Power Values of Host-, Virus- and Treatment-related Factors and Virological Response</outcome_measure>
      <outcome_measure>Duration of Treatment in Participants With SVR by HCV Genotype</outcome_measure>
      <outcome_measure>Cumulative PEG-IFN Alfa-2a Dose in Participants With SVR by HCV Genotype</outcome_measure>
      <outcome_measure>Cumulative Ribavirin Dose in Participants With SVR by HCV Genotype</outcome_measure>
      <outcome_measure>Percentage of Participants With Virological Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Bulgaria</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01392742</url>
  </study>
  <study rank="243">
    <nct_id>NCT00983853</nct_id>
    <title>Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">telaprevir or matching placebo</intervention>
      <intervention type="Drug">telaprevir or matching placebo</intervention>
      <intervention type="Biological">peginterferon alfa-2a</intervention>
      <intervention type="Drug">ribavirin (fixed dose)</intervention>
      <intervention type="Drug">ribavirin (weight-based dose)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
      <collaborator>Tibotec Pharmaceutical Limited</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>62</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX08-950-110</other_id>
    </other_ids>
    <first_received>September 22, 2009</first_received>
    <start_date>October 2009</start_date>
    <last_updated>August 2, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>August 2, 2013</firstreceived_results_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of Subjects Achieving Undetectable HCV RNA at Week 12</outcome_measure>
      <outcome_measure>Proportion of Subjects Achieving Undetectable HCV RNA at Week 4 and Week 12</outcome_measure>
      <outcome_measure>Proportion of Subjects Who Have Undetectable HCV RNA 12 Weeks (SVR12) and 24 Weeks (SVR24) After Last Planned Dose of Study Treatment</outcome_measure>
      <outcome_measure>Effect of Efavirenz-based (EFV) and Atazanavir-based (ATV/r) Highly Active Antiretroviral Therapy(HAART) on Telaprevir Exposure</outcome_measure>
      <outcome_measure>Median Trough Plasma Concentration (Ctrough) Ratios of Efavirenz and Tenofovir (Part B Only, Subjects on EFV-based HAART)</outcome_measure>
      <outcome_measure>Median Trough Plasma Concentration (Ctrough) Ratios of Atazanavir (ATZ), Ritonavir, and Tenofovir (Part B Only, Subjects on ATV-based HAART)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
      <country>Germany</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>New York</state>
      <state>Ohio</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00983853</url>
  </study>
  <study rank="244">
    <nct_id>NCT00724451</nct_id>
    <title>Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alfa-2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Biological">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1128</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P05488</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>July 2008</start_date>
    <completion_date>October 2011</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>October 5, 2012</firstreceived_results_date>
    <primary_completion_date>October 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Not Eligible for Antiviral Treatment by Reason for Non-eligibility</outcome_measure>
      <outcome_measure>Number of Participants Discontinued From Treatment by Reason for Discontinuation</outcome_measure>
      <outcome_measure>Number of Participants With Treatment Failure by Reason for Failure</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00724451</url>
  </study>
  <study rank="245">
    <nct_id>NCT01140997</nct_id>
    <title>Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ypeginterferon alfa-2b</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Xiamen Amoytop Biotech Co., Ltd.</lead_sponsor>
      <collaborator>Peking University People's Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>211</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TB1006IFN</other_id>
    </other_ids>
    <first_received>June 8, 2010</first_received>
    <start_date>July 2010</start_date>
    <completion_date>March 2012</completion_date>
    <last_updated>January 31, 2013</last_updated>
    <last_verified>June 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PEGIFN</acronym>
    <primary_completion_date>January 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01140997</url>
  </study>
  <study rank="246">
    <nct_id>NCT01598090</nct_id>
    <title>Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon Lambda-1a</intervention>
      <intervention type="Biological">Peginterferon Alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>636</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI452-020</other_id>
      <other_id>2011-004695-11</other_id>
    </other_ids>
    <first_received>May 9, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>December 8, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PEDESTAL</acronym>
    <primary_completion_date>February 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Part A: Proportion of subjects achieving efficacy as measured by Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>Part A: Safety as measured by the frequency of deaths, Serious Adverse Events (SAEs), drug related Adverse Events (AEs), dose reductions and discontinuations due to AEs</outcome_measure>
      <outcome_measure>Part B: Proportion of subjects achieving efficacy as measured by Sustained Virologic Response at post-treatment Week12 (SVR 12) defined as HCV RNA &lt; 25 IU/ml</outcome_measure>
      <outcome_measure>Part A: Proportion of subjects who achieve efficacy as measured by SVR12, defined as HCV RNA &lt; 25 IU/ml</outcome_measure>
      <outcome_measure>Part A: Proportion of subjects who achieve efficacy as measured by SVR24, defined as HCV RNA &lt; 25 IU/ml</outcome_measure>
      <outcome_measure>Part B: Proportion of subjects who achieve efficacy as measured by SVR12, defined as hepatitis C virus (HCV) RNA &lt; 25 IU/ml in treatment-naive subjects</outcome_measure>
      <outcome_measure>Part B: Proportion of subjects who achieve efficacy as measured by eRVR, defined as HCV RNA undetectable</outcome_measure>
      <outcome_measure>Part B: Proportion of subjects who achieve efficacy as measured by SVR 24, defined as HCV RNA &lt; 25 IU/ml</outcome_measure>
      <outcome_measure>Part B: Number of incidence for Cytopenic abnormalities (anemia is defined by Hb &lt; 10 g/dL, neutropenia as defined by ANC &lt; 750 mm3, thrombocytopenia as defined by platelets &lt; 50,000 mm3)</outcome_measure>
      <outcome_measure>Part B: Number of incidence for Flu-like symptoms (as defined by pyrexia or chills or pain)</outcome_measure>
      <outcome_measure>Part B: Number of incidence for Musculoskeletal symptoms (as defined by arthralgia or myalgia or back pain)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>Czech Republic</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>Missouri</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01598090</url>
  </study>
  <study rank="247">
    <nct_id>NCT01797848</nct_id>
    <title>Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naÃ¯ve Patients</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa 2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Placebo matching Daclatasvir</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI444-047</other_id>
    </other_ids>
    <first_received>February 21, 2013</first_received>
    <start_date>June 2014</start_date>
    <completion_date>November 2016</completion_date>
    <last_updated>November 21, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>COMMAND-Asia</acronym>
    <primary_completion_date>November 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of Genotype 1 subjects with SVR24, defined as HCV RNA &lt; Limit of quantification (LOQ) at follow-up Week 24 for each cohort</outcome_measure>
      <outcome_measure>Proportion of Genotype (GT) 4 subjects with SVR24</outcome_measure>
      <outcome_measure>Proportion of GT 1 &amp; 4 subjects who achieve HCV RNA &lt; LOQ or undetectable</outcome_measure>
      <outcome_measure>Frequency of Serious Adverse Events (SAEs)/discontinuations due to Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Discontinuations due to Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Proportion of subjects with Sustained Virologic Response at follow up week 12 (SVR12) or SVR24 by rs12979860 Single nucleotide polymorphism (SNP) in the IL28B gene</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01797848</url>
  </study>
  <study rank="248">
    <nct_id>NCT00221650</nct_id>
    <title>Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Treatment Failure</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Bordeaux</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
      <collaborator>Ministry of Health, France</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>17</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>9232-01</other_id>
      <other_id>2000-023</other_id>
    </other_ids>
    <first_received>September 13, 2005</first_received>
    <start_date>April 2002</start_date>
    <completion_date>June 2004</completion_date>
    <last_updated>June 12, 2007</last_updated>
    <last_verified>June 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ROCO2</acronym>
    <outcome_measures>
      <outcome_measure>Proportion of patients with a sustained virological response, defined as an undetectable HCV RNA level</outcome_measure>
      <outcome_measure>Proportion of patients with a virological response</outcome_measure>
      <outcome_measure>Safety of treatment</outcome_measure>
      <outcome_measure>Influence of anti-HCV treatment on CD4 count and HIV RNA</outcome_measure>
      <outcome_measure>Proportion of patients with histological response 24 weeks after the end of anti-HCV treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00221650</url>
  </study>
  <study rank="249">
    <nct_id>NCT01616524</nct_id>
    <title>Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus (HCV)</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated interferon lambda (pegIFNÎ»)</intervention>
      <intervention type="Biological">Pegylated interferon lambda (pegIFNÎ»)</intervention>
      <intervention type="Biological">Pegylated interferon alfa-2a (pegIFNÎ±-2a)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
      <intervention type="Drug">Placebo matching Daclatasvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>880</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI452-017</other_id>
      <other_id>2011-004885-14</other_id>
    </other_ids>
    <first_received>June 7, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PRINCIPAL</acronym>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects who achieve Sustained Virologic Response at post-treatment follow-up week 12 (SVR12)</outcome_measure>
      <outcome_measure>Proportion of subjects with Rapid virologic response (RVR) [undetectable Hepatitis C virus (HCV) Ribonucleic acid (RNA)]</outcome_measure>
      <outcome_measure>Proportion of subjects with treatment emergent cytopenic abnormalities (anemia as defined by Hb &lt; 10 g/dL, neutropenia as defined by ANC &lt; 750 mm3 or thrombocytopenia as defined by platelets &lt; 50,000 mm3)</outcome_measure>
      <outcome_measure>Proportion of subjects with on-treatment interferon-associated flu-like symptoms (as defined by pyrexia or chills or pain)</outcome_measure>
      <outcome_measure>Proportion of subjects with on-treatment musculoskeletal symptoms (as defined by arthralgia or myalgia or back pain)</outcome_measure>
      <outcome_measure>Proportion of subjects with Sustained Virologic Response at post-treatment follow-up week 24 (SVR24) by treatment group</outcome_measure>
      <outcome_measure>Proportion of subjects with on-treatment Serious adverse events (SAEs)</outcome_measure>
      <outcome_measure>Proportion of subjects with dose reductions</outcome_measure>
      <outcome_measure>Proportion of subjects who discontinue due to Adverse events (AEs)</outcome_measure>
      <outcome_measure>Proportion of subjects with SVR12 in subjects with genotype-3 (GT-3) chronic HCV infection</outcome_measure>
      <outcome_measure>Proportion of subjects with on-treatment constitutional symptoms (fatigue or asthenia)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Belgium</country>
      <country>Chile</country>
      <country>Finland</country>
      <country>France</country>
      <country>Greece</country>
      <country>Hong Kong</country>
      <country>Italy</country>
      <country>Japan</country>
      <country>Korea, Republic of</country>
      <country>Mexico</country>
      <country>Netherlands</country>
      <country>New Zealand</country>
      <country>Russian Federation</country>
      <country>Singapore</country>
      <country>Taiwan</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Michigan</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Utah</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01616524</url>
  </study>
  <study rank="250">
    <nct_id>NCT00526448</nct_id>
    <title>Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">epoetin beta</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hospital Carlos III, Madrid</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>384</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2006-005940-99</other_id>
    </other_ids>
    <first_received>September 5, 2007</first_received>
    <start_date>June 2007</start_date>
    <completion_date>February 2010</completion_date>
    <last_updated>January 28, 2009</last_updated>
    <last_verified>January 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PERICO</acronym>
    <outcome_measures>
      <outcome_measure>% patients with RNA-HCV &lt; 50 UI/ml</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00526448</url>
  </study>
  <study rank="251">
    <nct_id>NCT01903954</nct_id>
    <title>A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">placebo</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
      <intervention type="Drug">setrobuvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>283</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NP28302</other_id>
    </other_ids>
    <first_received>July 17, 2013</first_received>
    <start_date>January 2011</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients achieving sustained virologic response (SVR24), defined as undetectable HCV RNA at 24 weeks after discontinuation of all study drugs</outcome_measure>
      <outcome_measure>Proportion of patients achieving undetectable HCV RNA (defined as HCV RNA &lt; 15 IU/mL) at each visit through Week 24</outcome_measure>
      <outcome_measure>Proportion of treatment-naÃ¯ve patients eligible to stop all treatment at Week 28</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01903954</url>
  </study>
  <study rank="252">
    <nct_id>NCT02201407</nct_id>
    <title>An Open-Label, Multicenter, National Observational Study in Patients With Chronic Hepatitis B Receiving Therapy With PEGASYS (Peginterferon Alfa-2a 40kD) - The PRO B Study</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML29062</other_id>
    </other_ids>
    <first_received>July 22, 2014</first_received>
    <start_date>December 2014</start_date>
    <completion_date>May 2016</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of patients with HBeAg-positive CHB acheiving sustained immune control, defined as a combined response: post-treatment HBeAg seroconversion, and HBV levels &lt; 2,000 IU/ml, and ALT normalization</outcome_measure>
      <outcome_measure>Percentage of patients with HBeAg-negative CHB acheiving sustained immune control, defined as combined response: HBV DNA levels &lt; 2,000 IU/ml, and ALT normalization</outcome_measure>
      <outcome_measure>Incidence of adverse events</outcome_measure>
      <outcome_measure>Percentage of patients with HBeAg-positive CHB acheiving combined response: post-treatment HBeAg seroconversion, and HBV levels &lt; 2,000 IU/ml, and ALT normalization</outcome_measure>
      <outcome_measure>Percentage of patients with HBeAg-negative CHB acheiving combined response: HBV DNA levels &lt; 2,000 IU/ml, and ALT normalization</outcome_measure>
      <outcome_measure>Incidence of laboratory test abnormalities</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Serbia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02201407</url>
  </study>
  <study rank="253">
    <nct_id>NCT00629967</nct_id>
    <title>A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Genotype</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon alpha 2a and ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kaohsiung Medical University Chung-Ho Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KMUH-IRB-94045</other_id>
    </other_ids>
    <first_received>February 26, 2008</first_received>
    <start_date>April 2005</start_date>
    <completion_date>May 2007</completion_date>
    <last_updated>February 26, 2008</last_updated>
    <last_verified>January 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy - Sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.</outcome_measure>
      <outcome_measure>Safety - adverse event rate and profile</outcome_measure>
      <outcome_measure>Early virological response (EVR), by PCR-negative or 2 logs decline from baseline at week 12</outcome_measure>
      <outcome_measure>Rapid virologic response (RVR), HCV RNA seronegative by PCR at week 4.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00629967</url>
  </study>
  <study rank="254">
    <nct_id>NCT01290731</nct_id>
    <title>A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Pegylated interferon (pegIFN alpha-2a)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Pharmaceutical K.K.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>49</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017698</other_id>
      <other_id>TMC435HPC3008</other_id>
    </other_ids>
    <first_received>February 3, 2011</first_received>
    <start_date>January 2011</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>December 16, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>October 17, 2013</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants With a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>The Percentage of Participants With a Sustained Virologic Response 24 Weeks After the Actual End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up</outcome_measure>
      <outcome_measure>The Percentage of Participants With Undetectable Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) During Treatment and at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>The Number of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>The Number of Participants Demonstrating Viral Relapse</outcome_measure>
      <outcome_measure>Plasma Concentrations of TMC435</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hrs (AUC24h) for TMC435</outcome_measure>
      <outcome_measure>The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal ALT Levels at the End of Treatment (EOT)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01290731</url>
  </study>
  <study rank="255">
    <nct_id>NCT02201459</nct_id>
    <title>Nilotinib Â± Peg-IFN for First Line Chronic Phase CML Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Myeloid Leukemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nilotinib (Tasigna Â®), capsules of 150 mg</intervention>
      <intervention type="Drug">Nilotinib (Tasigna Â®) and Pegylated interferon alfa 2a (PegasysÂ®)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hospices Civils de Lyon</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2013.837</other_id>
    </other_ids>
    <first_received>June 24, 2014</first_received>
    <start_date>August 2014</start_date>
    <completion_date>August 2019</completion_date>
    <last_updated>August 6, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PETALs</acronym>
    <primary_completion_date>January 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Molecular response (MR) 4.5 at 12 months of nilotinib 300 mg twice a day versus a combination of low-dose Peg-Interferon (Peg-IFN) to nilotinib 300 mg twice a day in newly diagnosed CP-CML Chronic Phase Chronic Myelogenous Leukemia patients.</outcome_measure>
      <outcome_measure>Molecular Response 4.5 at 1, 2, 3, 6, 9, 12 months of nilotinib, and duration of MR4.5 during the second year of treatment (18, 24 and 36 months).</outcome_measure>
      <outcome_measure>Major Molecular Response at 1, 2, 3, 6, 9, 12 months of nilotinib, and duration of MMR during the second year of treatment (18, 24 and 36 months).</outcome_measure>
      <outcome_measure>Rate of patients with BCR-ABL/ABL (IS) â¥10% at 3 months.</outcome_measure>
      <outcome_measure>Rate of CCyR (complete cytogenetic responses: bone marrow Philadelphie positive at 0 % on at least 20 metaphases) at 3, 6, 12 months of nilotinib.</outcome_measure>
      <outcome_measure>Safety of the nilotinib combined to Peg-IFN or not (hematological and non-hematological adverse events (AE) graded according to the NCI CTC AE v3).</outcome_measure>
      <outcome_measure>Quality of life of patients treated in both arms</outcome_measure>
      <outcome_measure>Doses-reductions/interruptions of drugs in both arms. Mean daily doses of nilotinib and Peg-IFN administered.</outcome_measure>
      <outcome_measure>Compliance to drugs in each arms</outcome_measure>
      <outcome_measure>Molecular relapse rate at 6 and 12 months after nilotinib withdrawal in patients obtaining 2-year stable MR4.5.</outcome_measure>
      <outcome_measure>Event-free survival.</outcome_measure>
      <outcome_measure>Progression-free survival</outcome_measure>
      <outcome_measure>Overall survival.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02201459</url>
  </study>
  <study rank="256">
    <nct_id>NCT01821963</nct_id>
    <title>Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon Alfa 2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>M.D. Anderson Cancer Center</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2012-0977</other_id>
    </other_ids>
    <first_received>March 27, 2013</first_received>
    <start_date>April 2013</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>February 23, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>February 23, 2015</firstreceived_results_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Undetectable Viral Load 12 Weeks Post-transplant</outcome_measure>
      <outcome_measure>Sustained Virological Response (SVR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01821963</url>
  </study>
  <study rank="257">
    <nct_id>NCT01585324</nct_id>
    <title>A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML25186</other_id>
      <other_id>2011-001256-10</other_id>
    </other_ids>
    <first_received>April 24, 2012</first_received>
    <start_date>January 2012</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>June 25, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>June 25, 2015</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virological Response (SVR) 24 Weeks After End of Treatment</outcome_measure>
      <outcome_measure>Change From Baseline in Hemoglobin Level at Week 12 of Treatment Among Participants With or Without SVR</outcome_measure>
      <outcome_measure>Number of Participants With Decrease in Hemoglobin</outcome_measure>
      <outcome_measure>Lowest Hemoglobin Level During Treatment Among Participants With or Without SVR</outcome_measure>
      <outcome_measure>Number of Participants With Reduction in Ribavirin Dose Due to Drop in Hemoglobin Among Participants With or Without SVR</outcome_measure>
      <outcome_measure>Number of Participants With Neutropenia Among Participants With or Without SVR</outcome_measure>
      <outcome_measure>Number of Participants With Thrombocytopenia Among Participants With or Without SVR</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Czech Republic</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01585324</url>
  </study>
  <study rank="258">
    <nct_id>NCT00402428</nct_id>
    <title>Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">albumin interferon alfa-2b</intervention>
      <intervention type="Drug">peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Human Genome Sciences Inc.</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1331</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HGS1008-C1060</other_id>
      <other_id>ACHIEVE-1</other_id>
    </other_ids>
    <first_received>November 20, 2006</first_received>
    <start_date>December 2006</start_date>
    <completion_date>February 2009</completion_date>
    <last_updated>August 1, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR)</outcome_measure>
      <outcome_measure>Rapid virologic response</outcome_measure>
      <outcome_measure>Early virologic response</outcome_measure>
      <outcome_measure>Undetectable HCV RNA</outcome_measure>
      <outcome_measure>Normalization of ALT (a liver enzyme)</outcome_measure>
      <outcome_measure>Quality of life evaluation</outcome_measure>
      <outcome_measure>Safety assessments (physical exams, AE reporting, lab testing/analysis, HADS and Immunogenicity testing)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Czech Republic</country>
      <country>France</country>
      <country>Germany</country>
      <country>India</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Iowa</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00402428</url>
  </study>
  <study rank="259">
    <nct_id>NCT00144469</nct_id>
    <title>A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a</intervention>
      <intervention type="Drug">rivavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chugai Pharmaceutical</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>JV15725</other_id>
    </other_ids>
    <first_received>September 2, 2005</first_received>
    <start_date>May 2002</start_date>
    <completion_date>March 2005</completion_date>
    <last_updated>January 29, 2009</last_updated>
    <last_verified>January 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response, defined as undetectable HCV-RNA (&lt;50IU per milliliter) after 24 weeks of untreated follow-up (week 72).</outcome_measure>
      <outcome_measure>Biochemical response (normalization of serum alanine aminotransferase activity),</outcome_measure>
      <outcome_measure>Virological response (HCV-RNA &lt;50IU per milliliter) at the end of therapy.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00144469</url>
  </study>
  <study rank="260">
    <nct_id>NCT01579019</nct_id>
    <title>A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">RO5024048</intervention>
      <intervention type="Drug">RO5024048</intervention>
      <intervention type="Drug">danoprevir</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
      <intervention type="Drug">ritonavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV22877</other_id>
      <other_id>2010-022659-41</other_id>
    </other_ids>
    <first_received>April 16, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (defined as unquantifiable serum HCV RNA) 12 weeks after treatment (SVR-12)</outcome_measure>
      <outcome_measure>Sustained virologic response 4 weeks after treatment (SVR-4)</outcome_measure>
      <outcome_measure>Sustained virologic response 24 weeks after treatment (SVR-24)</outcome_measure>
      <outcome_measure>Change in serum HCV RNA levels</outcome_measure>
      <outcome_measure>Virologic response over time</outcome_measure>
      <outcome_measure>Correlation between trough concentrations of RO4995855 and virologic response</outcome_measure>
      <outcome_measure>Incidence of direct-acting antiviral (DAA) resistance, including re-emergence of protease inhibitor resistant virus</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01579019</url>
  </study>
  <study rank="261">
    <nct_id>NCT01416610</nct_id>
    <title>An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>88</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML25159</other_id>
    </other_ids>
    <first_received>August 12, 2011</first_received>
    <start_date>April 2010</start_date>
    <completion_date>October 2014</completion_date>
    <last_updated>November 4, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>November 4, 2015</firstreceived_results_date>
    <acronym>PEGHOPE</acronym>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virological Response 24 Weeks After Completing Treatment (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With SVR 12</outcome_measure>
      <outcome_measure>Percentage of Participants With End of Treatment Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Virological Relapse</outcome_measure>
      <outcome_measure>Short Form Health Survey (SF-36) Scores by Visit</outcome_measure>
      <outcome_measure>Fatigue Severity Scale (FSS) Score by Visit</outcome_measure>
      <outcome_measure>Beschwerdeliste (BL) Score by Visit</outcome_measure>
      <outcome_measure>Beck Depression Inventory (BDI) Score by Visit</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01416610</url>
  </study>
  <study rank="262">
    <nct_id>NCT01439373</nct_id>
    <title>Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GSK2336805</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">GSK2336805 Matching Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
      <collaborator>PPD</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>17</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>115519</other_id>
    </other_ids>
    <first_received>July 7, 2011</first_received>
    <start_date>July 2011</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>November 15, 2012</last_updated>
    <last_verified>June 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety/tolerability of GSK2336805 in comparison with placebo.</outcome_measure>
      <outcome_measure>HCV viral load reduction from baseline</outcome_measure>
      <outcome_measure>Composite of pharmacokinetics, Day 1</outcome_measure>
      <outcome_measure>Composite of pharmacokinetics, Days 7, 14, 21</outcome_measure>
      <outcome_measure>Composite of pharmacokinetics, Day 28</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Nevada</state>
      <state>Oklahoma</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01439373</url>
  </study>
  <study rank="263">
    <nct_id>NCT00148863</nct_id>
    <title>Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-interferon alpha 2a (drug)</intervention>
      <intervention type="Drug">Ribavirin (drug)</intervention>
      <intervention type="Drug">Interferon gamma (drug)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Agency for Research on AIDS and Viral Hepatitis</lead_sponsor>
      <collaborator>InterMune</collaborator>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>65</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2004-005033-19</other_id>
      <other_id>ANRS HC16 Gammatri</other_id>
    </other_ids>
    <first_received>September 7, 2005</first_received>
    <start_date>June 2004</start_date>
    <completion_date>August 2007</completion_date>
    <last_updated>August 29, 2007</last_updated>
    <last_verified>August 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Virological response as defined by an HCV RNA measure non detectable at W28 with qualitative PCR (centralized measure)</outcome_measure>
      <outcome_measure>Virological response at W72</outcome_measure>
      <outcome_measure>Biochemical response at W72 (ALT below normal value)</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>Immunologic response (CD4 and CD8 HCV specific)</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00148863</url>
  </study>
  <study rank="264">
    <nct_id>NCT01604291</nct_id>
    <title>An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
      <collaborator>Clalit Health Services</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>959</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML28268</other_id>
    </other_ids>
    <first_received>May 21, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virological Response (SVR)-24 rate: Percentage of patients with HCV RNA &lt;50 IU/mL at 24 weeks post completion of treatment</outcome_measure>
      <outcome_measure>Dual versus triple Pegasys-based therapy: SVR-24 rates</outcome_measure>
      <outcome_measure>Correlation between SVR-24 and clinical/demographic baseline values</outcome_measure>
      <outcome_measure>Predictive value of on-treatment factors (RVR, eRVR, EVR, EOT) on virological response (HCV-RNA &lt;50 IU/mL): Percentage of patients with rapid/rapid extended/early/end of treatment response</outcome_measure>
      <outcome_measure>Treatment duration</outcome_measure>
      <outcome_measure>Dose reductions/treatment discontinuations</outcome_measure>
      <outcome_measure>Correlation between dose reductions/treatment interruptions and sustained virological response (SVR)</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events (dual versus triple therapy)</outcome_measure>
      <outcome_measure>Rate of treatment-induced anemia (dual versus triple therapy)</outcome_measure>
      <outcome_measure>Treatment regimens for HCV treatment induced anemia in routine clinical practice</outcome_measure>
      <outcome_measure>Rate of virological relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Israel</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01604291</url>
  </study>
  <study rank="265">
    <nct_id>NCT02471430</nct_id>
    <title>Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Panobinostat</intervention>
      <intervention type="Drug">Pegylated Interferon-alpha2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Massachusetts General Hospital</lead_sponsor>
      <collaborator>Novartis</collaborator>
      <collaborator>Genentech, Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>U01AI117841</other_id>
      <other_id>12049</other_id>
    </other_ids>
    <first_received>June 11, 2015</first_received>
    <start_date>September 2015</start_date>
    <completion_date>February 2020</completion_date>
    <last_updated>August 5, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ACTIVATE</acronym>
    <primary_completion_date>September 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Occurrence of Grade â¥ 1 Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Change in CD4 T Cell-Associated Proviral HIV-1 DNA from Baseline</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02471430</url>
  </study>
  <study rank="266">
    <nct_id>NCT01884402</nct_id>
    <title>Observational,Prospective Study to Develop and Validate a Prognostic Tool to Optimize Therapy in Patients With HCV G1/4</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>FundaciÃ³n PÃºblica Andaluza para la gestiÃ³n de la InvestigaciÃ³n en Sevilla</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>770</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>FPS-PEG-2010-01</other_id>
    </other_ids>
    <first_received>June 18, 2013</first_received>
    <start_date>October 2010</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>September 3, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>OPTIM</acronym>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Viral Response (RVS)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01884402</url>
  </study>
  <study rank="267">
    <nct_id>NCT00535847</nct_id>
    <title>A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon alfa 2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
      <collaborator>Tibotec, Inc</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>117</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX06-950-107</other_id>
    </other_ids>
    <first_received>September 25, 2007</first_received>
    <start_date>October 2007</start_date>
    <completion_date>February 2010</completion_date>
    <last_updated>July 9, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>June 22, 2011</firstreceived_results_date>
    <primary_completion_date>February 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Treatment</outcome_measure>
      <outcome_measure>Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Percentage of Prior Relapsers With Undetectable HCV RNA</outcome_measure>
      <outcome_measure>Percentage of Subjects With End of Treatment Response</outcome_measure>
      <outcome_measure>Percentage of Subjects With Undetectable HCV RNA at Week 48 After Completion of Treatment Among Subjects Who Completed Assigned Treatment</outcome_measure>
      <outcome_measure>Cross Tabulation of Extended Rapid Viral Response (eRVR) and Sustained Viral Response (SVR) in With Prior Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Austria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Netherlands</country>
      <country>Puerto Rico</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maine</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00535847</url>
  </study>
  <study rank="268">
    <nct_id>NCT00962975</nct_id>
    <title>A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>29</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PP22612</other_id>
    </other_ids>
    <first_received>August 19, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>April 7, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The longitudinal effect on HBV-related markers: viral load, viral antigen/antibody, viral sequence, cellular and humoral immune responses, RNA</outcome_measure>
      <outcome_measure>Safety and tolerability: AEs, laboratory parameters, vital signs, concomitant medications</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>New Zealand</country>
      <country>Singapore</country>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00962975</url>
  </study>
  <study rank="269">
    <nct_id>NCT01900886</nct_id>
    <title>Epidemiological Study to Evaluate Personality Disorders in Prison Populations in Treatment for Hepatitis C</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Personality Disorders in Prison</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Grupo de Enfermedades Infecciosas de la Sociedad EspaÃ±ola de Sanidad Penitenciaria</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>263</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>GEI-HCC-2010-01</other_id>
    </other_ids>
    <first_received>July 8, 2013</first_received>
    <start_date>December 2010</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>July 12, 2013</last_updated>
    <last_verified>December 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Perseo</acronym>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Viral Response (SVR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01900886</url>
  </study>
  <study rank="270">
    <nct_id>NCT01080222</nct_id>
    <title>A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-NaÃ¯ve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">telaprevir</intervention>
      <intervention type="Drug">VX-222</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Biological">peginterferon-alfa-2a</intervention>
      <intervention type="Drug">VX-222</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>152</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX09-222-103</other_id>
    </other_ids>
    <first_received>March 1, 2010</first_received>
    <start_date>August 2010</start_date>
    <completion_date>November 2013</completion_date>
    <last_updated>February 28, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety and Tolerability</outcome_measure>
      <outcome_measure>Proportion of Subjects Who Achieve a Sustained Viral Response</outcome_measure>
      <outcome_measure>Undetectable HCV RNA Measurements</outcome_measure>
      <outcome_measure>Proportion of Subjects Who Have a Viral Breakthrough or Relapse</outcome_measure>
      <outcome_measure>Plasma Exposures of VX-222 and Telaprevir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>New Zealand</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01080222</url>
  </study>
  <study rank="271">
    <nct_id>NCT00122616</nct_id>
    <title>Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon alpha-2a (PegasysÂ®)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">HIV antiretroviral therapy</intervention>
      <intervention type="Drug">HIV antiretroviral therapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Agency for Research on AIDS and Viral Hepatitis</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRSHC12 FIBROSTOP</other_id>
    </other_ids>
    <first_received>July 19, 2005</first_received>
    <start_date>November 2003</start_date>
    <completion_date>March 2009</completion_date>
    <last_updated>February 21, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of patients who experienced one point decreases of their fibrosis histological score (Metavir).</outcome_measure>
      <outcome_measure>Distribution of the change of fibrosis Metavir score in each group</outcome_measure>
      <outcome_measure>Distribution of fibrosis score from Chevallier classification</outcome_measure>
      <outcome_measure>Plasmatic fibrosis markers dosages</outcome_measure>
      <outcome_measure>Viral load quantification for HIV and HCV</outcome_measure>
      <outcome_measure>Number and percentage of CD4/CD8 cell count throughout the study</outcome_measure>
      <outcome_measure>Number and percentage of patient had more thand 200 copies/ml throughout the study</outcome_measure>
      <outcome_measure>Occurrence of hepatic complication related to HCV</outcome_measure>
      <outcome_measure>Survival throughout the study</outcome_measure>
      <outcome_measure>Quality of life questionnaire</outcome_measure>
      <outcome_measure>Fibrotest (plasmatic fibrosis marker)</outcome_measure>
      <outcome_measure>Histological improvement according to the total interferon dose received</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00122616</url>
  </study>
  <study rank="272">
    <nct_id>NCT00192569</nct_id>
    <title>Australian Trial in Acute Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon alfa 2a</intervention>
      <intervention type="Drug">Ribavirin (HIV conifected patients only)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kirby Institute</lead_sponsor>
      <collaborator>The University of New South Wales</collaborator>
      <collaborator>National Institutes of Health (NIH)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>167</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1R01DA015999-01</other_id>
      <other_id>ATAHC</other_id>
    </other_ids>
    <first_received>September 11, 2005</first_received>
    <start_date>July 2004</start_date>
    <completion_date>June 2010</completion_date>
    <last_updated>April 13, 2011</last_updated>
    <last_verified>October 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy of peg-interferon alpha 2a (and ribavirin for HIV/HCV coifection)</outcome_measure>
      <outcome_measure>Natural history of acute hepatitis C</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00192569</url>
  </study>
  <study rank="273">
    <nct_id>NCT00882908</nct_id>
    <title>A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Ribavirin (R)</intervention>
      <intervention type="Drug">PegIFNÎ±-2a (P)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec Pharmaceuticals, Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>386</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR015799</other_id>
      <other_id>TMC435-TiDP16-C205</other_id>
      <other_id>2008-007147-13</other_id>
    </other_ids>
    <first_received>April 16, 2009</first_received>
    <start_date>June 2009</start_date>
    <completion_date>April 2011</completion_date>
    <last_updated>May 19, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>December 18, 2013</firstreceived_results_date>
    <acronym>PILLAR</acronym>
    <primary_completion_date>April 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Less Than 25 IU/mL Undetectable During Treatment and Follow-up</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Less Than 25 IU/mL Detectable or Undetectable During Treatment and Follow-up</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Greater Than or Equal to 2 log10 Drop During Treatment</outcome_measure>
      <outcome_measure>The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving an Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>Number of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>The Number of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normalized ALT Levels at the End of Treatment (EOT)</outcome_measure>
      <outcome_measure>Plasma Concentrations of TMC435</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24h) for TMC435</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Germany</country>
      <country>New Zealand</country>
      <country>Norway</country>
      <country>Poland</country>
      <country>Russian Federation</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Louisiana</state>
      <state>Minnesota</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Tennessee</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00882908</url>
  </study>
  <study rank="274">
    <nct_id>NCT01645969</nct_id>
    <title>A Follow-Up Study of Patients With HBeAg Positive Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML22265</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>65</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML25647</other_id>
    </other_ids>
    <first_received>July 18, 2012</first_received>
    <start_date>April 2011</start_date>
    <completion_date>October 2012</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Duration of response (HBeAg seroconversion/HBV DNA reduction/HBsAg loss/seroconversion) after end of treatment</outcome_measure>
      <outcome_measure>Correlation of duration of response with on-treatment response (HBeAg/HBV DNA/HBsAg/ALT)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01645969</url>
  </study>
  <study rank="275">
    <nct_id>NCT01886300</nct_id>
    <title>An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive Chronic Hepatitis B in Vietnam</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML27807</other_id>
    </other_ids>
    <first_received>June 21, 2013</first_received>
    <start_date>September 2012</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>November 2, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained off-treatment response rate (based on HBeAg seroconversion) at 6 months after the end of treatment</outcome_measure>
      <outcome_measure>Sustained off-treatment response rate (based on HBeAg seroconversion) at 12 months after the end of treatment</outcome_measure>
      <outcome_measure>Percentage of patients with suppression of HBV DNA to &lt; 2,000 IU/mL during the observation period</outcome_measure>
      <outcome_measure>Incidence of HBsAg clearance</outcome_measure>
      <outcome_measure>Incidence of normalization of serum ALT</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Vietnam</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01886300</url>
  </study>
  <study rank="276">
    <nct_id>NCT01734018</nct_id>
    <title>An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML25614</other_id>
    </other_ids>
    <first_received>November 21, 2012</first_received>
    <start_date>August 2011</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in HBsAg (IU/ml) levels during therapy (up to 48 weeks) and follow-up</outcome_measure>
      <outcome_measure>Change in HBV DNA (IU/ml) during therapy (up to 48 weeks) and follow-up</outcome_measure>
      <outcome_measure>Percentage of patients with sustained immune control (sustained HBV DNA &lt;2000 IU/ml in HBeAg-negative and HBeAg-positive patients or HBeAg seroconversion in HBeAg-positive patients)</outcome_measure>
      <outcome_measure>Percentage of patients with normalisation of serum alanine transaminase (ALT) levels</outcome_measure>
      <outcome_measure>Percentage of patients with HBsAg clearance/seroconversion</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01734018</url>
  </study>
  <study rank="277">
    <nct_id>NCT01332955</nct_id>
    <title>Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>HIV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Biological">pegIFN alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
      <collaborator>Janssen-Cilag Ltd.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2010-023287-41</other_id>
      <other_id>ANRS HC26 TelapreVIH</other_id>
    </other_ids>
    <first_received>March 28, 2011</first_received>
    <start_date>April 2011</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>January 22, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>TelapreVIH</acronym>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Estimation of SVR following a 12 wks treatment by telaprevir combined with a 48 or 72 wks peginterferon-ribavirin treatment, based upon the rapid virological response, and comparison to 20% (which would correspond to a significant therapeutic benefit)</outcome_measure>
      <outcome_measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</outcome_measure>
      <outcome_measure>Estimation of the Sustained Virological Response defined as undetectable HCV-RNA at Week 12 after the end of HCV treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01332955</url>
  </study>
  <study rank="278">
    <nct_id>NCT00892697</nct_id>
    <title>Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Weill Medical College of Cornell University</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>0810010040</other_id>
    </other_ids>
    <first_received>April 30, 2009</first_received>
    <start_date>May 2009</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>March 9, 2015</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>December 18, 2014</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Intrahepatic and Plasma HCV Viral Kinetics</outcome_measure>
      <outcome_measure>Intrahepatic and Peripheral Pharmacokinetic Assessment of Telaprevir</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00892697</url>
  </study>
  <study rank="279">
    <nct_id>NCT00088504</nct_id>
    <title>Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Hepatitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Merimepodib</intervention>
      <intervention type="Drug">PEG-Interferon-alpha 2a (PegasysÂ®)</intervention>
      <intervention type="Drug">Ribavirin (CopegusÂ®)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>315</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX03-497-205</other_id>
    </other_ids>
    <first_received>July 27, 2004</first_received>
    <start_date>July 2004</start_date>
    <completion_date>October 2006</completion_date>
    <last_updated>December 17, 2007</last_updated>
    <last_verified>December 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Idaho</state>
      <state>Illinois</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00088504</url>
  </study>
  <study rank="280">
    <nct_id>NCT02362490</nct_id>
    <title>Efficacy of Peginterferon Alpha 2a Therapy in Chronic Hepatitis B Patients Being Treated With Nucleoside(Acid) Analogues</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alpha 2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Beijing Ditan Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>DTXY004</other_id>
    </other_ids>
    <first_received>February 9, 2015</first_received>
    <start_date>January 2013</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>March 1, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>rate of HBsAg loss</outcome_measure>
      <outcome_measure>decline of HBsAg level</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02362490</url>
  </study>
  <study rank="281">
    <nct_id>NCT01070550</nct_id>
    <title>PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naÃ¯ve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>4598</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>MV21012</other_id>
    </other_ids>
    <first_received>February 9, 2010</first_received>
    <start_date>June 2007</start_date>
    <completion_date>July 2011</completion_date>
    <last_updated>November 2, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Predictive values of virological response 4 and 12 weeks after treatment initiation on sustained virological response (SVR) by HCV genotype</outcome_measure>
      <outcome_measure>Identification and confirmation of host-, virus- and treatment-related factors influencing viral response, SVR and relapse</outcome_measure>
      <outcome_measure>Correlation between overall treatment duration/treatment duration after HCV RNA becomes negative and SVR by genotype</outcome_measure>
      <outcome_measure>Correlation of cumulative ribavirin and peginterferon dose with SVR by genotype</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
      <country>Austria</country>
      <country>Brazil</country>
      <country>Croatia</country>
      <country>France</country>
      <country>Hungary</country>
      <country>Macedonia, The Former Yugoslav Republic of</country>
      <country>Mexico</country>
      <country>Morocco</country>
      <country>Poland</country>
      <country>Romania</country>
      <country>Serbia</country>
      <country>Slovenia</country>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01070550</url>
  </study>
  <study rank="282">
    <nct_id>NCT00048945</nct_id>
    <title>Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEGASYS</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>WV16240</other_id>
    </other_ids>
    <first_received>November 12, 2002</first_received>
    <last_updated>August 11, 2005</last_updated>
    <last_verified>August 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Brazil</country>
      <country>China</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Korea, Republic of</country>
      <country>New Zealand</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Singapore</country>
      <country>Switzerland</country>
      <country>Taiwan</country>
      <country>Thailand</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Nebraska</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00048945</url>
  </study>
  <study rank="283">
    <nct_id>NCT00433069</nct_id>
    <title>Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pioglitazone</intervention>
      <intervention type="Drug">Interferon Alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Geneva</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>5</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GE-DMI-05-116</other_id>
    </other_ids>
    <first_received>February 8, 2007</first_received>
    <start_date>January 2007</start_date>
    <completion_date>January 2008</completion_date>
    <last_updated>May 27, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Early virological response</outcome_measure>
      <outcome_measure>Undetectable serum HCV RNA after 4, 24 weeks and 48 weeks of therapy</outcome_measure>
      <outcome_measure>Changes (vs. baseline) of body weight, HOMA score, after 4, 12 and 48 weeks of therapy and after 24 weeks of follow-up</outcome_measure>
      <outcome_measure>Improvement (vs. baseline) of glucose tolerance parameters after 12 and 48 weeks of therapy and after 24 weeks of follow-up</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00433069</url>
  </study>
  <study rank="284">
    <nct_id>NCT01066793</nct_id>
    <title>PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naÃ¯ve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>2272</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>MV21020</other_id>
    </other_ids>
    <first_received>February 9, 2010</first_received>
    <start_date>October 2007</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>November 2, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Predictive values of virological response 4 and 12 weeks after treatment initiation on sustained virological response (SVR) by HCV genotype</outcome_measure>
      <outcome_measure>Identification and confirmation of host-, virus- and treatment-related factors influencing viral response, SVR and relapse</outcome_measure>
      <outcome_measure>Correlation between overall treatment duration/treatment duration after HCV RNA becomes negative and SVR by genotype</outcome_measure>
      <outcome_measure>Correlation of cumulative ribavirin and peginterferon dose with SVR by genotype</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
      <country>Ireland</country>
      <country>Italy</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01066793</url>
  </study>
  <study rank="285">
    <nct_id>NCT01750216</nct_id>
    <title>An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-NaÃ¯ve Patients With Chronic Hepatitis C Genotype 1</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>196</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML28344</other_id>
    </other_ids>
    <first_received>December 12, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>January 2015</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR) rate, in relation to rapid virological response (RVR) in different stages of liver fibrosis in treatment-naÃ¯ve patients with chronic hepatitis C genotype 1</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
      <outcome_measure>Sustained virological response (SVR) rate, in relation to early virological response (EVR) in different stages of liver fibrosis in treatment naÃ¯ve patients with chronic hepatitis C genotype 1</outcome_measure>
      <outcome_measure>Response rates (RVR, EVR, SVR) according to host/virus/treatment-related factors in different stages of liver fibrosis (F&gt;/=3 and &lt;/=3)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Poland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01750216</url>
  </study>
  <study rank="286">
    <nct_id>NCT01066819</nct_id>
    <title>PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naÃ¯ve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1611</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>MV21542</other_id>
    </other_ids>
    <first_received>February 9, 2010</first_received>
    <start_date>January 2008</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>November 2, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Predictive values of virological response 4 and 12 weeks after treatment initiation on sustained virological response (SVR) by HCV genotype</outcome_measure>
      <outcome_measure>Identification and confirmation of host-, virus- and treatment-related factors influencing viral response, SVR and relapse</outcome_measure>
      <outcome_measure>Correlation between overall treatment duration/treatment duration after HCV RNA becomes negative and SVR by genotype</outcome_measure>
      <outcome_measure>Correlation of cumulative ribavirin and peginterferon dose with SVR by genotype</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Iowa</state>
      <state>Kansas</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
      <state>West Virginia</state>
      <state>Wyoming</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01066819</url>
  </study>
  <study rank="287">
    <nct_id>NCT01447394</nct_id>
    <title>Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus (HCV)</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated Interferon Lambda</intervention>
      <intervention type="Biological">Pegylated Interferon Alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI452-013</other_id>
      <other_id>2011-003748-31</other_id>
    </other_ids>
    <first_received>October 4, 2011</first_received>
    <start_date>March 2012</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>February 2, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy of Lambda + Ribavirin (RBV) compared to Alfa + RBV in achieving a sustained virological response</outcome_measure>
      <outcome_measure>The safety of Lambda + RBV compared to Alfa + RBV in reducing cytopenic abnormalities</outcome_measure>
      <outcome_measure>Proportion of interferon-associated symptoms: a) Flu-like symptoms b) Musculoskeletal symptoms c) Neurologic symptoms d) Psychiatric symptoms e) Constitutional symptoms</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>China</country>
      <country>Colombia</country>
      <country>Czech Republic</country>
      <country>Egypt</country>
      <country>Hong Kong</country>
      <country>Hungary</country>
      <country>India</country>
      <country>Ireland</country>
      <country>Korea, Republic of</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Singapore</country>
      <country>Spain</country>
      <country>Taiwan</country>
      <country>Turkey</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>New York</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01447394</url>
  </study>
  <study rank="288">
    <nct_id>NCT00299923</nct_id>
    <title>Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Relapse</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a, Ribavirin, Amantadine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Hamburg</lead_sponsor>
      <collaborator>UniversitÃ¤tsklinikum Hamburg-Eppendorf</collaborator>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML 18545 (TRELA)</other_id>
      <other_id>EudraCT-Nr.: 2005-001207-19</other_id>
    </other_ids>
    <first_received>March 6, 2006</first_received>
    <start_date>November 2005</start_date>
    <last_updated>March 8, 2007</last_updated>
    <last_verified>March 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>- Comparison of the rate of relapse under the combination of standard dose PegIFN alfa-2a, Ribavirin and Amantadine given for 72 vs. 48 weeks.</outcome_measure>
      <outcome_measure>relationship between EVR during the first twelve weeks and SVR</outcome_measure>
      <outcome_measure>virological response to the combination of standard dose defined as reduction of HCV RNA at week 4, 12, 24, 48 and 72 of treatment, separated between HCV-Genotypes.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00299923</url>
  </study>
  <study rank="289">
    <nct_id>NCT00411385</nct_id>
    <title>Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">albumin interferon alfa-2b</intervention>
      <intervention type="Drug">peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Human Genome Sciences Inc.</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>933</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HGS1008-C1067</other_id>
      <other_id>ACHIEVE-2/3</other_id>
    </other_ids>
    <first_received>December 13, 2006</first_received>
    <start_date>February 2007</start_date>
    <completion_date>October 2008</completion_date>
    <last_updated>August 1, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR)</outcome_measure>
      <outcome_measure>Rapid virologic response</outcome_measure>
      <outcome_measure>Early virologic response</outcome_measure>
      <outcome_measure>Undetectable HCV RNA</outcome_measure>
      <outcome_measure>Normalization of ALT (a liver enzyme)</outcome_measure>
      <outcome_measure>Quality of life evaluation</outcome_measure>
      <outcome_measure>Safety assessments (physical exams, Ae reporting, lab testing/analysis, HADS and Immunogenicity results)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Germany</country>
      <country>India</country>
      <country>Israel</country>
      <country>Korea, Republic of</country>
      <country>Malaysia</country>
      <country>Mexico</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Singapore</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>Taiwan</country>
      <country>Thailand</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Minnesota</state>
      <state>New Hampshire</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00411385</url>
  </study>
  <study rank="290">
    <nct_id>NCT00527540</nct_id>
    <title>Effectiveness and Side Effects of Pegylated Interferon Alpha-2a (PegaferonÂ®) Plus Ribavirin in the Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon alpha 2a + Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tehran Hepatitis Center</lead_sponsor>
      <collaborator>Kermanshah University of Medical Sciences</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>THC-10</other_id>
    </other_ids>
    <first_received>September 8, 2007</first_received>
    <start_date>February 2007</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>January 18, 2009</last_updated>
    <last_verified>January 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>End of treatment response rate (HCV RNA:Neg)</outcome_measure>
      <outcome_measure>Sustain response rate (HCV RNA:Neg) 6 month after end of treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Iran, Islamic Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00527540</url>
  </study>
  <study rank="291">
    <nct_id>NCT01517308</nct_id>
    <title>24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon alpha 2a + ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Federico II University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>C.E. Federico II 47/11</other_id>
    </other_ids>
    <first_received>January 17, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>March 16, 2012</last_updated>
    <last_verified>March 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01517308</url>
  </study>
  <study rank="292">
    <nct_id>NCT01356160</nct_id>
    <title>GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GS-5885</intervention>
      <intervention type="Drug">GS-9451</intervention>
      <intervention type="Biological">peginterferon alfa-2a</intervention>
      <intervention type="Drug">ribavirin tablet</intervention>
      <intervention type="Drug">GS-9451 Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>351</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-256-0148</other_id>
    </other_ids>
    <first_received>May 2, 2011</first_received>
    <start_date>July 2011</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>January 2, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the antiviral efficacy of response guided therapy.</outcome_measure>
      <outcome_measure>To evaluate the safety and tolerability of each regimen.</outcome_measure>
      <outcome_measure>To characterize viral dynamics of GS-5885 and GS-9451 when administered with PEG and RBV.</outcome_measure>
      <outcome_measure>To characterize the viral resistance to GS-5885 and GS-9451 when administered in combination with PEG and RBV.</outcome_measure>
      <outcome_measure>To characterize steady state pharmacokinetics of GS-5885 and GS-9451 when administered with PEG and RBV.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01356160</url>
  </study>
  <study rank="293">
    <nct_id>NCT01725542</nct_id>
    <title>Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV-HIV Co-Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
      <collaborator>Bristol-Myers Squibb</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS HC30 QUADRIH</other_id>
      <other_id>2012-002589-11</other_id>
    </other_ids>
    <first_received>October 22, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>September 5, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>QUADRIH</acronym>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV Sustained virological response rate</outcome_measure>
      <outcome_measure>Number of participants with adverse events as a measure of safety and tolerability</outcome_measure>
      <outcome_measure>Kinetics of HCV Virological response</outcome_measure>
      <outcome_measure>Immunological and virological evolution of HIV infection</outcome_measure>
      <outcome_measure>Evolution of cirrhosis (for cirrhotic patients)</outcome_measure>
      <outcome_measure>Number of Participants with HIV and non HIV related clinical events</outcome_measure>
      <outcome_measure>Minimum Plasma Concentration (Cmin) of ribavirin</outcome_measure>
      <outcome_measure>Pharmacokinetics of Antiretroviral drugs</outcome_measure>
      <outcome_measure>Pharmacokinetics of Asunaprevir and Daclatasvir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01725542</url>
  </study>
  <study rank="294">
    <nct_id>NCT00834860</nct_id>
    <title>Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hepatocellular Carcinoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peginterferon alpha-2a and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kaohsiung Medical University Chung-Ho Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>179</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KMUH-IRB-960043</other_id>
    </other_ids>
    <first_received>February 1, 2009</first_received>
    <start_date>January 2007</start_date>
    <completion_date>February 2010</completion_date>
    <last_updated>February 11, 2010</last_updated>
    <last_verified>February 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy: sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.</outcome_measure>
      <outcome_measure>Rapid virologic response (RVR), HCV RNA seronegative by PCR at week 4.</outcome_measure>
      <outcome_measure>Early virological response (EVR), by PCR-negative or at least 2 logs decline from baseline of serum HCV RNA at 12 weeks of treatment.</outcome_measure>
      <outcome_measure>Safety: adverse event rate and profile.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00834860</url>
  </study>
  <study rank="295">
    <nct_id>NCT01172392</nct_id>
    <title>A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
      <condition>AgHbs Negativation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon-alpha-2a</intervention>
      <intervention type="Drug">Nucleotidic or Nucleosidic Treatment</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
      <collaborator>Roche Pharma AG</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>185</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2010-019367-11</other_id>
      <other_id>ANRS HB 06 PEGAN</other_id>
    </other_ids>
    <first_received>July 28, 2010</first_received>
    <start_date>January 2011</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>March 28, 2013</last_updated>
    <last_verified>February 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PEGAN</acronym>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HbsAg negativation at week 96</outcome_measure>
      <outcome_measure>Kinetics of HbsAg</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01172392</url>
  </study>
  <study rank="296">
    <nct_id>NCT00743795</nct_id>
    <title>Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">placebo</intervention>
      <intervention type="Drug">GS-9190</intervention>
      <intervention type="Drug">Peginterferon Alfa 2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>252</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-196-0103</other_id>
    </other_ids>
    <first_received>August 27, 2008</first_received>
    <start_date>October 2008</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>October 11, 2013</last_updated>
    <last_verified>October 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Undetectable HCV RNA level</outcome_measure>
      <outcome_measure>Safety and tolerability</outcome_measure>
      <outcome_measure>GS-9190 plasma concentrations</outcome_measure>
      <outcome_measure>Undetectable HCV RNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Belgium</country>
      <country>Germany</country>
      <country>Ireland</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00743795</url>
  </study>
  <study rank="297">
    <nct_id>NCT01903278</nct_id>
    <title>Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis c</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-IFN-SA /RBV</intervention>
      <intervention type="Drug">Pegasys /RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Beijing Kawin Technology Share-Holding Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>719</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KAWIN-002-2</other_id>
    </other_ids>
    <first_received>July 17, 2013</first_received>
    <start_date>June 2013</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>September 24, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR (sustained virologic response)</outcome_measure>
      <outcome_measure>RVR(rapid virologic response)</outcome_measure>
      <outcome_measure>cEVR (complete early virologic response)</outcome_measure>
      <outcome_measure>ETVR( end of treatment virologic response)</outcome_measure>
      <outcome_measure>eRVR ( extended rapid virologic response)</outcome_measure>
      <outcome_measure>No-responses</outcome_measure>
      <outcome_measure>Breakthrough</outcome_measure>
      <outcome_measure>Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01903278</url>
  </study>
  <study rank="298">
    <nct_id>NCT01516918</nct_id>
    <title>A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">VX-222</intervention>
      <intervention type="Drug">telaprevir</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Biological">peginterferon-alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>103</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VX11-222-106</other_id>
    </other_ids>
    <first_received>January 13, 2012</first_received>
    <start_date>February 2012</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>October 9, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The proportion of subjects who have a sustained virologic response at 12 weeks after the last planned dose of treatment (SVR12)</outcome_measure>
      <outcome_measure>The safety and tolerability as assessed by adverse events, vital signs, 12-lead electrocardiograms and laboratory assessments.</outcome_measure>
      <outcome_measure>The proportion of subjects who have an SVR 24 weeks after the last planned dose of the study drug (SVR24)</outcome_measure>
      <outcome_measure>The proportion of subjects who achieve undetectable HCV RNA at Weeks 2, 4, 8, and 12 after the first dose of study drug, and at the end of planned study drug treatment</outcome_measure>
      <outcome_measure>The proportion of subjects who have on-treatment virologic failure defined as subjects who either meet a futility rule or who complete the assigned treatment duration and have HCV RNA at the end of study drug treatment</outcome_measure>
      <outcome_measure>The association of the IL-28B genotype with SVR12</outcome_measure>
      <outcome_measure>The amino acid sequence of the nonstructural (NS)3 and NS5B proteins in subjects who have treatment failure</outcome_measure>
      <outcome_measure>VX-222, telaprevir, and RBV plasma concentrations and Peg-IFN serum concentrations</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Germany</country>
      <country>Poland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New Hampshire</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01516918</url>
  </study>
  <study rank="299">
    <nct_id>NCT01323244</nct_id>
    <title>A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>142</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017983</other_id>
      <other_id>TMC435-TiDP16-C213</other_id>
    </other_ids>
    <first_received>March 24, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>March 2015</completion_date>
    <last_updated>April 7, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The proportion of participants with sustained viral response</outcome_measure>
      <outcome_measure>Number of participants with HCV RNA level &gt;1000 IU/mL</outcome_measure>
      <outcome_measure>Number of participants with viral breakthrough</outcome_measure>
      <outcome_measure>Number of participants with viral relapse</outcome_measure>
      <outcome_measure>Number of participants with normalized alanine aminotransferase levels</outcome_measure>
      <outcome_measure>Number of participants with on-treatment failure</outcome_measure>
      <outcome_measure>Number of participants affected by an adverse event</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>Bulgaria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Mexico</country>
      <country>Netherlands</country>
      <country>New Zealand</country>
      <country>Poland</country>
      <country>Portugal</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Ukraine</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Louisiana</state>
      <state>Mississippi</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01323244</url>
  </study>
  <study rank="300">
    <nct_id>NCT00629824</nct_id>
    <title>Pegylated Interferon Plus Ribavirin in Treating Older Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon alpha and plus ribavirin</intervention>
      <intervention type="Drug">pegylated interferon alpha and plus ribavirin</intervention>
      <intervention type="Drug">pegylated interferon alpha and plus ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kaohsiung Medical University Chung-Ho Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>250</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KMUH-IRB- 960047</other_id>
    </other_ids>
    <first_received>February 26, 2008</first_received>
    <start_date>February 2007</start_date>
    <completion_date>April 2009</completion_date>
    <last_updated>September 6, 2010</last_updated>
    <last_verified>February 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy: Sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.</outcome_measure>
      <outcome_measure>RVR, rapid virological response, defined as HCV RNA &lt; 50 IU/mL at treatment week 4</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00629824</url>
  </study>
  <study rank="301">
    <nct_id>NCT02541409</nct_id>
    <title>Directly Observed Therapy for HCV in Chennai, India</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Pegylated Interferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Johns Hopkins Bloomberg School of Public Health</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>YR Gaitonde Centre for AIDS Research and Education</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>R01DA02672</other_id>
      <other_id>R01DA026727</other_id>
    </other_ids>
    <first_received>August 31, 2015</first_received>
    <start_date>September 2015</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>C-DOT</acronym>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects that complete their course of treatment</outcome_measure>
      <outcome_measure>Sustained virologic response 12 weeks after treatment is completed (SVR12) as assessed by undetectable HCV RNA measured 12 weeks after treatment completion</outcome_measure>
      <outcome_measure>Number of participants with treatment-related serious adverse events by laboratory tests and physician examination</outcome_measure>
      <outcome_measure>Change in insulin resistance as assessed by homeostasis model assessment - insulin resistance (HOMA-IR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>India</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02541409</url>
  </study>
  <study rank="302">
    <nct_id>NCT00441584</nct_id>
    <title>The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PegIntron (peginterferon alfa-2b)</intervention>
      <intervention type="Drug">Rebetol (ribavirin)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
      <collaborator>Integrated Therapeutics Group</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>117</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P03833</other_id>
      <other_id>ESPECIAL</other_id>
    </other_ids>
    <first_received>February 28, 2007</first_received>
    <start_date>July 2005</start_date>
    <completion_date>June 2008</completion_date>
    <last_updated>October 7, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>June 18, 2009</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Subjects Who Have Achieved Sustained Virological Response (SVR) at 24 Weeks Post End of Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00441584</url>
  </study>
  <study rank="303">
    <nct_id>NCT01679834</nct_id>
    <title>An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>7500</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML25724</other_id>
    </other_ids>
    <first_received>September 3, 2012</first_received>
    <start_date>November 2014</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response</outcome_measure>
      <outcome_measure>Rapid virological response</outcome_measure>
      <outcome_measure>Early Virological Response</outcome_measure>
      <outcome_measure>Safety: incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01679834</url>
  </study>
  <study rank="304">
    <nct_id>NCT01567735</nct_id>
    <title>A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-NaÃ¯ve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>107</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100695</other_id>
      <other_id>TMC435HPC3011</other_id>
      <other_id>2011-004097-29</other_id>
    </other_ids>
    <first_received>January 24, 2012</first_received>
    <start_date>March 2012</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>April 13, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>RESTORE</acronym>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants achieving sustained virologic response 12 weeks after planned end of treatment (SVR12)</outcome_measure>
      <outcome_measure>Efficacy of TMC435 with respect to proportion of participants achieving sustained virologic response 24 weeks after planned end of treatment (SVR24)</outcome_measure>
      <outcome_measure>On-treatment virologic response</outcome_measure>
      <outcome_measure>On-treatment virologic failure</outcome_measure>
      <outcome_measure>Evaluation of the viral breakthrough rate</outcome_measure>
      <outcome_measure>Evaluation of viral relapse rate</outcome_measure>
      <outcome_measure>Evaluation the safety and tolerability</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01567735</url>
  </study>
  <study rank="305">
    <nct_id>NCT01433887</nct_id>
    <title>Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic Hepatitis C Genotypes 1 Versus 2/3 Versus 6</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">48-weeks course</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Third Affiliated Hospital, Sun Yat-Sen University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>535</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TAH5010G6HCV</other_id>
    </other_ids>
    <first_received>September 11, 2011</first_received>
    <start_date>November 2011</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>November 14, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR)</outcome_measure>
      <outcome_measure>Change in health related quality as measured by short form 36 (SF-36) from baseline to 24 weeks after the end of treatment</outcome_measure>
      <outcome_measure>Sick leave in patients treated for 24 or 48 weeks treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01433887</url>
  </study>
  <study rank="306">
    <nct_id>NCT01011738</nct_id>
    <title>An Observational Cohort Study in Patients With Chronic Hepatitis B Receiving Pegasys</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1847</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>MV22009</other_id>
    </other_ids>
    <first_received>November 10, 2009</first_received>
    <start_date>April 2009</start_date>
    <completion_date>November 2014</completion_date>
    <last_updated>November 2, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HBsAg clearance</outcome_measure>
      <outcome_measure>suppression of HBV DNA, HBeAg seroconversion, quantitative HBsAg, serum ALT</outcome_measure>
      <outcome_measure>Safety: incidence of CHB-associated clinical endpoints, serious and non-serious adverse drug reactions</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>Bahrain</country>
      <country>Bangladesh</country>
      <country>Bosnia and Herzegovina</country>
      <country>Bulgaria</country>
      <country>China</country>
      <country>Egypt</country>
      <country>France</country>
      <country>Germany</country>
      <country>Hong Kong</country>
      <country>India</country>
      <country>Indonesia</country>
      <country>Ireland</country>
      <country>Jordan</country>
      <country>Korea, Republic of</country>
      <country>Lebanon</country>
      <country>Macedonia, The Former Yugoslav Republic of</country>
      <country>Morocco</country>
      <country>New Zealand</country>
      <country>Pakistan</country>
      <country>Poland</country>
      <country>Portugal</country>
      <country>Romania</country>
      <country>Saudi Arabia</country>
      <country>Thailand</country>
      <country>United Arab Emirates</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01011738</url>
  </study>
  <study rank="307">
    <nct_id>NCT00991289</nct_id>
    <title>Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>HIV Infection</condition>
      <condition>Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitazoxanide (NTZ)</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a (PEG)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>68</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>A5269</other_id>
      <other_id>10764</other_id>
      <other_id>ACTG A5269</other_id>
    </other_ids>
    <first_received>October 7, 2009</first_received>
    <start_date>January 2010</start_date>
    <completion_date>January 2012</completion_date>
    <last_updated>November 19, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>August 29, 2011</firstreceived_results_date>
    <primary_completion_date>November 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events of Grade 2 or Higher</outcome_measure>
      <outcome_measure>Change in Hemoglobin Level From Study Entry</outcome_measure>
      <outcome_measure>Percent Change in Fasting Insulin Level From Study Entry</outcome_measure>
      <outcome_measure>Percent Change in Fasting Glucose Level From Study Entry</outcome_measure>
      <outcome_measure>Percent Change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) From Study Entry</outcome_measure>
      <outcome_measure>Change in log10 HCV Viral Load After 4 Weeks of Nitazoxanide (NTZ) Monotherapy.</outcome_measure>
      <outcome_measure>Number of Participants With HCV Genotype 1</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Massachusetts</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00991289</url>
  </study>
  <study rank="308">
    <nct_id>NCT02377856</nct_id>
    <title>Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon alpha 2a, ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kaohsiung Medical University Chung-Ho Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KMUH-IRB-960056</other_id>
      <other_id>KMUH</other_id>
    </other_ids>
    <first_received>September 9, 2014</first_received>
    <start_date>June 2007</start_date>
    <completion_date>December 2020</completion_date>
    <last_updated>March 5, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <outcome_measures>
      <outcome_measure>treatment efficacy in terms of SVR rate</outcome_measure>
      <outcome_measure>safety issues regarding adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02377856</url>
  </study>
  <study rank="309">
    <nct_id>NCT00720434</nct_id>
    <title>A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PF-00868554</intervention>
      <intervention type="Drug">PF-00868554</intervention>
      <intervention type="Drug">PF-00868554</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>35</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>A8121007</other_id>
    </other_ids>
    <first_received>July 18, 2008</first_received>
    <start_date>August 2008</start_date>
    <completion_date>March 2010</completion_date>
    <last_updated>June 18, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>June 18, 2013</firstreceived_results_date>
    <primary_completion_date>March 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 4 - Full Analysis Set</outcome_measure>
      <outcome_measure>Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 4 - Modified Analysis Set</outcome_measure>
      <outcome_measure>Proportion of Participants Achieving Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Alanine Aminotransferase (ALT) Levels</outcome_measure>
      <outcome_measure>Population Pharmacokinetics (PK) of PF-00868554</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Massachusetts</state>
      <state>New York</state>
      <state>Oklahoma</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00720434</url>
  </study>
  <study rank="310">
    <nct_id>NCT01200225</nct_id>
    <title>An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1155</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML22790</other_id>
    </other_ids>
    <first_received>September 10, 2010</first_received>
    <start_date>February 2010</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Effect of insulin resistance, defined as HOMA index &gt; 2, on sustained virological response (HCV RNA assessed by Polymerase Chain Reaction assay)</outcome_measure>
      <outcome_measure>Host-, virus- and treatment-related factors influencing virological response and sustained virological response</outcome_measure>
      <outcome_measure>Parameters of metabolic syndrome</outcome_measure>
      <outcome_measure>Management of insulin resistance</outcome_measure>
      <outcome_measure>Quality of life: Hepatitis Quality of Life Questionnaire (HQLQ)</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
      <outcome_measure>Patient characteristics</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01200225</url>
  </study>
  <study rank="311">
    <nct_id>NCT02106156</nct_id>
    <title>Observational Study Evaluating the Quality of Pegasys and Copegus Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>9729</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML21645</other_id>
    </other_ids>
    <first_received>April 3, 2014</first_received>
    <start_date>January 2008</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Rapid virologic response (RVR)</outcome_measure>
      <outcome_measure>Early virologic response (EVR)</outcome_measure>
      <outcome_measure>End of treatment response (EOT)</outcome_measure>
      <outcome_measure>Sustained virologic response (SVR)</outcome_measure>
      <outcome_measure>Incidence of severe adverse events</outcome_measure>
      <outcome_measure>Patient demographics</outcome_measure>
      <outcome_measure>Hepatitis C medical history</outcome_measure>
      <outcome_measure>Treatment/dosage data</outcome_measure>
      <outcome_measure>Viral genotype</outcome_measure>
      <outcome_measure>Viral load</outcome_measure>
      <outcome_measure>Concomitant treatment information (medication type, dosage)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02106156</url>
  </study>
  <study rank="312">
    <nct_id>NCT00996476</nct_id>
    <title>A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">PegIFNÎ±-2a</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Pharmaceutical K.K.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>92</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR016402</other_id>
      <other_id>TMC435-TiDP16-C215</other_id>
    </other_ids>
    <first_received>October 15, 2009</first_received>
    <start_date>July 2009</start_date>
    <completion_date>January 2011</completion_date>
    <last_updated>March 21, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>October 17, 2013</firstreceived_results_date>
    <acronym>DRAGON</acronym>
    <primary_completion_date>January 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels From Baseline to Week 4</outcome_measure>
      <outcome_measure>The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels During the Study</outcome_measure>
      <outcome_measure>The Percentage of Participants With a Decrease of Greater Than or Equal to 2 log10 IU/mL From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Through the Post-treatment Follow-up Period</outcome_measure>
      <outcome_measure>The Percentage of Participants With Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Undetectable or Below the Limit of Quantification (&lt;1.2 log10 IU/mL Detectable) During Treatment and During Post Treatment Follow-up</outcome_measure>
      <outcome_measure>The Number of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>The Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Actual Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values up to Week 24 in the Post-treatment Follow-up Period</outcome_measure>
      <outcome_measure>The Number of Participants With Alanine Aminotransaminase (ALT) Values Within the Normal Range at the End-of-treatment (EOT)</outcome_measure>
      <outcome_measure>The Percentage of Participants With Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Predose Plasma Concentrations (C0h) of TMC435 (Sparse Blood Sampling)</outcome_measure>
      <outcome_measure>Predose Plasma Concentrations (C0h) of TMC435 (Intensive Blood Sampling)</outcome_measure>
      <outcome_measure>The Area Under the Plasma Concentration-time Curve From the Time of Administration up to 24 Hours After Dosing (AUC24) for TMC435</outcome_measure>
      <outcome_measure>Time to Reach the Maximum Plasma Concentration (Tmax) of TMC435</outcome_measure>
      <outcome_measure>The Number of Participants Who Met Virologic Stopping/Continuation Rules and Completed All Study Medications</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00996476</url>
  </study>
  <study rank="313">
    <nct_id>NCT01194037</nct_id>
    <title>A Phase 1b/2a, Open-label,Randomized, Safety, Tolerability, Dose Finding, PK/PD, and Preliminary Efficacy Study of SC Hanferonâ¢ in Combination With Ribavirin in Treatment-naÃ¯ve Subjects With Genotype 1 Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
      <condition>Genotype 1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">recombinant variant of interferon-alpha 2b</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>HanAll BioPharma Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HL-143IFN-SC-US-001</other_id>
    </other_ids>
    <first_received>September 1, 2010</first_received>
    <start_date>June 2011</start_date>
    <completion_date>June 2012</completion_date>
    <last_updated>February 24, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV RNA level</outcome_measure>
      <outcome_measure>Proportion of patients who reach RVR</outcome_measure>
      <outcome_measure>PK &amp; PD</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01194037</url>
  </study>
  <study rank="314">
    <nct_id>NCT01798576</nct_id>
    <title>An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>282</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML28498</other_id>
    </other_ids>
    <first_received>February 22, 2013</first_received>
    <start_date>November 2012</start_date>
    <completion_date>July 2016</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR) rate, defined as percentage of patients with HCV RNA &lt;50 IU/mL at 24 weeks post completion of treatment (overall and stratified by prior treatment outcome: non-response and relapse)</outcome_measure>
      <outcome_measure>Percentage of patients with rapid virological response (RVR), defined as HCV RNA &lt;50 IU/mL at Week 4 (overall and stratified by prior treatment outcome: non-response and relapse)</outcome_measure>
      <outcome_measure>Percentage of patients with early virological response (EVR), defined as HCV RNA &lt;50 IU/mL or an at least 2-log drop from baseline in HCV RNA at Week 12, but with no RVR (overall and stratified by prior treatment outcome: non-response and relapse)</outcome_measure>
      <outcome_measure>Percentage of patients with non-response/relapse/virological breakthrough/virological rebound</outcome_measure>
      <outcome_measure>Duration of treatment</outcome_measure>
      <outcome_measure>Time to safety-related dose reduction/treatment discontinuation of any of the treatment compounds</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Romania</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01798576</url>
  </study>
  <study rank="315">
    <nct_id>NCT01794234</nct_id>
    <title>An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis B Who Have Failed Antiviral Treatment With Nucleoside (Nucleotide) Analogues</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>44</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML28346</other_id>
    </other_ids>
    <first_received>February 15, 2013</first_received>
    <start_date>August 2012</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy: HBsAg seroclearance/seroconversion rate at the end of Week 72 (48 weeks of treatment and 24 weeks of follow-up)</outcome_measure>
      <outcome_measure>HBs levels in correlation with treatment outcome</outcome_measure>
      <outcome_measure>For HBeAg positive patients: Proportion of patients with HBeAg loss and presence of anti HBe (HBeAg seroconversion) at the end of Week 72 (48 weeks of treatment and 24 weeks of follow-up)</outcome_measure>
      <outcome_measure>For HBeAg negative patients: Proportion of patients with HBV DNA &lt;/= 2000 IU/ml and ALT normalization</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Poland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01794234</url>
  </study>
  <study rank="316">
    <nct_id>NCT00561015</nct_id>
    <title>A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tibotec BVBA</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR013513</other_id>
      <other_id>VX-950-TiDP24-C209</other_id>
    </other_ids>
    <first_received>November 19, 2007</first_received>
    <start_date>December 2007</start_date>
    <completion_date>May 2009</completion_date>
    <last_updated>June 7, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>March 8, 2013</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Log 10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level at Day 15</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) for Telaprevir on Day 1</outcome_measure>
      <outcome_measure>Time to Reach Maximum Plasma Concentration (Tmax) for Telaprevir on Day 1</outcome_measure>
      <outcome_measure>Area Under Plasma Concentration-Time Curve Over Dosing Interval (AUCtau) for Telaprevir on Day 1</outcome_measure>
      <outcome_measure>Area Under Plasma Concentration-Time Curve Over Dosing Interval (AUCtau) for Telaprevir on Day 15</outcome_measure>
      <outcome_measure>Change From Baseline in Log 10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level at Week 24 and Week 26</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) for Telaprevir on Day 15</outcome_measure>
      <outcome_measure>Minimum Plasma Concentration (Cmin) for Telaprevir on Day 15</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Virological Response (HCV RNA Level &lt; 10 IU/ml)</outcome_measure>
      <outcome_measure>Median Time to Virological Response (HCV RNA Level &lt; 10 IU/ml)</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants Who Demonstrated Virological Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieved Sustained Virological Response (SVR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
      <country>Sweden</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00561015</url>
  </study>
  <study rank="317">
    <nct_id>NCT01439776</nct_id>
    <title>Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Vit D</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hanyang University</lead_sponsor>
      <collaborator>Roche Pharma AG</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>222</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML25569</other_id>
    </other_ids>
    <first_received>September 16, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>September 22, 2011</last_updated>
    <last_verified>September 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Addwin</acronym>
    <primary_completion_date>February 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants with Sustained virologic response (SVR)</outcome_measure>
      <outcome_measure>Number of participants with End of treatment response (ETR)</outcome_measure>
      <outcome_measure>Number of participants with Rapid virological response (RVR)</outcome_measure>
      <outcome_measure>Number of participants with Early virological response (EVR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Korea, Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01439776</url>
  </study>
  <study rank="318">
    <nct_id>NCT02381379</nct_id>
    <title>Malaysia Stop Tyrosine Kinase Inhibitor Trial</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Leukemia, Chronic Myeloid</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon-Î±-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ministry of Health, Malaysia</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>118</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NMRR-13-1186-15491</other_id>
    </other_ids>
    <first_received>March 2, 2015</first_received>
    <start_date>March 2015</start_date>
    <completion_date>March 2019</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>MSIT</acronym>
    <primary_completion_date>March 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Relapse rate</outcome_measure>
      <outcome_measure>The number of patients who developed adverse side-effects of interferon</outcome_measure>
      <outcome_measure>The rate of reattaining deep MR</outcome_measure>
      <outcome_measure>Time to regain deep MR after relapse</outcome_measure>
      <outcome_measure>Quality of life (QoL) assessment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Malaysia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02381379</url>
  </study>
  <study rank="319">
    <nct_id>NCT01855997</nct_id>
    <title>A Study to Collect Blood Biomarker Samples From Patients With Chronic Hepatitis B Who Received Treatment With Pegasys (Peginterferon Alfa-2a) +/- Nucleos(t)Ide Analogue</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1398</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
    </study_designs>
    <other_ids>
      <other_id>GV28855</other_id>
    </other_ids>
    <first_received>May 8, 2013</first_received>
    <start_date>August 2013</start_date>
    <completion_date>November 2014</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in HBV DNA (quantitative PCR Test in iU/ml)</outcome_measure>
      <outcome_measure>Change in HBsAg/anti-HBs</outcome_measure>
      <outcome_measure>Change in HBeAg/anti-HBe</outcome_measure>
      <outcome_measure>Exploratory analysis of association of single nucleotide polymorphisms and treatment responses</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events related to study-specific procedures</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
      <country>Bulgaria</country>
      <country>China</country>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>New Zealand</country>
      <country>Poland</country>
      <country>Portugal</country>
      <country>Romania</country>
      <country>Taiwan</country>
      <country>Thailand</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01855997</url>
  </study>
  <study rank="320">
    <nct_id>NCT00926614</nct_id>
    <title>Efficacy of Actos Lipitor Pegasys &amp; Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis c</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pioglitazone (Actos)</intervention>
      <intervention type="Drug">atorvastatin (Lipitor)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Brooke Army Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>C.2008.153</other_id>
    </other_ids>
    <first_received>June 22, 2009</first_received>
    <start_date>September 2008</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>February 13, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Improvement is seen in insulin resistance patients to be in a position to respond more favorably to current antiviral therapy consisting of pegylated interferon and ribavirin.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00926614</url>
  </study>
  <study rank="321">
    <nct_id>NCT00381953</nct_id>
    <title>High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Interferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Foundation for Liver Research</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>33</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HCV02-01</other_id>
    </other_ids>
    <first_received>September 27, 2006</first_received>
    <start_date>February 2003</start_date>
    <completion_date>July 2006</completion_date>
    <last_updated>March 12, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To compare pharmacokinetics by IFN assays and pharmacodynamics by patient's HCV RNA suppression of 360 mug peginterferon alfa-2a QW, 9 MU interferon alfa-2a daily or 4,5 interferon alfa-2a daily in combination with 180 mug peginterferon alfa-2a QW</outcome_measure>
      <outcome_measure>To compare the virological breakthrough/relapse rate after dose adjustments (at 4,24,72) weeks.</outcome_measure>
      <outcome_measure>To compare the sustained virological response rate at 24 weeks after end of treatment.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00381953</url>
  </study>
  <study rank="322">
    <nct_id>NCT00172809</nct_id>
    <title>Interferon Treatment for Patients With Chronic Hepatitis C and End Stage Renal Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>End Stage Renal Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Interferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>940209</other_id>
    </other_ids>
    <first_received>September 12, 2005</first_received>
    <start_date>July 2005</start_date>
    <completion_date>January 2007</completion_date>
    <last_updated>March 5, 2008</last_updated>
    <last_verified>June 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained histological response and sustained virological response 6 months after the completion of the intervention</outcome_measure>
      <outcome_measure>The overall tolerance of the two different regimens and the comparison of the rates of side effects</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00172809</url>
  </study>
  <study rank="323">
    <nct_id>NCT01890200</nct_id>
    <title>The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">TCM-700C</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>TCM Biotech International Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>598</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>TCM-700-02-01</other_id>
    </other_ids>
    <first_received>June 26, 2013</first_received>
    <start_date>June 2015</start_date>
    <completion_date>June 2018</completion_date>
    <last_updated>December 14, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>sustained virologic response (SVR) rate</outcome_measure>
      <outcome_measure>Virologic response (VR)</outcome_measure>
      <outcome_measure>relapse rate</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01890200</url>
  </study>
  <study rank="324">
    <nct_id>NCT01012895</nct_id>
    <title>Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-790052</intervention>
      <intervention type="Drug">BMS-650032</intervention>
      <intervention type="Drug">BMS-650032</intervention>
      <intervention type="Drug">BMS-650032</intervention>
      <intervention type="Drug">Pegylated-interferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>215</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI447-011</other_id>
      <other_id>2010-024637-23</other_id>
    </other_ids>
    <first_received>November 12, 2009</first_received>
    <start_date>December 2009</start_date>
    <completion_date>February 2014</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Hepatitis C virus (HCV) ribonucleic acid (RNA) levels in subjects' blood before, during and after treatment</outcome_measure>
      <outcome_measure>Safety assessments will be based on medical review of the frequency of SAEs and AEs, discontinuations due to AEs, and abnormalities observed from vital sign and ECG measurements, physical examinations and clinical laboratory results</outcome_measure>
      <outcome_measure>Pharmacokinetic parameter maximum observed concentration [Cmax] will be derived from plasma concentration versus time. Trough concentration (Ctrough) and sparse Pharmacokinetics (PK) samples will also be collected.</outcome_measure>
      <outcome_measure>Pharmacokinetic parameter trough observed concentration [Cmin] will be derived from plasma concentration versus time. Trough concentration (Ctrough) and sparse Pharmacokinetics (PK) samples will also be collected.</outcome_measure>
      <outcome_measure>Pharmacokinetic parameter time of maximum observed concentration [Tmax] will be derived from plasma concentration versus time. Trough concentration (Ctrough) and sparse Pharmacokinetics (PK) samples will also be collected.</outcome_measure>
      <outcome_measure>Pharmacokinetic parameter area under the concentration-time curve in one dosing interval [AUC(TAU)] will be derived from plasma concentration versus time. Trough concentration (Ctrough) and sparse Pharmacokinetics (PK) samples will also be collected.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01012895</url>
  </study>
  <study rank="325">
    <nct_id>NCT00437476</nct_id>
    <title>Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LPV/r</intervention>
      <intervention type="Drug">Nucleoside Reverse Transcriptase Inhibitors</intervention>
      <intervention type="Drug">PEG-IFNa 2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>IRCCS San Raffaele</lead_sponsor>
      <collaborator>Abbott</collaborator>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Kamon 1</other_id>
    </other_ids>
    <first_received>February 20, 2007</first_received>
    <start_date>February 2007</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>February 5, 2009</last_updated>
    <last_verified>February 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To assess if the combination of LPV/r monotherapy in association with</outcome_measure>
      <outcome_measure>anti-HCV therapy (PEG IFN alfa 2a + Ribavirin) does not match with additional</outcome_measure>
      <outcome_measure>toxicity induced by the combination of optimized HAART (Lopinavir/ritonavir + selected Nucs) and PEG-IFN alfa 2a+Ribavirin</outcome_measure>
      <outcome_measure>in patients naÃ¯ve for HIV and HCV</outcome_measure>
      <outcome_measure>To assess if LPV/r monotherapy during the HCV treatment</outcome_measure>
      <outcome_measure>is associated with anti HIV efficacy and a better patient satisfaction</outcome_measure>
      <outcome_measure>vs optimized HAART.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00437476</url>
  </study>
  <study rank="326">
    <nct_id>NCT01384383</nct_id>
    <title>GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-NaÃ¯ve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GS-5885</intervention>
      <intervention type="Drug">GS-9451</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">PEG</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>248</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-248-0121</other_id>
    </other_ids>
    <first_received>June 22, 2011</first_received>
    <start_date>August 2011</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>January 2, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR)</outcome_measure>
      <outcome_measure>Safety and tolerability of therapy</outcome_measure>
      <outcome_measure>Virologic response</outcome_measure>
      <outcome_measure>Compare SVR</outcome_measure>
      <outcome_measure>Viral resistance</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>New Zealand</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Indiana</state>
      <state>Massachusetts</state>
      <state>Nevada</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oregon</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01384383</url>
  </study>
  <study rank="327">
    <nct_id>NCT00221624</nct_id>
    <title>Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Infection</condition>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">amantadine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Bordeaux</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>131</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>7929-01</other_id>
      <other_id>2000-030</other_id>
    </other_ids>
    <first_received>September 13, 2005</first_received>
    <start_date>November 2001</start_date>
    <completion_date>April 2004</completion_date>
    <last_updated>June 12, 2007</last_updated>
    <last_verified>June 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PEGARI</acronym>
    <outcome_measures>
      <outcome_measure>sustained virological response, defined as an undetectable HCV RNA level 24 weeks after the end of anti HCV treatment (i.e. overall 72 weeks after randomization)</outcome_measure>
      <outcome_measure>ALT &lt; upper limit of normal values,</outcome_measure>
      <outcome_measure>histological response according to METAVIR score</outcome_measure>
      <outcome_measure>adverse effects</outcome_measure>
      <outcome_measure>quality of life assessed</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00221624</url>
  </study>
  <study rank="328">
    <nct_id>NCT01001754</nct_id>
    <title>Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-rIL-29</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>ZymoGenetics</lead_sponsor>
      <collaborator>Bristol-Myers Squibb</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>526H04</other_id>
      <other_id>2009-011786-80</other_id>
    </other_ids>
    <first_received>October 23, 2009</first_received>
    <start_date>May 2010</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>December 2, 2011</last_updated>
    <last_verified>December 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>EMERGE</acronym>
    <primary_completion_date>November 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV RNA</outcome_measure>
      <outcome_measure>Incidence and severity of adverse events</outcome_measure>
      <outcome_measure>Incidence and severity of adverse events and laboratory abnormalities</outcome_measure>
      <outcome_measure>PD biomarkers</outcome_measure>
      <outcome_measure>Quality of life assessments</outcome_measure>
      <outcome_measure>Serum drug concentration profile</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01001754</url>
  </study>
  <study rank="329">
    <nct_id>NCT00611819</nct_id>
    <title>Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Co-Infection HIV-HCV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg interferon + Ribavirin</intervention>
      <intervention type="Drug">Peg interferon + Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Valencia</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>59</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KHRONOS</other_id>
      <other_id>2005-000203-34</other_id>
    </other_ids>
    <first_received>January 25, 2008</first_received>
    <start_date>November 2005</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>January 25, 2008</last_updated>
    <last_verified>January 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>% of patients with RNA-HCV undetectable 24 weeks</outcome_measure>
      <outcome_measure>% of patients at the end of treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00611819</url>
  </study>
  <study rank="330">
    <nct_id>NCT01498068</nct_id>
    <title>Open-Label, Bridging Study of Telaprevir in Treatment-NaÃ¯ve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Genotype 1 Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Pegylated-interferon-alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen-Cilag International NV</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100676</other_id>
      <other_id>VX-950HPC3007</other_id>
    </other_ids>
    <first_received>December 6, 2011</first_received>
    <start_date>January 2012</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>January 29, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>September 11, 2013</firstreceived_results_date>
    <primary_completion_date>April 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>Median Change in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)</outcome_measure>
      <outcome_measure>Number of Participants With Rapid Virologic Response (RVR) at Week 4</outcome_measure>
      <outcome_measure>Number of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Less Than 25 IU/mL, (Target Not Detected) at Weeks 8, 12, 24, 32, 40 and 48</outcome_measure>
      <outcome_measure>Number of Participants With Virologic Failure</outcome_measure>
      <outcome_measure>Number of Participants in Each Specific Category of Treatment Outcome</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Russian Federation</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01498068</url>
  </study>
  <study rank="331">
    <nct_id>NCT01241760</nct_id>
    <title>VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naÃ¯ve Participants With Genotype 1 Chronic Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Genotype 1 Chronic Hepatitis C</condition>
      <condition>Treatment Naive</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a</intervention>
      <intervention type="Drug">Telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Infectious Diseases BVBA</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>744</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR013711</other_id>
      <other_id>OPTIMIZE-HCV</other_id>
      <other_id>VX-950-C211</other_id>
      <other_id>2010-021628-84</other_id>
    </other_ids>
    <first_received>October 28, 2010</first_received>
    <start_date>December 2010</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>May 14, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>September 23, 2013</firstreceived_results_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After the Last Planned Dose of Study Drugs (SVR12 Planned)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 24 Weeks After the Last Planned Dose of Study Drugs (SVR24 Planned)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 72 Weeks After the Start of Study Medication (SVR72 Planned)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values of Less Than 25 IU/ml, Target Not Detected, at Different Time Points.</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Virologic Failure Which Required Them to Permanently Discontinue All Study Drugs</outcome_measure>
      <outcome_measure>Percentage of Participants Who Relapsed During Follow-up Period</outcome_measure>
      <outcome_measure>Percentage of Participants of Each IL28B Genotype Achieving Sustained Virologic Response 12 Weeks After the Last Planned Dose of Study Medication (SVR12 Planned)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Germany</country>
      <country>Ireland</country>
      <country>Mexico</country>
      <country>Poland</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>South Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01241760</url>
  </study>
  <study rank="332">
    <nct_id>NCT01283074</nct_id>
    <title>An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HbeAg-negative Chronic Hepatitis B (Perseas)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>107</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML22016</other_id>
    </other_ids>
    <first_received>January 24, 2011</first_received>
    <start_date>May 2009</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of patients with combined (virological and biochemical) response</outcome_measure>
      <outcome_measure>Normalization of serum alanine aminotransferase</outcome_measure>
      <outcome_measure>Safety (Incidence of adverse events)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Greece</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01283074</url>
  </study>
  <study rank="333">
    <nct_id>NCT01581203</nct_id>
    <title>Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Asunaprevir (ASV)</intervention>
      <intervention type="Drug">Daclatasvir (DCV)</intervention>
      <intervention type="Drug">Pegylated-interferon alfa 2a (PegIFN)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>748</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI447-028</other_id>
      <other_id>2011-005446-35</other_id>
    </other_ids>
    <first_received>April 18, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Hallmark DUAL</acronym>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of treated subjects with SVR12, defined as HCV RNA &lt; LOQ at post treatment Week 12, for subjects who are prior null or partial responders to P/R or are treatment-naive</outcome_measure>
      <outcome_measure>Proportion of treated subjects with SVR12, defined as HCV RNA &lt; LOQ at post-treatment Week 12, for subjects who are intolerant or ineligible to P/R</outcome_measure>
      <outcome_measure>On treatment safety, as measured by frequency of Serious Adverse Events (SAEs) and discontinuations due to Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Differences in rates of selected grade 3-4 laboratory abnormalities during the first 12 weeks between treatments (ASV + DCV vs PBO) for naive subjects</outcome_measure>
      <outcome_measure>Proportion of genotype 1b subjects with SVR12 (HCV RNA &lt; LOQ at post treatment Week 12) by the rs12979860 single nucleotide polymorphisms (SNP) in the IL28B gene for each cohort</outcome_measure>
      <outcome_measure>Proportion of genotype 1b subjects with HCV RNA undetectable</outcome_measure>
      <outcome_measure>Proportion of genotypes 1b subjects with HCV RNA &lt; LOQ</outcome_measure>
      <outcome_measure>Proportion of subjects with anemia</outcome_measure>
      <outcome_measure>Proportion of subjects with rash</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Ireland</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>Netherlands</country>
      <country>New Zealand</country>
      <country>Poland</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Taiwan</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01581203</url>
  </study>
  <study rank="334">
    <nct_id>NCT01464008</nct_id>
    <title>The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa-2a and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Beijing Ditan Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>297</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>DTH-XY001</other_id>
    </other_ids>
    <first_received>October 28, 2011</first_received>
    <start_date>January 2004</start_date>
    <completion_date>September 2011</completion_date>
    <last_updated>November 1, 2011</last_updated>
    <last_verified>October 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virus response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01464008</url>
  </study>
  <study rank="335">
    <nct_id>NCT02583685</nct_id>
    <title>Switching Regimen in Treating Cirrhotic HCV GT1b Subjects</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PR4 + LDV/SOF + ASV 4 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + SMV 4 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + ASV 6 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + SMV 6 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + ASV 8 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + SMV 8 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + ASV 12 wk</intervention>
      <intervention type="Drug">PR4 + LDV/SOF + SMV 12 wk</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Humanity &amp; Healthy GI and Liver Centre</lead_sponsor>
      <collaborator>Beijing 302 Hospital</collaborator>
      <collaborator>Nanfang Hospital of Southern Medical University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>160</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>H&amp;H_SWITCH-1</other_id>
    </other_ids>
    <first_received>October 12, 2015</first_received>
    <start_date>May 2015</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>October 20, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>SWITCH-1</acronym>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks (SVR12) after discontinuation of therapy</outcome_measure>
      <outcome_measure>Proportion of participants with adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with unquantifiable HCV viral load at specified time points during and after treatment</outcome_measure>
      <outcome_measure>Treatment adherence</outcome_measure>
      <outcome_measure>Change in health related quality of life evaluated with questionnaires</outcome_measure>
      <outcome_measure>Change in mental health evaluated with questionnaires</outcome_measure>
      <outcome_measure>Liver disease progression</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02583685</url>
  </study>
  <study rank="336">
    <nct_id>NCT01697501</nct_id>
    <title>A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Interleukin 28B testing</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>88</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML28470</other_id>
      <other_id>2012-002777-56</other_id>
    </other_ids>
    <first_received>September 28, 2012</first_received>
    <start_date>November 2012</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>October 1, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>June 10, 2015</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Viral Response (SVR) Defined as HBV DNA â¤ 2000 IU/ml at IL28B Genotype rs12979860 at End of Follow-up (EoF)</outcome_measure>
      <outcome_measure>Percentage of Participants With SVR Defined as HBV DNA â¤ 2000 IU/ml at IL28B Genotype rs8099917 at EoF</outcome_measure>
      <outcome_measure>Percentage of Participants With HBV DNA â¤ 2000 IU/ml at IL28B Genotype rs12979860 at End of Treatment (EoT)</outcome_measure>
      <outcome_measure>Percentage of Participants With HBV DNA â¤ 2000 IU/ml at IL28B Genotype rs8099917 at EoT</outcome_measure>
      <outcome_measure>Percentage of Participants With HBsAg &lt; 0.05 IU/ml at IL28B Genotype rs12979860 at EoT and EoF</outcome_measure>
      <outcome_measure>Percentage of Participants With HBsAg &lt; 0.05 IU/ml at IL28B Genotype rs8099917 at EoT and EoF</outcome_measure>
      <outcome_measure>Percentage of Participants With HBsAg â¤ 10 IU/ml at IL28B Genotype rs12979860 at EoT and EoF</outcome_measure>
      <outcome_measure>Percentage of Participants With HBsAg â¤ 10 IU/ml at IL28B Genotype rs8099917 at EoT and EoF</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01697501</url>
  </study>
  <study rank="337">
    <nct_id>NCT01861444</nct_id>
    <title>An Observational Study on the Prevalence of Chronic Hepatitis D in Romania and the Efficacy of Treatment With Pegasys (Peginterferon Alfa-2a)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis D, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML25581</other_id>
    </other_ids>
    <first_received>May 2, 2013</first_received>
    <start_date>March 2011</start_date>
    <completion_date>October 2014</completion_date>
    <last_updated>October 20, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of chronic hepatitis B patients in Romania with chronic hepatitis D infection</outcome_measure>
      <outcome_measure>Response rate: Proportion of patients achieving ALT normalization and HDV RNA negativity 24 weeks after the end of treatment</outcome_measure>
      <outcome_measure>Virological characteristics (HBeAg/anti-HBe/HBV DNA/anti-HDV Ab/HDV RNA) of patients with chronic hepatitis D</outcome_measure>
      <outcome_measure>Proportion of chronic hepatitis D patients with liver cirrhosis</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Romania</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01861444</url>
  </study>
  <study rank="338">
    <nct_id>NCT02118597</nct_id>
    <title>An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Pegasys and Ribivarin in the Re-Treatment of Chronic Hepatitis C Patients</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML29278</other_id>
    </other_ids>
    <first_received>April 16, 2014</first_received>
    <start_date>May 2014</start_date>
    <completion_date>April 2017</completion_date>
    <last_updated>April 16, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response 24 (SVR24), defined as percentage of patients with HCV RNA &lt; 15 IU/mL after the 24-week follow-up</outcome_measure>
      <outcome_measure>Virological response (HCV RNA &lt; 15 IU/mL)</outcome_measure>
      <outcome_measure>Virological breakthrough, defined as either HCV RNA &gt;/= 15 IU/mL in patients with prior virological response or as an increase in RCV RNA &gt;/= 1 log10 above nadir</outcome_measure>
      <outcome_measure>Virological relapse defined as HCV RNA &gt;/= 15 IU/mL during the treatment free follow-up period in patients with virological response at the end of treatment</outcome_measure>
      <outcome_measure>Incidence of treatment discontinuation due to futility, defined as: HCV RNA drop &lt; 3 log10 at Week 8, HCV RNA &gt;/= 100 IU/mL at Week 12, or HCV RNA &gt;/= 15 IU/mL at Week 24</outcome_measure>
      <outcome_measure>Incidence of treatment discontinuation</outcome_measure>
      <outcome_measure>Incidence of adverse events</outcome_measure>
      <outcome_measure>Predictive value of patient demographics</outcome_measure>
      <outcome_measure>Predictive value of liver fibrosis</outcome_measure>
      <outcome_measure>Predictive value of HCV disease characteristics</outcome_measure>
      <outcome_measure>Predictive value of previous virological response (null-response, partial response, or relapse)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02118597</url>
  </study>
  <study rank="339">
    <nct_id>NCT01380938</nct_id>
    <title>Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alpha-2a + Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Casa Sollievo della Sofferenza IRCCS</lead_sponsor>
      <collaborator>Casa di Cura Mater Dei</collaborator>
      <collaborator>IRCCS L. Spallanzani</collaborator>
      <collaborator>Ospedale Francesco Ferrari</collaborator>
      <collaborator>Azienda Ospedaliero Universitaria di Sassari</collaborator>
      <collaborator>IRCCS Policlinico S. Matteo</collaborator>
      <collaborator>Arcispedale S. Anna, Ferrara</collaborator>
      <collaborator>Azienda Ospedaliero-Universitaria, Catania</collaborator>
      <collaborator>Ospedale di Venosa</collaborator>
      <collaborator>Ospedale R. Dimiccoli, Barletta</collaborator>
      <collaborator>IRCCS De Bellis, Castellana</collaborator>
      <collaborator>USL Napoli 1</collaborator>
      <collaborator>Ospedale San Giuseppe Moscati, Avellino</collaborator>
      <collaborator>Cardarelli Hospital</collaborator>
      <collaborator>Ospedale Civile Vittorio Emanuele II, Bisceglie</collaborator>
      <collaborator>Azienda Ospedaliero-Universitaria Careggi</collaborator>
      <collaborator>Azienda Ospedaliera V. Cervello</collaborator>
      <collaborator>Ospedale Civile Spirito Santo</collaborator>
      <collaborator>Ospedale di Canosa di Puglia</collaborator>
      <collaborator>University of Palermo</collaborator>
      <collaborator>San Camillo Hospital, Rome</collaborator>
      <collaborator>Campus Bio-Medico University</collaborator>
      <collaborator>Ospedale Sandro Pertini, Roma</collaborator>
      <collaborator>Ospedali Riuniti di Foggia</collaborator>
      <collaborator>Ospedale SS. Annunziata, Taranto</collaborator>
      <collaborator>Ospedale di Mottola</collaborator>
      <collaborator>Ospedale Santa Caterina Novella, Galatina</collaborator>
      <collaborator>University of Florence</collaborator>
      <collaborator>Ospedale Valduce, Como</collaborator>
      <collaborator>University of Bari</collaborator>
      <collaborator>Azienda Ospedaliera, Siracusa</collaborator>
      <collaborator>Azienda Ospedaliera, Lucca</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Single Blind (Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>EPAT-01-2010</other_id>
    </other_ids>
    <first_received>June 23, 2011</first_received>
    <start_date>October 2010</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>April 14, 2012</last_updated>
    <last_verified>April 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>WRITE</acronym>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological Response (SVR)</outcome_measure>
      <outcome_measure>Rapid virological response (RVR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01380938</url>
  </study>
  <study rank="340">
    <nct_id>NCT00078442</nct_id>
    <title>Safety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ACTG A5192</other_id>
      <other_id>DAIDS-ES ID 10013</other_id>
    </other_ids>
    <first_received>February 25, 2004</first_received>
    <start_date>May 2006</start_date>
    <last_updated>August 6, 2009</last_updated>
    <last_verified>August 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>CD4 count</outcome_measure>
      <outcome_measure>CD8 count</outcome_measure>
      <outcome_measure>Laboratory and clinical adverse effects</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Illinois</state>
      <state>North Carolina</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00078442</url>
  </study>
  <study rank="341">
    <nct_id>NCT00680173</nct_id>
    <title>Peripheral Blood Mononuclear Cell (PBMC) Gene Expression in HCV Genotype 1 Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon alpha 2a and plus ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kaohsiung Medical University Chung-Ho Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KMUH-IRB- 950419</other_id>
    </other_ids>
    <first_received>May 15, 2008</first_received>
    <start_date>August 2006</start_date>
    <completion_date>October 2017</completion_date>
    <last_updated>April 1, 2015</last_updated>
    <last_verified>August 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PBMC</acronym>
    <primary_completion_date>April 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy - Sustained virological response (SVR), HCV RNA seronegative by PCR throughout 24-week off-treatment period.</outcome_measure>
      <outcome_measure>Rapid virologic response (RVR), HCV RNA seronegative by PCR at week 4.</outcome_measure>
      <outcome_measure>Early virological response (EVR), by PCR-negative or at least 2 logs decline from baseline of serum HCV RNA at 12 weeks of treatment.</outcome_measure>
      <outcome_measure>Safety - adverse event rate and profile</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00680173</url>
  </study>
  <study rank="342">
    <nct_id>NCT01263860</nct_id>
    <title>A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-6 Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Third Affiliated Hospital, Sun Yat-Sen University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>242</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TAH115G6HCV</other_id>
    </other_ids>
    <first_received>December 20, 2010</first_received>
    <start_date>December 2010</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>November 14, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR)</outcome_measure>
      <outcome_measure>Change in health related quality as measured by short from 36 (SF-36) from baseline to 24 weeks after the end of treatment</outcome_measure>
      <outcome_measure>Sick leave in patients treated for 24 or 48 weeks treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01263860</url>
  </study>
  <study rank="343">
    <nct_id>NCT01441804</nct_id>
    <title>A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for Patients With Genotype 1 Hepatitis C and IL28B CC Polymorphism</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Third Affiliated Hospital, Sun Yat-Sen University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TAHG1IL-28BCC</other_id>
    </other_ids>
    <first_received>September 24, 2011</first_received>
    <start_date>May 2011</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>September 28, 2013</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR)</outcome_measure>
      <outcome_measure>Change in health related quality as measured by short from 36 (SF-36) from baseline to 24 weeks after the end of treatment</outcome_measure>
      <outcome_measure>Sick leave in patients treated for 24 or 48 weeks treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01441804</url>
  </study>
  <study rank="344">
    <nct_id>NCT01153919</nct_id>
    <title>Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia</title>
    <recruitment open="N">Suspended</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
      <condition>Thrombocytopenia</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">romiplostim</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Other">placebo</intervention>
      <intervention type="Biological">PEG-interferon alfa-2a</intervention>
      <intervention type="Other">laboratory biomarker analysis</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Southern California</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NC-HEM-07-5</other_id>
      <other_id>NCI-2010-00358</other_id>
    </other_ids>
    <first_received>June 24, 2010</first_received>
    <start_date>March 2010</start_date>
    <completion_date>April 2017</completion_date>
    <last_updated>October 24, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Mean platelet count for actively treated and placebo treated subjects</outcome_measure>
      <outcome_measure>Incidence of adverse events, including clinically significant changes in laboratory values and the incidence of antibody formation</outcome_measure>
      <outcome_measure>Number of subjects in each treatment group who achieve a platelet count of greater or equal to 100,000/L</outcome_measure>
      <outcome_measure>Number of patients originally receiving active treatment who maintain a platelet count &amp;gt; 50,000/L while receiving anti-viral therapy with pegylated interferon and ribavirin</outcome_measure>
      <outcome_measure>Changes in plasma HCV viral load during treatment with romiplostim alone</outcome_measure>
      <outcome_measure>Incidence of sustained viral response achieved during treatment with anti-viral therapy in combination with romiplostim</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01153919</url>
  </study>
  <study rank="345">
    <nct_id>NCT01371604</nct_id>
    <title>Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">IDX184</intervention>
      <intervention type="Biological">Peginterferon alfa-2a (Peg-IFN)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>68</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>2355-005</other_id>
      <other_id>IDX-08C-005</other_id>
      <other_id>2011-001878-25</other_id>
    </other_ids>
    <first_received>June 9, 2011</first_received>
    <start_date>July 2011</start_date>
    <completion_date>October 2014</completion_date>
    <last_updated>February 5, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of participants who experience a serious adverse event</outcome_measure>
      <outcome_measure>Percentage of participants who experience an adverse event</outcome_measure>
      <outcome_measure>Percentage of participants who experience a grade 1-4 laboratory abnormality</outcome_measure>
      <outcome_measure>Percentage of participants who achieve undetectable HCV ribonucleic acid (RNA) viral levels at Week 12</outcome_measure>
      <outcome_measure>Percentage of participants who achieve undetectable HCV RNA viral levels at Week 4</outcome_measure>
      <outcome_measure>Percentage of participants who achieve undetectable HCV RNA viral levels at the end of treatment</outcome_measure>
      <outcome_measure>Percentage of participants who achieve sustained virologic response (SVR)</outcome_measure>
      <outcome_measure>Percentage of participants who achieve HCV RNA viral levels below the lower level of quantification (LLOQ) at Week 4</outcome_measure>
      <outcome_measure>Percentage of participants who achieve HCV RNA viral levels below LLOQ at the end of treatment</outcome_measure>
      <outcome_measure>Percentage of participants who achieve HCV RNA viral levels below LLOQ at follow-up (24 weeks after the last dose)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01371604</url>
  </study>
  <study rank="346">
    <nct_id>NCT00437684</nct_id>
    <title>Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LPV/r</intervention>
      <intervention type="Drug">PEG-IFNa 2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">NUCS</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>IRCCS San Raffaele</lead_sponsor>
      <collaborator>Abbott</collaborator>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Kamon 2</other_id>
      <other_id>NTC00437684</other_id>
    </other_ids>
    <first_received>February 20, 2007</first_received>
    <start_date>February 2007</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>February 5, 2009</last_updated>
    <last_verified>February 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To assess if the combination of LPV/r monotherapy in association with anti-HCV</outcome_measure>
      <outcome_measure>Nucs) and PEG-IFN alfa 2a +Ribavirin in patients naÃ¯ve for HCV treatment</outcome_measure>
      <outcome_measure>without previous failure or detection of any mutations related to PI resistance.</outcome_measure>
      <outcome_measure>To assess if LPV/r monotherapy during the HCV treatment is associated with</outcome_measure>
      <outcome_measure>anti HIV/HCV efficacy and a better patient satisfaction vs optimized HAART.</outcome_measure>
      <outcome_measure>To assess the number and type of HIV-1 resistance mutations in patients with</outcome_measure>
      <outcome_measure>virological failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00437684</url>
  </study>
  <study rank="347">
    <nct_id>NCT01730508</nct_id>
    <title>An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>978</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML28516</other_id>
    </other_ids>
    <first_received>November 15, 2012</first_received>
    <start_date>November 2012</start_date>
    <completion_date>April 2017</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Incidence of sustained suppression of HBV DNA &lt;2000 IU/mL one year after treatment cessation</outcome_measure>
      <outcome_measure>Incidence of suppression of HBV DNA &lt;2000 IU/mL at the end of treatment and 6 months post-treatment</outcome_measure>
      <outcome_measure>Incidence of HBV DNA undetectable (&lt;400 IU/mL) at the end of treatment and 1 year post-treatment</outcome_measure>
      <outcome_measure>Incidence of HBsAg loss/seroconversion</outcome_measure>
      <outcome_measure>Incidence of normalization of serum ALT levels</outcome_measure>
      <outcome_measure>Dosage/schedule of Pegasys treatment in real-life clinical setting</outcome_measure>
      <outcome_measure>Clinical/demographic patient characteristics at initiation of treatment</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01730508</url>
  </study>
  <study rank="348">
    <nct_id>NCT02087111</nct_id>
    <title>Telaprevir in Genotype 3 HCV</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">40 Kd Pegylated interferon alfa 2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Queen Mary University of London</lead_sponsor>
      <collaborator>Janssen-Cilag Ltd.</collaborator>
      <collaborator>Barts &amp; The London NHS Trust</collaborator>
      <collaborator>St George's Healthcare NHS Trust</collaborator>
      <collaborator>Bradford Teaching Hospitals NHS Foundation Trust</collaborator>
      <collaborator>Nottingham University Hospitals NHS Trust</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>9132</other_id>
      <other_id>2013-003729-27</other_id>
      <other_id>13/LO/1473</other_id>
    </other_ids>
    <first_received>March 12, 2014</first_received>
    <start_date>April 2014</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>July 11, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>TIG3</acronym>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (SVR) 12 weeks after end of treatment (SVR12)</outcome_measure>
      <outcome_measure>Response rate prediction</outcome_measure>
      <outcome_measure>Sustained virological response 24 weeks after end of treatment.</outcome_measure>
      <outcome_measure>Treatment Success</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02087111</url>
  </study>
  <study rank="349">
    <nct_id>NCT02068365</nct_id>
    <title>An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepaititis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegyinterferon-alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chinese University of Hong Kong</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML28486</other_id>
    </other_ids>
    <first_received>January 28, 2014</first_received>
    <start_date>June 2013</start_date>
    <last_updated>February 2, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained response (HBeAg seroconversion and HBV DNA &lt;2000 IU/ml)</outcome_measure>
      <outcome_measure>HBeAg loss and seroconversion</outcome_measure>
      <outcome_measure>HBsAg loss and seroconversion</outcome_measure>
      <outcome_measure>HBV DNA &lt;2000IU/ml and undetectable</outcome_measure>
      <outcome_measure>ALT normalization</outcome_measure>
      <outcome_measure>Sustained response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02068365</url>
  </study>
  <study rank="350">
    <nct_id>NCT01504581</nct_id>
    <title>Safety, Pharmacokinetic, Pharmacodynamic Study of LAPS-IFNa in Healthy Adult Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">HM10660A</intervention>
      <intervention type="Biological">HM10660A placebo</intervention>
      <intervention type="Biological">Pegasys</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hanmi Pharmaceutical Company Limited</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>11-HM10660A-101</other_id>
    </other_ids>
    <first_received>December 27, 2011</first_received>
    <start_date>March 2011</start_date>
    <last_updated>February 6, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants with AE occurrence, clinically significant clinical lab, vital sign, and/or ECG change</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01504581</url>
  </study>
  <study rank="351">
    <nct_id>NCT01587586</nct_id>
    <title>Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With HCV Genotype 1 Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegasys</intervention>
      <intervention type="Biological">P1101, 48 doses</intervention>
      <intervention type="Biological">P1101, 24 doses</intervention>
      <intervention type="Biological">P1101, 12 doses</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>PharmaEssentia</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>208</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>A11-201</other_id>
    </other_ids>
    <first_received>April 26, 2012</first_received>
    <start_date>October 2011</start_date>
    <last_updated>April 27, 2012</last_updated>
    <last_verified>April 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01587586</url>
  </study>
  <study rank="352">
    <nct_id>NCT01278134</nct_id>
    <title>A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-NaÃ¯ve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Copegus placebo</intervention>
      <intervention type="Drug">RO5024048</intervention>
      <intervention type="Drug">danoprevir</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin [Copegus]</intervention>
      <intervention type="Drug">ritonavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>170</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>PP25213</other_id>
      <other_id>2010-022067-35</other_id>
    </other_ids>
    <first_received>January 14, 2011</first_received>
    <start_date>February 2011</start_date>
    <completion_date>October 2012</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response, defined as undetectable HVC RNA measured by Roche COBAS TaqMan HCV test</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
      <outcome_measure>Virological response (HCV RNA measured by Roche COBAS Taqman HCV test)</outcome_measure>
      <outcome_measure>Impact of Copegus (ribavirin) on efficacy of the direct-acting antiviral combination regimen: viral response (HCV RNA measured by Roche COBAS TaqMan HCV test)</outcome_measure>
      <outcome_measure>Comparison of 12 and 24 weeks of treatment duration: viral response (HCV RNA measured by Roche COBAS TaqMan HCV test)</outcome_measure>
      <outcome_measure>Pharmacokinetics: Plasma concentrations of danoprevir, ritonavir, RO4995855 (parent drug of RO5024048) and ribavirin</outcome_measure>
      <outcome_measure>Viral resistance: HCV RNA sequencing and phenotypic analyses</outcome_measure>
      <outcome_measure>Effect of interleukin 28B genotype on efficacy: viral response (HCV RNA measured by Roche COBAS TaqMan HCV test)</outcome_measure>
      <outcome_measure>Quality of life: SF-36 questionnaire, Fatigue Severity Scale</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
      <country>Germany</country>
      <country>New Zealand</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01278134</url>
  </study>
  <study rank="353">
    <nct_id>NCT00502788</nct_id>
    <title>Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Thalassemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon Alfa-2a and Ribavirin</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>New England Research Institutes</lead_sponsor>
      <collaborator>National Heart, Lung, and Blood Institute (NHLBI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>503</other_id>
      <other_id>U01HL065238</other_id>
      <other_id>U01HL065238-07</other_id>
    </other_ids>
    <first_received>July 16, 2007</first_received>
    <start_date>May 2003</start_date>
    <completion_date>August 2006</completion_date>
    <last_updated>March 3, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HepC</acronym>
    <primary_completion_date>June 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety of peginterferon alfa-2a and ribavirin in individuals with thalassemia (measured by changes in liver iron stores and development of iron overload-related complications)</outcome_measure>
      <outcome_measure>Mean change in hepatic iron concentration from baseline biopsy to follow-up biopsy; relationship of change to baseline level</outcome_measure>
      <outcome_measure>Transfusion frequency and volume required to maintain trough Hb 9.0-10.5 g/dL during treatment, as compared to that required in the 6 months prior to hepatitis C treatment</outcome_measure>
      <outcome_measure>Cumulate change in deferoxamine dose; evidence for deferoxamine toxicity during hepatitis C treatment</outcome_measure>
      <outcome_measure>Response rate (undetectable hepatitis C virus RNA)</outcome_measure>
      <outcome_measure>Sustained virologic response rate (undetectable hepatitis C virus RNA 24 weeks after the end of treatment) and its association with baseline hepatic iron concentration</outcome_measure>
      <outcome_measure>Rate of viral clearance from serum in the first 4 weeks of treatment, rate of early virologic response at week 12, and each rate's association with sustained virologic response</outcome_measure>
      <outcome_measure>Change in liver inflammation and fibrosis scores from baseline to 48 weeks</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Cardiac adverse events, defined as either symptomatic left ventricular dysfunction requiring medication or pathologic arrhythmia requiring medication</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>New York</state>
      <state>Pennsylvania</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00502788</url>
  </study>
  <study rank="354">
    <nct_id>NCT00199732</nct_id>
    <title>Evaluation of cccDNA and Total HBV DNA Kinetics in Lymphocytes, Total Blood and Serum in Chronic Hepatitis B Patients Treated With Adefovir Dipivoxil and Peg Interferon Alpha 2a</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>University Hospital, Limoges</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>19</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>I04002</other_id>
    </other_ids>
    <first_received>September 14, 2005</first_received>
    <start_date>December 2004</start_date>
    <completion_date>July 2009</completion_date>
    <last_updated>April 16, 2013</last_updated>
    <last_verified>September 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>DNA-EVAL</acronym>
    <primary_completion_date>July 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Kinetic cccDNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00199732</url>
  </study>
  <study rank="355">
    <nct_id>NCT00221286</nct_id>
    <title>Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon alfa-2a</intervention>
      <intervention type="Drug">tenofovir DF / emtricitabine combination therapy</intervention>
      <intervention type="Drug">pegIFN / TDF / FTC combination therapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Bonn</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML-18150</other_id>
    </other_ids>
    <first_received>September 14, 2005</first_received>
    <start_date>September 2004</start_date>
    <completion_date>January 2007</completion_date>
    <last_updated>February 17, 2009</last_updated>
    <last_verified>February 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Efficacy: HBeAg seroconversion (HBeAg loss and presence of anti HBe) ; intent to treat analysis.</outcome_measure>
      <outcome_measure>Safety: study discontinuation due to adverse events; intent to treat analysis.</outcome_measure>
      <outcome_measure>Efficacy: loss of HBe-Ag,HBV-DNA &lt; 5x10Â³ copies/ml(COBAS TaqMan HBV Test),decrease of HBV-DNA &gt; 2xlog10 compared to baseline</outcome_measure>
      <outcome_measure>normalization of ALT,intent to treat and as treated analysis; Viral kinetics of HBV-DNA; Paired liver biopsy comparison according to METAVIR-activity and fibrosis score.</outcome_measure>
      <outcome_measure>for Arm B (B1 and B2): HIV-RNA &lt; 50 copies/ml and CD4-cell increase intent to treat and as treated analysis</outcome_measure>
      <outcome_measure>Safety: number of adverse events, according to type and severity.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00221286</url>
  </study>
  <study rank="356">
    <nct_id>NCT00078403</nct_id>
    <title>Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
      <condition>Liver Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>338</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>A5178</other_id>
      <other_id>10008</other_id>
    </other_ids>
    <first_received>February 24, 2004</first_received>
    <start_date>July 2004</start_date>
    <completion_date>February 2009</completion_date>
    <last_updated>August 13, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>November 5, 2010</firstreceived_results_date>
    <primary_completion_date>May 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time-scaled Change in Metavir Liver Fibrosis Score (SCMFS)</outcome_measure>
      <outcome_measure>Number of Participants With Detectable HCV RNA Viral Load (&gt;= 60 IU/mL)</outcome_measure>
      <outcome_measure>Time-scaled Change in Ishak Liver Inflammation Score (SCIIS)</outcome_measure>
      <outcome_measure>Number of Participants With Anemia</outcome_measure>
      <outcome_measure>Number of Participants With Neutropenia</outcome_measure>
      <outcome_measure>Number of Participants With Thrombocytopenia</outcome_measure>
      <outcome_measure>Number of Participants With Depression and/or Other Psychological Events</outcome_measure>
      <outcome_measure>Other High-grade Signs and Symptoms and Laboratory Values</outcome_measure>
      <outcome_measure>Number of Participants With Dose Modifications, Temporary Stops, and Premature Treatment Discontinuations</outcome_measure>
      <outcome_measure>Symptom Distress</outcome_measure>
      <outcome_measure>Quality of Life</outcome_measure>
      <outcome_measure>Number of Participants Adherent to Study Medications</outcome_measure>
      <outcome_measure>HCV Polymorphisms</outcome_measure>
      <outcome_measure>HCV-specific Immune Response in Intrahepatic Lymphocytes</outcome_measure>
      <outcome_measure>Noninvasive Measures of Liver Fibrosis, Including Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Bilirubin, Albumin, and Protein Measurements</outcome_measure>
      <outcome_measure>Number of Participants With Undetectable HIV Viral Load (&lt;50 Copies/mL)</outcome_measure>
      <outcome_measure>Metabolic Parameters Including Insulin Resistance, Defined as Fasting Glucose, and Weight.</outcome_measure>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
      <outcome_measure>Use of Antianorexia Agents, Such as Megestrol and Dronabinol</outcome_measure>
      <outcome_measure>Prescription as Needed of Erythropoietin (EPO), Granulocyte Colony-stimulating Factor (GCSF), and Granulocyte-monocyte Colony-stimulating Factor (GM-CSF)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00078403</url>
  </study>
  <study rank="357">
    <nct_id>NCT01908335</nct_id>
    <title>A Phase â¡ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-IFN-SA /RBV low dose</intervention>
      <intervention type="Drug">PEG-IFN-SA /RBV middle dose</intervention>
      <intervention type="Drug">PEG-IFN-SA /RBV high dose</intervention>
      <intervention type="Drug">Pegasys /RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Beijing Kawin Technology Share-Holding Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>212</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>KAWIN-002-1</other_id>
    </other_ids>
    <first_received>July 23, 2013</first_received>
    <start_date>October 2012</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>October 16, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>cEVR (complete early virologic response)</outcome_measure>
      <outcome_measure>Proportion of patients who had undetectable plasma HCV RNA</outcome_measure>
      <outcome_measure>HCV RNA load reduction</outcome_measure>
      <outcome_measure>eRVR ( extended rapid virologic response)</outcome_measure>
      <outcome_measure>Breakthrough</outcome_measure>
      <outcome_measure>Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01908335</url>
  </study>
  <study rank="358">
    <nct_id>NCT01442311</nct_id>
    <title>Directly Observed Hepatitis C Treatment in Methadone Clinics</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Medication Adherence</condition>
    </conditions>
    <interventions>
      <intervention type="Other">enhanced DOT (both pegylated interferon alfa-2a and ribavirin)</intervention>
      <intervention type="Other">standard DOT (PEG-DOT control arm)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Albert Einstein College of Medicine of Yeshiva University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2006-224</other_id>
      <other_id>K23DA022454-01A1</other_id>
    </other_ids>
    <first_received>September 27, 2011</first_received>
    <start_date>October 2007</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>June 25, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Adherence</outcome_measure>
      <outcome_measure>sustained viral response (SVR)</outcome_measure>
      <outcome_measure>end of treatment response (ETR)</outcome_measure>
      <outcome_measure>treatment completion</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01442311</url>
  </study>
  <study rank="359">
    <nct_id>NCT00485342</nct_id>
    <title>RIBAJUSTE Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-interferon alpha 2a and ribavin</intervention>
      <intervention type="Drug">ribavirin with adaptation dose</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hospices Civils de Lyon</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>236</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2005-400</other_id>
    </other_ids>
    <first_received>June 8, 2007</first_received>
    <start_date>April 2006</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>January 6, 2012</last_updated>
    <last_verified>January 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>RIBAJUSTE</acronym>
    <primary_completion_date>March 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Inter-group comparison of sustained virological response rates as defined by the proportion of subjects with a negative PCR HCV-RNA test at Week 72</outcome_measure>
      <outcome_measure>Efficacy endpoints</outcome_measure>
      <outcome_measure>safety endpoints</outcome_measure>
      <outcome_measure>Economic endpoints</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00485342</url>
  </study>
  <study rank="360">
    <nct_id>NCT00204529</nct_id>
    <title>Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Melanoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon-alpha-2a</intervention>
      <intervention type="Drug">interferon-alpha-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital Tuebingen</lead_sponsor>
      <collaborator>Dermatologic Cooperative Oncology Group</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>880</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML17840</other_id>
    </other_ids>
    <first_received>September 12, 2005</first_received>
    <start_date>October 2004</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>April 21, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Time to distant metastasis</outcome_measure>
      <outcome_measure>Disease free survival</outcome_measure>
      <outcome_measure>Overall survival</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>Number and Grade of Adverse Events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00204529</url>
  </study>
  <study rank="361">
    <nct_id>NCT01180790</nct_id>
    <title>Safety, Tolerability and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in HCV Positive Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ACH-0141625 (Sovaprevir)</intervention>
      <intervention type="Drug">ACH-0141625 (Sovaprevir)</intervention>
      <intervention type="Drug">ACH-0141625 (Sovaprevir)</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Pegylated Interferon alpha-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Achillion Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>122</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>ACH625-003</other_id>
      <other_id>2010-022092-65</other_id>
    </other_ids>
    <first_received>August 11, 2010</first_received>
    <start_date>September 2010</start_date>
    <completion_date>April 2013</completion_date>
    <last_updated>September 8, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>July 29, 2014</firstreceived_results_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Segment 1: Safety</outcome_measure>
      <outcome_measure>Segment 1 : Rapid Viral Response at Week 4 (RVR4)</outcome_measure>
      <outcome_measure>Segment 2: Safety</outcome_measure>
      <outcome_measure>Segment 2: Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Segment 1: Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Segment 2: RVR4 (Rapid Viral Response at 4 Weeks)</outcome_measure>
      <outcome_measure>Segment 1 and Segment 2: End of Treatment Response</outcome_measure>
      <outcome_measure>Segment 1 and Segment 2: Sustained Virologic Response 12 Weeks ( Three Months Post Dosing) (SVR12)</outcome_measure>
      <outcome_measure>Segment 1 and Segment 2: Sustained Virologic Response ( Six Months Post Dosing) (SVR24)</outcome_measure>
      <outcome_measure>Segment 1 and Segment 2: HCV RNA Change From Baseline</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Belgium</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Kansas</state>
      <state>Missouri</state>
      <state>Nevada</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01180790</url>
  </study>
  <study rank="362">
    <nct_id>NCT00877760</nct_id>
    <title>Augmenting Response to Entecavir With Peginterferon a-2a for the Treatment of HBeAg-positive Chronic Hepatitis B</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon a-2a</intervention>
      <intervention type="Drug">Entecavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Foundation for Liver Research</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>184</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HBV 09-01</other_id>
    </other_ids>
    <first_received>April 7, 2009</first_received>
    <start_date>August 2009</start_date>
    <completion_date>July 2013</completion_date>
    <last_updated>March 27, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ARES</acronym>
    <primary_completion_date>July 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The combined presence of HBV DNA level &lt; 200 IU/mL and HBeAg loss</outcome_measure>
      <outcome_measure>ALT normalization</outcome_measure>
      <outcome_measure>Undetectable HBV DNA &lt;60 IU/mL</outcome_measure>
      <outcome_measure>HBsAg and HBeAg loss from serum</outcome_measure>
      <outcome_measure>The emergence of HBV polymerase mutations associated with reduced susceptibility to entecavir</outcome_measure>
      <outcome_measure>Sustained response defined as the combined presence of HBV DNA level &lt; 200 IU/mL and HBeAg loss</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>Romania</country>
      <country>Turkey</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00877760</url>
  </study>
  <study rank="363">
    <nct_id>NCT00028093</nct_id>
    <title>Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a with Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>020065</other_id>
      <other_id>02-DK-0065</other_id>
    </other_ids>
    <first_received>December 11, 2001</first_received>
    <start_date>December 2001</start_date>
    <completion_date>June 2010</completion_date>
    <last_updated>September 4, 2013</last_updated>
    <last_verified>May 2013</last_verified>
    <firstreceived_results_date>May 26, 2011</firstreceived_results_date>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in Hepatitis C Virus RNA Levels During Phase I</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00028093</url>
  </study>
  <study rank="364">
    <nct_id>NCT01567540</nct_id>
    <title>A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sitagliptin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>3</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>C10-54</other_id>
      <other_id>2011-000823-34</other_id>
    </other_ids>
    <first_received>March 2, 2012</first_received>
    <start_date>March 2013</start_date>
    <completion_date>January 2014</completion_date>
    <last_updated>January 17, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety (Number of adverse events, Toxicity grade &gt; 3)</outcome_measure>
      <outcome_measure>Change in Viral Load as compared to baseline</outcome_measure>
      <outcome_measure>Metabolic studies: Oral glucose tolerance will be assessed</outcome_measure>
      <outcome_measure>Immunologic study</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01567540</url>
  </study>
  <study rank="365">
    <nct_id>NCT02057887</nct_id>
    <title>Safety,Tolerability and Pharmacokinetic Study of Recombinant Human Interferon Alfa 2B in Chronic Hepatitis C Patients (HM10660A)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus Genotype I</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">HM10660A</intervention>
      <intervention type="Drug">Pegasys</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hanmi Pharmaceutical Company Limited</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>64</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HM-IFN-201</other_id>
    </other_ids>
    <first_received>August 8, 2013</first_received>
    <start_date>July 2013</start_date>
    <last_updated>February 6, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV RNA Viral load</outcome_measure>
      <outcome_measure>Safety/tolerability</outcome_measure>
      <outcome_measure>Rapid virologic response (RVR)</outcome_measure>
      <outcome_measure>Early virologic response (EVR)</outcome_measure>
      <outcome_measure>Sustained virologic response (SVR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Mexico</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02057887</url>
  </study>
  <study rank="366">
    <nct_id>NCT00516321</nct_id>
    <title>Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">eltrombopag</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>687</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>TPL103922</other_id>
    </other_ids>
    <first_received>August 13, 2007</first_received>
    <start_date>October 2007</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>October 10, 2013</last_updated>
    <last_verified>August 2012</last_verified>
    <firstreceived_results_date>March 22, 2012</firstreceived_results_date>
    <primary_completion_date>April 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase</outcome_measure>
      <outcome_measure>Number of Participants Whose Platelet Count Increased From a Baseline Count of &lt;75 Gi/L to a Count Greater Than or Equal to (&gt;=) 90 Giga (10^9) Cells Per Liter (Gi/L) During the Open-label (OL) Pre-Antiviral Treatment Phase</outcome_measure>
      <outcome_measure>Number of Participants Receiving the Indicated Doses of Eltrombopag in the OL Phase Who Initiated Antiviral Therapy (Peginterferon Alfa-2a and Ribavirin) in the DB Phase</outcome_measure>
      <outcome_measure>Median Platelet Count at the Indicated Time Points During the OL Phase</outcome_measure>
      <outcome_measure>Median Platelet Count at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants in the Indicated Categories for Minimum Platelet Count With Antiviral Therapy During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants With Rapid Virological Response (RVR) and Extended RVR (eRVR) During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants With Early Virological Response (EVR) and Complete EVR (cEVR) During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants With End of Treatment Response (ETR) and Sustained Virological Response at Week 12 of Follow-up (SVR12) During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants in the Indicated Categories for Antiviral Therapy Dose Reductions in the DB Phase</outcome_measure>
      <outcome_measure>Time to First Dose Reduction of Peginterferon Alfa-2a and Ribavirin Therapy in the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Levels of Peginterferon Dose Reductions in the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants Who Prematurely Discontinued Antiviral Therapy in the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants (Par.) Categorized as Responders (R) and Non-responders (NR) for SVR and RVR to Antiviral Therapy in the Indicated Variants of Interleukin 28B (IL28B) (or Interferon, Lambda 3) During the DB Phase</outcome_measure>
      <outcome_measure>Number of Par. With the Indicated Shift From Baseline (BL) in Severity Grades for Clinical Chemistry Parameters (Calcium, Glucose [Glu.], Potassium [Pot.], and Sodium [Sod.]), Per Division of Acquired Immunodeficiency Syndrome (DAIDS) During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters (Hemoglobin, Lymphocytes [Lym.], Total Neutrophils [Tot Neu.], and White Blood Cells [WBC]), Per DAIDS During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants in the Indicated Categories for Cataract Event During the DB Phase, Per Clinical Events Committee (CEC) Adjudication During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants Assessed as Normal and Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants With CS and NCS Change From Baseline for 12-lead ECG at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Heart Rate at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Weight at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Body Mass Index (BMI) at the Indicated Time Points During the DB Phase</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>Czech Republic</country>
      <country>France</country>
      <country>Germany</country>
      <country>Hong Kong</country>
      <country>India</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>Netherlands</country>
      <country>Pakistan</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Slovakia</country>
      <country>Spain</country>
      <country>Taiwan</country>
      <country>Thailand</country>
      <country>Ukraine</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>Arkansas</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Kentucky</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00516321</url>
  </study>
  <study rank="367">
    <nct_id>NCT00466219</nct_id>
    <title>Ribavirin/Pegasys Treatment of Recurrent Hepatitis C After Liver Transplant</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon alpha2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Geneva</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>SASL17</other_id>
    </other_ids>
    <first_received>April 25, 2007</first_received>
    <start_date>May 2002</start_date>
    <completion_date>December 2006</completion_date>
    <last_updated>April 25, 2007</last_updated>
    <last_verified>April 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Biochemical (normalization of serum transaminases levels),</outcome_measure>
      <outcome_measure>virological (disappearance of HCV RNA from serum)</outcome_measure>
      <outcome_measure>and histological (amelioration of the histological signs of hepatitis) response.</outcome_measure>
      <outcome_measure>Correlation of the above outcome measures with early on-treatment HCV RNA dynamics (if applicable).</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00466219</url>
  </study>
  <study rank="368">
    <nct_id>NCT02368288</nct_id>
    <title>Efficacies of Entecavir Add on HBeAg Positive Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">entecavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Beijing Ditan Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>DTXY005</other_id>
    </other_ids>
    <first_received>February 14, 2015</first_received>
    <start_date>January 2013</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>February 14, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>rate of HBeAg seroconversion</outcome_measure>
      <outcome_measure>rate of HBsAg loss</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02368288</url>
  </study>
  <study rank="369">
    <nct_id>NCT01294618</nct_id>
    <title>Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Myelogenous Leukemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nilotinib,Novartis,300 mg twice a day +Pegylated interferon 2a,Roche, 45 microg weekly starting Month 2-Month 12 or beyond according to investigator choice.</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hospices Civils de Lyon</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2009-560</other_id>
    </other_ids>
    <first_received>February 7, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>August 25, 2014</last_updated>
    <last_verified>February 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>NILOPEG</acronym>
    <primary_completion_date>March 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Cumulative incidence of complete molecular remissions after 12 months of treatment with nilotinib + Pegylated Interferon (PEG-IFN)</outcome_measure>
      <outcome_measure>Kinetics of Complete Molecular Response (CMR) at 1, 2, 3, 6, 9, 12, 15, 18 and 24 months.</outcome_measure>
      <outcome_measure>Stability of CMR : Proportion of patients maintaining their CMR at 18 and 24 months</outcome_measure>
      <outcome_measure>Kinetics of Major Molecular Response (MMR) at 1, 2, 3, 6, 9, 12, 15, 18 and 24 months.</outcome_measure>
      <outcome_measure>Stability of MMR : proportion of patients maintaining their MMR at 18 and 24 months</outcome_measure>
      <outcome_measure>Cumulative Complete Cytogenetic Remission (CCyR) rates at 3, 6 and 12 months.</outcome_measure>
      <outcome_measure>Safety (hematologic and non-hematologic) of the combination nilotinib + PEG-IFN</outcome_measure>
      <outcome_measure>Dose reductions or interruptions of each treatment studied</outcome_measure>
      <outcome_measure>Progression free survival.</outcome_measure>
      <outcome_measure>Overall survival.</outcome_measure>
      <outcome_measure>Quality of life on nilotinib + PEG-IFN</outcome_measure>
      <outcome_measure>Event free survival.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01294618</url>
  </study>
  <study rank="370">
    <nct_id>NCT02365402</nct_id>
    <title>Efficacies of Entecavir Add on HBeAg Negative Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Entecavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Beijing Ditan Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>180</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>DTXY006</other_id>
    </other_ids>
    <first_received>February 15, 2015</first_received>
    <start_date>January 2013</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>February 15, 2015</last_updated>
    <last_verified>February 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>rate of sustained virual response</outcome_measure>
      <outcome_measure>rates of HBsAg loss during treatment course and at the end of follow-up</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02365402</url>
  </study>
  <study rank="371">
    <nct_id>NCT00241241</nct_id>
    <title>Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Polycythemia Vera</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon-alfa 2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>PV-Nord</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PVN1</other_id>
    </other_ids>
    <first_received>October 17, 2005</first_received>
    <start_date>September 2004</start_date>
    <completion_date>January 2008</completion_date>
    <last_updated>October 20, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>response rate after one year of treatment</outcome_measure>
      <outcome_measure>safety</outcome_measure>
      <outcome_measure>molecular response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00241241</url>
  </study>
  <study rank="372">
    <nct_id>NCT01343186</nct_id>
    <title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Assessment of Ypeginterferon Alfa-2a in Healthy Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy Subjects</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa</intervention>
      <intervention type="Drug">Peginterferon alfa 2a</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Xiamen Amoytop Biotech Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>39</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>TB1012IFN</other_id>
    </other_ids>
    <first_received>April 24, 2011</first_received>
    <start_date>January 2011</start_date>
    <completion_date>November 2011</completion_date>
    <last_updated>January 30, 2012</last_updated>
    <last_verified>December 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Measuring interferon levels in blood samples</outcome_measure>
      <outcome_measure>Different blood interferon biomarkers (such as 2,5-OAS, neopterin)</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Anti-interferon antibody</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01343186</url>
  </study>
  <study rank="373">
    <nct_id>NCT00143000</nct_id>
    <title>Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a 40KD and Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>NORDynamIC Study Group</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>392</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Swedish MPA nr. 151:2004/3458</other_id>
      <other_id>Ethical Committee nr. Ã 763/03</other_id>
    </other_ids>
    <first_received>September 1, 2005</first_received>
    <start_date>April 2004</start_date>
    <completion_date>October 2006</completion_date>
    <last_updated>April 4, 2008</last_updated>
    <last_verified>April 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Sustained Viral Response (SVR) rate defined as percentage of patients with non-detectable HCV-RNA as measured by COBAS TaqMan 48â¢ (&lt;50 IU/mL) at 24 weeks post completion of the 12 or 24 week treatment period.</outcome_measure>
      <outcome_measure>ALT measurements at 24 weeks post completion of the 12 or 24 week treatment period.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00143000</url>
  </study>
  <study rank="374">
    <nct_id>NCT00100581</nct_id>
    <title>Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Efavirenz</intervention>
      <intervention type="Drug">Lamivudine</intervention>
      <intervention type="Drug">Lopinavir/ritonavir</intervention>
      <intervention type="Drug">Pegylated interferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Tenofovir disoproxil fumarate</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>A5184</other_id>
      <other_id>10133</other_id>
      <other_id>ACTG A5184</other_id>
    </other_ids>
    <first_received>January 3, 2005</first_received>
    <completion_date>January 2007</completion_date>
    <last_updated>May 17, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>HCV viral load at least 2 log10 less than baseline or below the limit of detection by quantitative assay at 12 weeks after the start of HCV treatment (early virologic response)</outcome_measure>
      <outcome_measure>HIV and/or HCV treatment-limiting or Grade 4 or higher signs and symptoms and laboratory values</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New York</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00100581</url>
  </study>
  <study rank="375">
    <nct_id>NCT00008463</nct_id>
    <title>A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Interferon alfa-2a</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>132</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>A5071</other_id>
      <other_id>10675</other_id>
      <other_id>Substudy AACTG A5091s</other_id>
      <other_id>ACTG A5071</other_id>
      <other_id>AACTG A5071</other_id>
    </other_ids>
    <first_received>January 9, 2001</first_received>
    <start_date>November 2000</start_date>
    <completion_date>August 2006</completion_date>
    <last_updated>June 7, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Indiana</state>
      <state>Iowa</state>
      <state>Massachusetts</state>
      <state>Minnesota</state>
      <state>New York</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00008463</url>
  </study>
  <study rank="376">
    <nct_id>NCT01083251</nct_id>
    <title>The Beneficial Effect of Vitamin D Supplement to Peg Interferon Alpha 2a or to Telbivudine Monotherapy in Patients With Chronic Hepatitis B Virus (HBV) Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon + Vitamin D</intervention>
      <intervention type="Drug">Peginterferon</intervention>
      <intervention type="Drug">Sebivo</intervention>
      <intervention type="Drug">entecavir+ vitamin d</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Ziv Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>004-10</other_id>
    </other_ids>
    <first_received>March 3, 2010</first_received>
    <start_date>March 2010</start_date>
    <completion_date>December 2012</completion_date>
    <last_updated>January 17, 2011</last_updated>
    <last_verified>March 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>treatment efficacy</outcome_measure>
      <outcome_measure>histologic response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Israel</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01083251</url>
  </study>
  <study rank="377">
    <nct_id>NCT00361179</nct_id>
    <title>Long Term Effects of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/B Co-Infection and Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coinfection With Hepatitis B Virus and Hepatitis C Virus</condition>
      <condition>Monoinfection With Hepatitis C Virus</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>320</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Defined Population</study_design>
      <study_design>Observational Model: Natural History</study_design>
      <study_design>Time Perspective: Longitudinal</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>9561706020</other_id>
    </other_ids>
    <first_received>August 4, 2006</first_received>
    <start_date>May 2006</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>August 4, 2006</last_updated>
    <last_verified>August 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00361179</url>
  </study>
  <study rank="378">
    <nct_id>NCT01120795</nct_id>
    <title>Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon and ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Melbourne Health</lead_sponsor>
      <collaborator>The University of New South Wales</collaborator>
      <collaborator>St Vincent's Hospital, Sydney</collaborator>
      <collaborator>Western Hospital, Australia</collaborator>
      <collaborator>Monash University</collaborator>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>55</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HREC 2000.175</other_id>
    </other_ids>
    <first_received>May 6, 2010</first_received>
    <start_date>February 2004</start_date>
    <completion_date>July 2006</completion_date>
    <last_updated>May 27, 2010</last_updated>
    <last_verified>May 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01120795</url>
  </study>
  <study rank="379">
    <nct_id>NCT00662220</nct_id>
    <title>High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Foundation for Liver Research</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>110</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HCV07-01</other_id>
      <other_id>2007-005344-25</other_id>
    </other_ids>
    <first_received>April 17, 2008</first_received>
    <start_date>April 2008</start_date>
    <completion_date>November 2013</completion_date>
    <last_updated>July 11, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>VIRID</acronym>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HCV-RNA negativity by qualitative assay 24 weeks after end of treatment (sustained virological response, SVR)</outcome_measure>
      <outcome_measure>HCV-RNA negativity at week 4 (rapid virological response, RVR)</outcome_measure>
      <outcome_measure>HCV-RNA negativity at week 12 (complete early virological response, cEVR)</outcome_measure>
      <outcome_measure>HCV-RNA â¥ 2log10 drop at week 12, but HCV-RNA still detectable (partial early virological response, pEVR)</outcome_measure>
      <outcome_measure>HCV- RNA negativity at week 48 (end of treatment response, ETR)</outcome_measure>
      <outcome_measure>Relapse rate after ETR</outcome_measure>
      <outcome_measure>Safety and tolerability of high-dose daily ribavirin (serious adverse events, grade 4 NCI toxicity, percentage of patients completing treatment on full or &gt;80% of total intended dose and reasons for dose adjustments)</outcome_measure>
      <outcome_measure>Biochemical response (normalization of serum ALT at the end of therapy and at the end of follow-up)</outcome_measure>
      <outcome_measure>Health related quality of life and psychopathology before, during and after treatment by SF-36 and SCL-90 questionnaires</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00662220</url>
  </study>
  <study rank="380">
    <nct_id>NCT01686789</nct_id>
    <title>Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alpha-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>King Abdulaziz Medical City</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>190</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>RC08-064</other_id>
    </other_ids>
    <first_received>September 13, 2012</first_received>
    <start_date>January 2011</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>September 18, 2012</last_updated>
    <last_verified>September 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response</outcome_measure>
      <outcome_measure>Requirement of blood-related products</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Saudi Arabia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01686789</url>
  </study>
  <study rank="381">
    <nct_id>NCT01336010</nct_id>
    <title>Treatment of Recently Acquired Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kirby Institute</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>82</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>5R01DA015999-07</other_id>
    </other_ids>
    <first_received>April 13, 2011</first_received>
    <start_date>August 2011</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>August 31, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ATAHC-II</acronym>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluate the safety and efficacy of response-guided pegylated interferon and ribavirin for the treatment of recent HCV infection. Response-guided means the duration of treatment will be determined by the subject's early response to treatment.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01336010</url>
  </study>
  <study rank="382">
    <nct_id>NCT01072695</nct_id>
    <title>Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GS-9256</intervention>
      <intervention type="Drug">GS-9190</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>46</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-196-0112</other_id>
    </other_ids>
    <first_received>February 19, 2010</first_received>
    <start_date>February 2010</start_date>
    <completion_date>January 2012</completion_date>
    <last_updated>May 30, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of subjects achieving rapid virologic response (RVR)</outcome_measure>
      <outcome_measure>AEs, physical examination and clinical laboratory test findings, vital signs, ECGs</outcome_measure>
      <outcome_measure>Plasma pharmacokinetics</outcome_measure>
      <outcome_measure>Viral resistance</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01072695</url>
  </study>
  <study rank="383">
    <nct_id>NCT00911963</nct_id>
    <title>Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">VCH-222 or matching placebo</intervention>
      <intervention type="Drug">VCH-222 or matching placebo</intervention>
      <intervention type="Biological">peginterferon alfa-2a</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Vertex Pharmaceuticals Incorporated</lead_sponsor>
      <collaborator>ViroChem Pharma</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>49</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>VCH-222-102</other_id>
    </other_ids>
    <first_received>May 29, 2009</first_received>
    <start_date>April 2009</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>February 6, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To assess the antiviral activity of VCH-222, in subjects with genotype 1 hepatitis C virus (HCV) infection after once (QD) or twice (b.i.d.) daily dosing for 3 days (Part A)</outcome_measure>
      <outcome_measure>To assess the antiviral activity of VCH-222, in subjects with genotype 1 HCV infection after b.i.d. daily dosing for 12 weeks in combination with Peg-interferon-alfa-2a and ribavirin (Part B)</outcome_measure>
      <outcome_measure>Assess the safety and tolerability of VCH-222 when administered in combination with Peg-IFN-alfa-2a/RBV for 12 weeks (Part B)</outcome_measure>
      <outcome_measure>To assess the safety and tolerability of VCH-222 when administered for 3 days in monotherapy (Part A)</outcome_measure>
      <outcome_measure>To evaluate the pharmacokinetic (PK) profile of VCH-222 in HCV infected subjects (Part B)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Argentina</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Georgia</state>
      <state>Michigan</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00911963</url>
  </study>
  <study rank="384">
    <nct_id>NCT01011166</nct_id>
    <title>Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">IDX184</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Biological">Peginterferon alfa-2a (Peg-IFN)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>81</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>2355-004</other_id>
      <other_id>IDX-08C-004</other_id>
    </other_ids>
    <first_received>October 2, 2009</first_received>
    <start_date>November 2009</start_date>
    <completion_date>July 2010</completion_date>
    <last_updated>April 22, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in HCV ribonucleic acid (RNA) level from Baseline to Day 15</outcome_measure>
      <outcome_measure>Percentage of participants experiencing adverse events (AEs)</outcome_measure>
      <outcome_measure>Percentage of participants experiencing serious adverse events (SAEs)</outcome_measure>
      <outcome_measure>Percentage of participants experiencing dose-limiting toxicities (DLTs)</outcome_measure>
      <outcome_measure>Percentage of participants experiencing Grade 1-4 laboratory abnormalities</outcome_measure>
      <outcome_measure>Change in HCV RNA level from Baseline to Day 28</outcome_measure>
      <outcome_measure>Percentage of participants with undetectable HCV RNA at Day 15</outcome_measure>
      <outcome_measure>Percentage of participants with undetectable HCV RNA at Day 28</outcome_measure>
      <outcome_measure>Percentage of participants experiencing virologic breakthrough while on study therapy</outcome_measure>
      <outcome_measure>Change in alanine aminotransferase (ALT) level from Baseline to Day 15</outcome_measure>
      <outcome_measure>Change in ALT level from Baseline to Day 28</outcome_measure>
      <outcome_measure>Maximum concentration (Cmax)</outcome_measure>
      <outcome_measure>Time to maximum concentration (Tmax)</outcome_measure>
      <outcome_measure>Area under the drug concentration-time curve (AUC) from time 0 to last measurable concentration (AUC0-t)</outcome_measure>
      <outcome_measure>AUC from time zero to infinity (AUC0-~)</outcome_measure>
      <outcome_measure>Trough concentration (Ctrough)</outcome_measure>
      <outcome_measure>Observed terminal half-life (Thalf)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01011166</url>
  </study>
  <study rank="385">
    <nct_id>NCT01925183</nct_id>
    <title>Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alpha-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Markus Peck-Radosavljevic</lead_sponsor>
      <collaborator>Medical University of Vienna</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HIVCOBOC-RGT</other_id>
      <other_id>2012-005591-33</other_id>
    </other_ids>
    <first_received>August 15, 2013</first_received>
    <start_date>August 2013</start_date>
    <last_updated>August 16, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HIVCOBOC-RGT</acronym>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR12)</outcome_measure>
      <outcome_measure>Adverse events (AEs) and severe adverse events (SAEs)</outcome_measure>
      <outcome_measure>Sustained virologic response (SVR24)</outcome_measure>
      <outcome_measure>Anemia</outcome_measure>
      <outcome_measure>Thrombocytopenia</outcome_measure>
      <outcome_measure>Neutropenia</outcome_measure>
      <outcome_measure>Erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) analogues use</outcome_measure>
      <outcome_measure>Treatment discontinuation due to AEs</outcome_measure>
      <outcome_measure>Drop-outs</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01925183</url>
  </study>
  <study rank="386">
    <nct_id>NCT00395421</nct_id>
    <title>Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">NM283 plus Peg-IFNÎ±-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
      <collaborator>Novartis Pharmaceuticals</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>114</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Single Blind (Subject)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NV-08A-008</other_id>
    </other_ids>
    <first_received>November 1, 2006</first_received>
    <start_date>October 2006</start_date>
    <completion_date>August 2008</completion_date>
    <last_updated>June 9, 2010</last_updated>
    <last_verified>June 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Georgia</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00395421</url>
  </study>
  <study rank="387">
    <nct_id>NCT01483742</nct_id>
    <title>A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-NaÃ¯ve Patients With Chronic Hepatitis C and Compensated Cirrhosis</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">RO5024048</intervention>
      <intervention type="Drug">danoprevir</intervention>
      <intervention type="Drug">peginterferon alfa-2a [Pegasys]</intervention>
      <intervention type="Drug">ribavirin</intervention>
      <intervention type="Drug">ritonavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>43</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NP27946</other_id>
      <other_id>2011-004129-28</other_id>
    </other_ids>
    <first_received>November 30, 2011</first_received>
    <start_date>April 2012</start_date>
    <completion_date>September 2013</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
      <outcome_measure>Pharmacokinetics: Area under the concentration-time curve (AUC)</outcome_measure>
      <outcome_measure>Antiviral activity: HCV RNA levels assessed by Roche COBAS Taqman HCV Test</outcome_measure>
      <outcome_measure>Emergence of viral resistance: HCV RNA gene sequence variations</outcome_measure>
      <outcome_measure>Virologic response: HCV RNA levels</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>France</country>
      <country>New Zealand</country>
      <country>Poland</country>
      <country>Slovakia</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Louisiana</state>
      <state>Michigan</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01483742</url>
  </study>
  <study rank="388">
    <nct_id>NCT01277601</nct_id>
    <title>Efficacy &amp; Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon Î±-2a (PEG) Versus TDF or PEG Monotherapy in Chronic Hepatitis B</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TDF</intervention>
      <intervention type="Drug">PEG</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>751</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-174-0149</other_id>
    </other_ids>
    <first_received>January 13, 2011</first_received>
    <start_date>April 2011</start_date>
    <completion_date>July 2015</completion_date>
    <last_updated>September 9, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>August 10, 2015</firstreceived_results_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With HBsAg Loss at Week 72 Following Treatment With 48 Weeks of TDF Plus PEG Combination Versus PEG Alone for 48 Weeks or TDF Alone</outcome_measure>
      <outcome_measure>Percentage of Participants With HBsAg Loss at Week 72 Following Treatment With TDF (48 Weeks) Plus PEG (16 Weeks) Combination Versus PEG Alone for 48 Weeks or TDF Alone</outcome_measure>
      <outcome_measure>Percentage of Participants With HBsAg Seroconversion at Week 72</outcome_measure>
      <outcome_measure>Percentage of Participants With HBeAg Loss and Seroconversion at Week 72</outcome_measure>
      <outcome_measure>Percentage of Participants With Virological Response (HBV DNA &lt; 117 IU/mL) at Week 72</outcome_measure>
      <outcome_measure>Percentage of Participants With Normal ALT at Week 72</outcome_measure>
      <outcome_measure>Percentage of Participants Who Required Retreatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>Hong Kong</country>
      <country>India</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>Portugal</country>
      <country>Romania</country>
      <country>Singapore</country>
      <country>Spain</country>
      <country>Taiwan</country>
      <country>Turkey</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01277601</url>
  </study>
  <study rank="389">
    <nct_id>NCT00100659</nct_id>
    <title>PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon/ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>Roche Pharma AG</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>114</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>67767 (completed)</other_id>
    </other_ids>
    <first_received>January 4, 2005</first_received>
    <start_date>December 2004</start_date>
    <completion_date>February 2010</completion_date>
    <last_updated>July 10, 2013</last_updated>
    <last_verified>July 2013</last_verified>
    <firstreceived_results_date>May 10, 2013</firstreceived_results_date>
    <primary_completion_date>August 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Viral Response (SVR)</outcome_measure>
      <outcome_measure>Vital Signs Events.</outcome_measure>
      <outcome_measure>Laboratory Assessments</outcome_measure>
      <outcome_measure>Adverse Events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>New York</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00100659</url>
  </study>
  <study rank="390">
    <nct_id>NCT00274495</nct_id>
    <title>Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
      <condition>Fatty Liver</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rosiglitazone and Pegasys/Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Beth Israel Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>098-04</other_id>
    </other_ids>
    <first_received>January 9, 2006</first_received>
    <start_date>January 2006</start_date>
    <completion_date>October 2007</completion_date>
    <last_updated>October 31, 2007</last_updated>
    <last_verified>January 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>To compare the efficacy of Rosiglitazone in combination with pegylated interferon alfa-2a and ribavirin (weight-based) to that of pegylated interferon alfa-2a and ribavirin alone in terms of sustained viral response.</outcome_measure>
      <outcome_measure>To compare the safety and tolerability of Rosiglitazone in combination with pegylated interferon-2a and ribavirin to that of pegylated interferon alfa-2a and ribavirin alone in terms of adverse events.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00274495</url>
  </study>
  <study rank="391">
    <nct_id>NCT00763763</nct_id>
    <title>Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Leukemia, Lymphocytic, Acute</condition>
      <condition>Philadelphia Chromosome</condition>
      <condition>Blast Crisis</condition>
      <condition>Leukemia, Myeloid, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Imatinib mesylate</intervention>
      <intervention type="Drug">Interferon</intervention>
      <intervention type="Drug">Vincristine</intervention>
      <intervention type="Drug">Dexamethasone</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Assistance Publique - HÃ´pitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>55</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P030425</other_id>
    </other_ids>
    <first_received>July 25, 2008</first_received>
    <start_date>December 2004</start_date>
    <completion_date>January 2010</completion_date>
    <last_updated>October 4, 2011</last_updated>
    <last_verified>October 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>AFR07</acronym>
    <primary_completion_date>October 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To determine the rate of hematological response induced by Gleevecâ¢ combined with vincristine and dexamethasone</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00763763</url>
  </study>
  <study rank="392">
    <nct_id>NCT00152581</nct_id>
    <title>Analysis of the Duration of Combination Therapy That is Necessary for HCV Genotype 1 Eradication</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C, HCV Genotype 1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon-alfa2a (Pegasys); ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University College London Hospitals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>01/0277</other_id>
    </other_ids>
    <first_received>September 7, 2005</first_received>
    <start_date>April 2002</start_date>
    <last_updated>November 29, 2005</last_updated>
    <last_verified>September 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response (HCV RNA negative) 6 months post-treatment cessation</outcome_measure>
      <outcome_measure>Hepatic and serum HCV RNA levels as a predictor for treatment duration</outcome_measure>
      <outcome_measure>HCV-specific T-cell reactivity as a predictor for treatment duration</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00152581</url>
  </study>
  <study rank="393">
    <nct_id>NCT00984620</nct_id>
    <title>Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naÃ¯ve Patients (SILEN-C3)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">BI 201335</intervention>
      <intervention type="Drug">Pegylated Interferon-alpha (IFN)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>160</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1220.40</other_id>
      <other_id>2009-012579-90</other_id>
    </other_ids>
    <first_received>September 24, 2009</first_received>
    <start_date>September 2009</start_date>
    <last_updated>August 7, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>July 3, 2015</firstreceived_results_date>
    <primary_completion_date>April 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Virological Response at Week 28 (W28VR)</outcome_measure>
      <outcome_measure>Rapid Virological Response at Week 4 (RVR)</outcome_measure>
      <outcome_measure>Virological Response at Week 24 (W24VR)</outcome_measure>
      <outcome_measure>Virological Response at Week 36 (W36VR)</outcome_measure>
      <outcome_measure>End of Treatment Response (ETR)</outcome_measure>
      <outcome_measure>Sustained Virological Response (SVR24) at 24 Weeks After Completion of All Therapy</outcome_measure>
      <outcome_measure>Viral Load (HCV RNA) at All Visits During Treatment and Follow-up</outcome_measure>
      <outcome_measure>Time to Reach a Plasma HCV RNA Level BLD While on Treatment</outcome_measure>
      <outcome_measure>Laboratory Test Abnormalities and Study Medication Tolerabilities</outcome_measure>
      <outcome_measure>Number of Participants With Clinically Relevant Abnormalities Vital Signs, and Physical Examination</outcome_measure>
      <outcome_measure>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (1)</outcome_measure>
      <outcome_measure>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (2)</outcome_measure>
      <outcome_measure>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (3)</outcome_measure>
      <outcome_measure>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (4)</outcome_measure>
      <outcome_measure>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (5)</outcome_measure>
      <outcome_measure>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (6)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Austria</country>
      <country>France</country>
      <country>Germany</country>
      <country>Romania</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Mississippi</state>
      <state>New York</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00984620</url>
  </study>
  <study rank="394">
    <nct_id>NCT00530972</nct_id>
    <title>Pilot Study of Patients Chronic Hepatitis C in Co-infected HIV Patients Relapsers After Previous Therapies</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a plus ribavirin adjusted to body weight</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hospital Carlos III, Madrid</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2005-001192-34</other_id>
    </other_ids>
    <first_received>September 17, 2007</first_received>
    <start_date>March 2006</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>September 4, 2009</last_updated>
    <last_verified>September 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PILOT-NR</acronym>
    <primary_completion_date>December 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>% of patients with RNA-HCV undetectable</outcome_measure>
      <outcome_measure>% of patients with RNA-HCV undetectable at different moments of the treatment according genotype, viremia, liver fibrosis, number of CD4 cells and previous therapy</outcome_measure>
      <outcome_measure>Ribavirin levels</outcome_measure>
      <outcome_measure>Impact of dose reduction peg-interferon and/or ribavirin</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00530972</url>
  </study>
  <study rank="395">
    <nct_id>NCT01260350</nct_id>
    <title>Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-NaÃ¯ve Patients With HCV GT2 or GT3</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">PEG</intervention>
      <intervention type="Drug">LDV</intervention>
      <intervention type="Drug">GS-9669</intervention>
      <intervention type="Drug">LDV/SOF</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>292</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P7977-0523</other_id>
      <other_id>Medsafe</other_id>
    </other_ids>
    <first_received>December 13, 2010</first_received>
    <start_date>December 2010</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>November 7, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>November 7, 2014</firstreceived_results_date>
    <primary_completion_date>October 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Who Experienced Adverse Events</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks Following Completion of Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LOD at Week 6</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LOD at Week 8</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LOD at Week 12</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 6</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 8</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA at Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>New Zealand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01260350</url>
  </study>
  <study rank="396">
    <nct_id>NCT01405027</nct_id>
    <title>Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Genotype 1</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Educational Intervention</intervention>
      <intervention type="Other">Patient education and management skills training</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Chronic Liver Disease Foundation</lead_sponsor>
      <collaborator>SCRI Development Innovations, LLC</collaborator>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>197</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CLDF-MER-001-00</other_id>
      <other_id>20111013</other_id>
    </other_ids>
    <first_received>July 25, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>December 22, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>November 17, 2014</firstreceived_results_date>
    <acronym>OPTIMAL</acronym>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Treatment Duration Compliance Rate</outcome_measure>
      <outcome_measure>Drug Exposure</outcome_measure>
      <outcome_measure>Determination of the Rate of Sustained Viral Response (SVR) for HCV Patients Treated With Boceprevir, Peginterferon and Ribavirin at Community Sites and at HCEEs.</outcome_measure>
      <outcome_measure>Short Form Health Survey Measuring Quality of Life Reported at Baseline, End of Treatment, and Follow-up Week 24 (36 Multiple Choice Questions)</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Iowa</state>
      <state>Louisiana</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01405027</url>
  </study>
  <study rank="397">
    <nct_id>NCT01808248</nct_id>
    <title>Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">PEG</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>47</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0151</other_id>
    </other_ids>
    <first_received>March 1, 2013</first_received>
    <start_date>February 2013</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>September 5, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>September 5, 2014</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing On-treatment Virologic Failure</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01808248</url>
  </study>
  <study rank="398">
    <nct_id>NCT01188772</nct_id>
    <title>Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Placebo to match sofosbuvir</intervention>
      <intervention type="Drug">PEG</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>147</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P7977-0422</other_id>
    </other_ids>
    <first_received>August 23, 2010</first_received>
    <start_date>August 2010</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>April 2, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>January 6, 2014</firstreceived_results_date>
    <primary_completion_date>April 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Who Experienced Adverse Events During the Sofosbuvir Treatment Period</outcome_measure>
      <outcome_measure>Change in HCV RNA From Baseline to Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Complete Early Virologic Response at Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With Extended Rapid Virologic Response</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Response at the End of Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Post-treatment Week 12 (SVR12) and 24 (SVR24)</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007 (Cmax at Day 8)</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007 (Cmax at Day 15)</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007 (Cmax at Day 29)</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007 (AUCtau at Day 8)</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007 (AUCtau at Day 15)</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007 (AUCtau at Day 29)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Developed Resistance to Sofosbuvir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01188772</url>
  </study>
  <study rank="399">
    <nct_id>NCT00203606</nct_id>
    <title>Pegylated Interferon Plus Ribavirin in the Treatment of Active and Past Intravenous Drug Users Infected With Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis c</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon alfa-2a ( Roche) and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Calgary</lead_sponsor>
      <collaborator>Canadian Institutes of Health Research (CIHR)</collaborator>
      <collaborator>Roche Pharma AG</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>66</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>21995</other_id>
    </other_ids>
    <first_received>September 13, 2005</first_received>
    <start_date>January 2004</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>August 3, 2011</last_updated>
    <last_verified>August 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained viral response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00203606</url>
  </study>
  <study rank="400">
    <nct_id>NCT01758588</nct_id>
    <title>Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Myelofibrosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Weill Medical College of Cornell University</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>47</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1202012178</other_id>
    </other_ids>
    <first_received>December 24, 2012</first_received>
    <start_date>January 2013</start_date>
    <completion_date>January 2016</completion_date>
    <last_updated>April 11, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evidence of improved clinical status</outcome_measure>
      <outcome_measure>Progression free survival and overall survival</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Georgia</state>
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01758588</url>
  </study>
  <study rank="401">
    <nct_id>NCT00188240</nct_id>
    <title>Insulin Resistance Associated With Chronic Hepatitis C (CHC) and the Effect of Antiviral Therapy</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegasys; Copegus.</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Health Network, Toronto</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>03-0510-AE 04-0292-A</other_id>
    </other_ids>
    <first_received>September 9, 2005</first_received>
    <start_date>August 2003</start_date>
    <last_updated>November 28, 2005</last_updated>
    <last_verified>September 2005</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Phase I - To evaluate the prevalence of insulin resistance in patients with hepatitis C without cirrhosis and compare it to that observed in patients with hepatitis B also without cirrhosis.</outcome_measure>
      <outcome_measure>Phase II - Interventional phase - To evaluate the effect of anti-viral therapy on insulin resistance, determined by the OGTT method, in patients with hepatitis C found to have insulin resistance pre-treatment.</outcome_measure>
      <outcome_measure>- To evaluate the safety, efficacy and tolerability of Pegasys (peginterferon alfa-2a) given in combination with Copegus (ribavirin) given for 24 weeks or 48 weeks in treatment naÃ¯ve patients with chronic hepatitis C (CHC).</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00188240</url>
  </study>
  <study rank="402">
    <nct_id>NCT01997944</nct_id>
    <title>Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase Ib Study in Chronic Hepatitis B Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Human Serum ALbumin/interferon alpha2a</intervention>
      <intervention type="Biological">Pegasys</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Beijing Bio-Fortune Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>921302</other_id>
    </other_ids>
    <first_received>November 21, 2013</first_received>
    <start_date>November 2013</start_date>
    <completion_date>November 2014</completion_date>
    <last_updated>November 14, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of adverse events</outcome_measure>
      <outcome_measure>Decrease of HBV DNA</outcome_measure>
      <outcome_measure>AUCss</outcome_measure>
      <outcome_measure>Css_av</outcome_measure>
      <outcome_measure>Css_min</outcome_measure>
      <outcome_measure>Css-max</outcome_measure>
      <outcome_measure>T1/2</outcome_measure>
      <outcome_measure>Tmax</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01997944</url>
  </study>
  <study rank="403">
    <nct_id>NCT01760122</nct_id>
    <title>Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ypeginterferon alfa-2b</intervention>
      <intervention type="Drug">Pegasys</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Xiamen Amoytop Biotech Co., Ltd.</lead_sponsor>
      <collaborator>Peking University First Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>820</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TB1211IFN</other_id>
    </other_ids>
    <first_received>December 30, 2012</first_received>
    <start_date>March 2013</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>August 28, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients with HBeAg seroconversion at week72</outcome_measure>
      <outcome_measure>Proportion of Patients with HBeAg seroconversion at week 12,24,48</outcome_measure>
      <outcome_measure>Proportion fo patients with HBeAg undetectable at week 12, 24, 48, and 72.</outcome_measure>
      <outcome_measure>Average of HBV DNA decline level at week 12, 24,48 and 72</outcome_measure>
      <outcome_measure>Average of HBsAg decline level at week 12, 24, 48 and 72, and Proportion of patients with HBsAg undetectable and HBsAg seroconversion at week 12, 24, 48 and 72.</outcome_measure>
      <outcome_measure>Proportion of patients with ALT normalization at week 12,24, 48 and 72.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01760122</url>
  </study>
  <study rank="404">
    <nct_id>NCT01659567</nct_id>
    <title>An Observational Study of Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>530</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML25544</other_id>
    </other_ids>
    <first_received>July 27, 2012</first_received>
    <start_date>April 2011</start_date>
    <completion_date>October 2015</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Predictive values of sustained virological response</outcome_measure>
      <outcome_measure>Correlation of patient characteristics and sustained virological response</outcome_measure>
      <outcome_measure>Overall treatment duration</outcome_measure>
      <outcome_measure>Treatment duration after sustained virological response</outcome_measure>
      <outcome_measure>Correlation of treatment dose and sustained virological response</outcome_measure>
      <outcome_measure>Sustained virological response</outcome_measure>
      <outcome_measure>Safety: incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Georgia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01659567</url>
  </study>
  <study rank="405">
    <nct_id>NCT02387684</nct_id>
    <title>Efficay of Extended Peginterferon Alpha 2a Treatment in HBeAg Negative Chronic Hepatitis B Patients</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Beijing Ditan Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>DTXY007</other_id>
    </other_ids>
    <first_received>March 1, 2015</first_received>
    <start_date>April 2012</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>March 8, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>rate of sustained viral response</outcome_measure>
      <outcome_measure>rate of HBsAg loss</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02387684</url>
  </study>
  <study rank="406">
    <nct_id>NCT02387463</nct_id>
    <title>Efficacy of Extended Peginterferon Alpha 2a Treatment in HBeAg Positive Chronic Hepatitis B Patients</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Beijing Ditan Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>140</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>DTXY008</other_id>
    </other_ids>
    <first_received>March 8, 2015</first_received>
    <start_date>March 2012</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>March 12, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>rate of HBeAg seroconversion (defined as HBeAg loss with anti-HBe positive after PEG-IFN a-2a treatment and follow up)</outcome_measure>
      <outcome_measure>rate of HBsAg loss (defined as HBsAg level lower than 0.05 IU/ml)</outcome_measure>
      <outcome_measure>rate of sustained viral response (defined as serum HBV DNA undetectable at the end of treatment and the end of follow up)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02387463</url>
  </study>
  <study rank="407">
    <nct_id>NCT00114361</nct_id>
    <title>48 Weeks Combination Therapy for Patients With HBeAg-negative Chronic Hepatitis B Virus (HBV) Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alpha 2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Foundation for Liver Research</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>138</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>HBV05-01</other_id>
      <other_id>EudraCT: 2004-004736-30</other_id>
    </other_ids>
    <first_received>June 14, 2005</first_received>
    <start_date>March 2005</start_date>
    <completion_date>April 2010</completion_date>
    <last_updated>June 18, 2010</last_updated>
    <last_verified>June 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The combined presence of HBV DNA level &lt; 10E4 copies/ml and ALT normalization at the end of follow-up</outcome_measure>
      <outcome_measure>ALT normalization</outcome_measure>
      <outcome_measure>HBV DNA negativity(undetectable by Taqman PCR)</outcome_measure>
      <outcome_measure>HBsAg loss from serum</outcome_measure>
      <outcome_measure>Improvement liver histology</outcome_measure>
      <outcome_measure>Combined virological, biochemical and histological response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00114361</url>
  </study>
  <study rank="408">
    <nct_id>NCT00842205</nct_id>
    <title>Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic HCV Infection</condition>
      <condition>Nonalcoholic Steatohepatitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon</intervention>
      <intervention type="Drug">Ribavarin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Charles University, Czech Republic</lead_sponsor>
      <collaborator>IGA MZ, Czech Republic</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>IGA MZ CR NR9412-3</other_id>
    </other_ids>
    <first_received>February 11, 2009</first_received>
    <start_date>January 2007</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>February 11, 2009</last_updated>
    <last_verified>February 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>1. the relation between HO activity and basic virologic and histologic parameters in chronic HCV patients. 2. changes of HO activity within antiviral treatment 3. relation of HO gene polymorphisms to the course of disease</outcome_measure>
      <outcome_measure>Relation of HO gene polymorphisms and UGT1A1*28 polymorphism.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Czech Republic</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00842205</url>
  </study>
  <study rank="409">
    <nct_id>NCT00964665</nct_id>
    <title>Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">albinterferon alfa-2b</intervention>
      <intervention type="Drug">albinterferon alfa-2b</intervention>
      <intervention type="Drug">albinterferon alfa-2b</intervention>
      <intervention type="Drug">albinterferon alfa-2b</intervention>
      <intervention type="Drug">PegasysÂ®</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Human Genome Sciences Inc.</collaborator>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>141</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CABF656A2206</other_id>
      <other_id>EudraCT 2008-006933-29</other_id>
    </other_ids>
    <first_received>August 24, 2009</first_received>
    <start_date>July 2009</start_date>
    <last_updated>January 5, 2011</last_updated>
    <last_verified>January 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Evaluate the safety, tolerability and pharmacodynamic effect of various doses of albinterferon alfa-2b in hepatitis B patients on seroconversion of hepatitis markers. Measure: Clinical laboratory. HBV DNA level and HBeAg seroconversion rate.</outcome_measure>
      <outcome_measure>Evaluate the pharmacokinetics at different doses of albinterferon alfa-2b in patients with chronic hepatitis B infection. Measure: Serum concentration of albinterferon alfa-2b</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
      <country>Hong Kong</country>
      <country>Poland</country>
      <country>Taiwan</country>
      <country>Thailand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00964665</url>
  </study>
  <study rank="410">
    <nct_id>NCT02216045</nct_id>
    <title>Effect of Camel Milk on Chronic Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon, Ribavirin, camel milk</intervention>
      <intervention type="Drug">Peginterferon, Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Mashhad University of Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Mashhad UMS</other_id>
    </other_ids>
    <first_received>July 26, 2014</first_received>
    <start_date>June 2014</start_date>
    <completion_date>February 2015</completion_date>
    <last_updated>August 12, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HCV</acronym>
    <primary_completion_date>February 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Early Virologic Responses(EVR)</outcome_measure>
      <outcome_measure>Complete early virological response (cEVR)</outcome_measure>
      <outcome_measure>o Complete early virological response (cEVR)</outcome_measure>
      <outcome_measure>o Sustained virological response (SVR)</outcome_measure>
      <outcome_measure>o Normalization of ALT( Alanine Aminotransferase)</outcome_measure>
      <outcome_measure>o Normalization of ALT</outcome_measure>
      <outcome_measure>o Adverse events(AE)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Iran, Islamic Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02216045</url>
  </study>
  <study rank="411">
    <nct_id>NCT00943761</nct_id>
    <title>A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vaniprevir 600 mg b.i.d.</intervention>
      <intervention type="Drug">Vaniprevir 300 mg b.i.d.</intervention>
      <intervention type="Drug">Pegylated interferon</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>7009-028</other_id>
      <other_id>2009_615</other_id>
      <other_id>2009-013053-15</other_id>
    </other_ids>
    <first_received>July 21, 2009</first_received>
    <start_date>October 2009</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>September 26, 2014</firstreceived_results_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Who Experienced an Adverse Event</outcome_measure>
      <outcome_measure>Number of Participants Who Experienced a Serious Adverse Event</outcome_measure>
      <outcome_measure>Number of Participants Who Discontinued Study Treatment Due to an Adverse Event</outcome_measure>
      <outcome_measure>Percentage of Participants Who Achieved Sustained Viral Response 24 Weeks After the End of Treatment (SVR24)</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00943761</url>
  </study>
  <study rank="412">
    <nct_id>NCT01447446</nct_id>
    <title>An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>4449</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>MV25599</other_id>
    </other_ids>
    <first_received>October 4, 2011</first_received>
    <start_date>September 2011</start_date>
    <completion_date>September 2015</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response rate, defined as percentage of patients with HCV RNA &lt;50 IU/mL at 24 weeks past completion of treatment</outcome_measure>
      <outcome_measure>Virological response (in correlation with on-treatment factors)</outcome_measure>
      <outcome_measure>Duration of treatment</outcome_measure>
      <outcome_measure>Percentage of patients treated according to label / Summary of Product Characteristics (SPC)</outcome_measure>
      <outcome_measure>Treatment discontinuation (time, reasons)</outcome_measure>
      <outcome_measure>Sustained virological response in correlation with dose reductions/treatment interruptions</outcome_measure>
      <outcome_measure>Treatment (drugs, regimen) in relation to medical history/concomitant medical conditions</outcome_measure>
      <outcome_measure>Incidence of viral rebound on DAA based triple therapy</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
      <country>Egypt</country>
      <country>Estonia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>Hungary</country>
      <country>Ireland</country>
      <country>Italy</country>
      <country>Kuwait</country>
      <country>Lebanon</country>
      <country>Macedonia, The Former Yugoslav Republic of</country>
      <country>Morocco</country>
      <country>Oman</country>
      <country>Pakistan</country>
      <country>Portugal</country>
      <country>Qatar</country>
      <country>Romania</country>
      <country>Saudi Arabia</country>
      <country>Serbia</country>
      <country>Sweden</country>
      <country>Switzerland</country>
      <country>Syrian Arab Republic</country>
      <country>Taiwan</country>
      <country>Turkey</country>
      <country>United Arab Emirates</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01447446</url>
  </study>
  <study rank="413">
    <nct_id>NCT00051077</nct_id>
    <title>Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis B</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Adefovir dipivoxil</intervention>
      <intervention type="Drug">Peginterferon-alfa-2A</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Procedure">Liver Biopsy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>A5149</other_id>
      <other_id>10953</other_id>
      <other_id>ACTG A5149</other_id>
    </other_ids>
    <first_received>January 3, 2003</first_received>
    <last_updated>May 16, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00051077</url>
  </study>
  <study rank="414">
    <nct_id>NCT00158522</nct_id>
    <title>Efficacy of Pegylated Interferon Alone in Egyptian Patients With Acute Hepatitis C (ANRS 1213)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon alpha2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Agency for Research on AIDS and Viral Hepatitis</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>31</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS 1213</other_id>
    </other_ids>
    <first_received>September 8, 2005</first_received>
    <start_date>February 2003</start_date>
    <completion_date>December 2007</completion_date>
    <last_updated>February 6, 2008</last_updated>
    <last_verified>February 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Disappearance of HCV RNA by qualitative PCR 24 weeks after the end of treatment</outcome_measure>
      <outcome_measure>Changes in HCV RNA load</outcome_measure>
      <outcome_measure>Normalization of ALT during treatment and 24 weeks after the end of treatment</outcome_measure>
      <outcome_measure>Study of side effects</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00158522</url>
  </study>
  <study rank="415">
    <nct_id>NCT01508130</nct_id>
    <title>An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>672</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML27900</other_id>
    </other_ids>
    <first_received>January 9, 2012</first_received>
    <start_date>January 2012</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety: Time to premature treatment discontinuation due to any reason</outcome_measure>
      <outcome_measure>Efficacy: Sustained virological response rate, defined as percentage of patients with undetectable HCV RNA (HCV RNA &lt;/= 50 IU/mL) at 24 weeks post-completion of treatment</outcome_measure>
      <outcome_measure>Occurrence of premature discontinuation of treatment according to reasons (VR/resistance development/AE/compliance)</outcome_measure>
      <outcome_measure>Association between degree of dose reductions/treatment interruptions and sustained virological response</outcome_measure>
      <outcome_measure>Occurrence of virological rebound</outcome_measure>
      <outcome_measure>Virological response/virological rebound in correlation with hepatitis C virus genotype</outcome_measure>
      <outcome_measure>Virological response in relation to treatment duration after becoming HCV RNA undetectable</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
      <outcome_measure>Work Productivity and Activity Impairment Questionnaire: General Health (WPAI:GH)</outcome_measure>
      <outcome_measure>Virological response in correlation with baseline clinical/demographic patient characteristics</outcome_measure>
      <outcome_measure>Virological response in correlation with treatment (regimen/dosage/compliance/co-medication)</outcome_measure>
      <outcome_measure>Treatment duration according to treatment regimens</outcome_measure>
      <outcome_measure>Percentage of patients treated according to US labeling</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arkansas</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Vermont</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01508130</url>
  </study>
  <study rank="416">
    <nct_id>NCT01625338</nct_id>
    <title>Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">Peg-IFN</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>534</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0109</other_id>
      <other_id>2012-000571-16</other_id>
    </other_ids>
    <first_received>June 7, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>October 9, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>October 9, 2015</firstreceived_results_date>
    <primary_completion_date>October 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event</outcome_measure>
      <outcome_measure>Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Virologic Failure</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Austria</country>
      <country>Czech Republic</country>
      <country>Estonia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Netherlands</country>
      <country>New Zealand</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01625338</url>
  </study>
  <study rank="417">
    <nct_id>NCT01634919</nct_id>
    <title>Histologic Changes and Noninvasive Assessment in Hepatitis C Patients Treated With Peginterferon Alpha-2a and Ribavirin</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Device">chronic hepatitis C</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Seoul National University Boramae Hospital</lead_sponsor>
      <collaborator>Roche Pharma AG</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>55</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>06-2012-74</other_id>
    </other_ids>
    <first_received>July 3, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>December 2016</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Anti-fibrotic response</outcome_measure>
      <outcome_measure>Histologic and noninvasive fibrosis assessments</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Korea, Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01634919</url>
  </study>
  <study rank="418">
    <nct_id>NCT00158496</nct_id>
    <title>Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon alpha2a</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>French National Agency for Research on AIDS and Viral Hepatitis</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS 1211</other_id>
    </other_ids>
    <first_received>September 8, 2005</first_received>
    <start_date>August 2002</start_date>
    <completion_date>January 2005</completion_date>
    <last_updated>April 23, 2007</last_updated>
    <last_verified>April 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>- Disappearance of HCV RNA by qualitative PCR 24 weeks after the end of treatment</outcome_measure>
      <outcome_measure>Evaluation of HCV RNA at 12 and 24 weeks</outcome_measure>
      <outcome_measure>changes in HCV RNA load during treatment</outcome_measure>
      <outcome_measure>Normalization of ALT during treatment and 24 weeks after the end of treatment</outcome_measure>
      <outcome_measure>Study of side effects</outcome_measure>
      <outcome_measure>Histological changes 24 weeks after the end of treatment (decrease by at least 1 point of the Metavir score)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00158496</url>
  </study>
  <study rank="419">
    <nct_id>NCT00055341</nct_id>
    <title>Treatment of Hepatitis C in Hemophilic Patients With HIV</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Hepatitis C</condition>
      <condition>Hemophilia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>22</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1R01AI049508-01</other_id>
      <other_id>5R01AI049508-02</other_id>
    </other_ids>
    <first_received>February 25, 2003</first_received>
    <start_date>March 2002</start_date>
    <completion_date>June 2005</completion_date>
    <last_updated>July 29, 2008</last_updated>
    <last_verified>December 2006</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Ohio</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00055341</url>
  </study>
  <study rank="420">
    <nct_id>NCT01565889</nct_id>
    <title>Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">EFV/FTC/TDF</intervention>
      <intervention type="Drug">EFV</intervention>
      <intervention type="Drug">ZDV/3TC</intervention>
      <intervention type="Drug">ATV</intervention>
      <intervention type="Drug">Ritonavir</intervention>
      <intervention type="Drug">FTC/TDF</intervention>
      <intervention type="Drug">DRV</intervention>
      <intervention type="Drug">RAL</intervention>
      <intervention type="Drug">PEG</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P7977-1910</other_id>
    </other_ids>
    <first_received>March 27, 2012</first_received>
    <start_date>March 2012</start_date>
    <completion_date>November 2013</completion_date>
    <last_updated>September 25, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>August 28, 2014</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Part A: Plasma Pharmacokinetics of SOF, EFV, Tenofovir (TFV), and FTC: AUCtau at Day 7</outcome_measure>
      <outcome_measure>Part A: Plasma Pharmacokinetics of SOF, EFV, TFV, and FTC: Cmax at Day 7</outcome_measure>
      <outcome_measure>Part B: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)</outcome_measure>
      <outcome_measure>Part B: Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Part B: Percentage of Participants Experiencing Viral Breakthrough or Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01565889</url>
  </study>
  <study rank="421">
    <nct_id>NCT01369199</nct_id>
    <title>Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Entecavir and peginterferon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>University of Pittsburgh</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>DK082864 HBRN IT Adult Trial</other_id>
    </other_ids>
    <first_received>June 6, 2011</first_received>
    <start_date>May 2012</start_date>
    <completion_date>May 2016</completion_date>
    <last_updated>October 28, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HBRN</acronym>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety: Number, type and rate of adverse events/serious adverse events through treatment and end of follow-up 48 weeks after stopping treatment. Efficacy: HBeAg loss (lack of detectable HBeAg) AND HBV DNA â¤1,000 IU/mL 48 weeks after stopping treatment.</outcome_measure>
      <outcome_measure>HBeAg loss</outcome_measure>
      <outcome_measure>HBeAg seroconversion</outcome_measure>
      <outcome_measure>Time to HBsAg loss</outcome_measure>
      <outcome_measure>ALT &lt;45 IU/L for men, &lt;30 IU/L for women (approximately 1.5 ULN)</outcome_measure>
      <outcome_measure>ALT normalization (men &lt;30 IU/L, women &lt;20 IU/L)</outcome_measure>
      <outcome_measure>HBV DNA â¤1000 IU/mL</outcome_measure>
      <outcome_measure>HBV DNA &lt;20 IU/mL (LLOQ of COBAS Ampliprep/COBAS TaqMan HBV v2.0 test)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Hawaii</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01369199</url>
  </study>
  <study rank="422">
    <nct_id>NCT00788918</nct_id>
    <title>Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Cognition Disorders</condition>
      <condition>Fatigue Syndrome, Chronic</condition>
      <condition>Major Depressive Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Interferon and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Aarhus University Hospital</lead_sponsor>
      <collaborator>University of Aarhus</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>SKS-0078-HCVCNS</other_id>
      <other_id>EudraCT 2007-005707-18</other_id>
    </other_ids>
    <first_received>November 10, 2008</first_received>
    <start_date>November 2008</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>January 10, 2013</last_updated>
    <last_verified>January 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Neuropsychological test results, cytokine profile and MRI findings</outcome_measure>
      <outcome_measure>Interferon-induced depression</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Denmark</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00788918</url>
  </study>
  <study rank="423">
    <nct_id>NCT01197157</nct_id>
    <title>Study of the Impact of Nitazoxanide on Chronic Hepatitis Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Nitazoxanide</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Liver Institute, Egypt</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEAR trial</other_id>
    </other_ids>
    <first_received>August 9, 2010</first_received>
    <start_date>September 2010</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>September 27, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Assessment of efficacy of Nitazoxanide as an add-on therapy in terms of achieving a sustained virologic response</outcome_measure>
      <outcome_measure>assessment of rapid virologic response</outcome_measure>
      <outcome_measure>Assessment of early virologic response</outcome_measure>
      <outcome_measure>Assessment of end-of-treatment response</outcome_measure>
      <outcome_measure>Safety of Nitazoxanide</outcome_measure>
      <outcome_measure>Assessment of the efficacy of Nitazoxanide monotherapy following the lead-in phase</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01197157</url>
  </study>
  <study rank="424">
    <nct_id>NCT00040027</nct_id>
    <title>Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a</intervention>
      <intervention type="Drug">placebo + PEGinterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>SciClone Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>Ta1-CHC-2K0803a</other_id>
    </other_ids>
    <first_received>June 18, 2002</first_received>
    <start_date>April 2002</start_date>
    <last_updated>January 8, 2008</last_updated>
    <last_verified>January 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Idaho</state>
      <state>Illinois</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00040027</url>
  </study>
  <study rank="425">
    <nct_id>NCT01664845</nct_id>
    <title>Effects of Metformin, Pegylated Interferon Alpha and Ribavirin for Chronic Hepatitis C With Insulin Resistance</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis c</condition>
      <condition>Insulin Resistance</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">metformin</intervention>
      <intervention type="Drug">pegylated-IFN</intervention>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kaohsiung Veterans General Hospital.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VGHKS12-CT3-16</other_id>
    </other_ids>
    <first_received>August 10, 2012</first_received>
    <start_date>August 2012</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>August 13, 2012</last_updated>
    <last_verified>August 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>sustained virological response</outcome_measure>
      <outcome_measure>change of HOMA-IR</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01664845</url>
  </study>
  <study rank="426">
    <nct_id>NCT00093093</nct_id>
    <title>Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Viramidine</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">pegylated interferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Valeant Pharmaceuticals International, Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>900</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>RNA003142-302</other_id>
    </other_ids>
    <first_received>September 30, 2004</first_received>
    <start_date>June 2004</start_date>
    <completion_date>May 2006</completion_date>
    <last_updated>June 21, 2012</last_updated>
    <last_verified>June 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>VISER2</acronym>
    <primary_completion_date>May 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>- Efficacy: Undetectable plasma HCV RNA (less than 100 copies/mL) at the end of the 24-week post-treatment follow-up period.</outcome_measure>
      <outcome_measure>- Safety: The proportion of patients with hemoglobin less than 10 g/dL at any time during treatment or at least 2.5 g/dL drop from baseline.</outcome_measure>
      <outcome_measure>- Efficacy: Undetectable plasma HCV RNA at treatment week 24</outcome_measure>
      <outcome_measure>- Efficacy: Undetectable or at least a 2-log drop from baseline at treatment weeks 12 and 24</outcome_measure>
      <outcome_measure>- Safety: Monitoring of adverse events</outcome_measure>
      <outcome_measure>- Safety: Monitoring of abnormal changes in laboratory parameters that are not disease-related</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>France</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00093093</url>
  </study>
  <study rank="427">
    <nct_id>NCT01368497</nct_id>
    <title>Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Entecavir and peginterferon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>DK082864 HBRN IT Peds Trial</other_id>
    </other_ids>
    <first_received>June 6, 2011</first_received>
    <start_date>September 2012</start_date>
    <completion_date>September 2017</completion_date>
    <last_updated>October 28, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HBeAg loss (lack of detectable HBeAg) &amp; HBV DNA levels â¤1,000 IU/mL at time of last follow-up 48 weeks after end-of-treatment. Number, type &amp; rate of adverse events/serious adverse events through end of treatment (48 weeks) &amp; follow-up (96 weeks).</outcome_measure>
      <outcome_measure>Hepatitis B surface antigen (HBsAg) loss</outcome_measure>
      <outcome_measure>HBsAg loss</outcome_measure>
      <outcome_measure>Hepatitis B e antigen (HBeAg) loss</outcome_measure>
      <outcome_measure>HBeAg loss</outcome_measure>
      <outcome_measure>HBeAg seroconversion</outcome_measure>
      <outcome_measure>HBsAg seroconversion</outcome_measure>
      <outcome_measure>Alanine aminotransferase (ALT) â¤ 40 U/L for males, â¤ 35 U/L for females</outcome_measure>
      <outcome_measure>ALT â¤ 40 U/L for males, â¤ 35 U/L for females</outcome_measure>
      <outcome_measure>HBV DNA â¤1000 IU/mL</outcome_measure>
      <outcome_measure>HBV DNA &lt; 20 IU/mL (LLOQ of COBAS Ampliprep/COBAS TaqMan HBV v2.0 test)</outcome_measure>
      <outcome_measure>Absence of detectable antiviral drug-resistance HBV mutations</outcome_measure>
      <outcome_measure>Growth parameters</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Maryland</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01368497</url>
  </study>
  <study rank="428">
    <nct_id>NCT00556504</nct_id>
    <title>The Effects of Adding TCM-700C on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TCM-700C</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>TCM Biotech International Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>84</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>TCM-700-01-04</other_id>
    </other_ids>
    <first_received>November 8, 2007</first_received>
    <start_date>July 2007</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>August 4, 2014</last_updated>
    <last_verified>July 2014</last_verified>
    <firstreceived_results_date>June 5, 2013</firstreceived_results_date>
    <acronym>TCM-700C</acronym>
    <primary_completion_date>January 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Virologic Response</outcome_measure>
      <outcome_measure>ALT Response</outcome_measure>
      <outcome_measure>Sustained ALT Response</outcome_measure>
      <outcome_measure>Combined ALT and Virologic Response</outcome_measure>
      <outcome_measure>Immune Cell Normalization</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00556504</url>
  </study>
  <study rank="429">
    <nct_id>NCT01273948</nct_id>
    <title>Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Bavituximab</intervention>
      <intervention type="Drug">Pegylated interferon (PEG-IFN)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Peregrine Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>66</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>PPHM 1003</other_id>
    </other_ids>
    <first_received>January 7, 2011</first_received>
    <start_date>January 2011</start_date>
    <completion_date>February 2012</completion_date>
    <last_updated>February 2, 2012</last_updated>
    <last_verified>February 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Reduction in Hepatitis C Virus RNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Georgia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01273948</url>
  </study>
  <study rank="430">
    <nct_id>NCT00023322</nct_id>
    <title>Pegylated Interferon to Treat Chronic Hepatitis D</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis D</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon Alpha-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>13</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>010247</other_id>
      <other_id>01-DK-0247</other_id>
    </other_ids>
    <first_received>September 3, 2001</first_received>
    <start_date>August 2001</start_date>
    <completion_date>October 2012</completion_date>
    <last_updated>July 9, 2013</last_updated>
    <last_verified>July 2013</last_verified>
    <firstreceived_results_date>April 15, 2013</firstreceived_results_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Histological Response at 3 Years</outcome_measure>
      <outcome_measure>Histological Response at 5 Years</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00023322</url>
  </study>
  <study rank="431">
    <nct_id>NCT01276756</nct_id>
    <title>Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis c</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa-2a</intervention>
      <intervention type="Drug">Nitazoxanide</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Cairo University</lead_sponsor>
      <collaborator>Egyptian Railway Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Single Blind (Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>RAIL001</other_id>
    </other_ids>
    <first_received>January 12, 2011</first_received>
    <start_date>December 2010</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>March 19, 2013</last_updated>
    <last_verified>March 2013</last_verified>
    <firstreceived_results_date>January 30, 2013</firstreceived_results_date>
    <primary_completion_date>November 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
      <outcome_measure>Rapid Virological Response</outcome_measure>
      <outcome_measure>Early Virological Response</outcome_measure>
      <outcome_measure>End-of-treatment Response</outcome_measure>
      <outcome_measure>Safety of Nitazoxanide (Number of Participants Experiencing Adverse Events)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01276756</url>
  </study>
  <study rank="432">
    <nct_id>NCT00944684</nct_id>
    <title>High Dose Ribavirin in the Treatment of Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">High ribavirin dose</intervention>
      <intervention type="Drug">Standard ribavirin dose</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Bern</lead_sponsor>
      <collaborator>Roche Pharma AG</collaborator>
      <collaborator>University of Lausanne</collaborator>
      <collaborator>Cantonal Hospital of St. Gallen</collaborator>
      <collaborator>Stadtspital Waid, ZÃ¼rich, Switzerland</collaborator>
      <collaborator>University of Basel</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>091/07</other_id>
      <other_id>ML21071</other_id>
      <other_id>SASL-24</other_id>
    </other_ids>
    <first_received>July 17, 2009</first_received>
    <start_date>November 2007</start_date>
    <completion_date>April 2011</completion_date>
    <last_updated>November 10, 2011</last_updated>
    <last_verified>November 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response</outcome_measure>
      <outcome_measure>Adverse Events</outcome_measure>
      <outcome_measure>Rapid virological response at 4 weeks of treatment</outcome_measure>
      <outcome_measure>Early virological response at 12 weeks of treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Switzerland</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00944684</url>
  </study>
  <study rank="433">
    <nct_id>NCT00296972</nct_id>
    <title>Tolerability of Peginterferon Plus Ribavirin for Chronic Hepatitis C and HIV for Patients Receiving Antiretroviral Medication vs Not Receiving Antiretroviral Medication</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">peg interferon plus ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Health Network, Toronto</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML 18562A</other_id>
    </other_ids>
    <first_received>February 23, 2006</first_received>
    <start_date>July 2005</start_date>
    <completion_date>April 2007</completion_date>
    <last_updated>April 19, 2007</last_updated>
    <last_verified>April 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>To compare the safety and tolerability of PEG-IFN with ribavirin in HIV/HCV co-infected patients who continue HAART therapy compared to those who discontinue HAART therapy in the first 12 weeks</outcome_measure>
      <outcome_measure>To compare the sustained virological response.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00296972</url>
  </study>
  <study rank="434">
    <nct_id>NCT01497366</nct_id>
    <title>Phase 3 Study of Sofosbuvir and Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">PEG</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>527</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P7977-1231</other_id>
    </other_ids>
    <first_received>December 19, 2011</first_received>
    <start_date>December 2011</start_date>
    <completion_date>April 2013</completion_date>
    <last_updated>March 4, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>January 15, 2014</firstreceived_results_date>
    <acronym>FISSION</acronym>
    <primary_completion_date>January 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After Stopping All Study Drugs (SVR12)</outcome_measure>
      <outcome_measure>Number of Participants Who Experienced Adverse Events (AEs) and Graded Laboratory Abnormalities</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 24 Weeks After Stopping All Study Drugs (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LLOQ on Treatment</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure During Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse Following Treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Italy</country>
      <country>Netherlands</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Mississippi</state>
      <state>New Jersey</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01497366</url>
  </study>
  <study rank="435">
    <nct_id>NCT01329978</nct_id>
    <title>Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">PEG</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>332</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>P7977-0724</other_id>
    </other_ids>
    <first_received>March 30, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>August 2012</completion_date>
    <last_updated>April 24, 2014</last_updated>
    <last_verified>April 2014</last_verified>
    <firstreceived_results_date>January 6, 2014</firstreceived_results_date>
    <acronym>ATOMIC</acronym>
    <primary_completion_date>August 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 24 Weeks Following Completion of Treatment (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Experienced Adverse Events</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks Following Completion of Treatment (SVR12)</outcome_measure>
      <outcome_measure>Change in HCV RNA at Week 2</outcome_measure>
      <outcome_measure>Change in HCV RNA at Week 4</outcome_measure>
      <outcome_measure>Change in HCV RNA at Week 8</outcome_measure>
      <outcome_measure>Change in HCV RNA at Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA &lt; LOD at Week 2</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA Below &lt; LOD at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA Below &lt; LOD at Week 8</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA Below &lt; LOD at Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With HCV RNA Below &lt; LOD at Week 24</outcome_measure>
      <outcome_measure>Percentage of Participants With ALT Normalization at Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With ALT Normalization at Week 24</outcome_measure>
      <outcome_measure>Percentage of Participants With ALT Normalization at Post-treatment Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure During Treatment</outcome_measure>
      <outcome_measure>Percentage of Participants With Virologic Failure Following Treatment (Viral Relapse).</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arkansas</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New Mexico</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>South Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01329978</url>
  </study>
  <study rank="436">
    <nct_id>NCT01054729</nct_id>
    <title>Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment NaÃ¯ve GT 1 HCV Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">PEG</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>64</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>P7977-0221</other_id>
    </other_ids>
    <first_received>January 21, 2010</first_received>
    <start_date>January 2010</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>March 31, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>January 6, 2014</firstreceived_results_date>
    <primary_completion_date>April 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Who Experienced Adverse Events During the Sofosbuvir Treatment Period</outcome_measure>
      <outcome_measure>Change in Circulating HCV RNA at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) at 12 and 24 Weeks After Last Dose of PEG+RBV Following Completion of 48 Weeks of Treatment</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of Sofosbuvir: Cmax at Day 0</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of Sofosbuvir: Cmax at Day 27</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of Sofosbuvir: AUCinf at Day 0</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of Sofosbuvir: AUCtau at Day 27</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007: Cmax at Day 0</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007: Cmax at Day 27</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007: AUCinf at Day 0</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-331007: AUCtau at Day 27</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-566500: Cmax at Day 0</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-566500: Cmax at Day 27</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-566500: AUCinf at Day 0</outcome_measure>
      <outcome_measure>Plasma Pharmacokinetics of GS-566500: AUCtau at Day 27</outcome_measure>
      <outcome_measure>Percentage of Participants Who Developed Resistance to Sofosbuvir</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01054729</url>
  </study>
  <study rank="437">
    <nct_id>NCT00132210</nct_id>
    <title>Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Bonn</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>BN-102/02</other_id>
    </other_ids>
    <first_received>August 17, 2005</first_received>
    <start_date>September 2002</start_date>
    <completion_date>June 2010</completion_date>
    <last_updated>October 20, 2010</last_updated>
    <last_verified>November 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Negative hepatitis C ribonucleic acid (HCV-RNA) in peripheral serum</outcome_measure>
      <outcome_measure>Normal liver enzymes</outcome_measure>
      <outcome_measure>Negative HCV-RNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00132210</url>
  </study>
  <study rank="438">
    <nct_id>NCT01137383</nct_id>
    <title>Pegaferon and Ribavirin for Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegaferon (pegylated interferon alpha 2a) + ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Tehran University of Medical Sciences</lead_sponsor>
      <collaborator>Pars No Tarkib Co</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>108</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>DDRC.86.90</other_id>
    </other_ids>
    <first_received>June 3, 2010</first_received>
    <start_date>December 2007</start_date>
    <completion_date>February 2010</completion_date>
    <last_updated>June 28, 2010</last_updated>
    <last_verified>June 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained viral response</outcome_measure>
      <outcome_measure>Adverse drug events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Iran, Islamic Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01137383</url>
  </study>
  <study rank="439">
    <nct_id>NCT00039962</nct_id>
    <title>Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">thymalfasin (thymosin alpha 1)</intervention>
      <intervention type="Drug">PEGinterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>SciClone Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>Ta1-CHC-2K0804</other_id>
    </other_ids>
    <first_received>June 17, 2002</first_received>
    <start_date>May 2002</start_date>
    <last_updated>January 8, 2008</last_updated>
    <last_verified>January 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Idaho</state>
      <state>Illinois</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>South Carolina</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00039962</url>
  </study>
  <study rank="440">
    <nct_id>NCT01599130</nct_id>
    <title>Efficacy of Peg-interferon Î±-2a in Hepatitis B Patients Treated by Entecavir Without HBeAg Loss</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Entecavir</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Sun Yat-sen University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Zhangyufeng</other_id>
    </other_ids>
    <first_received>May 8, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>May 14, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HBeAg sericonversion rate</outcome_measure>
      <outcome_measure>HBeAg loss rate</outcome_measure>
      <outcome_measure>HBeAg quantification dynamic change</outcome_measure>
      <outcome_measure>HBsAg loss rate</outcome_measure>
      <outcome_measure>HBsAg seroconversion rate</outcome_measure>
      <outcome_measure>HBsAg quantification dynamic change</outcome_measure>
      <outcome_measure>ALT normalization rate</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01599130</url>
  </study>
  <study rank="441">
    <nct_id>NCT02480686</nct_id>
    <title>Neutrino Regimen for Treatment-experienced HCV GT1 Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF+PEG+RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Humanity &amp; Healthy GI and Liver Centre</lead_sponsor>
      <collaborator>Beijing 302 Hospital</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>H&amp;H_Neutrino Therapy</other_id>
    </other_ids>
    <first_received>June 21, 2015</first_received>
    <start_date>January 2015</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>June 22, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Proportion of participants with adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Change in HCV RNA From Baseline to Week 12</outcome_measure>
      <outcome_measure>Proportion of participants with on-treatment virologic breakthrough and relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02480686</url>
  </study>
  <study rank="442">
    <nct_id>NCT01743521</nct_id>
    <title>DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C)</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Early Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TPV/PEG-IFN/RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Kirby Institute</lead_sponsor>
      <collaborator>Janssen-Cilag Ltd.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>VHCRP1102</other_id>
      <other_id>VX-950HCP4010</other_id>
    </other_ids>
    <first_received>November 28, 2012</first_received>
    <start_date>January 2013</start_date>
    <completion_date>February 2016</completion_date>
    <last_updated>August 31, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>DARE-C</acronym>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR12</outcome_measure>
      <outcome_measure>SVR24</outcome_measure>
      <outcome_measure>Undetectable HCV RNA (ETR)</outcome_measure>
      <outcome_measure>Undetectable HCV RNA (weeks 1,2,3,4,5,6,8)</outcome_measure>
      <outcome_measure>gene IL28B polymorphism</outcome_measure>
      <outcome_measure>Baseline resistance-associated variants</outcome_measure>
      <outcome_measure>Resistance-associated variants</outcome_measure>
      <outcome_measure>Indicators of toxicity (ALT, HB, Neutrophils, Platelets)</outcome_measure>
      <outcome_measure>Plasma ribavirin levels and haemoglobin</outcome_measure>
      <outcome_measure>CD4 and HIV RNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01743521</url>
  </study>
  <study rank="443">
    <nct_id>NCT00575627</nct_id>
    <title>Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-Interferon alpha2a plus Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Turin, Italy</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>pNNALTHCV</other_id>
      <other_id>NNALT</other_id>
    </other_ids>
    <first_received>December 14, 2007</first_received>
    <start_date>September 2007</start_date>
    <completion_date>September 2010</completion_date>
    <last_updated>June 3, 2008</last_updated>
    <last_verified>June 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>To evaluate the efficacy of treatment and the outcome of treated patients compared with a control group of untreated patients.</outcome_measure>
      <outcome_measure>evaluation of liver fibrosis by Fibroscan after 48-72 weeks of inclusion</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00575627</url>
  </study>
  <study rank="444">
    <nct_id>NCT00543244</nct_id>
    <title>Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa and ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>National Science Council, Taiwan</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>200709053R</other_id>
    </other_ids>
    <first_received>October 10, 2007</first_received>
    <start_date>January 2006</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>November 20, 2008</last_updated>
    <last_verified>February 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Israel</country>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00543244</url>
  </study>
  <study rank="445">
    <nct_id>NCT00887081</nct_id>
    <title>Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hemoglobinopathies</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Azienda Ospedaliera V. Cervello</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AOVCervello1</other_id>
    </other_ids>
    <first_received>April 21, 2009</first_received>
    <start_date>January 2009</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>April 22, 2009</last_updated>
    <last_verified>April 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>IFNRIBAHE</acronym>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>A sustained virological response (SVR), defined as absence of HCV RNA in serum by a highly sensitive test at the end of treatment and 6 months late.</outcome_measure>
      <outcome_measure>Early virological response (EVR) , defined as the loss of HCV RNA during the first 12 weeks of therapy; main side effects enclosing changes in blood transfusion requirement; increase in ferritin levels and variations in chelation treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00887081</url>
  </study>
  <study rank="446">
    <nct_id>NCT02615639</nct_id>
    <title>A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in CHB</title>
    <recruitment open="Y">Not yet recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">HPDC-T cells &amp; Entecavir</intervention>
      <intervention type="Drug">Entecavir</intervention>
      <intervention type="Drug">HPDC-T cells &amp; IFN-a-2a</intervention>
      <intervention type="Drug">IFN-a-2a</intervention>
      <intervention type="Drug">HPDC-T cells &amp; Telbivudine</intervention>
      <intervention type="Drug">Telbivudine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Third Affiliated Hospital, Sun Yat-Sen University</lead_sponsor>
      <collaborator>Shanghai Jiao Tong University School of Medicine</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>450</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>SunYatSenIDD</other_id>
    </other_ids>
    <first_received>November 12, 2015</first_received>
    <start_date>November 2015</start_date>
    <completion_date>November 2018</completion_date>
    <last_updated>November 24, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>CTHBVACADCHB</acronym>
    <primary_completion_date>November 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Hepatitis B surface Antigen ï¼HBeAgï¼seroconversion</outcome_measure>
      <outcome_measure>Number of participants with treatment-related adverse events as assessed by low-grade fever, Infection and shock.</outcome_measure>
      <outcome_measure>Hepatitis B envelope Antigen ï¼HBeAgï¼ seroconversion</outcome_measure>
      <outcome_measure>HBV DNA clearance</outcome_measure>
      <outcome_measure>ALT recovery</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02615639</url>
  </study>
  <study rank="447">
    <nct_id>NCT00606086</nct_id>
    <title>Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Genotype 1 Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GI-5005</intervention>
      <intervention type="Drug">Pegylated Interferon and Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlobeImmune</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>140</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GI-5005-02</other_id>
    </other_ids>
    <first_received>January 18, 2008</first_received>
    <start_date>December 2007</start_date>
    <completion_date>November 2012</completion_date>
    <last_updated>June 17, 2014</last_updated>
    <last_verified>May 2014</last_verified>
    <firstreceived_results_date>May 5, 2014</firstreceived_results_date>
    <primary_completion_date>November 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>EVR (Early Virologic Response)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00606086</url>
  </study>
  <study rank="448">
    <nct_id>NCT01724086</nct_id>
    <title>A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC647055</intervention>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Ritonavir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated interferon alpha-2a (PegIFN)</intervention>
      <intervention type="Drug">GSK2336805</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100882</other_id>
      <other_id>TMC647055HPC2001</other_id>
      <other_id>2012-002555-42</other_id>
    </other_ids>
    <first_received>September 26, 2012</first_received>
    <start_date>October 2012</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>January 23, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients with a sustained virologic response (SVR) 12 Weeks after the actual end of treatment</outcome_measure>
      <outcome_measure>Number of patients with adverse events</outcome_measure>
      <outcome_measure>Number of patients with a sustained virological response (SVR at 4 and/or 24 Weeks after the actual end of treatment)</outcome_measure>
      <outcome_measure>HCV RNA levels over time</outcome_measure>
      <outcome_measure>Number of patients with undetectable hepatitis C virus (HCV) RNA (less than 25 IU/mL undetectable) and/or HCV RNA levels less than 25 IU/mL at all time points</outcome_measure>
      <outcome_measure>Number of patients with on-treatment virologic failure</outcome_measure>
      <outcome_measure>Number of patients with viral relapse</outcome_measure>
      <outcome_measure>Number of patients with presence of HCV variants associated with reduced susceptibility to investigational treatment</outcome_measure>
      <outcome_measure>Maximum plasma analyte concentration of TMC435</outcome_measure>
      <outcome_measure>Minimum plasma analyte concentration of TMC435</outcome_measure>
      <outcome_measure>Area under the plasma concentration-time curve of TMC435</outcome_measure>
      <outcome_measure>Maximum plasma analyte concentration of TMC647055</outcome_measure>
      <outcome_measure>Minimum plasma analyte concentration of TMC647055</outcome_measure>
      <outcome_measure>Area under the plasma concentration-time curve of TMC647055</outcome_measure>
      <outcome_measure>Maximum plasma analyte concentration of ritonavir (RTV)</outcome_measure>
      <outcome_measure>Minimum plasma analyte concentration of RTV</outcome_measure>
      <outcome_measure>Area under the plasma concentration-time curve of RTV</outcome_measure>
      <outcome_measure>Minimum and maximum plasma concentrations of GSK233680k</outcome_measure>
      <outcome_measure>Area under the plasma concentration-time curve of GSK233680k</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Belgium</country>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01724086</url>
  </study>
  <study rank="449">
    <nct_id>NCT00996216</nct_id>
    <title>Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Eltrombopag</intervention>
      <intervention type="Drug">Antiviral therapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>27</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>108392</other_id>
    </other_ids>
    <first_received>October 1, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>February 2013</completion_date>
    <last_updated>October 10, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>October 10, 2013</firstreceived_results_date>
    <acronym>ENABLE-ALL</acronym>
    <primary_completion_date>February 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) in Part 1</outcome_measure>
      <outcome_measure>Number of Participants With Any AE and Any SAE in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Worst-case Division of Acquired Immune Deficiency Syndrome (DAIDS) Grade Increases From Screening for the Indicated Clinical Chemistry Parameters During Part 1</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Worst-case DAIDS Grade Increases From the Antiviral Baseline Visit for the Indicated Clinical Chemistry Parameter During Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Worst-case DAIDS Grade Increases From Screening for the Indicated Hematology Parameters During Part 1</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Worst-case DAIDS Grade Increases From the Antiviral Baseline Visit for the Indicated Hematology Parameters During Part 2</outcome_measure>
      <outcome_measure>Number of Participants With a Decrease in Visual Acuity During Parts 1 and 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Change in logMAR Scale Values During Parts 1 and 2</outcome_measure>
      <outcome_measure>Number of Participants With a logMAR Change &gt;=0.15 During Parts 1 and 2</outcome_measure>
      <outcome_measure>Platelet Counts at the Indicated Time Points</outcome_measure>
      <outcome_measure>Number of Particpants Who Initiated Antiviral Therapy</outcome_measure>
      <outcome_measure>Number of Participants Achieving Antiviral Treatment Milestones of Sustained Virological Response (SVR), Rapid Virological Response (RVR), Early Virological Response (EVR), and End of Treatment Response (ETR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>Italy</country>
      <country>Pakistan</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Connecticut</state>
      <state>Hawaii</state>
      <state>New York</state>
      <state>Tennessee</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00996216</url>
  </study>
  <study rank="450">
    <nct_id>NCT00166296</nct_id>
    <title>Efficacy and Safety of Escitalopram for Prevention of Depression Induced by Peg-Interferon in Hepatitis C Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Major Depressive Disorder.</condition>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Escitalopram</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Germans Trias i Pujol Hospital</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
      <collaborator>H. Lundbeck A/S</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>133</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>PSQHEPGTP1</other_id>
      <other_id>EudraCT number: 2004-002982-19</other_id>
    </other_ids>
    <first_received>September 9, 2005</first_received>
    <start_date>March 2005</start_date>
    <completion_date>October 2007</completion_date>
    <last_updated>March 4, 2011</last_updated>
    <last_verified>March 2011</last_verified>
    <firstreceived_results_date>February 8, 2011</firstreceived_results_date>
    <primary_completion_date>October 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Who Developed a Major Depressive Episode According to Diagnostic &amp; Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) Criteria During the First 12 Weeks of Antiviral Treatment.</outcome_measure>
      <outcome_measure>Number of Participants With Sustained Hepatitis C Viral Response (Negativization of Serum Hepatitis C Virus Ribonucleic Acid).</outcome_measure>
      <outcome_measure>Total Score in the Montgomery-Asberg Depression Rating Scale</outcome_measure>
      <outcome_measure>Total Score in the Depression Subscale of the Hospital Anxiety and Depression Scale.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00166296</url>
  </study>
  <study rank="451">
    <nct_id>NCT01901198</nct_id>
    <title>Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase I Study in Chinese Healthy Volunteers</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy Volunteers</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C.</intervention>
      <intervention type="Biological">Peginterferon 180 mcg single dose S.C.</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Beijing Bio-Fortune Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>34</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>921301</other_id>
    </other_ids>
    <first_received>April 9, 2013</first_received>
    <start_date>April 2013</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>November 14, 2014</last_updated>
    <last_verified>November 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of participants with adverse events after single dose</outcome_measure>
      <outcome_measure>Plasma concentration of interferon after single dose</outcome_measure>
      <outcome_measure>Plasma concentration of Neopterin after single dose</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01901198</url>
  </study>
  <study rank="452">
    <nct_id>NCT02113631</nct_id>
    <title>Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C,</condition>
      <condition>Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">Boceprevir</intervention>
      <intervention type="Drug">Peg-IFN</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Louis Stokes VA Medical Center</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB #: 11064-H40</other_id>
    </other_ids>
    <first_received>March 30, 2014</first_received>
    <start_date>September 2011</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>April 10, 2014</last_updated>
    <last_verified>September 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Safety/Adverse Event Outcome Measure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Ohio</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02113631</url>
  </study>
  <study rank="453">
    <nct_id>NCT00560274</nct_id>
    <title>A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Anemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegasys</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">epoetin beta [NeoRecormon]</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>190</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML21362</other_id>
    </other_ids>
    <first_received>November 16, 2007</first_received>
    <start_date>March 2008</start_date>
    <completion_date>November 2011</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>November 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Blood pressure, pulse rate.</outcome_measure>
      <outcome_measure>AEs, and laboratory parameters.</outcome_measure>
      <outcome_measure>Percentage of patients achieving correction of anemia</outcome_measure>
      <outcome_measure>Percentage of patients not requiring blood transfusion</outcome_measure>
      <outcome_measure>Course of Hb concentration</outcome_measure>
      <outcome_measure>Percentage of patients maintaining initial ribavirin dose</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00560274</url>
  </study>
  <study rank="454">
    <nct_id>NCT01850745</nct_id>
    <title>Multidisciplinary Support Program in Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Multidisciplinary support program</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Parc de Salut Mar</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>447</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
    </study_designs>
    <other_ids>
      <other_id>HMAR-MSP-CHC</other_id>
    </other_ids>
    <first_received>May 7, 2013</first_received>
    <start_date>January 2003</start_date>
    <completion_date>January 2010</completion_date>
    <last_updated>May 7, 2013</last_updated>
    <last_verified>May 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Adherence to treatment</outcome_measure>
      <outcome_measure>Efficacy of treatment measured by sustained virological response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01850745</url>
  </study>
  <study rank="455">
    <nct_id>NCT01500772</nct_id>
    <title>Alisporivir With pegIFN/RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Alisporivir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>6</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CDEB025A2306</other_id>
      <other_id>2011-004653-31</other_id>
    </other_ids>
    <first_received>December 23, 2011</first_received>
    <start_date>February 2012</start_date>
    <last_updated>May 4, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>SVR12</outcome_measure>
      <outcome_measure>SVR24</outcome_measure>
      <outcome_measure>SVR12LOD</outcome_measure>
      <outcome_measure>Overall safety profile</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>France</country>
      <country>Germany</country>
      <country>Italy</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>Ohio</state>
      <state>Rhode Island</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01500772</url>
  </study>
  <study rank="456">
    <nct_id>NCT02063607</nct_id>
    <title>The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Peginterferon lambda</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Nanogen Pharmaceutical Biotechnology Co., Ltd</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NNG01</other_id>
    </other_ids>
    <first_received>February 11, 2014</first_received>
    <start_date>December 2013</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>February 13, 2014</last_updated>
    <last_verified>February 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Area Under the Concentration-Time Curve (AUC 0-336)</outcome_measure>
      <outcome_measure>Percentage of Patients achieving Rapid Virological Response (RVR)</outcome_measure>
      <outcome_measure>Number of subjects with incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Vietnam</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02063607</url>
  </study>
  <study rank="457">
    <nct_id>NCT00375895</nct_id>
    <title>Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Evidence of Liver Transplantation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ciclosporin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Rennes University Hospital</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>EudraCT 2006-002714-35</other_id>
      <other_id>LOC/06-05</other_id>
      <other_id>CIC0203/058</other_id>
    </other_ids>
    <first_received>September 12, 2006</first_received>
    <start_date>June 2006</start_date>
    <completion_date>December 2009</completion_date>
    <last_updated>March 1, 2012</last_updated>
    <last_verified>March 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Prolonged virological response</outcome_measure>
      <outcome_measure>Virological response 4, 7 and 13 months after the initiation of cyclosporin treatment</outcome_measure>
      <outcome_measure>Histological response: METAVIR score at 19 months</outcome_measure>
      <outcome_measure>Biological response: liver function at 4, 7, 13 and 19 months</outcome_measure>
      <outcome_measure>Incidence of acute or chronic graft rejection at 19 months</outcome_measure>
      <outcome_measure>Incidence of death, graft loss and retransplantation at 13 and 19 months</outcome_measure>
      <outcome_measure>Renal function at 4, 7, 13 and 19 months</outcome_measure>
      <outcome_measure>Incidence of treatment discontinuation at 4, 7, 13 and 19 months</outcome_measure>
      <outcome_measure>Incidence of adverse events (cancers in particular).</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00375895</url>
  </study>
  <study rank="458">
    <nct_id>NCT01185028</nct_id>
    <title>A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
      <condition>HIV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitazoxanide With Pegylated Interferon And Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institutes of Health Clinical Center (CC)</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>8</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>100183</other_id>
      <other_id>10-CC-0183</other_id>
    </other_ids>
    <first_received>August 18, 2010</first_received>
    <start_date>August 2010</start_date>
    <completion_date>October 2011</completion_date>
    <last_updated>May 16, 2013</last_updated>
    <last_verified>May 2013</last_verified>
    <firstreceived_results_date>March 21, 2013</firstreceived_results_date>
    <primary_completion_date>October 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Adverse Events</outcome_measure>
      <outcome_measure>Sustained Viral Response Rate</outcome_measure>
      <outcome_measure>Tolerability</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>District of Columbia</state>
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01185028</url>
  </study>
  <study rank="459">
    <nct_id>NCT02218164</nct_id>
    <title>Pegylated Interferon Alpha-2b and Capecitabine in Unresectable/Metastatic Cutaneous Squamous Cell</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Squamous Cell Carcinoma of Skin</condition>
      <condition>Carcinoma, Squamous Cell</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated Interferon alpha-2b</intervention>
      <intervention type="Drug">Capecitabine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>H. Lee Moffitt Cancer Center and Research Institute</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>MCC-17759</other_id>
    </other_ids>
    <first_received>August 14, 2014</first_received>
    <start_date>August 2014</start_date>
    <completion_date>September 2017</completion_date>
    <last_updated>August 5, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Objective Response Rate (ORR)</outcome_measure>
      <outcome_measure>Progression Free Survival (PFS)</outcome_measure>
      <outcome_measure>Overall Survival (OS)</outcome_measure>
      <outcome_measure>Occurence of Treatment Related Serious Adverse Events (SAEs)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Florida</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02218164</url>
  </study>
  <study rank="460">
    <nct_id>NCT01938781</nct_id>
    <title>Optimized Treatment and Regression of HBV-induced Liver Fibrosis</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Liver Fibrosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">entecavir</intervention>
      <intervention type="Drug">Peg-IFN</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Beijing Friendship Hospital</lead_sponsor>
      <collaborator>Peking University People's Hospital</collaborator>
      <collaborator>RenJi Hospital</collaborator>
      <collaborator>Peking University</collaborator>
      <collaborator>Shanghai Zhongshan Hospital</collaborator>
      <collaborator>Shanghai First People's Hospital</collaborator>
      <collaborator>Shanghai Public Health Clinical Center</collaborator>
      <collaborator>Nanfang Hospital of Southern Medical University</collaborator>
      <collaborator>Sir Run Run Shaw Hospital</collaborator>
      <collaborator>Beijing YouAn Hospital</collaborator>
      <collaborator>Peking University First Hospital</collaborator>
      <collaborator>Beijing 302 Hospital</collaborator>
      <collaborator>Peking Union Medical College Hospital</collaborator>
      <collaborator>Beijing Ditan Hospital</collaborator>
      <collaborator>Beijing Tiantan Hospital</collaborator>
      <collaborator>Huashan Hospital</collaborator>
      <collaborator>Tongji Hospital</collaborator>
      <collaborator>Tang-Du Hospital</collaborator>
      <collaborator>Fifth Hospital of Shijiazhuang City</collaborator>
      <collaborator>Logistics University of Chinese People's Armed Police Forces</collaborator>
      <collaborator>The First Affiliated Hospital of Shanxi Medical University</collaborator>
      <collaborator>The Affiliated Hospital of Yanbian University</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>2013ZX10002004-1</other_id>
    </other_ids>
    <first_received>September 5, 2013</first_received>
    <start_date>June 2013</start_date>
    <completion_date>December 2018</completion_date>
    <last_updated>July 27, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Regression Rate of HBV-induced Liver Fibrosis</outcome_measure>
      <outcome_measure>HBVDNA undetectable rate</outcome_measure>
      <outcome_measure>Fibroscan scores</outcome_measure>
      <outcome_measure>Life Quality</outcome_measure>
      <outcome_measure>Incidence of drug resistance</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01938781</url>
  </study>
  <study rank="461">
    <nct_id>NCT01726400</nct_id>
    <title>In Hepatitis C Patients Treated With Interferon and Ribavirin, Does Hepcidin Contribute to Treatment Induced Anaemia</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alpha</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Fremantle Hospital and Health Service</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>HEPCIDIN-11/225</other_id>
    </other_ids>
    <first_received>November 9, 2012</first_received>
    <start_date>December 2012</start_date>
    <completion_date>July 2014</completion_date>
    <last_updated>November 9, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Hepcidin levels</outcome_measure>
      <outcome_measure>iron metabolism markers</outcome_measure>
      <outcome_measure>heamolysis markers</outcome_measure>
      <outcome_measure>inosine triphosphatase genetic variants</outcome_measure>
      <outcome_measure>erythropoiesis markers</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Australia</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01726400</url>
  </study>
  <study rank="462">
    <nct_id>NCT01589952</nct_id>
    <title>Pegylated Interferon and Entecavir Combination in Chronic Hepatitis B (CHB)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegalyted interferon, Entecavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>BB1</other_id>
    </other_ids>
    <first_received>May 1, 2012</first_received>
    <start_date>March 2012</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>May 1, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Bangabandhu</acronym>
    <primary_completion_date>February 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Combination of half dose and reduced duration pegalyted interferon in combination with entecavir achieves biochemical and virologic response in chronic hepatitis B</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Bangladesh</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01589952</url>
  </study>
  <study rank="463">
    <nct_id>NCT01374308</nct_id>
    <title>NASVAC Phase-III Trial in Chronic Hepatitis B (CHB) Patients</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">NASVAC</intervention>
      <intervention type="Drug">Pegylated interferon alpha 2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Clinical Research Organization, Dhaka, Bangladesh</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>160</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NASVAC01</other_id>
    </other_ids>
    <first_received>June 12, 2011</first_received>
    <start_date>June 2011</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>December 11, 2012</last_updated>
    <last_verified>December 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>NASVAC</acronym>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of study participants with virological and or biochemical response as a measure of efficacy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Bangladesh</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01374308</url>
  </study>
  <study rank="464">
    <nct_id>NCT01273064</nct_id>
    <title>Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CTS-1027</intervention>
      <intervention type="Drug">pegylated interferon</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Conatus Pharmaceuticals Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>114</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CTS-1027-05</other_id>
    </other_ids>
    <first_received>December 21, 2010</first_received>
    <start_date>January 2011</start_date>
    <completion_date>October 2011</completion_date>
    <last_updated>June 4, 2012</last_updated>
    <last_verified>June 2012</last_verified>
    <firstreceived_results_date>March 29, 2012</firstreceived_results_date>
    <primary_completion_date>September 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Virologic Response</outcome_measure>
      <outcome_measure>Greater Than 2 Log Decline in HCV-RNA at Study Weeks 12, 24 and 48</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Kansas</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01273064</url>
  </study>
  <study rank="465">
    <nct_id>NCT01204762</nct_id>
    <title>Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegIFN</intervention>
      <intervention type="Drug">pegIFNÎ±-2a</intervention>
      <intervention type="Drug">PegIFN lambda</intervention>
      <intervention type="Drug">Entecavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>197</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI452-005</other_id>
      <other_id>2010-020387-38</other_id>
    </other_ids>
    <first_received>September 16, 2010</first_received>
    <start_date>November 2010</start_date>
    <completion_date>December 2013</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>LIRA-B</acronym>
    <primary_completion_date>December 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Part A: Proportion of subjects who achieve Hepatitis B e antigen (HBeAg) seroconversion</outcome_measure>
      <outcome_measure>Part A: Number and percent of subjects with serious adverse events (SAEs) and discontinuations due to adverse events</outcome_measure>
      <outcome_measure>Part B: Safety and tolerability of Lambda/ETV regimen as measured by the frequency of SAEs and discontinuations due to AEs</outcome_measure>
      <outcome_measure>Part A: Proportion of subjects who achieve an hepatitis B virus Deoxyribonucleic acid levels (HBV DNA) &lt; 50 IU/mL (approximately 300 copies/mL) using the Roche COBASÂ® TaqMan - High Pure System (HPS) assay</outcome_measure>
      <outcome_measure>Part A: Mean change from baseline in log10 HBV DNA levels over time (Proportion of subjects with Alanine amino transferase (ALT) normalization (â¤ 1 x upper limit of normal (ULN))</outcome_measure>
      <outcome_measure>Part A: Proportion of subjects with ALT normalization (â¤ 1 x ULN)</outcome_measure>
      <outcome_measure>Part A: Hepatitis E antigen (HBeAg) loss</outcome_measure>
      <outcome_measure>Part A: HBeAg seroconversion</outcome_measure>
      <outcome_measure>Part A: Mean change from baseline in log10 quantitative HBeAg levels over time</outcome_measure>
      <outcome_measure>Part A: Number and percent of subjects with adverse events (AEs) or laboratory abnormalities</outcome_measure>
      <outcome_measure>Part A: Pharmacokinetic (PK) parameter Maximum observed concentration (Cmax) of Pegylated interferon lambda (pegIFNÎ») will be derived from serum concentration versus time data</outcome_measure>
      <outcome_measure>Part A: Pharmacokinetic (PK) parameter Time of maximum observed concentration (Tmax) of Pegylated interferon lambda (pegIFNÎ») will be derived from serum concentration versus time data</outcome_measure>
      <outcome_measure>Part A: Pharmacokinetic (PK) parameter Trough serum concentration pre-dose (C0) of Pegylated interferon lambda (pegIFNÎ») will be derived from serum concentration versus time data</outcome_measure>
      <outcome_measure>Part A: PK parameter serum concentration 168 hours post observed dose [Cmin] (C0 will be used as an estimate of Cmin if sample is not collected) of pegIFNÎ» will be derived from serum concentration versus time data</outcome_measure>
      <outcome_measure>Part A: PK parameter Area under the concentration-time curve in 1 dosing interval from time 0 to 168 hours post observed dose [AUC(TAU)] of pegIFNÎ» will be derived from serum concentration versus time data</outcome_measure>
      <outcome_measure>Part A: PK parameter Accumulation index (AI) ratio of AUC(TAU) at steady-state to AUC(TAU) after the first dose (only conducted if data warrant) of pegIFNÎ» will be derived from serum concentration versus time data</outcome_measure>
      <outcome_measure>Part B: HBeAg seroconversion rate at 24 weeks off treatment</outcome_measure>
      <outcome_measure>Part B: Antiviral activity of Lambda/ETV regimen, as determined by the proportion of subjects who achieve an HBV DNA &lt; 50 IU/mL (approximately 300 copies/mL) using the Roche COBASÂ® TaqMan - HPS assay</outcome_measure>
      <outcome_measure>Part B: Mean change from baseline in HBV DNA over time in subjects treated with Lambda/ETV</outcome_measure>
      <outcome_measure>Part B: HBeAg loss and seroconversion in subjects treated with Lambda/ETV regimen</outcome_measure>
      <outcome_measure>Part B: HBeAg levels over time in subjects treated with Lambda/ETV regimen</outcome_measure>
      <outcome_measure>Part B: biochemical response rates in subjects treated with Lambda/ETV regimen</outcome_measure>
      <outcome_measure>Part B: Pharmacokinetic (PK) parameter Maximum observed concentration (Cmax) of Lambda/ETV regimen will be derived from serum concentration versus time data</outcome_measure>
      <outcome_measure>Part B: Pharmacokinetic (PK) parameter Time of maximum observed concentration (Tmax) of Lambda/ETV regimen will be derived from serum concentration versus time data</outcome_measure>
      <outcome_measure>Part B: Pharmacokinetic (PK) parameter Trough serum concentration pre-dose (C0) of Lambda/ETV regimen will be derived from serum concentration versus time data</outcome_measure>
      <outcome_measure>Part B: PK parameter Area under the concentration-time curve in 1 dosing interval from time 0 to 168 hours post observed dose [AUC(TAU)] of Lambda/ETV regimen will be derived from serum concentration versus time data</outcome_measure>
      <outcome_measure>Part B: PK parameter serum concentration 168 hours post observed dose [Cmin] (C0 will be used as an estimate of Cmin if sample is not collected) of Lambda/ETV regimen will be derived from serum concentration versus time data</outcome_measure>
      <outcome_measure>Part B: PK parameter Accumulation index (AI) ratio of AUC(TAU) at steady-state to AUC(TAU) after the first dose (only conducted if data warrant) of Lambda/ETV regimen will be derived from serum concentration versus time data</outcome_measure>
      <outcome_measure>Part B: Rate of resistance to ETV during treatment with the Lambda/ETV regimen</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Hong Kong</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>Netherlands</country>
      <country>Singapore</country>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Connecticut</state>
      <state>Georgia</state>
      <state>Maryland</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01204762</url>
  </study>
  <study rank="466">
    <nct_id>NCT01051921</nct_id>
    <title>Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CTS-1027</intervention>
      <intervention type="Drug">Pegylated interferon</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Conatus Pharmaceuticals Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>67</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CTS-1027-04</other_id>
    </other_ids>
    <first_received>January 18, 2010</first_received>
    <start_date>January 2010</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>April 10, 2012</last_updated>
    <last_verified>April 2012</last_verified>
    <firstreceived_results_date>March 13, 2012</firstreceived_results_date>
    <acronym>CTS-1027-04</acronym>
    <primary_completion_date>November 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Early Virologic Response (EVR)</outcome_measure>
      <outcome_measure>&gt; 2 Log Decline in Hepatitis C Virus Ribonucleic Acid (HCV-RNA) at 24 Weeks</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Georgia</state>
      <state>Louisiana</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>Ohio</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01051921</url>
  </study>
  <study rank="467">
    <nct_id>NCT00747539</nct_id>
    <title>Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV</condition>
      <condition>Hepatitis C</condition>
      <condition>Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
      <collaborator>National Institute of Mental Health (NIMH)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>330</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>R01MH083553</other_id>
      <other_id>DAHBR 9A-ASNM</other_id>
    </other_ids>
    <first_received>September 4, 2008</first_received>
    <start_date>September 2008</start_date>
    <completion_date>March 2014</completion_date>
    <last_updated>December 10, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Neurobehavioral deficits as observed on neuropsychological testing in HIV/HCV-coinfected individuals before and after receiving anti-HCV treatment.</outcome_measure>
      <outcome_measure>Psychiatric symptoms</outcome_measure>
      <outcome_measure>Neuroimaging data (from a nested cohort of participants)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00747539</url>
  </study>
  <study rank="468">
    <nct_id>NCT00514111</nct_id>
    <title>Factors Associated to Success of Hepatitis C Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated-interferon, conventional-interferon, ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>UPECLIN HC FM Botucatu Unesp</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>upeclin/HC/FMB-Unesp-16</other_id>
    </other_ids>
    <first_received>August 8, 2007</first_received>
    <start_date>August 2007</start_date>
    <completion_date>December 2008</completion_date>
    <last_updated>March 19, 2009</last_updated>
    <last_verified>March 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2008</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>Brazil</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00514111</url>
  </study>
  <study rank="469">
    <nct_id>NCT00178763</nct_id>
    <title>Hyperthermia With Chemotherapy for Locally Advanced or Metastatic Pancreas Cancer</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pancreatic Neoplasms</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Heckel Infrared Radiant Heat Device</intervention>
      <intervention type="Other">cisplatin, gemcitabine, interferon-alpha</intervention>
      <intervention type="Other">thermochemotherapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>The University of Texas Health Science Center, Houston</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HSC-MS-02-117</other_id>
    </other_ids>
    <first_received>September 13, 2005</first_received>
    <start_date>September 2003</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>March 2, 2011</last_updated>
    <last_verified>March 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>FR-WB-TT</acronym>
    <primary_completion_date>June 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Tumor response, disease-free survival</outcome_measure>
      <outcome_measure>Allow inoperable pancreatic cancer to be converted to operable disease</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00178763</url>
  </study>
  <study rank="470">
    <nct_id>NCT00047879</nct_id>
    <title>Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Glioma</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PEG-interferon alfa-2b</intervention>
      <intervention type="Drug">Thalidomide</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Cancer Institute (NCI)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>7</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>030002</other_id>
      <other_id>03-C-0002</other_id>
    </other_ids>
    <first_received>June 19, 2006</first_received>
    <start_date>October 2002</start_date>
    <completion_date>June 2009</completion_date>
    <last_updated>September 19, 2011</last_updated>
    <last_verified>September 2011</last_verified>
    <firstreceived_results_date>May 24, 2011</firstreceived_results_date>
    <primary_completion_date>June 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Progression-free Survival</outcome_measure>
      <outcome_measure>Number of Participants With Complete or Partial Response</outcome_measure>
      <outcome_measure>The Number of Participants With Adverse Events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00047879</url>
  </study>
  <study rank="471">
    <nct_id>NCT01826981</nct_id>
    <title>Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Subjects With Chronic Genotype 1, 2, 3, or 6 HCV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LDV/SOF FDC</intervention>
      <intervention type="Drug">SOF</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">PEG</intervention>
      <intervention type="Drug">GS-9669</intervention>
      <intervention type="Drug">GS-5816</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>362</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-337-0122</other_id>
    </other_ids>
    <first_received>April 1, 2013</first_received>
    <start_date>April 2013</start_date>
    <completion_date>May 2015</completion_date>
    <last_updated>June 3, 2015</last_updated>
    <last_verified>June 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Proportion of participants with adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with SVR through posttreatment Week 24</outcome_measure>
      <outcome_measure>Proportion of participants with on-treatment virologic failure and relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>New Zealand</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01826981</url>
  </study>
  <study rank="472">
    <nct_id>NCT00704405</nct_id>
    <title>Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vaniprevir</intervention>
      <intervention type="Drug">Pegylated Interferon (Peg-IFN)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">Placebo (PBO)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>285</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>7009-009</other_id>
      <other_id>2007_659</other_id>
    </other_ids>
    <first_received>June 23, 2008</first_received>
    <start_date>March 2009</start_date>
    <completion_date>September 2012</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>September 26, 2014</firstreceived_results_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving SVR24 Following Treatment With Vaniprevir 600 mg b.i.d.</outcome_measure>
      <outcome_measure>Number of Participants Experiencing an Adverse Event (AE)</outcome_measure>
      <outcome_measure>Number of Participants Discontinuing From Study Treatment Due to AEs</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR24 Following Treatment With Vaniprevir 300 mg b.i.d.</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving cEVR</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving SVR24 After 24 Weeks of Vaniprevir 600 mg b.i.d.</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00704405</url>
  </study>
  <study rank="473">
    <nct_id>NCT01625793</nct_id>
    <title>Inflammation, Stress &amp; Social Behavior: Using Ecological Assessments &amp; Model Systems to Enhance Relevance to Health Outcomes</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Interferon-alpha</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Arizona</lead_sponsor>
      <collaborator>Emory University</collaborator>
      <collaborator>National Center for Complementary and Integrative Health (NCCIH)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
      <study_design>Masking: Single Blind (Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>12-0166-02</other_id>
      <other_id>5R01AT007297-03</other_id>
    </other_ids>
    <first_received>June 11, 2012</first_received>
    <start_date>June 2012</start_date>
    <completion_date>July 2013</completion_date>
    <last_updated>July 18, 2013</last_updated>
    <last_verified>July 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percent time laughing</outcome_measure>
      <outcome_measure>Percent time expressing empathy for others</outcome_measure>
      <outcome_measure>Percent of time spent in substantive conversations</outcome_measure>
      <outcome_measure>Percent of time spent alone</outcome_measure>
      <outcome_measure>Cortisol concentrations in blood in response to stress test</outcome_measure>
      <outcome_measure>Interleukin (IL)-6 concentrations in the blood in response to stress test</outcome_measure>
      <outcome_measure>Diurnal plasma concentrations of interleukin-6 and tumor necrosis factor-alpha type II receptors in response to a stress test</outcome_measure>
      <outcome_measure>Diurnal plasma concentrations of inflamcortisol in response to a stress test</outcome_measure>
      <outcome_measure>Wake time after sleep onset measured by actigraphy</outcome_measure>
      <outcome_measure>Sleep latency by measured by actigraphy</outcome_measure>
      <outcome_measure>Total sleep time by actigraphy</outcome_measure>
      <outcome_measure>Sleep efficiency by actigraphy</outcome_measure>
      <outcome_measure>Structured Interview Guide for the Hamilton Depression Scale and Inventory of Depressive Symptomatology (SIGH-IDS)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>Georgia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01625793</url>
  </study>
  <study rank="474">
    <nct_id>NCT02364336</nct_id>
    <title>Mechanisms Associated With Favorable Responses to Peginterferon-Alpha Add-on Therapy Following Long-term Nucleos(t)Ide Analogue Treatment in Patients With Chronic Hepatitis B</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>150082</other_id>
      <other_id>15-DK-0082</other_id>
    </other_ids>
    <first_received>February 14, 2015</first_received>
    <start_date>February 2015</start_date>
    <completion_date>September 2017</completion_date>
    <last_updated>October 28, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change in interferon-stimulated-genes</outcome_measure>
      <outcome_measure>HBeAg and HBsAg seroconversion</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02364336</url>
  </study>
  <study rank="475">
    <nct_id>NCT01718301</nct_id>
    <title>HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV Infections</condition>
      <condition>COINFECTION</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">boceprevir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Peginterferon alfa-2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Anna Cruceta</lead_sponsor>
      <collaborator>Fundacion Clinic per a la Recerca BiomÃ©dica</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>128</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>BOC-HIV</other_id>
      <other_id>2012-003984-23</other_id>
    </other_ids>
    <first_received>October 25, 2012</first_received>
    <start_date>March 2013</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>July 8, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>BOC-HIV</acronym>
    <primary_completion_date>March 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Achievement of sustained virological response (SVR) at week 24</outcome_measure>
      <outcome_measure>Achievement of sustained virological response at weeks 2,4,8,12.</outcome_measure>
      <outcome_measure>The proportion of subjects with undetectable HCV-RNA at FW 12.</outcome_measure>
      <outcome_measure>The proportion of subjects with undetectable HCV-RNA at 72 weeks after randomization.</outcome_measure>
      <outcome_measure>Number of adverse events</outcome_measure>
      <outcome_measure>Resistance of HCV after boceprevir (BOC) containing regimen</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01718301</url>
  </study>
  <study rank="476">
    <nct_id>NCT01415141</nct_id>
    <title>Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">telaprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Vermont</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>240</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>M11-219</other_id>
    </other_ids>
    <first_received>August 1, 2011</first_received>
    <start_date>July 2011</start_date>
    <completion_date>June 2014</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virological response among subjects receiving a three drug versus two drug regimen of treatment</outcome_measure>
      <outcome_measure>Extended rapid virological response in patients receiving three drug versus two drug regimen</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Georgia</state>
      <state>Vermont</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01415141</url>
  </study>
  <study rank="477">
    <nct_id>NCT00475176</nct_id>
    <title>S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon alfa-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">S-adenosyl methionine for Chronic Liver Disease</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Pharmacodynamics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>070143</other_id>
      <other_id>07-DK-0143</other_id>
    </other_ids>
    <first_received>May 17, 2007</first_received>
    <start_date>May 2007</start_date>
    <completion_date>May 2011</completion_date>
    <last_updated>May 31, 2013</last_updated>
    <last_verified>May 2013</last_verified>
    <firstreceived_results_date>May 1, 2012</firstreceived_results_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Improvement in Viral Kinetics During the First 2 Weeks of Therapy</outcome_measure>
      <outcome_measure>2-log Decline in HCV RNA by Week 12 (Early Virological Response) and Sustained Eradication of HCV RNA (Sustained Virological Response).</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00475176</url>
  </study>
  <study rank="478">
    <nct_id>NCT01074008</nct_id>
    <title>A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HCV</condition>
      <condition>Chronic Hepatitis C Infection</condition>
      <condition>Hepatitis C Genotype 1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-450</intervention>
      <intervention type="Drug">ABT-072</intervention>
      <intervention type="Drug">ABT-333</intervention>
      <intervention type="Drug">Ritonavir</intervention>
      <intervention type="Drug">Peginterferon alpha-2a</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>74</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>M11-602</other_id>
    </other_ids>
    <first_received>February 22, 2010</first_received>
    <start_date>March 2010</start_date>
    <completion_date>January 2012</completion_date>
    <last_updated>December 29, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>December 29, 2014</firstreceived_results_date>
    <acronym>Champion2</acronym>
    <primary_completion_date>June 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Maximal Change From Baseline in Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels During ABT-450/r, ABT-333, or ABT-072 Monotherapy Treatment</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of ABT-450</outcome_measure>
      <outcome_measure>Time to Maximum Plasma Concentration (Tmax) of ABT-450</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of ABT-450</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of Ritonavir</outcome_measure>
      <outcome_measure>Time to Maximum Plasma Concentration (Tmax) of Ritonavir</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of Ritonavir</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of ABT-072</outcome_measure>
      <outcome_measure>Time to Maximum Plasma Concentration (Tmax) of ABT-072</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of ABT-072</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of ABT-333</outcome_measure>
      <outcome_measure>Time to Maximum Plasma Concentration (Tmax) of ABT-333</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 12 Hours (AUC12) Post-dose of ABT-333</outcome_measure>
      <outcome_measure>Percentage of Participants With Rapid Virologic Response (RVR) at Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants With Partial Early Virologic Response (EVR) at Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants With Complete Early Virologic Response (cEVR) at Week 12</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Washington</state>
      <state>Wisconsin</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01074008</url>
  </study>
  <study rank="479">
    <nct_id>NCT00253474</nct_id>
    <title>PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Neoplasm of Uncertain Malignant Potential</condition>
      <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">PEG-interferon alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institutes of Health Clinical Center (CC)</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>050232</other_id>
      <other_id>05-C-0232</other_id>
      <other_id>NCI-P6670</other_id>
      <other_id>CDR0000448811</other_id>
    </other_ids>
    <first_received>November 11, 2005</first_received>
    <start_date>September 2005</start_date>
    <completion_date>January 2011</completion_date>
    <last_updated>March 28, 2012</last_updated>
    <last_verified>March 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>District of Columbia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Pennsylvania</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00253474</url>
  </study>
  <study rank="480">
    <nct_id>NCT02430181</nct_id>
    <title>Lonafarnib With and Without Ritonavir in HDV (LOWR-1)</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis D Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">lonafarnib</intervention>
      <intervention type="Drug">peginterferon</intervention>
      <intervention type="Drug">Ritonavir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Eiger BioPharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>EIG-300</other_id>
      <other_id>Application #1128309</other_id>
    </other_ids>
    <first_received>April 21, 2015</first_received>
    <start_date>November 2014</start_date>
    <completion_date>November 2015</completion_date>
    <last_updated>April 25, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>LOWR-1</acronym>
    <primary_completion_date>May 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Improvement in quantitative serum HDV RNA levels after 28-84 days of lonafarnib therapy</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Turkey</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02430181</url>
  </study>
  <study rank="481">
    <nct_id>NCT01054573</nct_id>
    <title>VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telaprevir</intervention>
      <intervention type="Drug">pegylated interferon (Peg-IFN) alfa-2a</intervention>
      <intervention type="Drug">ribavirin (RBV)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen Infectious Diseases BVBA</lead_sponsor>
      <collaborator>Vertex Pharmaceuticals Incorporated</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR016678</other_id>
      <other_id>VX-TiDP24-C219</other_id>
      <other_id>2009-012613-21</other_id>
    </other_ids>
    <first_received>January 21, 2010</first_received>
    <start_date>April 2010</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>May 6, 2013</last_updated>
    <last_verified>May 2013</last_verified>
    <firstreceived_results_date>March 8, 2013</firstreceived_results_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The Percentage of Participants Achieving a Sustained Virologic Response (SVR) 24 Weeks After the Last Dose of Study Drug (SVR24 Actual)</outcome_measure>
      <outcome_measure>The Percentage of Participants Achieving Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values of Less Than 25 IU/ml, Target Not Detected at Different Time Points</outcome_measure>
      <outcome_measure>Percentage of Participants Who Met a Virologic Stopping Rule That Required Them to Permanently Discontinue Telaprevir and Continue Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) at Week 4 or Week 8</outcome_measure>
      <outcome_measure>Percentage of Participants Who Met a Virologic Stopping Rule That Required Them to Permanently Discontinue All Study Drugs at Week 12, 24, or 36</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving Extended Rapid Virologic Response (eRVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants Who Relapsed During Follow-Up</outcome_measure>
      <outcome_measure>Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values Over Time</outcome_measure>
      <outcome_measure>Change From Baseline in Log 10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Netherlands</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Indiana</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>South Carolina</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01054573</url>
  </study>
  <study rank="482">
    <nct_id>NCT01327729</nct_id>
    <title>Y- Shaped Pegylated Interferon (YPEG-IFNÎ±-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Self Efficacy</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon alpha 2a YPEG-IFN Î±-2a 180mcg</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>BioGeneric Pharma</lead_sponsor>
      <collaborator>Xiamen Amoytop Biotech Co., Ltd.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CHT00234</other_id>
    </other_ids>
    <first_received>March 31, 2011</first_received>
    <start_date>November 2010</start_date>
    <completion_date>May 2013</completion_date>
    <last_updated>April 1, 2011</last_updated>
    <last_verified>March 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>viral clearance at 72 weeks</outcome_measure>
      <outcome_measure>interferon level</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01327729</url>
  </study>
  <study rank="483">
    <nct_id>NCT01226771</nct_id>
    <title>Ribavirin Loading Dose or Priming and Concentration Targeting for HCV Genotype 1</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin &quot;loading&quot; dose given</intervention>
      <intervention type="Drug">&quot;Priming&quot; dose of ribavirin given</intervention>
      <intervention type="Drug">Group C (&quot;Standard-of-Care&quot;)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GÃ¶teborg University</lead_sponsor>
      <collaborator>The Swedish Research Council</collaborator>
      <collaborator>Roche Pharma AG</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>105</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>Eu-nr 2010-018332-41</other_id>
      <other_id>2010-018332-41</other_id>
    </other_ids>
    <first_received>October 21, 2010</first_received>
    <start_date>September 2010</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>March 23, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>RibaC</acronym>
    <primary_completion_date>September 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The early virological response as measured by decline in HCV-RNA during the first 12 weeks of peginterferon alpha-2a and ribavirin therapy in the three study arms.</outcome_measure>
      <outcome_measure>VRVR, RVR, cEVR, pEVR, SVR, and Relapse rates</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01226771</url>
  </study>
  <study rank="484">
    <nct_id>NCT01402583</nct_id>
    <title>Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PEG IFN/Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Prof. Facchinetti Fabio</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
      <collaborator>University of Modena and Reggio Emilia</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>RSO-321</other_id>
    </other_ids>
    <first_received>July 25, 2011</first_received>
    <start_date>July 2011</start_date>
    <completion_date>September 2011</completion_date>
    <last_updated>October 20, 2011</last_updated>
    <last_verified>October 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>MEN_EPID</acronym>
    <primary_completion_date>August 2011</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>Italy</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01402583</url>
  </study>
  <study rank="485">
    <nct_id>NCT01795911</nct_id>
    <title>Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated Interferon Lambda</intervention>
      <intervention type="Drug">Ribasphere</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>165</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI452-008 (Substudy Part C)</other_id>
      <other_id>2010-022568-11</other_id>
    </other_ids>
    <first_received>February 20, 2013</first_received>
    <start_date>March 2013</start_date>
    <completion_date>September 2014</completion_date>
    <last_updated>September 23, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>D-LITE</acronym>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Antiviral activity, as determined by the proportion of non-cirrhotic HCV GT-1b subjects with 12-week sustained virologic response (SVR12), defined as HCV RNA &lt; LLOQ target detected or not detected</outcome_measure>
      <outcome_measure>Proportion of non-cirrhotic HCV GT-1b subjects with eRVR, defined as HCV RNA &lt; LLOQ target not detected</outcome_measure>
      <outcome_measure>Proportion of non-cirrhotic HCV GT-1b subjects with treatment-emergent cytopenic abnormalities (anemia as defined by Hb &lt; 10 g/dL, and/or neutropenia as defined by ANC &lt; 750 mm3, and/or thrombocytopenia as defined by platelets &lt; 50,000 mm3) on treatment</outcome_measure>
      <outcome_measure>Proportion of non-cirrhotic HCV GT-1b subjects with on-treatment (maximum of 12 weeks) interferon-associated flu-like symptoms (pyrexia or chills or pain)</outcome_measure>
      <outcome_measure>Proportion of non-cirrhotic HCV GT-1b subjects with on-treatment (maximum of 12 weeks) interferon-associated musculoskeletal symptoms (arthralgia or myalgia or back pain)</outcome_measure>
      <outcome_measure>Proportion of non-cirrhotic HCV GT-1b subjects with SVR24, defined as HCV RNA &lt; LLOQ target detected or not detected</outcome_measure>
      <outcome_measure>Frequency of deaths among non-cirrhotic HCV GT-1b subjects through the end of follow-up (maximum of 60 weeks)</outcome_measure>
      <outcome_measure>Frequency of Serious adverse events (SAEs) among non-cirrhotic HCV GT-1b subjects through the end of follow-up (maximum of 60 weeks)</outcome_measure>
      <outcome_measure>Frequency of drug related Adverse events (AEs) among non-cirrhotic HCV GT-1b subjects through the end of treatment (maximum of 12 weeks)</outcome_measure>
      <outcome_measure>Frequency of dose reductions and discontinuations due to AEs among non-cirrhotic HCV GT-1b subjects through the end of treatment (maximum of 12 weeks)</outcome_measure>
      <outcome_measure>Frequency of treatment emergent laboratory abnormalities among non-cirrhotic HCV GT-1b subjects through the end of treatment (maximum of 12 weeks)</outcome_measure>
      <outcome_measure>Proportion of non-cirrhotic HCV GT-1b subjects with interferon-associated constitutional symptoms (fatigue or asthenia) through the end of treatment (maximum of 12 weeks)</outcome_measure>
      <outcome_measure>Proportion of non-cirrhotic HCV GT-1b subjects with interferon-associated neurologic symptoms (headache or dizziness) through the end of treatment (maximum of 12 weeks)</outcome_measure>
      <outcome_measure>Proportion of non-cirrhotic HCV GT-1b subjects with psychiatric symptoms (depression or irritability or insomnia) through the end of treatment (maximum of 12 weeks)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01795911</url>
  </study>
  <study rank="486">
    <nct_id>NCT02112630</nct_id>
    <title>Boceprevir in End Stage Renal Disease (ESRD)</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Infection</condition>
      <condition>End Stage Renal Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">P-IFN alfa 2a</intervention>
      <intervention type="Drug">P-IFN alfa 2b</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Boceprevir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Columbia University</lead_sponsor>
      <collaborator>Merck Sharp &amp; Dohme Corp.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AAAL5200</other_id>
    </other_ids>
    <first_received>April 2, 2014</first_received>
    <start_date>May 2013</start_date>
    <completion_date>February 2015</completion_date>
    <last_updated>September 21, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of patients who achieve sustained virologic response</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02112630</url>
  </study>
  <study rank="487">
    <nct_id>NCT01055821</nct_id>
    <title>Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pegylated interferon and ribavirin</intervention>
      <intervention type="Biological">TG4040 + SOC</intervention>
      <intervention type="Biological">TG4040 + SOC</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Transgene</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>140</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TG4040.02</other_id>
    </other_ids>
    <first_received>January 21, 2010</first_received>
    <start_date>May 2010</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>August 9, 2013</last_updated>
    <last_verified>August 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>HCVac</acronym>
    <primary_completion_date>October 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>complete early virologic response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01055821</url>
  </study>
  <study rank="488">
    <nct_id>NCT00199719</nct_id>
    <title>Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C. CINAM</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Limoges</lead_sponsor>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>I02022</other_id>
    </other_ids>
    <first_received>September 14, 2005</first_received>
    <start_date>June 2003</start_date>
    <completion_date>September 2006</completion_date>
    <last_updated>October 30, 2007</last_updated>
    <last_verified>June 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>CINAM</acronym>
    <outcome_measures>
      <outcome_measure>-Study of the complete pharmacokinetics of ribavirin at day 1, and day 84 (week 12).</outcome_measure>
      <outcome_measure>-Study of the complete pharmacokinetics of amantadin and ribavirin at week 12 + one day and at week 24</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00199719</url>
  </study>
  <study rank="489">
    <nct_id>NCT01896609</nct_id>
    <title>Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis c</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Reiferon Retard in Arm 1</intervention>
      <intervention type="Drug">Bon one in Arm 3</intervention>
      <intervention type="Drug">Xerovirinc in Arm 2</intervention>
      <intervention type="Drug">Ribavirin in Arm 1</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>MinaPharm Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>HCV05012012</other_id>
    </other_ids>
    <first_received>June 19, 2013</first_received>
    <start_date>June 2013</start_date>
    <completion_date>June 2015</completion_date>
    <last_updated>July 10, 2013</last_updated>
    <last_verified>July 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>Quadritherapy</acronym>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Early virological response</outcome_measure>
      <outcome_measure>Sustained Virological Response ( SVR )</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01896609</url>
  </study>
  <study rank="490">
    <nct_id>NCT00084279</nct_id>
    <title>CIFN and IFN Î³-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>InterMune</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>81</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AGHC-002</other_id>
    </other_ids>
    <first_received>June 9, 2004</first_received>
    <start_date>April 2004</start_date>
    <completion_date>April 2006</completion_date>
    <last_updated>July 1, 2009</last_updated>
    <last_verified>July 2009</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Virologic response defined as &gt;2 log (base 10) reduction in HCV RNA</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00084279</url>
  </study>
  <study rank="491">
    <nct_id>NCT01962441</nct_id>
    <title>Sofosbuvir+RBV for 16 or 24 Weeks and Sofosbuvir+PEG+RBV for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">PEG</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>601</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0153</other_id>
    </other_ids>
    <first_received>October 10, 2013</first_received>
    <start_date>September 2013</start_date>
    <completion_date>June 2016</completion_date>
    <last_updated>October 27, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants achieving sustained viral response 12 weeks after discontinuation of treatment (SVR12)</outcome_measure>
      <outcome_measure>Adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ during treatment</outcome_measure>
      <outcome_measure>Change from baseline in HCV RNA (log10 IU/mL)</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response (SVR) at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants experiencing viral breakthrough</outcome_measure>
      <outcome_measure>Proportion of participants experiencing viral relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>New Zealand</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Louisiana</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Minnesota</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01962441</url>
  </study>
  <study rank="492">
    <nct_id>NCT01636778</nct_id>
    <title>Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SB-497115-GR</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>116101</other_id>
    </other_ids>
    <first_received>July 5, 2012</first_received>
    <start_date>July 2012</start_date>
    <completion_date>November 2014</completion_date>
    <last_updated>September 10, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>January 22, 2015</firstreceived_results_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants Whose Platelet Count Increased From a Baseline Count of &lt; 80 Gi/L to a Count &gt;=100 Gi/L During Part 1</outcome_measure>
      <outcome_measure>Number of Participants Whose Platelet Counts Maintained at &gt;=50 Gi/L During Part 2</outcome_measure>
      <outcome_measure>Median Platelet Count at the Indicated Time Points in Part 1</outcome_measure>
      <outcome_measure>Time in Weeks to Achieve Platelet Count &gt;= 100 Gi/L</outcome_measure>
      <outcome_measure>Median Platelet Count at the Indicated Time Points in Part 2</outcome_measure>
      <outcome_measure>Median Platelet Count at the Indicated Time Points During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Minimum Platelet Count on Antiviral Therapy</outcome_measure>
      <outcome_measure>Dose of Eltrombopag That Enabled Initiation of Antiviral Therapy</outcome_measure>
      <outcome_measure>Number of Antiviral Therapy Dose Reductions in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Levels of Peg-IFN Alpha-2a Therapy Dose Reductions in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Levels of Peg-IFN Alpha-2b Therapy Dose Reductions in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Levels of RBV Therapy Dose Reductions in Part 2</outcome_measure>
      <outcome_measure>Time to First Dose Reduction of Antiviral Therapy in Part 2</outcome_measure>
      <outcome_measure>Number of Participants Who Discontinued Antiviral Therapy in Part 2</outcome_measure>
      <outcome_measure>Number of Participants Who Discontinued Peg-IFN Alpha-2a Therapy in Part 2</outcome_measure>
      <outcome_measure>Number of Participants Who Discontinued Peg-IFN Alpha-2b Therapy in Part 2</outcome_measure>
      <outcome_measure>Number of Participants Achieving Adherence to Antiviral Therapy in Part 2</outcome_measure>
      <outcome_measure>Number of Participants Achieving Adherence to Peg-IFN Alpha 2a Antiviral Therapy in Part 2</outcome_measure>
      <outcome_measure>Number of Participants Achieving Adherence to Peg-IFN Alpha-2b Antiviral Therapy in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With Sustained Virologic Response (SVR) in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With Rapid Virological Response (RVR) and Extended RVR (eRVR) in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With Early Virological Response (EVR) and Complete EVR (cEVR) in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With End of Treatment Response (ETR) for Undetectable HCV RNA at the End of Peg-IFN/RBV Treatment in Part 2</outcome_measure>
      <outcome_measure>Mean Serum HCV RNA at the Indicated Time Points In Part 2</outcome_measure>
      <outcome_measure>Mean Serum HCV RNA at the Indicated Time Points During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) in Part1</outcome_measure>
      <outcome_measure>Number of Participants With Any AE and Any SAE in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With Any AE and Any SAE During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points in Part 1 With Follow-up Period</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points in Part 2</outcome_measure>
      <outcome_measure>Mean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Heart Rate at the Indicated Time Points in Part 1 With Follow-up Period</outcome_measure>
      <outcome_measure>Mean Change From Antiviral Baseline in Heart Rate at the Indicated Time Points in Part 2</outcome_measure>
      <outcome_measure>Mean Heart Rate at the Indicated Time Points During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Weight at the Indicated Time Points in Part 1 With Follow-up Period</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Weight at the Indicated Time Points in Part 2</outcome_measure>
      <outcome_measure>Mean Weight at the Indicated Time Points During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Body Temperature at the Indicated Time Points in Part 1 With Follow-up Period</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Body Temperature at the Indicated Time Points in Part 2</outcome_measure>
      <outcome_measure>Mean Body Temperature at the Indicated Time Points During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Body Mass Index (BMI) at the Indicated Time Points in Part 1 With Follow-up Periodc</outcome_measure>
      <outcome_measure>Mean Change From Baseline in BMI at the Indicated Time Points in Part 2</outcome_measure>
      <outcome_measure>Mean BMI at the Indicated Time Points During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shift From Baseline in Severity Grades for Clinical Chemistry Parameters Per Division of Acquired Immunodeficiency Syndrome (DAIDS) in Part 1</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shift From Baseline in Severity Grades for Clinical Chemistry Parameters Per DAIDS in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shift From Baseline in Severity Grades for Clinical Chemistry Parameters Per DAIDS During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters Per DAIDS in Part 1</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters Per DAIDS in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shifts From BL in Severity Grades for Hematology Parameters Per DAIDS During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Urinalysis Parameters Tested by Dipstick at the Indicated Time Points in Part1 With Follow Up Period</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Urinalysis Parameters Tested by Dipstick at the Indicated Time Points in Part 2</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Urinalysis Parameters Tested by Dipstick at the Indicated Time Points During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Number of Participants Assessed as Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at the Indicated Time Points</outcome_measure>
      <outcome_measure>Number of Participants Assessed as Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) During Follow-up After Part 2</outcome_measure>
      <outcome_measure>Number of Participants With Abdominal Ultrasound With Doppler at the Indicated Time Points</outcome_measure>
      <outcome_measure>Number of Participants With Abdominal Ultrasound With Doppler During Follow-up Period After Part 2</outcome_measure>
      <outcome_measure>Spleen Measurements as Assessed by Abdominal Ultrasound With Doppler in the Study</outcome_measure>
      <outcome_measure>Spleen Measurements as Assessed by Abdominal Ultrasound With Doppler During Follow-up Period After Part 2</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01636778</url>
  </study>
  <study rank="493">
    <nct_id>NCT01821794</nct_id>
    <title>Tenofovir DF With or Without Peginterferon for Chronic Hepatitis B</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis B e Antigen Negative</condition>
      <condition>Chronic Hepatitis B e Antigen Positive</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon and Tenofovir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>31</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>130091</other_id>
      <other_id>13-DK-0091</other_id>
    </other_ids>
    <first_received>March 15, 2013</first_received>
    <start_date>March 2013</start_date>
    <completion_date>December 2021</completion_date>
    <last_updated>April 30, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2020</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HBsAg loss at the end of 48-weeks post-treatment follow-up (week 240)</outcome_measure>
      <outcome_measure>ALT normalization</outcome_measure>
      <outcome_measure>Cumulative HBsAg loss</outcome_measure>
      <outcome_measure>HBsAg seroconversion</outcome_measure>
      <outcome_measure>HBeAg loss</outcome_measure>
      <outcome_measure>ALT corresponding to approx 1.25XULN</outcome_measure>
      <outcome_measure>HBV DNA &amp; lt; 1000 IU/mL</outcome_measure>
      <outcome_measure>HBV DNA &amp; lt; 20 IU/m</outcome_measure>
      <outcome_measure>Absence antiviral drug-resistance HBV mu</outcome_measure>
      <outcome_measure>Sustained HBV DNA less than 1000 IU/mL</outcome_measure>
      <outcome_measure>Rate treatment discontinuation due to AE</outcome_measure>
      <outcome_measure>Rates of AE and SAE</outcome_measure>
      <outcome_measure>HBV DNA &amp; lt; 1000IU/mL &amp; amp; ALT approx 1.25XULN</outcome_measure>
      <outcome_measure>Rate of treatment failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
      <state>Minnesota</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01821794</url>
  </study>
  <study rank="494">
    <nct_id>NCT00546442</nct_id>
    <title>Treatment Insulin Resistence in HCV G-1 Patient</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Metformine</intervention>
      <intervention type="Other">Placebo of metformine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Valme University Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>126</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Single Blind (Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>2005-02446-19</other_id>
    </other_ids>
    <first_received>October 17, 2007</first_received>
    <start_date>May 2006</start_date>
    <completion_date>January 2007</completion_date>
    <last_updated>October 17, 2007</last_updated>
    <last_verified>October 2007</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>TRIC-1</acronym>
    <outcome_measures>
      <outcome_measure>Percentage of patients with HCV-RNA</outcome_measure>
      <outcome_measure>Percentage of patients who has erradicated the insulin resistance</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00546442</url>
  </study>
  <study rank="495">
    <nct_id>NCT00003542</nct_id>
    <title>Interferon Alfa in Treating Patients With Advanced Kidney Cancer</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Kidney Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">pegylated interferon alfa</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Memorial Sloan Kettering Cancer Center</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>98-052</other_id>
      <other_id>CDR0000066596</other_id>
      <other_id>ROCHE-NO15753C</other_id>
      <other_id>UCLA-9903045</other_id>
      <other_id>NCI-G98-1475</other_id>
    </other_ids>
    <first_received>November 1, 1999</first_received>
    <start_date>May 1998</start_date>
    <completion_date>April 2004</completion_date>
    <last_updated>June 24, 2013</last_updated>
    <last_verified>June 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2004</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00003542</url>
  </study>
  <study rank="496">
    <nct_id>NCT00684268</nct_id>
    <title>Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Silibinin</intervention>
      <intervention type="Drug">Silibinin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Medical University of Vienna</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>NRSili</other_id>
    </other_ids>
    <first_received>May 19, 2008</first_received>
    <start_date>October 2007</start_date>
    <completion_date>June 2011</completion_date>
    <last_updated>October 24, 2012</last_updated>
    <last_verified>October 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>NRSily</acronym>
    <primary_completion_date>February 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>viral response at week 24</outcome_measure>
      <outcome_measure>sustained virologic response</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Austria</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00684268</url>
  </study>
  <study rank="497">
    <nct_id>NCT00987337</nct_id>
    <title>Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis</condition>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Filibuvir</intervention>
      <intervention type="Drug">Filibuvir</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>288</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>A8121014</other_id>
    </other_ids>
    <first_received>September 29, 2009</first_received>
    <start_date>November 2009</start_date>
    <completion_date>January 2012</completion_date>
    <last_updated>December 10, 2013</last_updated>
    <last_verified>December 2013</last_verified>
    <firstreceived_results_date>December 10, 2013</firstreceived_results_date>
    <acronym>FITNESS</acronym>
    <primary_completion_date>January 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Viral Response (SVR) at Week 72</outcome_measure>
      <outcome_measure>Percentage of Participants With Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 4, 12, 24 and 48</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Viral Response at 12 Weeks Following Completion of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Viral Response at 24 Weeks Following Completion of Therapy (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With Breakthrough Viremia</outcome_measure>
      <outcome_measure>Percentage of Participants With Relapsed Response</outcome_measure>
      <outcome_measure>Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 4, 12 and 24</outcome_measure>
      <outcome_measure>Number of Adverse Events (AEs) by Severity (All Causality)</outcome_measure>
      <outcome_measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Relationship to Study Drug (Any Therapy)</outcome_measure>
      <outcome_measure>Number of Participants Who Discontinued Study Due to Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Number of Participants With Dose Reduction or Temporary Discontinuation Due to Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Number of Participants With Laboratory Test Abnormalities by Severity</outcome_measure>
      <outcome_measure>Plasma Concentration of Filibuvir, Pegylated Interferon and Ribavirin</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Hungary</country>
      <country>Korea, Republic of</country>
      <country>Puerto Rico</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Massachusetts</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00987337</url>
  </study>
  <study rank="498">
    <nct_id>NCT00947349</nct_id>
    <title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Pharmacokinetics</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ribavirin (RBV)</intervention>
      <intervention type="Drug">pegylated interferon (PegIFN) alfa-2a</intervention>
      <intervention type="Drug">pegylated interferon (PegIFN) alfa-2a</intervention>
      <intervention type="Drug">ribavirin (RBV)</intervention>
      <intervention type="Drug">BI 201335 NA low placebo</intervention>
      <intervention type="Drug">pegylated interferon (PegIFN) alfa-2a</intervention>
      <intervention type="Drug">ribavirin (RBV)</intervention>
      <intervention type="Drug">BI 201335 NA high</intervention>
      <intervention type="Drug">BI 201335 NA low</intervention>
      <intervention type="Drug">BI 201335 NA high placebo</intervention>
      <intervention type="Drug">BI 201335 NA high</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>22</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>1220.14</other_id>
    </other_ids>
    <first_received>July 21, 2009</first_received>
    <start_date>July 2009</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>July 3, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>January 22, 2015</firstreceived_results_date>
    <primary_completion_date>August 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Investigator Defined Drug-related Adverse Events in Triple Combination Therapy</outcome_measure>
      <outcome_measure>Number of Patients With Possible Clinically Significant Laboratory Abnormalities in Triple Combination Therapy</outcome_measure>
      <outcome_measure>Assessment of Tolerability in Triple Combination Therapy</outcome_measure>
      <outcome_measure>Week 2 Virological Response (W2VR)</outcome_measure>
      <outcome_measure>Week 4 Virological Response (W4VR)</outcome_measure>
      <outcome_measure>Rapid Virological Response (RVR)</outcome_measure>
      <outcome_measure>Change From Baseline in HCV Viral Load</outcome_measure>
      <outcome_measure>Day 28 Virologic Response</outcome_measure>
      <outcome_measure>Early Virological Response (EVR)</outcome_measure>
      <outcome_measure>Complete Early Virological Response (cEVR)</outcome_measure>
      <outcome_measure>End of Treatment Response (ETR)</outcome_measure>
      <outcome_measure>Sustained Virologic Response (SVR)</outcome_measure>
      <outcome_measure>Number of Participants With Investigator Defined Drug-related Adverse Events in Standard of Care (SOC) With PegIFN Î±-2a and RBV</outcome_measure>
      <outcome_measure>Number of Patients With Possible Clinically Significant Laboratory Abnormalities in Standard of Care (SOC) With PegIFN Î±-2a and RBV</outcome_measure>
      <outcome_measure>Assessment of Tolerability in Standard of Care (SOC) With PegIFN Î± -2a and RBV</outcome_measure>
      <outcome_measure>AUCÏ,1 for BI 201335 ZW</outcome_measure>
      <outcome_measure>Cmax of BI 201335 ZW</outcome_measure>
      <outcome_measure>AUCÏ,ss of BI 201335 ZW</outcome_measure>
      <outcome_measure>Cmax,ss of BI 201335 ZW</outcome_measure>
      <outcome_measure>AUCÏ,1 for Ribavirin (RBV)</outcome_measure>
      <outcome_measure>Cmax of RBV</outcome_measure>
      <outcome_measure>AUCÏ,ss of RBV</outcome_measure>
      <outcome_measure>Cmax,ss of RBV</outcome_measure>
      <outcome_measure>Tmax for BI 201335 ZW</outcome_measure>
      <outcome_measure>Tmax for RBV</outcome_measure>
      <outcome_measure>Tmax, ss for BI 201335 ZW</outcome_measure>
      <outcome_measure>Tmax, ss for RBV</outcome_measure>
      <outcome_measure>t1/2,ss for BI 201335 ZW</outcome_measure>
      <outcome_measure>Cmin,ss for BI 201335 ZW</outcome_measure>
      <outcome_measure>Cmin,ss for RBV</outcome_measure>
      <outcome_measure>Cavg for BI 201335 ZW</outcome_measure>
      <outcome_measure>Cavg for RBV</outcome_measure>
      <outcome_measure>CL/F,ss for BI 201335 ZW</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00947349</url>
  </study>
  <study rank="499">
    <nct_id>NCT01741545</nct_id>
    <title>Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pegylated-Interferon-lambda</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Daclatasvir</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>51</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>AI452-030</other_id>
      <other_id>2012-003463-22</other_id>
    </other_ids>
    <first_received>December 3, 2012</first_received>
    <start_date>March 2013</start_date>
    <completion_date>January 2015</completion_date>
    <last_updated>March 16, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>MAGNITUDE</acronym>
    <primary_completion_date>January 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of subjects who achieve SVR12 (HCV RNA &lt; LLOQ target not detected)</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve Rapid virologic response (RVR) [HCV RNA &lt; LLOQ target not detected at Week 4]</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve Complete early virologic response (cEVR) [HCV RNA &lt; LLOQ target not detected at Week 12]</outcome_measure>
      <outcome_measure>Proportion of subjects who have HCV RNA &lt; LLOQ target not detected at Week 24</outcome_measure>
      <outcome_measure>Proportion of subjects with treatment emergent cytopenic abnormalities through end of treatment (Week 12 for Genotype-2, -3 and Week 24 for Genotype-1b, -4)</outcome_measure>
      <outcome_measure>Proportion of subjects who experience on-treatment Interferon (IFN)-associated symptoms such as flu-like systems or musculoskeletal symptoms</outcome_measure>
      <outcome_measure>Proportion of subjects who achieve SVR24 by treatment group</outcome_measure>
      <outcome_measure>Proportion of subjects with serious adverse events (SAEs), discontinuation due to adverse events (AEs) and dose reductions through end of follow-up (maximum of 60 weeks for Genotype-2, -3 and 72 weeks for Genotype-1b, -4)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>France</country>
      <country>Italy</country>
      <country>Netherlands</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Spain</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Illinois</state>
      <state>Pennsylvania</state>
      <state>Utah</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01741545</url>
  </study>
  <study rank="500">
    <nct_id>NCT00262379</nct_id>
    <title>Use or Non-use of Epoetin Beta in Patients Infected by Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">epoetin beta (NeoRecormonÂ®)</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University Hospital, Angers</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>229</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CP 2005-01</other_id>
    </other_ids>
    <first_received>December 5, 2005</first_received>
    <start_date>December 2005</start_date>
    <completion_date>June 2009</completion_date>
    <last_updated>December 11, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Viral Response (Week 72)</outcome_measure>
      <outcome_measure>â¢ Viral Response at the End of Treatment (Week 48)</outcome_measure>
      <outcome_measure>â¢ Quality of life</outcome_measure>
      <outcome_measure>â¢ Cumulative dose of ribavirin from D0-W24 and from W24-W48 periods</outcome_measure>
      <outcome_measure>â¢ Clinical and biological tolerance</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00262379</url>
  </study>
  <study rank="501">
    <nct_id>NCT01314261</nct_id>
    <title>Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
      <condition>Hepatitis C Virus (HCV) Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABT-267</intervention>
      <intervention type="Drug">Pegylated interferon (pegIFN)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Other">Placebo for ABT-267</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>AbbVie (prior sponsor, Abbott)</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>37</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>M12-114</other_id>
    </other_ids>
    <first_received>March 11, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>February 2013</completion_date>
    <last_updated>January 21, 2015</last_updated>
    <last_verified>January 2015</last_verified>
    <firstreceived_results_date>December 29, 2014</firstreceived_results_date>
    <primary_completion_date>January 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With 4-week Rapid Virologic Response (RVR)</outcome_measure>
      <outcome_measure>Maximum Plasma Concentration (Cmax) of ABT-267</outcome_measure>
      <outcome_measure>Time to Maximum Plasma Concentration (Tmax) of ABT-267</outcome_measure>
      <outcome_measure>Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of ABT-267</outcome_measure>
      <outcome_measure>Plasma Concentrations of Ribavirin (RBV)</outcome_measure>
      <outcome_measure>Serum Concentrations of Pegylated Interferon (pegIFN)</outcome_measure>
      <outcome_measure>Percentage of Participants With Partial Early Virologic Response (pEVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Complete Early Virologic Response (cEVR)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-pegylated Interferon/Ribavirin (pegIFN/RBV) Dosing</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 24 Weeks (SVR24) Post-pegylated Interferon/Ribavirin (pegIFN/RBV) Dosing</outcome_measure>
      <outcome_measure>Median Time to Suppression of Hepatitis C Virus Ribonucleic Acid (HCV RNA)</outcome_measure>
      <outcome_measure>Percentage of Participants With Extended Rapid Virologic Response (eRVR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>California</state>
      <state>Florida</state>
      <state>Hawaii</state>
      <state>Indiana</state>
      <state>Missouri</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01314261</url>
  </study>
  <study rank="502">
    <nct_id>NCT01725529</nct_id>
    <title>An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">Peginterferon-alpha (PegIFNÎ±-2a)</intervention>
      <intervention type="Drug">Ribavirin (RBV)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>457</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR017962</other_id>
      <other_id>TMC435HPC3005</other_id>
    </other_ids>
    <first_received>November 9, 2012</first_received>
    <start_date>November 2012</start_date>
    <completion_date>November 2014</completion_date>
    <last_updated>July 15, 2015</last_updated>
    <last_verified>July 2015</last_verified>
    <firstreceived_results_date>July 15, 2015</firstreceived_results_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Study Drug Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 24 Weeks After End of Study Drug Treatment (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response at Week 72 (SVRW72)</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Failure</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Breakthrough</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
      <outcome_measure>Percentage of Participants With On-treatment Normalization of Alanine Aminotransferase Level</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
      <country>Korea, Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01725529</url>
  </study>
  <study rank="503">
    <nct_id>NCT00219739</nct_id>
    <title>STI571 ProspectIve RandomIzed Trial: SPIRIT</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Myeloid Leukemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Imatinib mesylate 400 mg</intervention>
      <intervention type="Drug">Imatinib mesylate 600 mg</intervention>
      <intervention type="Drug">Imatinib 400 mg + Peg-Interferon</intervention>
      <intervention type="Drug">Imatinib mesylate 400 mg + Cytarabine</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Poitiers University Hospital</lead_sponsor>
      <collaborator>Ministry of Health, France</collaborator>
      <collaborator>Novartis</collaborator>
      <collaborator>Roche Pharma AG</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>789</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>030482</other_id>
    </other_ids>
    <first_received>September 13, 2005</first_received>
    <start_date>September 2003</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>May 22, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>SPIRIT</acronym>
    <primary_completion_date>December 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Overall survival improvement</outcome_measure>
      <outcome_measure>Molecular response improvement at 1 year</outcome_measure>
      <outcome_measure>Hematological, cytogenetic responses improvement</outcome_measure>
      <outcome_measure>Duration of responses improvement</outcome_measure>
      <outcome_measure>Survival without progression improvement</outcome_measure>
      <outcome_measure>Acceptable toxicity</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>France</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00219739</url>
  </study>
  <study rank="504">
    <nct_id>NCT00774397</nct_id>
    <title>Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&amp;2)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BI 201335 NA 240 mg QD / LI</intervention>
      <intervention type="Drug">PegIFN/RBV</intervention>
      <intervention type="Drug">BI 201335 NA 120mg QD / LI</intervention>
      <intervention type="Drug">PegIFN/RBV</intervention>
      <intervention type="Drug">BI 201335 NA 240 mg QD</intervention>
      <intervention type="Drug">PegIFN/RBV</intervention>
      <intervention type="Drug">BI 201335 NA 240 mg QD</intervention>
      <intervention type="Drug">PegIFN/RBV</intervention>
      <intervention type="Drug">BI 201335 NA 240 mg BID</intervention>
      <intervention type="Drug">PegIFN/RBV</intervention>
      <intervention type="Drug">PegIFN/RBV</intervention>
      <intervention type="Drug">BI 201335 NA 240 mg QD</intervention>
      <intervention type="Drug">PegIFN/RBV</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>719</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double-Blind</study_design>
    </study_designs>
    <other_ids>
      <other_id>1220.5</other_id>
      <other_id>2008-003538-11</other_id>
    </other_ids>
    <first_received>October 16, 2008</first_received>
    <start_date>October 2008</start_date>
    <last_updated>October 14, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>July 3, 2015</firstreceived_results_date>
    <primary_completion_date>November 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Virological Response 4 Weeks After the End of Treatment With BI 201335 or Placebo</outcome_measure>
      <outcome_measure>Sustained Virological Response 24 Weeks (SVR24) After Completion of All Therapy</outcome_measure>
      <outcome_measure>Virological Response at Week 2</outcome_measure>
      <outcome_measure>Virological Response at Week 4</outcome_measure>
      <outcome_measure>Early Virological Response (EVR)</outcome_measure>
      <outcome_measure>Extended Rapid Virological Response (eRVR)</outcome_measure>
      <outcome_measure>Complete Early Virological Response (cEVR)</outcome_measure>
      <outcome_measure>End of Treatment Response at Week 24</outcome_measure>
      <outcome_measure>End of Treatment Response at End of All Therapy</outcome_measure>
      <outcome_measure>Sustained Virological Response 12 Weeks (SVR12) After Completion of All Therapy</outcome_measure>
      <outcome_measure>Time to Reach a Plasma HCV RNA Level Below the Lower Limit of Detection</outcome_measure>
      <outcome_measure>Time to Loss of Virological Response</outcome_measure>
      <outcome_measure>Virological Rebound</outcome_measure>
      <outcome_measure>Breakthrough on BI 201335/Placebo (Rebound While All 3 Treatments Were Still Ongoing)</outcome_measure>
      <outcome_measure>Breakthrough on PegIFN/RBV (Rebound While Only PegIFN/RBV Treatment Alone Was Still Ongoing)</outcome_measure>
      <outcome_measure>Relapse</outcome_measure>
      <outcome_measure>Change From Baseline to Week 24 in Diastolic Blood Pressure and Systolic Blood Pressure</outcome_measure>
      <outcome_measure>Change From Baseline to Week 24 in Pulse Rate</outcome_measure>
      <outcome_measure>Change From Baseline to Week 24 in Weight of the Patients</outcome_measure>
      <outcome_measure>Global Assessment of Tolerability</outcome_measure>
      <outcome_measure>Change From Baseline to Week 24 in Haemoglobin of the Patients</outcome_measure>
      <outcome_measure>Number of Patients [N(%)] With Transitions Relative to Reference Range for Laboratory Parameter Haemoglobin</outcome_measure>
      <outcome_measure>Change From Baseline to Week 24 in Absolute Neutrophils of the Patients</outcome_measure>
      <outcome_measure>Number of Patients [N(%)] With Transitions Relative to Reference Range for Laboratory Parameter Absolute Neutrophils</outcome_measure>
      <outcome_measure>Change From Baseline to Week 24 in ALT/GPT,SGPT of the Patients</outcome_measure>
      <outcome_measure>Number of Patients [N(%)] With Transitions Relative to Reference Range for Laboratory Parameter ALT/GPT,SGPT</outcome_measure>
      <outcome_measure>Change From Baseline to Week 24 in Total Bilirubin of the Patients</outcome_measure>
      <outcome_measure>Number of Patients [N(%)] With Transitions Relative to Reference Range for Laboratory Parameter Total Bilirubin</outcome_measure>
      <outcome_measure>Trough Concentration (Cpre,ss) of Faldaprevir at Steady State</outcome_measure>
      <outcome_measure>Trough Concentration (Cpre,ss) of Ribavirin at Steady State (Receiving 1000 mg/Day RBV)</outcome_measure>
      <outcome_measure>Trough Concentration (Cpre,ss) of Ribavirin at Steady State (Receiving 1200 mg/Day RBV)</outcome_measure>
      <outcome_measure>Trough Concentration (Cpre,ss) of PegIFN at Steady State</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>Czech Republic</country>
      <country>France</country>
      <country>Germany</country>
      <country>Korea, Republic of</country>
      <country>Netherlands</country>
      <country>Portugal</country>
      <country>Romania</country>
      <country>Spain</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>New York</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00774397</url>
  </study>
  <study rank="505">
    <nct_id>NCT00529568</nct_id>
    <title>Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">eltrombopag</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>759</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>TPL108390</other_id>
    </other_ids>
    <first_received>September 12, 2007</first_received>
    <start_date>October 2007</start_date>
    <completion_date>August 2011</completion_date>
    <last_updated>October 10, 2013</last_updated>
    <last_verified>March 2013</last_verified>
    <firstreceived_results_date>April 19, 2012</firstreceived_results_date>
    <primary_completion_date>August 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase</outcome_measure>
      <outcome_measure>Number of Participants Whose Platelet Count Increased From a Baseline Count of &lt;75 Gi/L to a Count Greater Than or Equal to (&gt;=) 100 Giga (10^9) Cells Per Liter (Gi/L) During the Open-label (OL) Pre-Antiviral Treatment Phase</outcome_measure>
      <outcome_measure>Number of Participants Receiving the Indicated Doses of Eltrombopag in the OL Phase Who Initiated Antiviral Therapy (Peginterferon Alfa-2a and Ribavirin) in the DB Phase</outcome_measure>
      <outcome_measure>Median Platelet Count at the Indicated Time Points During the OL Phase</outcome_measure>
      <outcome_measure>Median Platelet Count at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants in the Indicated Categories for Minimum Platelet Count With Antiviral Therapy</outcome_measure>
      <outcome_measure>Number of Participants With Rapid Virological Response (RVR) and Extended RVR (eRVR) During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants With Early Virological Response (EVR) and Complete EVR (cEVR) During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants With End of Treatment Response (ETR) and Sustained Virological Response at Week 12 of Follow-up (SVR12) During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants in the Indicated Categories for Antiviral Therapy Dose Reductions in the DB Phase</outcome_measure>
      <outcome_measure>Time to First Dose Reduction of Peginterferon Alfa-2a and Ribavirin Therapy in the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Levels of Peginterferon Dose Reductions in the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants Who Prematurely Discontinued Antiviral Therapy in the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants Categorized as Responders (R) and Non-responders (NR) for SVR and RVR to Antiviral Therapy in the Indicated Variants of Interleukin 28B (IL28B) (or Interferon, Lambda 3)</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shift From Baseline (BL) in Severity Grades for Clinical Chemistry Parameters (Calcium, Glucose [Glu.], Potassium [Pot.], and Sodium [Sod.]), Per Division of Acquired Immunodeficiency Syndrome (DAIDS)</outcome_measure>
      <outcome_measure>Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters (Hemoglobin, Lymphocytes [Lym.], Total Neutrophils [Tot Neu.], and White Blood Cells [WBC]), Per DAIDS</outcome_measure>
      <outcome_measure>Number of Participants in the Indicated Categories for Cataract Event During the DB Phase, Per Clinical Events Committee (CEC) Adjudication</outcome_measure>
      <outcome_measure>Number of Participants Assessed as Normal and Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Number of Participants With CS and NCS Change From Baseline for 12-lead ECG at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Heart Rate at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Weight at the Indicated Time Points During the DB Phase</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Body Mass Index (BMI) at the Indicated Time Points During the DB Phase</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>Czech Republic</country>
      <country>Egypt</country>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>India</country>
      <country>Israel</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>Pakistan</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Slovakia</country>
      <country>Spain</country>
      <country>Taiwan</country>
      <country>Ukraine</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Colorado</state>
      <state>Connecticut</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>New Hampshire</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Oklahoma</state>
      <state>Oregon</state>
      <state>Pennsylvania</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00529568</url>
  </study>
  <study rank="506">
    <nct_id>NCT01941680</nct_id>
    <title>High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>T-cell Lymphoma</condition>
      <condition>Leukaemia</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire de Fort-de-France</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Ecologic or Community</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>13/B/04</other_id>
      <other_id>2013-A00327-38</other_id>
    </other_ids>
    <first_received>September 3, 2013</first_received>
    <start_date>October 2013</start_date>
    <completion_date>October 2018</completion_date>
    <last_updated>November 23, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ATLL-HR-01</acronym>
    <primary_completion_date>September 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Number of patients with relapse</outcome_measure>
      <outcome_measure>Evidence of presence of gene expression of Tax and HBZ confirmed by Rt-PCR</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Guadeloupe</country>
      <country>Martinique</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01941680</url>
  </study>
  <study rank="507">
    <nct_id>NCT00209898</nct_id>
    <title>Hepatitis C Treatment of Inmates</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Fast initiation procedure</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Haukeland University Hospital</lead_sponsor>
      <collaborator>Bergen Prison, Norwegian correctional service</collaborator>
      <collaborator>Hoffmann-La Roche</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>42</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>12952</other_id>
    </other_ids>
    <first_received>September 13, 2005</first_received>
    <start_date>August 2003</start_date>
    <completion_date>January 2009</completion_date>
    <last_updated>March 19, 2015</last_updated>
    <last_verified>June 2003</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PEGPRI</acronym>
    <primary_completion_date>January 2009</primary_completion_date>
    <outcome_measures>
      <outcome_measure>- adherence</outcome_measure>
      <outcome_measure>- Sustained virologic response rates defined as percentage of patients with non-detectable HCV-RNA as measured by Roche AMPLICOR HCV Test, v2.0 (&gt;50 IU/mL).</outcome_measure>
      <outcome_measure>Percentage of patients with non-detectable HCV-RNA at study week 12, 24 and 48 as measured by Roche AMPLICOR HCV Test v2.0 (&lt;50 IU/mL).</outcome_measure>
      <outcome_measure>- adverse event rate and profile</outcome_measure>
      <outcome_measure>- Hemoglobin</outcome_measure>
      <outcome_measure>- Other laboratory tests</outcome_measure>
      <outcome_measure>- Medical Outcomes Study 36 Item Short Form health Survey (SF-36)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Norway</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00209898</url>
  </study>
  <study rank="508">
    <nct_id>NCT02259855</nct_id>
    <title>Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatic Insufficiency</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tipranavir</intervention>
      <intervention type="Drug">Ritonavir</intervention>
      <intervention type="Drug">Pegylated interferon</intervention>
      <intervention type="Drug">Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>1182.59</other_id>
    </other_ids>
    <first_received>September 24, 2014</first_received>
    <start_date>January 2006</start_date>
    <last_updated>October 7, 2014</last_updated>
    <last_verified>October 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2008</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Area under the concentration-time curve from 0 to 12 hours of ribavirin (RBV), tipranavir (TPV) and ritonavir (RTV) in the plasma (AUC0-12h)</outcome_measure>
      <outcome_measure>Area under the concentration-time curve from 0 to 24 hours of pegylated interferon (Peg IFN) in the plasma (AUC0-24h)</outcome_measure>
      <outcome_measure>Maximum measured concentration of RBV, Peg INF, TPV and RTV in the plasma (Cmax)</outcome_measure>
      <outcome_measure>Measured concentration of RBV, TPV and RTV in the plasma at 12 hours (Cp12h)</outcome_measure>
      <outcome_measure>Measured concentration of Peg INF in the plasma at 24 hours (Cp24h)</outcome_measure>
      <outcome_measure>Area under the concentration-time curve from 0 extrapolated to infinity of TPV and RTV in the plasma (AUC0-â)</outcome_measure>
      <outcome_measure>Time from dosing to the maximum concentration of the analytes in the plasma (tmax)</outcome_measure>
      <outcome_measure>Terminal half-life of the analytes in the plasma (t1/2)</outcome_measure>
      <outcome_measure>Apparent clearance of the analytes in the plasma after extra vascular administration (CL/F)</outcome_measure>
      <outcome_measure>Apparent volume of distribution of the analytes in the plasma (Vz/F)</outcome_measure>
      <outcome_measure>Number of patients with clinically significant changes in laboratory values</outcome_measure>
      <outcome_measure>Number of patients with adverse events</outcome_measure>
      <outcome_measure>Number of patients with clinically significant changes in vital signs (seated blood pressure, pulse rate)</outcome_measure>
      <outcome_measure>Number of patients with clinically significant changes from baseline in 12-lead ECG</outcome_measure>
      <outcome_measure>Assessment of tolerability by the investigator</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02259855</url>
  </study>
  <study rank="509">
    <nct_id>NCT01182298</nct_id>
    <title>Open Label Study to Evaluate Chronic Hepatitis C Treatment in Latino Subjects With and Without HIV Co-infection</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>FundaciÃ³n de InvestigaciÃ³n de Diego</collaborator>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>100159</other_id>
      <other_id>10-I-0159</other_id>
    </other_ids>
    <first_received>August 13, 2010</first_received>
    <start_date>July 2010</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>September 26, 2014</last_updated>
    <last_verified>September 2014</last_verified>
    <firstreceived_results_date>April 23, 2014</firstreceived_results_date>
    <acronym>LATHCV</acronym>
    <primary_completion_date>March 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Median Log Change in HCV RNA Levels on Day 7</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01182298</url>
  </study>
  <study rank="510">
    <nct_id>NCT01344889</nct_id>
    <title>An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>4459</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>MV22255</other_id>
    </other_ids>
    <first_received>April 27, 2011</first_received>
    <start_date>October 2009</start_date>
    <completion_date>June 2013</completion_date>
    <last_updated>December 1, 2015</last_updated>
    <last_verified>December 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Correlation between baseline patient characteristics and safety related dose reductions/treatment discontinuations of the long-acting interferon or ribavirin</outcome_measure>
      <outcome_measure>Correlation between safety related dose reductions/treatment discontinuations and sustained virological response (SVR: defined as HCV RNA &lt;50 IU/mL at 24 weeks after completion of treatment)</outcome_measure>
      <outcome_measure>Correlation of on-treatment factors and dose reduction/treatment discontinuation</outcome_measure>
      <outcome_measure>Correlation between degree of dose reductions/treatment interruptions (percentage of actual exposure/treatment administrations in relation to target exposure) and SVR</outcome_measure>
      <outcome_measure>Comparison of on-treatment virological response (rapid virological response, early virological response) in treatment-naÃ¯ve and treatment experienced patients</outcome_measure>
      <outcome_measure>Safety: Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Albania</country>
      <country>Algeria</country>
      <country>Bahrain</country>
      <country>Belgium</country>
      <country>Bosnia and Herzegovina</country>
      <country>Brazil</country>
      <country>Egypt</country>
      <country>Greece</country>
      <country>Hungary</country>
      <country>India</country>
      <country>Iran, Islamic Republic of</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>Kuwait</country>
      <country>Lebanon</country>
      <country>Macedonia, The Former Yugoslav Republic of</country>
      <country>Morocco</country>
      <country>Pakistan</country>
      <country>Poland</country>
      <country>Portugal</country>
      <country>Qatar</country>
      <country>Romania</country>
      <country>Serbia</country>
      <country>Slovakia</country>
      <country>United Arab Emirates</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01344889</url>
  </study>
  <study rank="511">
    <nct_id>NCT00115908</nct_id>
    <title>A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Albuferon</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">PEG-IFNalfa2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Human Genome Sciences Inc.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>458</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>ALFR-HC-04</other_id>
    </other_ids>
    <first_received>June 26, 2005</first_received>
    <start_date>May 2005</start_date>
    <completion_date>May 2007</completion_date>
    <last_updated>November 5, 2013</last_updated>
    <last_verified>November 2013</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response (SVR), defined as undetectable HCV RNA at 24 weeks after the end of therapy.</outcome_measure>
      <outcome_measure>Virologic response at Week 4 (VR4), defined as undetectable HCV RNA or a &gt; 2-log reduction in HCV RNA.</outcome_measure>
      <outcome_measure>Early virologic response at Week 12 (EVR12), defined as undetectable HCV RNA or a &gt; 2-log reduction in HCV RNA.</outcome_measure>
      <outcome_measure>Undetectable HCV RNA at Week 24.</outcome_measure>
      <outcome_measure>End of treatment response (ETR), defined as undetectable HCV RNA at Week 48</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
      <country>Australia</country>
      <country>Czech Republic</country>
      <country>France</country>
      <country>Germany</country>
      <country>Israel</country>
      <country>Poland</country>
      <country>Romania</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00115908</url>
  </study>
  <study rank="512">
    <nct_id>NCT01641094</nct_id>
    <title>Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>Foundation for Liver Research</lead_sponsor>
      <collaborator>Janssen-Cilag B.V.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ETIM</other_id>
    </other_ids>
    <first_received>July 12, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>December 2014</completion_date>
    <last_updated>March 10, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>ETIM</acronym>
    <primary_completion_date>June 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Determine functionality of immune cells in the liver and blood in chronic HCV patients before, during and after treatment with telaprevir, pegylated-IFN-a and ribavirin</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Netherlands</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01641094</url>
  </study>
  <study rank="513">
    <nct_id>NCT01623778</nct_id>
    <title>Optimization of Antiviral Therapy of Chronic HBV Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Australia Antigen Positive</condition>
      <condition>Hepatitis B</condition>
      <condition>Adverse Effects</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Interferon Alfa-2a add on ADV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Changhai Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>67</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>HBV2012</other_id>
    </other_ids>
    <first_received>June 16, 2012</first_received>
    <start_date>January 2009</start_date>
    <completion_date>December 2011</completion_date>
    <last_updated>June 19, 2012</last_updated>
    <last_verified>June 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <outcome_measures>
      <outcome_measure>HBeAg seroconversion rate</outcome_measure>
      <outcome_measure>HBV DNA decline</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01623778</url>
  </study>
  <study rank="514">
    <nct_id>NCT01062659</nct_id>
    <title>Cellular Immune Responses in the Liver in Chronic Hepatitis C (CHC) Patients</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Liver Diseases</condition>
      <condition>Virus Diseases</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>University of Ulm</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>TCell</other_id>
    </other_ids>
    <first_received>February 3, 2010</first_received>
    <start_date>February 2010</start_date>
    <completion_date>March 2013</completion_date>
    <last_updated>March 31, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <outcome_measures/>
    <unique_countries>
      <country>Germany</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01062659</url>
  </study>
  <study rank="515">
    <nct_id>NCT00655226</nct_id>
    <title>Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients</title>
    <recruitment open="N">Terminated</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
      <condition>Depressive Disorder, Major</condition>
      <condition>Depressive Disorder</condition>
      <condition>Depression</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Hepatitis C educational support groups</intervention>
      <intervention type="Behavioral">Cognitive Behavioral Therapy skills based group sessions</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Icahn School of Medicine at Mount Sinai</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>26</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GCO# 05-0961</other_id>
      <other_id>R21DA021531</other_id>
    </other_ids>
    <first_received>April 3, 2008</first_received>
    <start_date>March 2008</start_date>
    <completion_date>May 2010</completion_date>
    <last_updated>August 5, 2011</last_updated>
    <last_verified>August 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Depression measured by PHQ-9</outcome_measure>
      <outcome_measure>Depressive symptoms (measured by Beck Depression Inventory-II)</outcome_measure>
      <outcome_measure>medication adherence</outcome_measure>
      <outcome_measure>hepatitis C treatment completion</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>New York</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00655226</url>
  </study>
  <study rank="516">
    <nct_id>NCT02101177</nct_id>
    <title>Evaluation of the National Treatment Program of Hepatitis C in Egypt</title>
    <recruitment open="N">Withdrawn</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</lead_sponsor>
      <collaborator>Institut Pasteur</collaborator>
      <collaborator>National Hepatology &amp; Tropical Medicine Research Institute</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANRS 12291</other_id>
    </other_ids>
    <first_received>March 26, 2014</first_received>
    <start_date>April 2014</start_date>
    <completion_date>December 2015</completion_date>
    <last_updated>July 22, 2014</last_updated>
    <last_verified>March 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>eNTC</acronym>
    <primary_completion_date>June 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Estimate &quot;real life&quot; Sustained Virological Response rate</outcome_measure>
      <outcome_measure>Compare the efficacy of ReiferonÂ®, a biosimilar produced by a local company, MinapharmÂ©, to that of other pegylated interferon of known efficacy (PegasysÂ®, PegintronÂ®)</outcome_measure>
      <outcome_measure>Understand the determinants of not returning for follow-up among defaulting patients</outcome_measure>
      <outcome_measure>Optimize selection criteria for patients to be enrolled in the National Treatment Program</outcome_measure>
      <outcome_measure>Estimate &quot;real life&quot; Response rate at the end of treatment</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02101177</url>
  </study>
  <study rank="517">
    <nct_id>NCT00110799</nct_id>
    <title>SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
      <condition>Hepatitis C</condition>
      <condition>Thrombocytopenia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SB497115</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>TPL102357</other_id>
    </other_ids>
    <first_received>May 13, 2005</first_received>
    <start_date>April 2005</start_date>
    <completion_date>November 2006</completion_date>
    <last_updated>May 31, 2012</last_updated>
    <last_verified>March 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2006</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Treatment response, assessed by the proportion of subjects with a shift from baseline platelet count (20, 000 to &lt;70,000ÂµL) to =100,000/ÂµL after 4 weeks of study treatment.</outcome_measure>
      <outcome_measure>Mean increase in platelet counts and markers of thrombopoiesis. Safety and tolerability, population PK, pharmacodynamics. Effect of antiviral outcome measures during and after therapy.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>France</country>
      <country>Germany</country>
      <country>Puerto Rico</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Colorado</state>
      <state>Massachusetts</state>
      <state>Michigan</state>
      <state>Missouri</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00110799</url>
  </study>
  <study rank="518">
    <nct_id>NCT01318694</nct_id>
    <title>Efficacy and Safety Study of DEB025/Alisporivir Combined to Peg-IFN and Ribavirin in Chronic Hepatitis C Genotype 1 Treatment-naÃ¯ve Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peg-IFN once weekly + Ribavirin BID + DEB025 600 mg QD</intervention>
      <intervention type="Drug">Peg-IFN once weekly + Ribavirin BID + DEB025 400 mg BID</intervention>
      <intervention type="Drug">Peg-IFN once weekly + Ribavirin BID + DEB025 600 mg QD</intervention>
      <intervention type="Drug">PegIFN once weekly + Ribavirin + Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1073</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CDEB025A2301</other_id>
      <other_id>2010-022867-37</other_id>
    </other_ids>
    <first_received>March 17, 2011</first_received>
    <start_date>March 2011</start_date>
    <completion_date>August 2013</completion_date>
    <last_updated>October 13, 2015</last_updated>
    <last_verified>October 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained Viral Response Week 12 (SVR 12) defined as serum HCV RNA undetectable by limit of detection (LOD) 24 weeks after treatment completion</outcome_measure>
      <outcome_measure>Rapid Virological response by limit of detection (RVR4LOD), Rapid Virological response by limit of quantification (RVR4LOQ) - defined as serum HCV RNA below LOD or LOQ respectively after 4 weeks of treatment</outcome_measure>
      <outcome_measure>Early Virological Response (EVR): serum HCV RNA reduction by at least 2Log10 or serum HCV RNA below LOQ 12 weeks after treatment start</outcome_measure>
      <outcome_measure>End of treatment response (ETR) - defined as HCV RNA undetectable by limit of detection</outcome_measure>
      <outcome_measure>Change in liver enzyme (ALT and bilirubin) and hematological patient profiles (platelets, neutrophils, hemoglobin) during treatment phase.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Belgium</country>
      <country>France</country>
      <country>Germany</country>
      <country>Hong Kong</country>
      <country>Hungary</country>
      <country>Italy</country>
      <country>Korea, Republic of</country>
      <country>Mexico</country>
      <country>Poland</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Russian Federation</country>
      <country>Spain</country>
      <country>Taiwan</country>
      <country>Thailand</country>
      <country>United Kingdom</country>
      <country>Vietnam</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Florida</state>
      <state>Illinois</state>
      <state>Indiana</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Minnesota</state>
      <state>Missouri</state>
      <state>Nebraska</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Texas</state>
      <state>Utah</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01318694</url>
  </study>
  <study rank="519">
    <nct_id>NCT00980161</nct_id>
    <title>Micro RNA-122 and the Clinical Course of Patients With Chronic Hepatitis C</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
      <collaborator>National Science Council, Taiwan</collaborator>
      <collaborator>Department of Health, Executive Yuan, R.O.C. (Taiwan)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>200908039R</other_id>
    </other_ids>
    <first_received>September 16, 2009</first_received>
    <start_date>September 2009</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>March 25, 2010</last_updated>
    <last_verified>March 2010</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Serum micro RNA-122 and sustained virologic response (SVR)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00980161</url>
  </study>
  <study rank="520">
    <nct_id>NCT01465919</nct_id>
    <title>Efficacy Study of Mirtazapine to Treat Interferon-related Depression During Antiviral Therapy for Hepatitis C</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Depression</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Mirtazapine</intervention>
      <intervention type="Other">Supportive psychotherapy</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Seoul National University Boramae Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>56</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>06-2011-130</other_id>
    </other_ids>
    <first_received>October 31, 2011</first_received>
    <start_date>August 2011</start_date>
    <completion_date>March 2016</completion_date>
    <last_updated>May 18, 2015</last_updated>
    <last_verified>May 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Change from baseline in Hamilton Depression Rating Scale (HAMD)-17 at 8 weeks</outcome_measure>
      <outcome_measure>Change from baseline in quality of life at 8 weeks</outcome_measure>
      <outcome_measure>Genetic polymorphism</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Korea, Republic of</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01465919</url>
  </study>
  <study rank="521">
    <nct_id>NCT02340962</nct_id>
    <title>A Study to Evaluate the Efficacy and Safety of TG-2349 in Combination With Peg-interferon and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1b Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TG-2349</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Interferon Alfa-2a</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>TaiGen Biotechnology Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>TG-2349-03</other_id>
    </other_ids>
    <first_received>January 8, 2015</first_received>
    <start_date>May 2015</start_date>
    <completion_date>June 2017</completion_date>
    <last_updated>November 2, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Antiviral efficacy of TG-2349 in combination with Peg-interferon (IFN) and Ribavirin (RBV) in treatment naÃ¯ve East Asian subjects with HCV GT1b infection</outcome_measure>
      <outcome_measure>Proportion of subjects achieving sustained viral response at 4, 8, and 24 weeks after the end of treatment (SVR4, SVR8, and SVR24)</outcome_measure>
      <outcome_measure>Proportion of subjects achieving HCV RNA &lt; lower limit of quantification, target detected or target not detected (&lt; LLOQ, TD or TND)</outcome_measure>
      <outcome_measure>Proportion of subjects achieving HCV RNA &lt; LLOQ, TND</outcome_measure>
      <outcome_measure>Mean absolute values and change from baseline in HCV RNA (log10 IU/mL)</outcome_measure>
      <outcome_measure>Proportion of subjects experiencing virologic failure during treatment and viral relapse after the end of treatment.</outcome_measure>
      <outcome_measure>Number of subjects with virologic failure (VF)</outcome_measure>
      <outcome_measure>Proportion of subjects with abnormal alanine aminotransferase (ALT) levels at baseline who achieved normal limit of ALT at final treatment visit.</outcome_measure>
      <outcome_measure>Area under the plasma concentration time curve from 0 to the last measurable concentration (AUC0-t) of TG-2349 and Ribavirin</outcome_measure>
      <outcome_measure>Area under the plasma concentration time curve from 0 to infinity (AUC0-inf) of TG-2349 and Ribavirin</outcome_measure>
      <outcome_measure>Maximum plasma concentration (Cmax) of TG-2349 and Ribavirin</outcome_measure>
      <outcome_measure>Time at which maximum plasma concentration is observed (Tmax) of TG-2349 and Ribavirin</outcome_measure>
      <outcome_measure>Terminal elimination half-life (t1/2) of TG-2349 and Ribavirin</outcome_measure>
      <outcome_measure>Apparent terminal elimination rate constant (Î»z) of TG-2349 and Ribavirin</outcome_measure>
      <outcome_measure>Apparent total body clearance (CL/F) of TG-2349 and Ribavirin</outcome_measure>
      <outcome_measure>Apparent volume of distribution (V/F) of TG-2349 and Ribavirin</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Taiwan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02340962</url>
  </study>
  <study rank="522">
    <nct_id>NCT00147784</nct_id>
    <title>HEPMET-1: Evaluate the Feasibility, Mental Sideeffects and the Efficacy of Hepatitis C Treatment in a MMT Group.</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opiate Dependence</condition>
      <condition>Hepatitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Pegylated Interferon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Sorlandet Hospital HF</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>SSHF-70332</other_id>
      <other_id>Protocol no 9772387</other_id>
      <other_id>EudraCT no 2005-002869-37</other_id>
    </other_ids>
    <first_received>September 6, 2005</first_received>
    <start_date>March 2006</start_date>
    <completion_date>January 2008</completion_date>
    <last_updated>March 26, 2008</last_updated>
    <last_verified>March 2008</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>June 2007</primary_completion_date>
    <outcome_measures>
      <outcome_measure>- Percent of patients with sustained virological response, defined as undetectable HCV RNA 24 weeks after end of treatment</outcome_measure>
      <outcome_measure>Retention in treatment, compliance, psychological distress, measures of quality of life, perceived drug use control and urine toxicology</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Norway</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00147784</url>
  </study>
  <study rank="523">
    <nct_id>NCT01655966</nct_id>
    <title>Vitamin D as an add-on Therapy With Pegylated Interferon and Ribavirin for Chronic Hepatitis c</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis c</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">vitamin D +pegylated interferon + ribavirin</intervention>
      <intervention type="Drug">pegylated interferon + ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Cairo University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>RAIL002</other_id>
    </other_ids>
    <first_received>July 31, 2012</first_received>
    <start_date>May 2012</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>January 28, 2014</last_updated>
    <last_verified>January 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Sustained virologic response</outcome_measure>
      <outcome_measure>rapid virologic response</outcome_measure>
      <outcome_measure>End-of-treatment response</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>early virologic response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Egypt</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01655966</url>
  </study>
  <study rank="524">
    <nct_id>NCT01485991</nct_id>
    <title>TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFÎ±-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFÎ±-2a and Ribavirin Therapy</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TMC435</intervention>
      <intervention type="Drug">TVR</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Janssen R&amp;D Ireland</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>771</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR100677</other_id>
      <other_id>TMC435HPC3001</other_id>
    </other_ids>
    <first_received>November 25, 2011</first_received>
    <start_date>February 2012</start_date>
    <completion_date>April 2014</completion_date>
    <last_updated>April 9, 2015</last_updated>
    <last_verified>April 2015</last_verified>
    <firstreceived_results_date>March 27, 2015</firstreceived_results_date>
    <acronym>ATTAIN</acronym>
    <primary_completion_date>April 2014</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)</outcome_measure>
      <outcome_measure>Percentage of Participants With Viral Relapse</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
      <country>Australia</country>
      <country>Argentina</country>
      <country>Austria</country>
      <country>Belgium</country>
      <country>Brazil</country>
      <country>Bulgaria</country>
      <country>Czech Republic</country>
      <country>Denmark</country>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>Hungary</country>
      <country>Israel</country>
      <country>Norway</country>
      <country>Poland</country>
      <country>Portugal</country>
      <country>Puerto Rico</country>
      <country>Romania</country>
      <country>Spain</country>
      <country>Sweden</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>District of Columbia</state>
      <state>Florida</state>
      <state>Georgia</state>
      <state>Hawaii</state>
      <state>Illinois</state>
      <state>Kentucky</state>
      <state>Louisiana</state>
      <state>Maryland</state>
      <state>Mississippi</state>
      <state>Missouri</state>
      <state>Montana</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>Ohio</state>
      <state>Pennsylvania</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01485991</url>
  </study>
  <study rank="525">
    <nct_id>NCT01796457</nct_id>
    <title>HBRN: Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis B</condition>
    </conditions>
    <interventions/>
    <sponsors>
      <lead_sponsor>University of Pittsburgh</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>165</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <study_designs>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>DK082864 Immunology Treatment</other_id>
      <other_id>U01DK082864</other_id>
    </other_ids>
    <first_received>February 19, 2013</first_received>
    <start_date>March 2013</start_date>
    <completion_date>March 2018</completion_date>
    <last_updated>March 4, 2015</last_updated>
    <last_verified>March 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Immune regulatory and effector responses relative to HBV DNA, ALT and clinical outcome</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Canada</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Massachusetts</state>
      <state>Minnesota</state>
      <state>Texas</state>
      <state>Virginia</state>
      <state>Washington</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01796457</url>
  </study>
  <study rank="526">
    <nct_id>NCT01872442</nct_id>
    <title>Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Phase of Chronic Myeloid Leukemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dasatinib</intervention>
      <intervention type="Drug">Peg-Interferon alpha2b</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Poitiers University Hospital</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs/>
    <other_ids>
      <other_id>DASA-PegIFN</other_id>
    </other_ids>
    <first_received>May 14, 2013</first_received>
    <start_date>October 2013</start_date>
    <last_updated>December 11, 2014</last_updated>
    <last_verified>December 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>October 2018</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Cumulative rate of molecular response</outcome_measure>
      <outcome_measure>Rate of complete cytogenetic response</outcome_measure>
      <outcome_measure>Rate of major molecular responses</outcome_measure>
      <outcome_measure>Rate of molecular response</outcome_measure>
      <outcome_measure>Kinetics and duration</outcome_measure>
      <outcome_measure>Rate of PegIFN-Î±2b and dasatinib discontinuation</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01872442</url>
  </study>
  <study rank="527">
    <nct_id>NCT01097395</nct_id>
    <title>Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>University of Colorado, Denver</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases/>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>08-1198</other_id>
      <other_id>K23DK082621</other_id>
    </other_ids>
    <first_received>March 30, 2010</first_received>
    <start_date>February 2010</start_date>
    <completion_date>August 2015</completion_date>
    <last_updated>August 6, 2015</last_updated>
    <last_verified>August 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <outcome_measures>
      <outcome_measure>ribavirin AUC-12 variability</outcome_measure>
      <outcome_measure>safety - absolute hemoglobin declines</outcome_measure>
      <outcome_measure>efficacy - early and sustained virologic response</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Colorado</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT01097395</url>
  </study>
  <study rank="528">
    <nct_id>NCT00759200</nct_id>
    <title>Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">alb-interferon alfa 2b</intervention>
      <intervention type="Drug">alb-interferon alfa 2b</intervention>
      <intervention type="Drug">alb-interferon alfa 2b</intervention>
      <intervention type="Drug">alb-interferon alfa 2b</intervention>
      <intervention type="Drug">peg-interferon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Novartis</lead_sponsor>
      <collaborator>Human Genome Sciences Inc.</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>525</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>CABF656B2202</other_id>
    </other_ids>
    <first_received>September 23, 2008</first_received>
    <start_date>October 2008</start_date>
    <completion_date>December 2010</completion_date>
    <last_updated>April 18, 2011</last_updated>
    <last_verified>April 2011</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Viral load</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Canada</country>
      <country>Australia</country>
      <country>France</country>
      <country>Germany</country>
      <country>Greece</country>
      <country>India</country>
      <country>Italy</country>
      <country>Poland</country>
      <country>Spain</country>
      <country>Taiwan</country>
      <country>Thailand</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00759200</url>
  </study>
  <study rank="529">
    <nct_id>NCT00718172</nct_id>
    <title>Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Liver Biopsy</intervention>
      <intervention type="Drug">Peginterferon &amp; amp; Ribavirin for Hepatitis C</intervention>
      <intervention type="Drug">Pre-treatment Ribavirin</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>81</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Pharmacokinetics/Dynamics Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>080182</other_id>
      <other_id>08-DK-0182</other_id>
    </other_ids>
    <first_received>July 16, 2008</first_received>
    <start_date>July 2008</start_date>
    <completion_date>August 2014</completion_date>
    <last_updated>August 20, 2014</last_updated>
    <last_verified>August 2014</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <outcome_measures>
      <outcome_measure>Improved viral kinetics with ribavirin pretreatment.</outcome_measure>
      <outcome_measure>Changes in gene expression during peginterferon and/or ribavirin thereapy, effect of treatment on NK cell function.</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Maryland</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT00718172</url>
  </study>
  <study rank="530">
    <nct_id>NCT02021643</nct_id>
    <title>Efficacy and Safety of Sofosbuvir Plus Ribavirin in Subjects With Chronic HCV Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic HCV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir</intervention>
      <intervention type="Drug">RBV</intervention>
      <intervention type="Drug">PegIFNÎ±</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>657</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Open Label</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-334-0115</other_id>
    </other_ids>
    <first_received>November 26, 2013</first_received>
    <start_date>December 2013</start_date>
    <completion_date>October 2016</completion_date>
    <last_updated>November 30, 2015</last_updated>
    <last_verified>November 2015</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Proportion of participants permanently discontinuing study drug(s) due to an adverse event (AE)</outcome_measure>
      <outcome_measure>Proportion of participants with: HCV RNA &lt; LLOQ at 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants experiencing viral breakthrough</outcome_measure>
      <outcome_measure>Proportion of participants experiencing viral relapse</outcome_measure>
      <outcome_measure>Change from baseline in HCV RNA (log10 IU/mL)</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
      <country>Hong Kong</country>
      <country>Korea, Republic of</country>
      <country>Taiwan</country>
      <country>Vietnam</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02021643</url>
  </study>
  <study rank="531">
    <nct_id>NCT00880763</nct_id>
    <title>A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Hepatitis C</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vaniprevir</intervention>
      <intervention type="Drug">Pegylated Interferon (peg-IFN)</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Comparator: Placebo</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Merck Sharp &amp; Dohme Corp.</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>7009-016</other_id>
      <other_id>2009_576</other_id>
    </other_ids>
    <first_received>April 10, 2009</first_received>
    <start_date>April 2009</start_date>
    <completion_date>February 2012</completion_date>
    <last_updated>September 1, 2015</last_updated>
    <last_verified>September 2015</last_verified>
    <firstreceived_results_date>September 26, 2014</firstreceived_results_date>
    <primary_completion_date>June 2010</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Achieving Rapid Viral Response</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving a &gt; or = 2-log10 Decrease in HCV RNA From Baseline to Week 4</outcome_measure>
      <outcome_measure>Percentage of Participants Achieving a &gt; or = 3-log10 Decrease in HCV RNA From Baseline to Week 4</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA in log10 at Week 4</outcome_measure>
      <outcome_measure>Number of Participants Who Experienced at Least One Adverse Event</outcome_measure>
      <outcome_measure>Number of Participants Who Discontinued Study Drug Due to an Adverse Event</outcome_measure>
    </outcome_measures>
    <unique_countries/>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT00880763</url>
  </study>
  <study rank="532">
    <nct_id>NCT01605513</nct_id>
    <title>Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">interferon</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>First Hospital of Jilin University</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
      <study_design>Masking: Double Blind (Subject, Caregiver)</study_design>
    </study_designs>
    <other_ids>
      <other_id>2011L0901</other_id>
    </other_ids>
    <first_received>May 10, 2012</first_received>
    <start_date>June 2011</start_date>
    <completion_date>May 2012</completion_date>
    <last_updated>May 23, 2012</last_updated>
    <last_verified>May 2012</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <acronym>PEG-IFN-SA</acronym>
    <primary_completion_date>May 2012</primary_completion_date>
    <outcome_measures>
      <outcome_measure>The proportions of absence of detectable HCV RNA after the 12th treatment</outcome_measure>
      <outcome_measure>The proportions of absence of detectable HCV RNA after the 4th and 8th treatment</outcome_measure>
      <outcome_measure>HCV RNA levels after the 4th, 8th and 12th treatment</outcome_measure>
      <outcome_measure>The test of Liver function</outcome_measure>
      <outcome_measure>The test of Kidney function</outcome_measure>
      <outcome_measure>The test of Peripheral blood</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>China</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT01605513</url>
  </study>
</search_results>
